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Background and Aim: Axial spondyloarthritis (axSpA) patients have higher risk of co-
existing medical conditions – comorbidities – than the general population, yet management 
guidelines are largely based on randomised controlled trials that often exclude those with 
comorbidities. The overarching aim of this thesis was to describe the patterns of 
comorbidity and their impact on treatment using three real-world axSpA populations.  
Methods: Three datasets were used: one from a specialist axSpA service (Aintree cohort) 
and one from tertiary hospitals in Boston, Massachusetts (Boston cohort), and a 
longitudinal national axSpA register – the British Society for Rheumatology Biologics 
Register for axSpA (BSRBR-AS). Chapter 4 compared the prevalence of 39 comorbidities 
between two axSpA phenotypes – non-radiographic and radiographic axSpA – using the 
Boston and Aintree cohorts. Cluster analysis was then used to examine how comorbidities 
co-exist in the Aintree cohort, and how clusters relate to axSpA severity using multivariable 
regression models. Chapter 5 applied multivariable regression models to baseline BSRBR-AS 
data to examine whether axSpA disease assessment using various indices were 
differentially influenced by 14 comorbidities. Chapter 6 applied conditional models to 
longitudinal data from the BSRBR-AS to investigate the association between comorbidity 
and treatment response. Chapter 7 focused on the potential causal association of baseline 
mental health symptoms on treatment outcomes using marginal models. 
Results: The Boston cohort included 775 patients (mean age 53 (SD 17) years, 74% male), 
Aintree 421 patients (46 (SD 14) years, 69% male), and BSRBR-AS 2042 patients (49 (SD 15) 
years, 67% male). Around half of each cohort had at least one comorbidity. Comorbidity 
patterns and counts were similar between radiographic and non-radiographic axSpA in 
Boston (mean 1.5 vs. 1.3, respectively) and Aintree cohorts (1.4 vs. 1.3). Mental health 
conditions tended to co-exist and were associated with greater axSpA disease severity. In 
the baseline BSRBR-AS data, each additional comorbidity was associated with higher 
BASDAI (Bath AS Disease Activity Index) by 0.40 units (95% CI 0.27, 0.52) and ASDAS (AS 
Disease Activity Score) by 0.09 units (95% CI 0.03, 0.15). Among 994 BSRBR-AS patients 
starting TNF inhibitors (TNFi), those with multiple comorbidities had similar absolute 
improvement in disease activity but reduced improvement in function (by 1.0 unit in BASFI 
at 6 months) and health-related quality of life (2.3 ASQoL units). Compared to those with 
less than mild depressive symptoms, patients with moderate-severe symptoms had 
reduced response at 6 months, by approximately 2 BASDAI units and 0.9 ASDAS units. 
Patients with moderate-severe anxiety symptoms had increased treatment discontinuation 
(HR 1.59; 95% CI 1.12 to 2.26) than those with less than mild anxiety.  
Conclusions: Comorbidities are highly prevalent in axSpA, in particular cardiovascular and 
mental health disorders. Comorbidities are associated with axSpA disease activity at 
baseline and adverse treatment outcomes, particularly depression and anxiety. These 
results have important clinical and policy implications for the current approach to disease 
assessment. Clinicians should record and refer comorbidities for optimal management, 
particularly mental health disorders. 
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Chapter 1: Introduction 
 
This chapter provides an overview of axial spondyloarthritis (axSpA). Aspects of the disease 
that are necessary to provide a background for the thesis are described, including clinical 
features, epidemiology, diagnosis and classification, pathophysiology, and management. 
This chapter will also introduce the importance of comorbidities and related terminology. 
 
1.1 What is axial spondyloarthritis? 
The concept of seronegative spondyloarthritides was first introduced by Moll and Wright in 
the 1970s [1]; seronegativity for rheumatoid factor, along with clinical features, helped 
distinguished it from rheumatoid arthritis. The more modern term ‘spondyloarthritis’ (SpA) 
includes several pathomechanistically related diseases, such as the prototype ankylosing 
spondylitis (AS), reactive arthritis, and SpA associated with psoriasis or inflammatory bowel 
disease (IBD) (Figure 1.1) [2]. 
Figure 1. 1: The spondyloarthritides. 
 
Adapted from the Assessment of SpondyloArthritis international Society (ASAS) slide library 
(www.asas-group.org). axSpA, axial spondyloarthritis; IBD, inflammatory bowel disease. 
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These diseases share similar clinical features and a common association with the human 
leukocyte antigen B27 (HLA-B27). From a practical viewpoint (e.g., for management), SpA 
can be grouped into disease that has predilection for the axial or peripheral joints [3]. 
Patients can, and often do, have both patterns of joint involvement; those with purely axial 
disease at presentation can develop peripheral arthritis over time and vice versa. This thesis 
will focus entirely on axial SpA. 
Axial spondyloarthritis (axSpA) is a relatively recent disease concept that includes AS, as 
well as ‘non-radiographic axSpA’ (nr-axSpA). AS can be considered an advanced stage of the 
disease spectrum, which is characterised by abnormal, excessive bone formation in the 
axial skeleton. Nr-axSpA was introduced to recognise early disease without observable 
damage on plain radiographs [2]. Some consider the two as difference conditions, as only a 
minority of nr-axSpA progress to AS [4,5].  
1.1.1 Clinical features 
AxSpA patients can have a diverse combination of disease features that develop in varying 
chronological order. The commonest presentation is chronic inflammatory back pain: lower 
back and/or buttock pain that improves with activity and non-steroidal anti-inflammatory 
drugs (NSAIDs), often causing nocturnal wakening and, upon waking, early morning 
stiffness. Unlike other adult rheumatic diseases, symptoms of axSpA typically begin at a 
relatively young age. The mean age of symptom onset in UK cohorts is the early 20s [6,7] - a 
critical time for education, career, social networks and development of personal identity in 
general. Consequently, axSpA significant impacts quality of life and work productivity over 
the life course, at costs to both the individual and the economy [8]. Symptoms of poor 
mental health are common [9], and this is at least partly due to uncertainty and frustration 
through the often prolonged delay to diagnosis (mean of 6.7 years [10]). 
Peripheral articular features – arthritis, enthesitis and dactylitis – are present in around half 
of axSpA patients and contribute to additional symptom burden [11]. Arthritis, or synovitis, 
affect around 29% of patients [12], causing pain, stiffness and functional limitation as in 
rheumatoid arthritis (RA). Unlike RA, joint involvement is more often asymmetrical, 
oligoarticular, and associated with a better prognosis (i.e., less structural damage). There is 
evidence to suggest that synovitis in axSpA is preceded by, and may be a result of cytokine 
spill over from, adjacent enthesitis [13].  
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Enthesitis involves localised inflammation at the point of ligament, tendon or capsule 
insertion into the bone. Enthesitis is common, present in 29-35% of axSpA patients, and can 
cause widespread pain and tenderness not only in the limbs, but also at spinous processes, 
costochondral junctions, sternal articulations and iliac crests [12]. These symptoms can 
present challenges to axSpA diagnosis and management, since widespread tenderness can 
also be caused by fibromyalgia [14]. 
Another peripheral feature is dactylitis. It is present in around 6% of axSpA patients and is 
characterised by inflammation and circumferential thickening of whole digits [12]. Dactylitis 
may also be a manifestation of enthesitis: inflammation of multiple digital entheseal 
insertions result in flexor tenosynovitis and extensive soft-tissue swelling outside the joint 
capsule [13]. It is a cardinal feature of another member of the SpA family, psoriatic arthritis 
(PsA), where it is present in a quarter of patients and may be associated with greater 
radiographic damage [15].  
1.1.2 Extra-articular manifestations (EAMs) 
AxSpA is also strongly associated with extra-articular, or extra-skeletal, manifestations. The 
prevalence of uveitis among axSpA patients is 26%, while 9% have psoriasis and 7% IBD 
[16]. The hazard of uveitis was 16-fold higher (95% CI 11.6 to 20.7), psoriasis 50% higher 
(95% CI 1.1 to 1.9) and IBD 3-fold higher (95% CI 2.3 to 4.8) in axSpA (n=4101) than age- and 
sex-matched controls (n=28,591) in the UK primary care population [17]. Presence of one 
EAM can influence the chances of having others [18]. Research into their pathophysiology 
has improved understanding of the axSpA disease mechanism (Section 1.3). The presence 
of EAMs also help diagnosis and classification of axSpA (Section 1.4). Patients with EAMs 
often require collaborative cross-specialty management, which is relevant for healthcare 
resource use [16]. Most importantly, EMAs impact quality of life and work outcomes, and 
have also been associated with greater disease activity, functional impairment and 
radiographic progression in axSpA [18].  
1.1.2.1 Acute anterior uveitis (AAU) 
Anterior uveitis is defined by inflammation of the anterior uvea (iris and ciliary body) and 
can be acute (<3 months duration) or chronic (≥3 months). AAU is, by definition, self-
limiting and usually managed with topical corticosteroids. It is typically unilateral and 
recurrent in around half of patients [19]. Symptoms include acute onset of eye redness, 
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pain, photophobia and miosis. Visual acuity is generally preserved but can be reduced in 8% 
of cases [20]. 
AAU occurs in around a quarter of axSpA patients – higher in HLA-B27 positive individuals. 
Its prevalence becomes higher with longer disease duration as reported in meta-regression 
of published studies (17% among studies reporting with a mean disease duration of <10 
years to 39% with a mean disease duration of >20 years) [20]. AAU and SpA likely share the 
same underlying disease mechanism [21]. It may the first clinical manifestation of axSpA. In 
the SENTINEL study of 798 patients with anterior uveitis, over half of patients were found 
to have axSpA - 70% if HLA-B27 positive [22]. AAU also impacts treatment decisions; 
monoclonal antibodies to TNF reduce incidence and relapse of AAU, whereas etanercept is 
less efficacious (see Section 1.5.3.2). 
1.1.2.2 Psoriasis 
Psoriasis is characterised by keratinocyte proliferation, which results in erythematous, scaly 
plaques on the body, as well as nail deformities. The disease is not limited to the skin – 
there are significant associations with metabolic syndrome and depression [23]. Thirty 
percent of psoriasis patients develop articular involvement, including SpA. Conversely, 
around 9% of axSpA patients have psoriasis; these individuals are also more likely to have 
peripheral joint involvement [24].  
Due to shared inflammatory pathways, many treatments are approved for psoriasis, PsA 
and axSpA. Some drugs, such as ustekinumab (IL12/23 inhibitor), guselkumab (IL23 
inhibitor), and apremilast (phosphodiesterase 4 inhibitor) are effective for psoriasis but not 
axial symptoms. Interestingly, around 1.5 to 5% of patients treated with TNFi develop 
paradoxical psoriasis [25]; the mechanism of which is not yet fully understood. 
1.1.2.3 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) includes ulcerative colitis (mostly affecting continuous 
portions of the colon), Crohn’s disease (skip lesions anywhere from mouth to anus), and 
indeterminate colitis. Approximately 10% of patients with IBD develop arthritis – the most 
common extra-intestinal manifestation [26]. Conversely, around 7% of axSpA patients are 
diagnosed with IBD [16] and over half have microscopic inflammatory gut lesions [27]. 
Microscopic bowel inflammation has been associated with more extensive inflammation of 
the sacroiliac joints [28]. Co-existing IBD and axSpA impacts treatment decisions for both 
treating specialties; for example, vedolizumab (integrin inhibitor) and ustekinumab are 
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effective treatments for IBD but not for concurrent axSpA, whereas etanercept for axSpA is 
not effective for IBD. 
 
1.2 Epidemiology 
1.2.1 Prevalence and incidence 
Estimates for the prevalence of axSpA vary according to geography (mostly due to 
background HLA-B27 prevalence), sampling method and disease definition. Most 
epidemiological studies have focused on AS, where the mean prevalence was estimated as 
0.19% in Europe (95% CI calculated from reported data: 0.13 to 0.28%) and 0.32% in North 
America (95% CI 0.19 to 0.53%) [29]. The incidence of AS was estimated to be 7 cases per 
100,000 in both continents [30]. Similar studies of axSpA are scarce. Extrapolating from 
chronic back pain populations, the prevalence of axSpA in the US and Netherlands were 
both 0.7% [31,32]. There are no studies of axSpA incidence. 
1.2.2 Non-environmental risk factors 
AS has traditionally been described as a disease of young males. Earlier studies quoted 
male:female ratios as high as 9:1, although males only outnumber females by 2-3:1 in more 
recent studies [30]. This is more likely due to phenotypic differences between the sexes 
rather than a true difference in prevalence, since sex ratios in early stages of the disease 
process (i.e., before progression to ankylosis) are typically balanced [12]. 
Genetic factors are estimated to contribute >90% of the overall susceptibility to AS, half of 
which due to HLA-B27 and other major histocompatibility complex (MHC) genes [33]. The 
prevalence of HLA-B27 is around 80% in advanced AS cohorts, but lower in nr-axSpA. The 
risk of AS was 63% in one monozygotic twin if the other was affected [34]. In one Icelandic 
study, first degree relatives of AS patients had a 76-fold higher risk of having the condition 
[35].  
1.2.3 Environmental risk factors 
Recent studies demonstrated distinctive microbial signature (e.g., abundance of 
Ruminococcaceae) in gut biopsies and faeces of patients with AS/SpA compared with 
controls [37,38]. This rekindled interest in dietary risk factors, originally ignited by the 
hypothesis that Klebsiella infection is a trigger for axSpA. There is indeed evidence that diet 
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has a strong impact on the composition of the gut microbiota [39]. However, no specific 
dietary components have been identified that can impact the risk or severity of AS. Studies 
of the gut microbiome have not confirmed the Klebsiella hypothesis. 
The most studied environmental risk factor is cigarette smoking. Smoking is a major risk 
factor for the incidence and severity of RA, and it is also a causal contributor to numerous 
comorbidities and mortality in all rheumatic diseases. However, its role in axSpA risk and 
treatment response is less clear. A body of work was performed in parallel to this thesis, 
since smoking is intimately related to comorbidities but not commonly included as one. In 
brief, smoking is consistently associated with greater axSpA disease severity and risk of 
psoriasis and uveitis flares [7,40]. However, evidence for an independent causal role of 
smoking on axSpA incidence and treatment response had important methodological 
limitations [9,41,42] (see list of Publications).  
 
1.3 Pathophysiology 
Around 80% of axSpA patients are positive for HLA-B27 [2]. This association remains the 
strongest between any disease and an MHC antigen. However, the precise mechanism(s) 
through which it causes disease is unclear. It may induce cellular stress and cytokine 
production directly or through protein misfolding, present ‘arthrogenic’ microbial peptides 
to cytotoxic T-cells, and/or cause disease through modulation of the skin and bowel 
microbiome [2]. 
AxSpA differs from autoimmune diseases, such as RA, that are typically characterised by T 
and B cell dysfunction, disease-specific autoantibodies, and female predominance. Instead, 
it has more in common with auto-inflammatory diseases, where localised stress at specific 
tissue sites lead to abnormal innate immune responses. AxSpA is clinically, genetically and 
pathophysiologically related to barrier dysfunction diseases such as psoriasis and IBD; many 
features of axSpA occur at sites of high mechanical stress, such as those of the sacroiliac 
joints, spine and entheses [21].  
The interplay between genetic predisposition and mechanical stress has become clearer in 
recent decades. HLA-B27 misfolding and bowel inflammation both induce IL23 expression. 
IL23 responsive resident T cells, thought responsible for abnormal innate immune response 
to mechanical stress, have been found at the entheses and aortic root. Overexpressing IL23 
in mice activates these T cells to produce peripheral and axial enthesitis, aortitis and uveitis. 
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IL23 also activates T helper (Th17) cells that produce IL17A/F and TNF [43]. There is 
evidence to suggest they, and other related cytokines, contribute to the osteoproliferation 
that characterises AS [2]. The role of these downstream cytokines has been confirmed by 
clinical efficacy of their blockade [2]. 
 
1.4 Diagnosis and Classification 
Diagnostic and classification criteria are seldom interchangeable. This distinction is 
sometimes neglected, partly because the same clinical, laboratory and imaging features are 
often used for both diagnostic and classification purposes in axSpA. Diagnostic criteria are 
‘a set of signs, symptoms, and tests developed for use in routine clinical care to guide the 
care of individual patients [44].’ In contrast, classification criteria are ‘standardised 
definitions that are primarily intended to enable clinical studies to have uniform cohorts for 
research [44].’ Diagnostic criteria need to account for disease heterogeneity and have high 
sensitivity (as well as specificity), whereas classification criteria create homogeneous 
patient groups and need to have high specificity (rather than sensitivity). 
1.4.1 Diagnosis 
There are no diagnostic criteria for axSpA (or any members of the SpA family), which is 
unlikely to change [44]. There are many problems with applying diagnostic criteria, such as 
their dependence on the disease prevalence and range of differential diagnoses (i.e., the 
pre-test probability). Nevertheless, algorithms, such as the one shown in Table 1.1, can aid 
diagnostic decisions by providing relative ‘importance’ of each disease feature [45]. The 
Assessment of SpondyloArthritis international Society (ASAS) used this data to propose a 




Table 1. 1: Likelihood ratios to aid diagnosis of axial spondyloarthritis. 




HLA-B27 9.0 0.11 
Sacroiliitis on MRI 9.0 0.11 
Anterior uveitis 7.3  
Positive family history* 6.4 0.72 
Good response to NSAIDs 5.1 0.27 
Dactylitis 4.5  
Peripheral arthritis 4.0  
Inflammatory bowel disease 4.0  
Heel pain (enthesitis) 3.4  
Inflammatory back pain 3.1 0.33 
Psoriasis 2.5  
Raised CRP/ESR 2.5 0.63 
Adapted from Rudwaleit et al [45].  
*Family history for axSpA, reactive arthritis, psoriasis, IBD or 
anterior uveitis.  
HLA-B27, human leukocyte antigen B27; MRI, magnetic resonance 
imaging; NSAIDs, non-steroidal anti-inflammatory drugs; CRP, C-
reactive protein; ESR, erythrocyte sedimentation rate. 
 
 
Figure 1. 2: Diagnostic algorithm for axial spondyloarthritis by the Assessment of 
SpondyloArthritis international Society (ASAS). 
 
Adapted from van den Berg et al. 2013 [46]. HLA-B27, human leukocyte antigen B27; MRI, 




In the absence of diagnostic criteria, features selected for classification are often used to 
assist the diagnostic process. Describing the evolution of the axSpA concept retrospectively 
can be confusing using current terminology; to clarify, AS and SpA are longstanding 
concepts but axSpA was not defined until 2009. The first criteria for the classification of AS 
was introduced in 1961 [47]. This was subsequently developed into the modified New York 
criteria in 1984 [48], shown in Box 1.1. 
The modified New York criteria require a substantial degree of structural damage of the 
sacroiliac joints that typically occur in advanced stages of the disease process; these criteria 
are therefore unable to classify early disease. Patients with peripheral symptoms are also 
excluded. Partly in response to these limitations, ASAS developed further classification 





Box 1.1: The modified New York criteria for ankylosing spondylitis. 
A. Diagnosis 
1. Clinical criteria: 
a) Low back pain and stiffness for >3 months which improves with exercise, 
but is not relieved by rest 
b) Limitation of motion of the lumbar spine in both the sagittal and frontal 
panes 
c) Limitation of chest expansion relative to normal values corrected for age 
and sex 
2. Radiologic criteria: 
a) Bilateral grade 2-4 sacroiliitis or 
b) Unilateral grade 3-4 sacroiliitis 
B. Grading 
1. Definite AS if the radiologic criteria is associated with ≥1 clinical criterion 
2. Probable AS if: 
a) 3 clinical criteria are present 
b) The radiologic criterion is present without any signs or symptoms 
satisfying the clinical criteria. 
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Accessibility of MRI to detect early inflammatory changes, as well as the number of 
effective pharmacological treatments, have both increased in recent decades. Therefore, it 
became more important to recognise and treat early forms of the disease. To facilitate 
research and development in this area, ASAS met and developed classification criteria (Box 
1.2) for the new entity ‘axial SpA’ [51]. The equivalent was also developed for ‘peripheral 
SpA’ [52], but will not be discussed further in this thesis. This new concept includes the 
whole spectrum of disease from early non-radiographic forms (nr-axSpA) to more advanced 




Box 1.2. ASAS criteria for axial spondyloarthritis. 
In patients with ≥3 months back pain and age at onset <45 years: 
• Sacroiliitis on imaging* plus ≥1 SpA feature** (imaging arm) or  
• HLA-B27 plus ≥2 SpA features** (clinical arm) 
* Sacroiliitis on imaging: 
1. Active inflammation on MRI highly suggestive of sacroiliitis associated with SpA;  
2. Definite radiographic sacroiliitis (grade ≥2 bilaterally or grade ≥3 unilaterally) 
** SpA features include:  
1. Inflammatory back pain: any 4 of the following: (1) age at onset <40 years, (2) 
insidious onset, (3) improvement with exercise, (4) no improvement with rest, 
(5) pain at night (with improvement upon getting up) 
2. HLA-B27 positive  
3. Anterior uveitis: confirmed by ophthalmologist 
4. Psoriasis: diagnosed by a doctor 
5. IBD: diagnosed by a doctor 
6. Arthritis (i.e., synovitis): diagnosed by a doctor 
7. Dactylitis: diagnosed by a doctor 
8. Heel enthesitis: at the Achilles tendon or plantar fascia insertion 
9. Good response to NSAIDs: back pain is resolved or much better 24–48h after full 
dose 
10. Elevated CRP: above upper limit of normal without other causes 




Meta-analysis of the ASAS criteria performance (from 9 studies, 5739 patients) found high 
overall sensitivity (82%) and specificity (89%) [53]. The ASAS criteria for axSpA permitted 
classification via the ‘imaging’ or the ‘clinical’ arm (Box 1.2). For the former, the specificity 
of ‘positive MRI’ has been questioned, since 28% patients with non-specific back pain have 
demonstrated similar MRI findings [54]. The definition of a positive MRI finding also has a 
significant impact on its specificity [55]. The clinical arm has received even greater criticism 
since it does not require imaging at all. For example, a young, obese, HLA-B27 positive 
female with fibromyalgia could be misclassified as axSpA if she reports a good response to 
NSAIDs and is found to have an elevated ESR. 
When the United States (US) Food and Drug Administration (FDA) met to consider TNF 
inhibitors (TNFi) for patients with nr-axSpA, they raised concerns that patients with highly 
prevalent conditions such as fibromyalgia might be misdiagnosed as nr-axSpA and 
inappropriately treated. This was one reason why biologic treatment remained unlicensed 
for nr-axSpA in the USA until March 2019. Research are ongoing to validate the ASAS axSpA 
criteria and, if needed, to strengthen the MRI imaging definition and weighting of the SpA 
features. 
1.4.3 Differences between radiographic and non-radiographic axial spondyloarthritis 
Not all patients with nr-axSpA progress to AS [4]; therefore, there is some controversy over 
whether or not nr-axSpA is an early form of the axSpA spectrum. There are important 
differences between the two evident in observational cohorts: AS groups tend to be older, 
more frequently male, and have higher inflammatory markers and a higher proportion of 
HLA-B27 positivity than their nr-axSpA counterparts [56–58]. However, both have similar 
disease features, symptom burden and, importantly, similar response to treatment [59,60]. 
ASAS-EULAR (the European League against Rheumatism) recommends a unified treatment 
approach for all axSpA patients [61]. How management should be delivered for these two 
conditions has not yet been fully elucidated; for example, whether comorbidities differ 





This section is largely based on the 2016 ASAS-EULAR recommendations [62] – the only set 
developed by an international society (ASAS). Discussion is limited to aspects that are 
particularly relevant to this thesis, namely disease assessment and pharmacological 
management. 
1.5.1 Assessment 
ASAS has endorsed outcome measures for use in a range of settings [62]. The core set 
recommended for routine management [63] is shown in Box 1.3. BASDAI is a 6-item 
questionnaire, from which a score is derived ranging from 0 (low) to 10 (high disease 
activity). Spinal pain is assessed using two questions in the ASAS recommendations, one for  
pain from AS, and another for pain from AS at night. In routine UK clinical practice, only the 
former is used. BASFI is an average score from 10 questions, ranging from 0 (low) to 10 
(high functional impairment). Components of these indices are shown in Box 1.4. In the UK, 
treatment using biologics require mandatory assessment of BASDAI and spinal pain. For 
disease monitoring, ASAS-EULAR recommendations also specify the need to assess EAMs 
[62]. Other important patient reported outcomes, including health-related quality of life 









Box 1.3: Core outcome set recommended for routine management. 
• BASDAI, the Bath AS disease activity index 
• Spinal pain 
• BASFI, the Bath AS disease functional index 
• Patient global  
• Fatigue (BASDAI question 1) 
• Duration of morning stiffness (BASDAI question 6) 
• Spinal mobility (chest expansion, modified Schober, occiput to 
wall distance, cervical rotation, lateral lumbar flexion; note that 
these are not the same as items in BASMI) 
• 44 swollen joint count 
• Entheses (using a validated tool) 






Box 1.4: Components of key patient reported outcome measures used to monitor 
axSpA patients. 
BASDAI 
1. How would you describe the overall level of fatigue/tiredness you have 
experienced? 
2. How would you describe the overall level of AS neck, back or hip pain you 
have had? 
3. How would you describe the overall level of pain/swelling in joints other 
than the neck, back or hips you have had? 
4. How would you describe the overall level of discomfort you have from any 
areas tender to touch or pressure? 
5. How would you describe the overall level of morning stiffness you have had 
from the time you wake up? 
6. How long does your morning stiffness last from the time you wake up? 
Spinal pain 
How would you describe the overall level of pain you have experienced in your 
spine during the past week? 
BASFI 
Level of ability with each of the following activities during the past week: 
1. Putting on your socks or tights without help or aids (e.g., sock aid). 
2. Bending forward from the waist to pick up a pen from the floor without an 
aid. 
3. Reaching up to a high shelf without help or aids (e.g., helping hand). 
4. Getting up out of an armless dining room chair without using your hands or 
any other help. 
5. Getting up off the floor without help from lying on your back. 
6. Standing unsupported for 10 min without discomfort. 
7. Climbing 12 to 15 steps without using a handrail or walking aid. One foot at 
each step. 
8. Looking over your shoulder without turning your body. 
9. Doing physically demanding activities (e.g., physiotherapy, exercises, 
gardening or sports). 
10. Doing a full day’s activities, whether it be at home or at work. 
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Since the above recommendations, ASAS also introduced the AS disease activity score 
(ASDAS) [64,65], which has stronger associations with radiographic progression than 
BASDAI [219]. ASDAS was created with the aim of introducing more validity, discriminative 
capacity, and objectivity to disease activity assessment. It combines five disease activity 
variables with only partial overlap. ASAS preferentially recommends the ASDAS-CRP, with 
ASDAS-ESR as an alternative (Box 1.5). 
 
 
Four disease activity states were chosen by consensus with validated thresholds (Figure 
1.3). A change of ≥1.1 units is defined as ‘clinically important improvement’ and ≥2.0 units 
as ‘major improvement’ (ASDAS-MI). 
 




Inactive  Low  High  Very high  
Adapted from references [64,65]. 
Box 1.5: The ankylosing spondylitis disease activity score (ASDAS) formulae [8,9]. 
ASDAS combines three questions from the BASDAI with a patient global score and 
inflammatory marker (CRP in mg/l or ESR).  
1. Total back pain (BASDAI question 2) 
2. Peripheral pain/swelling (BASDAI question 3) 
3. Duration of morning stiffness (BASDAI question 6) 
4. Patient global: ‘How active was your spondylitis on average during the last 
week?’ 
ASDAS-CRP = 0.12 x Back Pain + 0.06 x Duration of Morning Stiffness + 0.07 x 
Peripheral Pain/Swelling + 0.11 x Patient Global + 0.58 x Ln(CRP+1) 
ASDAS-ESR = 0.08 x Back Pain + 0.07 x Duration of Morning Stiffness + 0.09 x 
Peripheral Pain/Swelling + 0.11 x Patient Global + 0.29 x √ESR 
<1.3 >3.5 <2.1 
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1.5.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs inhibit cyclo-oxygenase (COX) to reduce key mediators of inflammation. The 
maximum tolerated dose is recommended as the first line pharmacological option (Figure 
1.4), with response evaluated 2 to 4 weeks later. The ASAS-EULAR, as well as NICE (National 
Institute for Health and Care Excellence), guidelines recommend trial of at least two agents. 
Naproxen was able to induce ASAS partial remission in 35% of patients with early disease 
[66]. Continuous use of celecoxib, a selective COX-2 inhibitor, reduced radiographic 
progression [67]. 
 
Figure 1. 4. ASAS-EULAR recommendations for the management of axial spondyloarthritis 
Adapted from van der Heijde et al [62]. bDMARDs, biologic disease-modifying 
antirheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis 
factor. 
 
Not all patients are able to tolerate NSAIDs, for example, those with renal or cardiovascular 
diseases. Non-selective NSAIDs are associated with intestinal relapses in patients with 
active IBD and increased hospital admissions due to colitis [68]. In axSpA patients with IBD, 
selective COX-2 inhibitors may be safer alternatives [69,70]. North American guidelines 
conditionally recommended celecoxib over other NSAIDs for short courses [71]. When 
patients have sustained high disease activity despite NSAIDs, or develop toxicity, disease-
modifying antirheumatic drugs (DMARDs) are recommended. 
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1.5.3 Disease-modifying antirheumatic drugs (DMARDs) 
1.5.3.1 Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)  
There is evidence that csDMARDs - sulfasalazine, methotrexate and leflunomide - are not 
efficacious for axial symptoms. Patients with purely axial disease should not normally be 
treated with csDMARDs [62], although sulfasalazine may be considered in patients with 
peripheral joint involvement. 
1.5.3.2 Biologic disease-modifying antirheumatic drugs (bDMARDs) 
bDMARDs have revolutionised the treatment for those with sustained high disease activity 
despite the above treatment options. These are large, complex protein molecules that 
target specific cytokines, or their receptors, involved in the inflammatory pathway. Several 
TNF inhibitors (TNFi) have been approved for axSpA (Figure 1.5). All except infliximab have 
indications for both radiographic and nr-axSpA. TNFi for nr-axSpA was approved more 
recently: 2016 in the UK, and 2019 in the US (only certolizumab pegol). In the UK, biosimilar 
infliximab, adalimumab and etanercept are widely in use. In 2016, a new class of bDMARDs 




Figure 1. 5 Biologic disease-modifying antirheumatic drugs licenced for axSpA. 
 
 
All except etanercept are monoclonal antibodies. All are TNF inhibitors except 
secukinumab, which blocks IL17A. TNFR2, TNF receptor 2; Fc, fragment crystallisable region. 
 
Approximately half of patients started on TNFi achieve BASDAI 50 (50% reduction in 
BASDAI, sometimes labelled as BASDAI ‘major response’) at 3 months [42,72]. The efficacy 
of bDMARDs with regard to musculoskeletal signs and symptoms are comparable, although 
no head-to-head trials are available. Their efficacy for EAMs, however, differ significantly. 
Monoclonal antibodies against TNF are efficacious for both uveitis and IBD, whereas 
etanercept may not be optimal for the former and has no efficacy in the latter [62]. 
Etanercept may also be less efficacious for psoriasis [62]. The secukinumab trial in Crohn’s 
disease was terminated early because rates of adverse events and efficacy were worse than 
placebo [73]. In trials of psoriasis, PsA and AS, exacerbations and new onset of IBD occurred 
[74]. Therefore, secukinumab should be used with caution or avoided in patients with 
significant bowel symptoms even without a definitive diagnosis of IBD. 
44 
 
1.5.3.3 Targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) 
tsDMARDs are small molecule drugs that have specific intracellular targets of action. 
Apremilast (phosphodiesterase 4 inhibitor) is licensed for psoriasis and PsA, but has failed 
to demonstrate any difference from placebo in AS [75]. A more recent addition to the 
rheumatologists’ armamentarium is the group of Janus kinase (JAK) inhibitors. Tofacitinib – 
a JAK1/3 inhibitor already licenced for RA and PsA – showed superior efficacy to placebo in 
a phase 2 trial of AS patients (67% of active arm achieved ASAS 20% improvement, 27% 
higher than placebo [76,77]). Another phase 2 trial also demonstrated efficacy of filgotinib 
(selective JAK1 inhibitor) over placebo in AS [78]. Although none are currently licenced 
(September 2020), it is likely that JAK (and other kinase) inhibitors will play an important 
role in future axSpA management. 
 
1.6 Comorbidity 
Patients with axSpA frequently have other co-existing conditions – comorbidities – by 
chance or resulting from the disease process and its treatment. To provide holistic care, 
with the patient (rather than the disease) at the centre, clinicians need a proactive and 
pragmatic approach to managing comorbidities. Many conditions directly impact 
management, yet randomised controlled trials – the gold standard evidence-base – seldom 
include patients with comorbidities, thus the benefit/risk of these aforementioned 
pharmacological therapies are largely unknown. There is a pressing need for research about 
the impact of comorbidities on the disease process and their impact on treatment options 
to fill this gap in evidence-based practice. This section introduces why comorbidities are 
important for clinicians and researchers, accompanied by clarification of terminology.  
1.6.1 Comorbidity or multimorbidity 
The worldwide population is ageing, particularly in developed countries like the UK and 
United States. A 2012 study in the UK provided a clear demonstration of how comorbidity 
burden increases with age (Figure 1.6) [79]. Patients attending rheumatology clinics with 
multiple disorders are increasingly the norm. This demographic shift has occurred in parallel 
with increasing specialisation of disease management, aimed at improving the quality of 
care. It is essential that specialists remain proactive in identifying and managing 
comorbidities, not only because fragmented care can be inefficient [80] (e.g., several 
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healthcare providers treating overlapping conditions) but also because patients benefit 
from being treated holistically.  
 
Figure 1. 6: The number of co-existing conditions increases with age. 
 
Figure from Barnett et al 2012 [79]. 
 
The co-existence of two or more conditions is a seemingly simple concept but has a range 
of interpretations and definitions. ‘Comorbidity’ is defined by the co-existence of distinct 
morbidities in addition to an index disease of interest. This perspective is common in 
hospital settings, where each specialty manages the index disease and its manifestations, 
but often refers comorbidities to other healthcare providers. ‘Multimorbidity’ is a more 
patient-centred concept that refers to the co-existence of any two chronic conditions. This 
viewpoint is typical for primary care settings, but the two are not mutually exclusive. While 
the philosophy behind ‘multimorbidity’ is how patient-care should be delivered, 
‘comorbidity’ will be used throughout this thesis for clarity and familiarity. 
What counts as a ‘morbidity’ is also debated. EAMs share the same underlying 
pathophysiology as axial disease and are thus considered disease features, not 
comorbidities. This definition is not without problems; for example, conduction and 
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valvular defects of the heart also share mechanisms with axial inflammation [43], but would 
be more commonly considered as cardiovascular comorbidities. A helpful delineation is 
observed from RCTs: EAMs are actively included, while comorbidities are generally 
excluded. There is further ambiguity between comorbidity and complications, most notably 
regarding osteoporosis and fractures: reduced bone mineral density of the spine is 
considered a comorbidity but is related to effects of localised inflammation in the spine 
(i.e., the disease process); fractures can be due to vertebral fusion (complication) or 
osteoporosis (comorbidity). Chronic comorbidities are most commonly counted, but some 
indices also include acute conditions (e.g., myocardial infarction), health-related risk factors 
(e.g., obesity and hypertension) and/or symptoms (e.g., back pain and urinary 
incontinence) [81–83]. For example, hypertension is a risk factor for coronary heart disease 
and stroke, but also has a diagnostic definition and requires long-term management like 
many chronic diseases.  
The choice of which comorbidities to include depends somewhat on whether they are 
studied as outcomes (e.g., do bDMARDs increase risk of infections?) or exposures (does 
depression impact treatment response?). Rather than focusing on one definition, this thesis 
will examine aspects related to comorbidity from a flexible standpoint, to identify and 
contribute to areas of unmet research need. 
 
1.7 Summary 
AxSpA is a complex condition that presents with a range of disease features and unique 
challenges for management. Its onset in early adulthood can be deleterious to education, 
career, relationships, and mental health; improving care for axSpA patients is important as 
the disease has potential to disrupt the entire life-course. Although effective targeted 
treatments are increasingly available, most clinical trials have excluded patients with 
comorbidities. Description of comorbidity burden and patterns are scarce. How 
comorbidities impact axSpA outcomes, such as treatment response, are unclear. There is a 





Chapter 2: Background Literature Review 
 
This chapter systematically reviews the literature on comorbidities in axSpA and discusses 
areas in need of further research to support the aims and objectives of this thesis. 
 
2.1 Introduction 
Comorbidities are common in people with chronic rheumatic diseases. This may be due to 
shared risk factors, consequences of inflammation or its treatment (e.g., long-term NSAIDs). 
Comorbidities are associated with adverse health outcomes such as poorer physical 
function, quality of life, work productivity, and mortality [84]. Some, such as renal, 
cardiovascular and gastrointestinal diseases, influence treatment decisions [85]. A holistic, 
patient-centred approach is therefore essential in rheumatology, yet randomised controlled 
trials – the gold-standard on which management guidelines are largely based – often 
exclude patients with comorbidities. Observational research using real-world data are 
important in addressing this unmet need, but studies have historically been heterogeneous 
in design and quality. 
The majority of axSpA comorbidity research has focused on one or a few closely related 
conditions within one organ system; for example, depression in axSpA [9], or cardiovascular 
diseases (CVDs) in axSpA [86]. While this approach is valid for assessing the impact of one 
comorbid disease on axSpA and vice versa, it does not reflect the real-world setting where 
patients frequently have multiple inter-related comorbidities. Studying a broad range of 
comorbidities helps quantify their collective ‘burden’ on health, which in turn provides 
context for the relative importance of, and relationship between, individual conditions. For 
example, what are the relative impacts of CVDs and depression on outcomes such as 
quality of life? When commissioning interventions, which should be prioritised? Are there 
‘clusters’ of commonly co-existing comorbidities, such that the presence of one should 
trigger screening for others? These are some of many unmet research-needs in axSpA that 
motivated this thesis. This chapter begins by reviewing descriptive epidemiological studies 
of comorbidities in axSpA and then moves on to their impact on disease outcomes. A 






1. To describe the prevalence of commonly reported comorbidities in patients with 
axSpA and how they compare to control populations. 
2. To summarise what is known about the impact of comorbidity burden on 
longitudinal outcomes in patients with axSpA. 
3. To discuss implications of the systematic review findings on the aims and 
methodology of this thesis. 
 
2.3 Methods 
A systematic review was reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [11]. The protocol was pre-
registered with PROSPERO (CRD42019151105). Full details on methods and results for this 
review are published in reference [84]. Medline, PubMed, Scopus and Web of Science were 
searched for relevant literature on 27th of September 2019, using the following search 
terms: (ankylosing spondylitis [MeSH] OR axial spondyloarth*) AND (multimorbidy [MeSH] 
OR comorbidity [MesH] OR polymorbid* OR multi-morbid* OR co-morbid* OR poly-
morbid*). No additional date or language restrictions were used. Bibliographies of all 
eligible studies were also manually searched to identify additional titles. The review was 
updated on 30th of September 2020 to include articles published over the last 12 months. 
‘PICO’ was defined as: 
• Participants/population: Studies of axSpA, whether defined by classification criteria 
or otherwise. 
• Intervention/exposure: Not applicable for Aim 1. For Aim 2, ‘exposure’ was the 
presence of any or individual comorbidities versus none. 
• Comparator/control: For Aim 1, incidence and prevalence of comorbidities were 
compared against controls. The definition of the control group could be healthy 
(i.e., without rheumatic diseases) or general populations (i.e., including rheumatic 
disease). 
• Outcome: Aim 1 ‘outcomes’ of interest were incidence and prevalence of 
comorbidities. Aim 2 examined axSpA-specific (e.g., treatment response or disease 
severity indices) and general outcomes (e.g., mortality). 
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Published conference abstracts were considered, as some prevalence studies may not be 
published as full articles but nevertheless have sufficiently detailed methodology and 
results. Reviews, comments, and editorials were excluded. 
Studies were excluded if they focused on only one comorbid condition (e.g., stroke only) or 
a few closely related diseases in one organ system (e.g., cardiovascular diseases only). This 
distinguished studies of comorbidity from, e.g., cardiovascular risk. Studies that used non-
representative sampling (highly selective recruitment or randomised controlled trials) or 
had a samples size of less than 30 (to avoid unreliable prevalence estimates) were 
excluded. Extra-articular manifestations (EAMs) were excluded from the list of 
comorbidities, since they share pathogenesis with and aid diagnosis of axSpA (thereby 
determining study inclusion) [87,88].  
Two independent reviewers screened titles and abstracts, assessed full texts for eligibility 
and extracted data from qualifying studies. Any discrepancy at each stage was resolved 
through discussion moderated by a third reviewer. Information from included studies was 
extracted into predefined tabulated summaries. Studies were assessed for risk of bias using 
an adapted version of the Newcastle Ottawa Scale. 
For Aims 1 and 2, meta-analysis was performed for comorbidities reported by at least three 
studies. Pooled prevalence estimates were reported as percentages (95% confidence 
interval, I2 statistic), using random-effects models (DerSimonian-Laird). Double arcsine 
transformation was used, since traditional weighting methods are problematic when 
proportions are close to the bound limits. Heterogeneity of meta-analysis estimates were 
presented using the I2 statistic. Funnel plots were used to assess risk of publication bias. 





A total of 1522 publications were found from the literature search. After excluding 
duplicates, irrelevant and ineligible studies, 44 studies remained. Three used data from the 
ASAS-COMOSPA study [89–91], from which the paper by Nikiphorou et al was selected 
since it restricted to participants fulfilling ASAS criteria. Two articles used the OASIS registry 
[92,93]; Stolwijk et al was selected as it reported a greater range of comorbidities. The 
larger of 2 studies using United States’ claims data by Walsh et al was included [94,95]. 
Flowchart of the selection process is shown in Figure 2.1. 
The 40 included studies are summarised in Table 2.1 [7,86,90,93,95–129]. Sample size 
ranged from 74 to 21,872 [107,108]. Twenty-one studies used European cohorts 
[7,96,98,100,102,106,108–110,112–114,116,118,119,121–123,128–130], 7 were from Asia 
[101,104,111,115,117,124,125], 6 North America [86,95,97,103,126,127], 1 Argentina 
[120], 1 Australia [99] and 4 were multinational [90,93,105,107]. Mean age of study 
samples ranged from 29 (China [115]) to 59 (UK [109]). Mean BASDAI ranged from 3.4 
(China [115]) to 7.6 (Australia, cohort initiating TNFi [99]).  
AxSpA was defined using classification criteria in 20 studies (7 using the modified New York 
criteria only, 13 using the ASAS and/or mNY criteria), diagnostic codes in 14, physician 
diagnosis in 3 and self-report in 1. The number of comorbidities studied ranged from 3 to 
43 (excluding EAMs). Most studies used non-validated lists, while 13 used a validated index 
either directly or indirectly (to inform which comorbidities to include, e.g., Kang et al [101]): 
3 used the Charlson Comorbidity Index (CCI), 2 Elixhauser Comorbidity Index (ECI), 3 self-
reported comorbidity questionnaire (SCQ), 2 Rheumatic Disease Comorbidity Index (RDCI), 
2 multimorbidity index (MMI) and 1 Functional Comorbidity Index. EAMs were included as 
comorbidity in a minority (5 out of 40 studies), while 2 considered valvular heart disease 
and restrictive lung disease as EAMs. Two studies also included smoking as comorbidity.  
Most studies did not justify their sample size since they were not dedicated studies of 
comorbidities, thereby losing one point for bias. Taking this into account, most studies 
scored 4 or 5 out of a possible 6 points indicating minimal bias (summary in Table 2.1, 






















1,522 titles identified through 
database searching 
(PubMed 444, Web of Science 
457, Medline 410, Scopus 211) 
797 duplicates removed 
725 Records screened 
586 irrelevant titles 
139 Full-test articles assessed for 
eligibility 
95 excluded (e.g., single 
comorbidity studied, axSpA 
grouped with other rheumatic 
diseases) 
4 excluded for using the same 
cohort as included studies 
 
39 full-text studies and 1 





























Table 2. 1: Summary of characteristics of studies included in the systematic review of comorbidities in axial spondyloarthritis. 
Study Country Sample 
Size 
Diagnosis Mean Age Males 
% 







Netherlands 658 AS (physician 
diagnosed) 
na 71% na Hospital Self-reported 19 3 
Han 2006 
[97] 
USA 1843 AS (ICD) 47 60% na Health 
insurance 
ICD 8 4 
Ara 2008 
[98] 





Australia 198 AS (physician 
diagnosed, 
starting TNFi) 
45 (12) 72% 7.6 Hospital Self-reported 19 3 
Salaffi 2009 
[100] 
Italy 164 AS (mNY) 52 (9) 81% 5.5 (1.7) Hospital Self-reported SCQ 3 
Kang 2010 
[101] 
Taiwan 11701 AS (ICD) 67% <45yrs 79% na Health 
insurance 
ICD 31 ECI 4 
Bremander 
2011 [102] 
Sweden 935 AS (ICD) 52 (15) 67% na Population 
register 
ICD 7 4 
Gladman 
2011 [103] 
Canada 1108 axSpA 
(mNY/ASAS) 
31 (12) at 
diagnosis 












USA, Australia 801 AS (mNY) Median 46 73% na Hospital 
(PSOAS) 





98 AS (physician 
diagnosed, 
starting TNFi) 
54 (11) 70% 3.8 (2.2) Hospital 
(OASIS) 
Medical records 11 SCQ 5 
Dougados 
2015 [106] 
France 708 SpA (26% mNY, 
70% ASAS) 










74 AS (unclear, 
85% had 









Canada 21473 AS (ICD) 46 53% na Health 
insurance 
ICD 8 4 
Kristensen 
2015 [108] 
Sweden 21872 AS (ICD) Median 46 52% na Hospital ICD 7 3 
Ahmed 2016 
[109] 
UK 94 AS (Read code) 59 (13) 87% na Primary care Read code 4 4 
Essers 2016 
[110] 
UK 3809 AS (Read code) 46% 
<40years 
71% na Primary care Read code 11 4 
Exarchou 
2016 [130] 
Sweden 8600 AS (ICD) 42 (13) at 
diagnosis 
66% na Hospital ICD 12 3 
Garip 2016 
[111] 







Netherlands 461 axSpA 
(mNY/ASAS) 
45 (13) 66% 3.8 (2.3) Hospital Self-reported 15 mSCQ 3 
Cook 2018 
[113] 
UK 1254 AS (self-
reported) 
Median 59 63% na Population 
research 
cohort 






Italy 213 SpA (ASAS) 48 (13) 54% na Hospital Self-reported mRCDI 3 
Jiang 2018 
[115] 





Germany 10208 AS (ICD) 57 61% na Health 
insurance 
ICD 9 CCI 4 
Lee 2018 
[117] 
Korea 1111 AS (ICD) 51% <45yrs 65% na Health 
insurance 
ICD CCI 4 
Lindström 
2018 [118] 
Sweden 2577 AS (ICD, starting 
TNFi) 













- 22 Countries 
3370 SpA (ASAS) 43 (14) 66% 3.7 (2.4) Hospital Physician 
diagnosed 
10 RDCI 6 
Sommerfleck 
2018 [120] 
Argentina 86 axSpA 
(mNY/ASAS) 








USA 6679 AS (ICD) 51 (14) 61% na Health 
insurance 
ICD 20 4 
Zhao 2019 
[7] 
UK 2420 axSpA 
(mNY/ASAS) 







France 827 AS (ICD) 50 (14) 57% na Health 
insurance 




Spain 738 AS (mNY) 48 (12) 74% na Hospital Unclear 14 CCI 4 
Fitzgerald 
2019 [123] 
Ireland 734 axSpA (78% 
mNY, 94% 
ASAS) 









Singapore 262 axSpA 
(mNY/ASAS) 





Singapore 189 axSpA (ASAS) 38 (13) 76% 38% ≥4 Hospital Unclear 5 3 
Singh 2019 
[126] 
USA 10990 AS (unclear) na 50% na Hospital Unclear 6 1 
Zhao 2019 
[127] 
USA 775 axSpA (ASAS) 53 (17) 74% na Hospital ICD 39 4 
Zhao 2019 
[128]  








Germany 1776 AS (ICD) 56 54% na Health 
insurance 
ICD 9 ECI 4 
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na, not available; NOS, Newcastle-Ottawa Score for bias; mNY, modified New York criteria; ASAS, Assessment of SpondyloArthritis international Society 
criteria; axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; ICD, International Statistical Classification of Diseases; CCI, Charlson Comorbidity Index; 
SCQ, self-reported comorbidity questionnaire; RDCI, Rheumatic Disease Comorbidity Index; ECI, Elixhauser Comorbidity Index. 
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2.4.1 Prevalence of comorbidities 
A total of 40 studies reported prevalence of individual comorbidities with a combined 
sample size of 121,485 patients [7,86,90,94,97–99,101–113,115,116,118–121,123–132]. All 
studies reported one or more diseases of the cardiovascular system. Diverticulitis, irritable 
bowel syndrome, venous thromboembolism and bronchiectasis are examples of 
infrequently (reported by ≤2 studies) included conditions. 
Pooled prevalence estimates of individual comorbidities (reported by ≥3 studies) are 
summarised in Figure 2.2 with further details provided in Table 2.2. The top five most 
prevalent comorbidities reported were hypertension (23%), hyperlipidaemia (17%), 
hypercholesterolaemia (15%), obesity (14%) and any infection (14%). There was significant 
heterogeneity for most of the meta-analyses. Forest and funnel plots of the 37 meta-
analyses were published in reference [84]. Some examples of most frequently reported 
comorbidities are shown in Figures 2.3 to 2.5. 
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Table 2. 2: Meta-analysis estimates for prevalence of individual comorbidities in the 
included studies. 







I2, % Range 
Any cardiovascular 
disease 
13 12.0 5.9 to 19.3 95 2.7 to 34.4 
Any ischaemic heart 
disease 
19 5.3 3.7 to 7.2 99 0.9 to 16.2 
Angina 6 3.6 1.2 to 6.9 96 1.2 to 7.0 
Myocardial infarction 10 2.2 1.4 to 3.1 91 0 to 7.2 
Heart failure 12 1.7 1.2 to 2.3 94 0.5 to 5.8 
Arrhythmias 8 3.7 1.9 to 6.0 95 1.0 to 14.0 
Stroke 19 1.7 1.3 to 2.3 96 0 to 5.5 
Peripheral vascular 
disease 
9 1.1 0.6 to 1.9 97 0.2 to 2.8 
Hypertension 36 22.7 16.6 to 29.3 100 4.5 to 73.0 
Diabetes mellitus 33 6.1 4.8 to 7.6 98 0.3 to 18.0 
Hyperlipidaemia 11 16.8 10.1 to 24.7 100 4.2 to 33.1 
Hypercholesterolaemia 7 15.4 6.8 to 26.5 99 6.8 to 26.5 
Obesity 7 14.2 1.7 to 33.5 100 0.2 to 27.3 
Any pulmonary disease 7 6.5 3.0 to 11.1 98 1.9 to 15.5 
COPD 9 2.7 1.2 to 4.7 98 0.6 to 8.8 
Asthma 9 5.4 3.3 to 8.0 98 0.5 to 11.3 
Any infection 4 14.2 2.9 to 30.7 100 4.6 to 32.9 
TB 8 1.3 0.6 to 2.4 92 0 to 3.8 
Viral hepatitis 6 3.4 0.9 to 7.3 97 0.6 to 18.6 
HIV 3 0.1 0.04 to 0.3 13 0 to 0.3 
Any gastrointestinal 
disease 
6 10.5 3.2 to 20.9 99 1.0 to 31.3 
Peptic ulcer 13 6.6 3.2 to 10.9 99 1.1 to 20.9 
Liver disease 10 2.7 0.7 to 5.9 99 0 to 12.0 
Alcohol excess 4 3.2 0.0 to 8.3 99 0.3 to 9.4 
Drug misuse 3 2.7 0.4 to 6.6 96 1.1 to 4.8 
Depression 19 11.4 7.0 to 16.6 100 2.0 to 31.0 
Any cancer 18 3.9 0.9 to 8.7 100 0.3 to 29.5 
Solid cancer 4 2.3 0.7 to 4.6 96 0.6 to 12.0 
Renal disease 15 1.4 1.0 to 1.8 93 0.1 to 2.7 
Anaemia 6 6.0 2.0 to 11.7 97 1.0 to 14.1 
Thyroid disorders 8 4.5 0.2 to 12.3 99 0.2 to 28.2 
Osteoporosis 12 8.8 5.1 to 13.2 99 3.4 to 31.0 
Fibromyalgia 6 5.0 1.2 to 11.0 100 0.4 to 14.6 
Dementia 4 0.4 0.1 to 0.8 74 0 to 0.8 
Migraine 3 1.9 0.9 to 3.3 83 1.3 to 3.0 
Parkinson’s disease 3 0.3 0.2 to 0.4 0 0.1 to 0.3 
Multiple sclerosis 4 0.4 0.3 to 0.6 0 0.1 to 0.5 
Stroke includes cerebrovascular accidents and transient ischaemic attacks. COPD, chronic 
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Esser 2016  
Kristensen 2015  
Zhao 2019 (US)  
Png 2019  
Exarchou 2016  
Hong 2020  
Kang 2010  
Ara 2008 
Zaide 2020  
Zhao 2018  
Zhao 2019 (UK)  
Garip 2016  
Fitzgerald 2019  
Bremander  2011   
Hwang 2020  
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Q=22172.96, p=0.00, I2=100%
Maas 2016  
Haroon 2015  
Bindesbøll 2020  
Ward 2013  
Fernández-Carballido 2020  
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Walsh 2018  
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Ljung 2018  
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   0.05  (  0.03,  0.06)      2.8
   0.05  (  0.04,  0.07)      2.8
   0.08  (  0.06,  0.09)      2.8
   0.08  (  0.07,  0.09)      2.8
   0.09  (  0.09,  0.09)      2.8
   0.09  (  0.07,  0.11)      2.8
   0.12  (  0.07,  0.17)      2.7
   0.12  (  0.12,  0.13)      2.8
   0.14  (  0.10,  0.18)      2.8
   0.16  (  0.16,  0.17)      2.8
   0.17  (  0.11,  0.24)      2.7
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   0.23  (  0.20,  0.25)      2.8
   0.23  (  0.17,  0.29)    100.0
   0.23  (  0.19,  0.27)      2.8
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   0.37  (  0.34,  0.40)      2.8
   0.37  (  0.28,  0.47)      2.7
   0.45  (  0.40,  0.50)      2.8
   0.49  (  0.48,  0.50)      2.8
   0.52  (  0.49,  0.54)      2.8
   0.73  (  0.72,  0.74)      2.8
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   0.18  (  0.17,  0.19)      3.3
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2.4.2 Comorbidity in axSpA vs. controls 
Eleven studies compared comorbidities between axSpA and control groups 
[86,94,97,101,102,109,110,113,116,121,130]. Six studies selected controls without AS or 
inflammatory rheumatic diseases [86,95,110,113,116,121], while 5 others did not specify or 
selected from the whole population [97,101,102,109,130]. All studies compared 
prevalence; 9 used pairwise comparisons or odds ratios (OR) and 2 used standardised 
mortality ratios (SMR). All except one study [121] matched for at least age and sex. 
Cardiovascular comorbidities were the most commonly described. Almost all individual 
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Table 2. 3: Comparison of comorbidity prevalence between axSpA and controls. 
 Effect 
estimate 






























1.19 to 1.51 
1.02 to 1.56 
1.27 to 2.70 
1.30 to 2.28 
1.13 to 2.18 
0.98 to 1.43 














from a subset 


































































1.75 to 1.99 
2.15 to 3.49 
1.17 to 1.73 
1.58 to 2.09 
1.08 to 1.74 
0.87 to 1.17 
1.50 to 2.18 
1.35 to 1.57 
2.38 to 4.40 
0.88 to 1.10 
0.70 to 1.66 
0.98 to 1.22 
 
0.78 to 1.09 
 
1.80 to 2.37 
0.52 to 1.41 
0.86 to 1.42 
1.80 to 2.07 
3.39 to 3.88 
1.81 to 2.26 
0.52 to 2.39 
1.23 to 2.36 
2.36 to 3.18 
0.93 to 1.93 
0.91 to 1.34 
1.72 to 2.26 
1.43 to 1.90 
0.28 to 1.82 







with at least 1 
clinic visit and 
any diagnosis 
Hypertension 













1.72 to 2.28 
1.77 to 2.70 
0.81 to 2.04 
1.10 to 1.78 
1.90 to 7.30 
0.89 to 1.72 
















1.35 to 1.45 
1.46 to 3.36 















2.15 to 2.79 
0.89 to 1.28 





















1.07 to 2.79 
0.54 to 2.36 
0.59 to 2.61 













PsA, SLE or 
vasculitis 
CVD 



















0.98 to 1.32 
1.07 to 1.50 
1.04 to 1.75 
0.69 to 1.31 
0.98 to 2.39 
0.75 to 1.50 
0.96 to 1.23 
0.18 to 1.09 
0.85 to 1.19 








































1.87 to 2.07 
2.78 to 3.26 
1.64 to 2.00 
2.33 to 3.23 
1.46 to 2.28 
1.36 to 1.81 
1.06 to 1.32 
1.93 to 2.14 
1.19 to 1.48 




SMR UK biobank 
participants 
without AS, 















1.1 to 1.3 
1.1 to 1.7 
1.0 to 1.7 
1.0 to 2.0 
0.8 to 1.3 
1.6 to 2.6 


























1.14 to 1.24 
0.98 to 1.07 
1.34 to 1.47 
1.38 to 1.54 
































1.16 to 1.31 
1.19 to 1.34 
1.15 to 1.50 
1.22 to 2.11 
1.10 to 1.85 
1.01 to 1.59 
0.85 to 1.32 


























1.00 to 1.14 
0.84 to 1.01 
1.63 to 2.48 
2.08 to 3.92 
1.11 to 1.39 
3.45 to 5.04 
3.03 to 6.83 
1.77 to 2.15 
0.72 to 2.17 
1.16 to 2.85 





























1.6 to 3.9 
0.6 to 1.9 
0.7 to 4.5 
0.6 to 1.3 
1.9 to 9.6 
0.6 to 1.3 
0.7 to 6.8 
 
1.3 to 3.6 
Stroke includes cerebrovascular accidents and transient ischaemic attacks. CVD, cardiovascular 
disease; COPD, chronic obstructive pulmonary disease; GI gastrointestinal; MS, multiple 
sclerosis; PVD, peripheral vascular disease; VTE, venous thromboembolism. 
 
 
For the nine studies reporting OR (or from which OR would be calculated), comorbidities 
reported by ≥3 studies were pooled using meta-analysis (summarise in Figure 2.6 with 
further details in Table 2.4). The three most frequently reported comorbidities were 
hypertension, diabetes, and ischaemic heart disease. The largest effect sizes were: 84% 
higher odds of congestive heart failure in axSpA compared to controls; and 80% higher odds 
for depression. Heterogeneity was high for all meta-analysis estimates. Forrest and funnel 




Figure 2. 6: Meta-analysis estimates for odds ratios comparing comorbidities between 
axSpA and control groups. 
 
 
Table 2. 4: Meta-analysis estimates for odds ratios of comorbidities compared between 









I2, % OR range 




3 1.42 0.999 to 2.03 99 1.14 to 1.97 
Any ischaemic 
heart disease 
7 1.51 1.21 to 1.87 87 1.10 to 2.74 
Heart failure 4 1.84 1.25 to 2.73 89 1.42 to 2.74 
Stroke 6 1.30 1.04 to 1.62 81 0.95 to 1.80 
Peripheral 
vascular disease 
5 1.47 1.10 to 1.96 83 1.06 to 2.21 
Diabetes 8* 1.14 1.001 to 1.30 83 0.90 to 1.31 
Hyperlipidaemia 5 1.18 1.01 to 1.39 94 1.02 to 1.46 
Cancer 5** 1.22 1.01 to 1.47 93 0.80 to 1.59 
Depression 4 1.80 1.45 to 2.23 92 1.45 to 2.10 
Meta-analysis was only performed for conditions reported by 3 or more studies. 
*Diabetes without complications selected. **Solid cancer without metastasis chosen 
Stroke includes cerebrovascular accidents and transient ischaemic attacks. 
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2.4.3 Comorbidity and disease outcomes 
Seventeen studies reported the association between comorbidity burden and axSpA 
outcomes (Table 2.5). 
2.4.3.1 Cross-sectional designs 
Most studies were cross-sectional. Overall, axSpA patients with comorbidities had higher 
disease activity and functional impairment, more severe pain, and poorer quality of life 
than those without comorbidities. ESR and CRP were generally not significantly different 
between those with and without comorbidities.  
Three studies reported work-related measures. Nikiphorou et al found that RDCI was 
associated with reduced employment, increased time off due to health reasons 
(absenteeism) and reduced productivity at work (presenteeism) [90]. Stolwijk et al found 
that the SCQ score was associated with stopping work due to disability, but only in those 
with BASDAI<4 [131]. Boonen et al reported 3 fold higher odds of inability to perform paid 
work in AS patients with comorbidities than without [96]. No studies examined the relative 
contributions of individual comorbidities within this context.  
 
Table 2. 5: Cross-sectional studies examining the impact of comorbidity on disease indices 




Outcome Results (shown as pairwise 













Comorbidity was present in 41%. 
 
Odds of work disability higher in AS 
patients with comorbidities (OR 3.15; 







Quality of life 
(EQ5D) 
Comorbidity was present in 36%. 
 
AS patients with comorbidity reported 
lower QoL than those without (0.36 




SCQ BASDAI SCQ was associated with increased 









Quality of life 
(SF36) 
 
SCQ and mSCQ were associated with 
BASFI, but CCI and RDCI were not. 
SCQ and mSCQ were associated with 






SCQ and mSCQ were associated with 
work disability in BASDAI<4 (but not 









Comorbidity was present in 28%. 
 
In unadjusted comparisons, patients 
with comorbidities reported higher 
BASDAI (5.1 vs. 3.7), BASMI (4.3 vs. 
3.2), BASFI (5.8 vs. 2.4) and energy (52 
vs. 30), all p<0.05. 
 
Differences were not significant for 
sleep (41 vs. 33), social isolation (38 










In multivariable logistic regression: 
arrhythmia/valvular disease, 
atherosclerosis, fractures, and 
obstructive sleep apnoea were not 
associated with peripheral or extra-







In multilevel multivariable linear or 
logistic models, RDCI was associated 
with: 
BASFI (ß=0.37; 0.30 to 0.43), 
EQ5D (ß=-0.03; -0.04 to - 0.02), 
Work status (OR 0.83; 0.76 to 0.91), 
Absenteeism (OR 1.18; 1.04 to 1.34), 








BASFI CCI was not associated with BASFI 
(ß=0.03; CI -0.13 to 0.20) in 









Comorbidity was present in 55%. 
 
In unadjusted comparisons: axSpA 
with vs. without comorbidity had 
similar ESR (median 11 vs. 10, p=0.09) 
and CRP (3 vs. 2.5, p=0.18); similar 
peripheral and extra-articular 
features, except psoriasis (21 vs. 15%, 
p=0.02) and peripheral arthritis (38 vs. 
27%, P<0.01), 
 
Presence of comorbidity associated 
with higher BASDAI (ß=0.70; 0.34 to 
1.05), 
BASMI (ß=0.45; 0.09 to 0.80), 
BASFI (ß=0.50; 0.23 to 0.78), 
HAQ (ß=0.07; 0.00 to 0.13), 
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ASQoL (ß=0.87; 0.28 to 1.46). 
Number of 
comorbidities 
 The number of comorbidities was also 
significantly associated with: 
BASDAI (ß=0.23; 0.09 to 0.37), 
BASMI (ß=0.20; 0.05 to 0.34), 
BASFI (ß=0.21; 0.10 to 0.32), 
HAQ (ß=0.03; 0.01 to 0.06), 










In multivariable linear models, each 
unit increase in ECI was associated 
with: 
BASDAI (ß=0.12; 0.07 to 0.17), 









Comorbidity was present in 51%. 
 
MMI count was associated with 
pain (ß=0.21; 0.04 to 0.38), 
ESR (ß=2.04; 0.65 to 3.42), 
CRP (ß=4.93; 2.88 to 6.98) in age and 










Comorbidity was present in 61%. 
 
In unadjusted comparisons, presence 
of comorbidity not associated with 
peripheral or EAM. Patients with 
comorbidity had worse: 
EQ5D (0.5 vs. 0.6) 
global health (5.2 vs. 4.8) 
fatigue (6.3 vs. 5.1) 
BASDAI (6.4 vs. 5.6) 
spinal pain (7.0 vs. 6.0) 
BASFI (6.8 vs. 4.5), all p<0.05; 
but not ESR (13 vs. 10mm/hr) or CRP 
(5 vs. 4mg/l). 
 
In multivariable linear models, 
anxiety/depression and 
fibromyalgia/IBS clusters were 
associated with all outcomes, except 
ESR and CRP. 
Work status (working or not); Absenteeism (time off due to health reasons); Presenteeism 
(reduced productivity at work); CCI, Charlson Comorbidity Index; ECI, Elixhauser 
Comorbidity Index; SCQ, self-reported comorbidity questionnaire; RDCI, Rheumatic 





2.4.3.2 Longitudinal designs 
There were six longitudinal studies (Table 2.6) [86,114,117,118,130,134]. Three reported 
increased all-cause and ‘vascular’ mortality among axSpA patients with comorbidities 
[86,117,130]. Three others examined treatment outcomes [114,118,134].  
 
Table 2. 6: Longitudinal studies examining the impact of comorbidity on disease 




Outcome Results (95% confidence interval) 
Haroon 
2015 [86] 







Dementia (HR, 2.62; 1.32 to 5.23) 
and 
PVD (HR, 6.79; 2.45 to 18.84) 
were significantly associated with 
vascular mortality, but not 
diabetes, CKD, IBD or cancer. 
Exarchou 
2016 [130] 
Each of 5 
‘general’ 
comorbidities 
Mortality CVD (HR 1.99; 1.58 to 2.49), 
DM (HR 1.92; 1.51 to 2.45), 
Chronic pulmonary disease (HR 
3.03; 2.27 to 4.05), 
Malignancy (HR 1.67; 1.32 to 
2.12), 
Infections (HR 2.01; 1.68 to 2.34) 
were each independent 
predictors of mortality in separate 









In SpA patients, mRDCI correlated 
significantly with the number of 
biological drug switches 
(Spearman’s rank coefficient 0.26, 
p-value unreported) 
 
mRCDI was a significant 
independent predictor of drug 
discontinuation (HR 1.53; 1.02 to 
2.29) and ASDAS remission (HR 
0.43; 0.20 to 0.92) in multi-









In multivariable logistic models, 
CCI was associated with increased 
all-cause mortality (OR 1.07; 1.01 
to 1.13), but not physical disability 
(OR 1.01; 0.95 to 1.08). 
Lindström 
2018 [118] 




CVD (HR 1.24; 1.08 to 1.43), 
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Affective disorder (HR 1.81; 1.54 
to 2.13), 
Chronic lung disease (HR 1.49; 
1.22 to 1.82), 
Malignancy (HR 1.36; 1.06 to 
1.74), 
were associated with TNFi 
discontinuation in unadjusted Cox 
models, but not Diabetes (HR 
1.36; 0.99 to 1.87) or CKD (HR 
0.79; 0.41 to 1.52) 
Macfarlane 
2020 [134] 
Count of 14 
comorbidities 
TNFi response Per unit increase in comorbidity 
count was associated with: 
ASAS20 (OR 0.65; 95% CI 0.50 to 
0.84. ORadj not significant, not 
provided) 
ASAS40 (OR 0.57; 0.42 to 0.79. 
ORadj 0.64; 0.45 to 0.92) 
ASDAS improvement by ≥1.1 (OR 
0.60; 0.44 to 0.82. ORadj 0.57; 0.37 
to 0.88) 
ASDAS <2.1 (OR 0.51; 0.35 to 
0.75. ORadj 0.60; 0.38 to 0.95) 
ASDAS, Ankylosing spondylitis disease activity score; ASAS20, ASAS Response Criteria 
designed for clinical trials: improvement of at least 20% and an absolute improvement 
of at least 10 units on a 0-100 scale in at least three of the following: patient global 
assessment, pain assessment, function (BASFI), and inflammation (BASDAI); CCI, 
Charlson Comorbidity Index; CVD, cardiovascular disease; DM, diabetes mellitus; HR, 
hazard ratio; IBD, inflammatory bowel disease; OR, odds ratio; RDCI, Rheumatic Disease 
Comorbidity Index. 
 
2.4.3.2.1 Mortality outcomes 
Lee et al studied comorbidity burden using CCI, where each unit increase was associated 
with 7% higher odds of all-cause mortality [117]. Haroon et al found that dementia and PVD 
were associated with increased vascular mortality, but not diabetes, chronic kidney disease, 
IBD or cancer [86]. All comorbidities in the study by Exarchou et al were each significantly 
associated with all-cause mortality; AS patients with chronic pulmonary disease were at 
particularly higher risk of death (HR 3.0; 95% CI 2.3 to 4.1) [130]. 
2.4.3.2.2 Treatment outcomes 
Iannone [114] et al showed that mRCDI was significantly correlated (by Spearman’s rank) 
with the number of biologic switches, however, the Kaplan Meier curves showed no 
difference between mRDCI of 1 and 0, while the mRDCI≥2 group separated after 
approximately 1 year. These curves were difficult to interpret as they suggested: 1) 
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discontinuation was assessed at (large intervals of) discrete times, and 2) >90% of those 
with mRDCI 0 or 1, but 0% of those with mRDCI≥2, remained on treatment at end of follow-
up (approximately month 60). This clearly non-(log-)linear relationship with mRDCI was 
then modelled adjusting for gender and disease duration, showing mRDCI to be a significant 
predictor of drug discontinuation (HR 1.53; 95CI 1.02 to 2.29) for 635 patients with 
rheumatic diseases overall; no results were reported for the 213 SpA patients. Cox models 
were also used to assess (discrete-)time-to-remission (ASDAS<1.3) and reported HR 0.43 
(95% CI 0.20 to 0.92) for the comorbid SpA subgroup. 
The second study, by Lindström et al [118], examined risk of TNFi discontinuation in 
unadjusted Cox models for each of: cardiovascular disease (HR 1.24; 1.08 to 1.43), affective 
disorder (HR 1.81; 1.54 to 2.13), chronic lung disease (HR 1.49; 1.22 to 1.82), malignancy 
(HR 1.36; 1.06 to 1.74), diabetes (HR 1.36; 0.99 to 1.87) and chronic kidney disease (HR 
0.79; 0.41 to 1.52). These effect estimates did not account for confounding, thus are 
difficult to interpret causally. 
The third study used a sample of 335 BSRBR-AS participants to show continuous 
comorbidity count as a predictor of binary response [134] . The investigators showed each 
additional comorbidity to reduce odds of achieving clinically important improvement in 
ASDAS (≥1.1) by 43% (95% CI 0.37 to 0.88) and ASDAS<2.1 by 40% (95% CI 0.38 to 0.95) 





This systematic review aimed to summarise existing research on comorbidities in axSpA and 
identify unmet needs to inform aims of this thesis. A large body of literature consistently 
showed that comorbidities are common among axSpA patients, more so than age- and sex-
matched controls. Comorbidities were also consistently associated with greater disease 
severity in mostly cross-sectional studies. However, research into the impact of comorbidity 
burden on longitudinal outcomes in patients with axSpA were relatively scarce. 
Methodological approaches were highly heterogenous, for example, in the type and 
number of conditions included. 
A strength of this review is the breadth of the literature search, allowing a hypothesis-free 
(in terms of comorbidity selection) overview of the topic. It was not feasible to additionally 
combine results from studies of individual comorbid conditions in axSpA, which may have 
provided further insight. However, this thesis aimed to examine comorbidities overall 
rather than a priori comorbid diseases of interest. Meta-analysis results should be 
interpreted with limitations in mind. There was significant heterogeneity in the 
measurement of comorbidities and relative lack of data on severity. These factors will 
impact pooled prevalence estimates. Once patients develop symptoms of or are diagnosed 
with axSpA, it is likely that increased healthcare interaction will result in improved 
identification of comorbidities; therefore, prevalence may be higher than controls by this 
explanation alone. Well-established comorbidities such as hypertension may undergo more 
systematic screening and diagnosis than others. 
2.5.1 Prevalence of comorbidities 
Studies in this review consistently showed higher prevalence of comorbidities in axSpA 
patients than controls. Yet, in clinical practice, management of comorbidities for patients 
with chronic inflammatory rheumatic diseases are often poorer than in the general 
population [135]. The 2016 EULAR points to consider for comorbidities recommend 
rheumatology teams to detect and collect information on comorbidities, liaise with 
appropriate healthcare providers to treat comorbidities, and repeat comorbidity reviews 
[135]. They focused on six conditions – CVDs, depression, infections, malignancies, peptic 
ulcer, and osteoporosis – that map almost exactly with high-prevalence comorbidities in 
our meta-analysis. It may, however, be that under-recognised comorbidities have under-
estimated prevalence. Others have suggested including additional comorbidities [136], but 
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this may be limited by feasibility in daily practice - the six comorbidities alone require a 93-
item reporting form. 
Almost all comorbidities examined were more prevalent in axSpA patients than age- and 
sex-matched controls. AxSpA patients had markedly increased odds for depression and 
CVDs. Symptoms of axSpA typically begin in early adulthood, which is a critical time for 
careers, relationships, and general social and personal identity. Disruptive symptoms – 
sometimes undiagnosed for many years – may impact life-long mental health trajectory and 
contribute to depression rates. Unlike RA, axSpA is not typically associated with high levels 
of systemic inflammation – a key driver of CVD risk. Higher CVD prevalence may be related 
to treatment in addition to the disease process itself; incidence of myocardial infarction and 
ischaemic heart disease were no different between axSpA and controls after adjusting for 
NSAID-use [110]. Congestive heart failure is downstream of many CVDs, thus higher odds in 
axSpA may reflect the overall burden and severity of CVDs. It may also be due to more 
systematic identification when considering TNF inhibitors. These results are consistent with 
prior studies showing reduced systolic and diastolic function in axSpA patients compared to 
controls [137,138]. Heart failure can have significant impact on function and quality of life 
[139], thus optimal symptom management is important for patients already burdened by 
their rheumatic disease. 
In all studies, comorbidities were studied individually or as a count. Future studies should 
complement such analyses by interrogating the contribution of individual comorbidities in 
the context of comorbidity clusters [128] and their combined impact. To address these 
unmet needs, this thesis will examine individual conditions and total comorbidity burden in 
parallel. How individual comorbidities co-exist will also be examined. Existing studies 
described comorbidity epidemiology in AS or axSpA populations, but none have directly 
compared comorbidity patterns between AS and non-radiographic axSpA. These diagnoses 
of the axSpA spectrum have similar symptom burdens and clinical features, but AS cohorts 
differ from their nr-axSpA counterparts in being more frequently male and having higher 
levels of CRP [56,57]. Comorbidity patterns are different between the sexes (e.g., prostate 
disorders or osteoporosis) [140], while systemic inflammation is a risk factor for many 
comorbidities [141]. Characterising comorbidity burden in AS and nr-axSpA subgroups is 
important since comorbidities influence treatment decisions and disease outcomes [142]. 
The type and number of conditions included were highly heterogenous. The number of 
included comorbidities in this review ranged from 3 to 43. Most studies used investigator-
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defined lists that were not validated, and selection of diseases was seldom justified. While 
all studies consistently included CVDs, some important conditions were underrepresented, 
such as fibromyalgia, alcohol or drug abuse [143], and neurological disorders. Validated 
comorbidity indices can include rare comorbidities in axSpA (e.g., AIDS and dementia) but 
not common and important conditions (e.g., depression [9]). Some studies used indices that 
were weighted and validated for outcomes unrelated to their research question. 
Methodological approaches for comorbidity research could benefit from similar 
standardisation as suggested for clinical practice [144]. The following section will discuss 
comorbidity indices in detail and justify the approach used in this thesis. 
2.5.2 Methods for studying comorbidity 
There is a plethora of tools and checklists for measuring comorbidity in the clinical 
literature [145]. Conditions are typically selected based on some consensus of their 
perceived importance, or on prognostic factors such as mortality. They can be patient-
reported or derived from routine healthcare data. Individual conditions can be added as a 
count or weighted according to their impact on outcomes such as mortality or quality of 
life. Severity may also be considered for some conditions (e.g., malignancies and diabetes). 
Choice of which index to use should be based on the population and outcome of the 
original validation studies; for example, using the Charlson Comorbidity Index (CCI) – 
originally validated for inpatient mortality – may not be suitable for studying quality of life 
in outpatient settings. This is particularly relevant for weighted indices, whereas a simple 
count of the number of conditions will be less tied to specific outcomes. For example, CCI 
poorly correlated with most axSpA outcomes (e.g., Spearman’s rho=-0.01 for BASDAI) while 
both CCI and RDCI were poorly associated with BASFI and quality of life (Short Form 36) 
[131]. Studies should avoid using weighted indices that have not been validated for their 
main outcome of interest. 
The CCI and ECI were both validated using hospital inpatients and may be less suitable for 
primarily outpatient specialties such as rheumatology. The CCI has also been adapted into a 
self-administered comorbidity questionnaire (SCQ) which asks about 13 comorbidities 
[146]. Both indices were validated to predict mortality (ECI additionally for cost and length 
of stay). RDCI was developed in patients with rheumatic and musculoskeletal diseases and 
is better at predicting mortality and functional disability than the CCI [147].  
Only the SCQ was validated against health-related quality of life – a priority outcome in 
chronic disease management. One other index in the RA literature is an adapted version of 
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the list of 40 chronic conditions in the Barnett et al multimorbidity study of the Scottish 
primary care population [79]. Barnett et al selected these diseases based on 1) 
recommendations from systematic review, 2) the quality and outcomes framework of the 
UK general practice contract, and 3) long-term disorders identified as important by NHS 
Scotland [79]. Radner et al validated the index against the CCI and functional comorbidity 
index in two large RA samples [148]. The authors created a count version of the index and 
another weighted for health-related quality of life, but the latter was not meaningfully 
superior. Key characteristics of some of these tools are compared in Table 2.7. 
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Table 2. 7: Comparison of five common comorbidity tools in rheumatic diseases research. 
 Charlson [149] Elixhauser [150] SCQ [146] RDCI [147] Multimorbidity index [148] 




distinguished in 3) 
30 (severity 
distinguished in 2) 
13 (plus up to 3 additional) 11 40 





Inpatients Inpatients RA, 





One-year mortality Length of stay, hospital 
costs, and hospital 
mortality 
Quality of life, prescriptions Mortality, 
hospitalization, 
disability, and costs 
Health-related quality of life 
Weighted Yes Weighted and 
unweighted 


































High blood pressure 
Lung disease 
Diabetes 
Ulcer or Stomach disease 
Kidney disease 
Liver disease 




Pain and swelling in joints 













Peptic ulcer or stomach 
problems 
Glaucoma 





































Fluid and electrolyte 
disorders 






Up to 3 additional conditions Substance misuse 
Osteoporosis 
Psoriasis eczema 
Coronary heart disease 
Hearing loss 
Stroke/TIA 
Peripheral vascular disease 
Chronic kidney disease 

















AIDS, acquired immunodeficiency syndrome; COPD, chronic obstructive pulmonary disease; OA, osteoarthritis; RDCI, rheumatic disease comorbidity index; SCQ, 
self-administered comorbidity questionnaire; TIA, transient ischaemic attack. 
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AxSpA studies require additional considerations for which comorbidities should be 
included. For example, the SCQ includes osteoarthritis, back pain and RA that may be 
difficult for patients to distinguish from axSpA when self-reported [131]. The MMI includes 
inflammatory bowel disease and psoriasis that are not considered comorbidities, since they 
share pathogenesis with and aid diagnosis of axSpA [87,88]. EAMs are common, partly 
because they are included in the disease definition; including uveitis (prevalence around 
25% [151]) in comorbidity lists will dominate many less common conditions in analyses. 
Furthermore, including EAMs in the modified SCQ did not improve its validity [152]. These 
distinctions and their supportive evidence only emerged in more recent years. Two studies 
in this review included cigarette smoking as a comorbidity. The distinction between 
comorbidity and risk factor is not absolute (take for example hypertension). 
2.5.3 Association with axial spondyloarthritis outcomes 
In this literature review, the presence of comorbidities was consistently associated with 
greater axSpA disease severity as assessed by a range of indices. Individuals with more 
severe axSpA may be at higher risk of developing comorbidities directly (e.g., depression) or 
indirectly through treatment (e.g., dyspepsia or renal disease from NSAIDs). Conversely, 
many comorbidities (e.g., heart failure or COPD) will directly impact physical function and 
fatigue, while others (e.g., depression) may indirectly influence the perception and 
reporting of pain. In two individuals with identical underlying axSpA disease activity, the 
one with multiple comorbidities will likely report higher subjective symptom burden. This is 
highly relevant to axSpA management where most disease indices are completely patient 
reported (e.g., BASDAI, spinal pain, BASFI). Whether more objective indices (e.g., ASDAS) 
are less influenced by comorbidities has not been investigated. This is an important clinical 
question since many treatment decisions rely on these indices. For example, eligibility for 
bDMARDs in the UK is partly determined by BASDAI, which may be modified by the 
presence of comorbidities that influence fatigue and pain. This thesis will address this 
unmet need by investigating how robustly various outcomes (e.g., BASDAI vs. ASDAS) are 
related to comorbidities such as depression. 
Evidence beyond cross-sectional associations between comorbidities and axSpA severity 
were comparatively scarce. Increased mortality in individuals with multiple comorbidities 
has been repeatedly described in other populations [153] and replicated among axSpA 
patients. Only three studies examined longitudinal associations with treatment outcomes, 
each with important methodological limitations. Comorbid axSpA patients consistently had 
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more severe axSpA, which will influence how treatment response is defined. For example, 
patients with higher disease activity will need to achieve greater absolute improvement to 
reach a low disease activity or remission state, compared to those with less active disease. 
Prior studies have only analysed these potentially problematic binary response definitions. 
The choice of response definition has both statistical (power and bias) and philosophical 
(which matters more to patients or health economics) implications. A better approach 
would be to provide a range of complementary response definitions, and additionally 
include absolute change in disease indices (rarely used in the general rheumatology 
literature and not at all in the reviewed axSpA studies) and time to treatment 
discontinuation. Outcome definitions and justification for selection will be discussed in 
greater detail in the Methods chapter. 
2.5.4 Summary of literature review 
Comorbidities are common among axSpA patients and are associated with greater axSpA 
severity. Several unmet research needs of clinical relevance were identified, namely 
whether comorbidities differ between AS and nr-axSpA populations, whether comorbidities 
co-exist, whether they are differentially associated with disease activity indices, and 
whether they influence response to TNFi therapy. There is also need for improved 
methodological approaches, namely the assessment of comorbidities and definitions of 
treatment outcomes.  
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2.6 Thesis Aims and Objectives 
The main aim of this thesis is to describe the patterns and impact of comorbidity in axial 
spondyloarthritis using real-world patient populations. This body of work will approach 
comorbidity as a count (‘comorbidity burden’) and individual conditions to understand how 
they contribute to disease severity and treatment response. Three distinct populations – 
each with unique strengths and limitations – will be used to answer specific objectives and 
results from one data source will be validated in another where possible. 
The objectives were to: 
1. To describe the prevalence and patterns of comorbidities in axSpA and examine 
whether they differ between AS and nr-axSpA. 
2. To investigate whether and how comorbidities co-occur among people with axSpA 
and whether these patient ‘clusters’ are associated with axSpA disease severity. 
3. To determine whether comorbidities influence axSpA disease severity and compare 
whether these indices are differentially affected. 
4. To examine whether baseline comorbidity burden is associated with response to 
TNF inhibitors. 
As the thesis evolved, analyses addressing the above objectives repeatedly pointed to 
mental health conditions as a prevalent and important comorbidity. Thus, an additional 
objective was added: 




Chapter 3: Methods 
 
This chapter describes the study populations that will be use and how their data were 
collected and prepared for analyses. The main statistical methods used in this thesis will 
also be described. 
 
3.1 Study populations 
Three axSpA datasets were used for this thesis. The Aintree and Boston axSpA studies used 
cross-sectional data obtained from routine tertiary healthcare records. The British Society 
for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) was a 
nationwide longitudinal pharmacovigilance study, recruiting from secondary and tertiary 
rheumatology centres across the UK. The next three sections (3.2 to 3.4) describe the 
population context for each study, their study designs, and methods used to prepare the 
data for analyses. Section 3.5 introduces the common statistical methods used. 
 
3.2 Aintree axial spondyloarthritis registry 
3.2.1 Local population  
Liverpool is a city in the North West of England with a population of 466,000 according to 
the most recent (2011) census [154]. It is a relatively young population; nearly half are aged 
16 to 44 compared with 39% nationally. Only 14% of the overall population are of Black, 
Asian, and Minority Ethnicities, which is less diverse than figures for England and Wales 
(19%). Residents, particularly in the North of the city (where Aintree hospital is located), are 
predominantly White. 
Liverpool was the fourth most deprived local authority in England in 2015 [155]. Nearly half 
of the city is in the national top 10% most deprived areas, which are concentrated in the 
North (Figure 3.1). Twenty-two percent have university or higher degree qualifications and 
29% have no qualifications, compared to 27% and 23%, respectively, for England and 
Wales. Deprivation is also reflected in the population’s general health; Liverpool has lower 
levels of self-reported good health and higher levels of self-reported bad health than the 
national average (Figure 3.2). One third of the population have at least one morbidity and 
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15% have multimorbidity [155]. The 2016-2018 life expectancy estimates for Liverpool 
(males 76 years, females 80 years) were approximately 3 years lower than the national 
average [154]. 
 
Figure 3. 1: Map showing relative deprivation in Liverpool, using the post-code-based 
Index of Multiple Deprivation. 
 
Aintree University Hospital (blue) and Royal Liverpool and Broadgreen University Hospitals 




Figure 3. 2: Self-reported level of general health in Liverpool from the 2011 UK census. 
 
Data from the 2011 UK census [154]. 
 
3.2.2 Health provision and the Aintree University Hospital spondyloarthritis service 
There are two large university teaching hospitals in Liverpool that are in the process of 
merging (at the time of writing) to form ‘Liverpool University Hospitals’. Aintree University 
Hospital mainly serves the North Liverpool population from 3 Clinical Commissioning 
Groups (CCGs): Liverpool, Knowsley, and Sefton. The Royal Liverpool and Broadgreen 
University Hospital sites (Figure 3.1) serve Central and South Liverpool, although coverage 
by these hospitals overlap significantly. 
Aintree University Hospital hosts the main academic rheumatology centre in Merseyside 
and provides the only specialist spondyloarthritis service in Liverpool. Most Aintree axSpA 
patients come from North Liverpool. AxSpA patients from other parts of the region are 
predominantly managed in general rheumatology clinics of nearby hospitals. The specialist 
SpA service also accepts referrals (e.g., complex cases) from other parts of the region. At 
Aintree, almost all SpA patients are eventually seen in the specialist spondyloarthritis 

















Very good Good Fair Bad Very bad
Liverpool England & Wales
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At the first clinic visit, new patients complete a set of questionnaires, undergo a detailed 
clinical history and examination, followed by relevant investigations such as serum 
inflammatory makers and imaging. Questionnaires used in the clinic are for routine care 
purposes only, to assess disease activity and facilitate clinical assessment (e.g., BASDAI, 
BASFI, health-related quality of life). Clinical assessment is semi-structured including, for 
example, SpA features from classification criteria, past medical history, and social history 
(smoking status, pack-years, and alcohol status). Once a diagnosis of SpA is made or 
confirmed, patients are followed-up annually at a minimum. Axial SpA patients are 
generally seen in the dedicated axSpA clinic, which includes parallel reviews by a 
physiotherapist. Patients also have access to hydrotherapy as indicated. 
3.2.3 Electronic Health Records (EHRs) 
At the time of writing, the Aintree site uses a combined electronic health record (EHR) 
system. Medway Sigma (System C Healthcare) was introduced in 2009 including 10 years of 
backdated patient records. This system holds:  
1) Patient identifiable information,  
2) Text-documents of dictated clinic letters,  
3) EDMS (Engineering Document Management System) of scanned hand-written (in- 
and outpatient) clinical notes,  
4) Results of investigation such as blood tests and imaging reports, and  
5) Integrated PACS (Picture Archiving and Communication System) images.  
There is a separate electronic prescription system (predominantly used for inpatient care), 
which was not used for this study as outpatient medication were not consistently captured. 
Medication data were instead extracted from clinical letters and notes. 
3.2.4 Study design 
The Aintree axSpA registry was created by the thesis author with ethical approval granted 
by the National Research Ethics Committee in August 2015 (15/LO/1519). Individual patient 
consent was not required for this study. Active data collection continued to April 2018, and 
the study was formally ended in May 2020 to allow completion of analyses. It was a cross-
sectional observational study of consecutive axSpA patients at their first contact with the 
specialist SpA service (i.e., retrospective inception population). The registry held pseudo-




Although all types of SpA are seen in the specialist service, only physician diagnosed axSpA 
patients were eligible for inclusion into the study. Patients were required to be adults (≥18 
years) fulfilling the ASAS criteria for axial SpA or modified New York criteria for AS [15, 16]. 
PsA patients with axial involvement were also included if they met these criteria. Existing 
patients who did not have records of their baseline visit (e.g., pre-EHR coverage) were 
excluded. 
3.2.4.2 Representativeness 
As discussed above, a small minority of patients are referred from regions outside of North 
Liverpool; these patients may have more complex disease on average. It is also possible 
that patients on stable conservative management (e.g., NSAIDs only) are more likely to stop 
attending clinic. Patients who became lost to follow-up before 2015 would not have been 
included in the study, which could bias the sample toward more severe cases. Both 
instances are likely to be rare. Aintree’s annual report records a population of 330 thousand 
[156]; therefore 600 cases would give a prevalence of 0.18%, which is similar to the 
prevalence estimated for European (0.19% [29]). Of note, there is a significant proportion 
of patients who are only managed in primary care, to whom this study’s conclusions may 
not apply. In Scotland, two-thirds of all axSpA patients are managed in primary care only 
[157]. 
3.2.4.3 Data collection 
Each patient’s baseline (i.e., first clinic assessment) data were entered into the registry by 
two means: 1) prospective entry of consecutive new patients attending the SpA service, 
and 2) retrospective entry of consecutive follow-up-review patients, which increased the 
efficiency of patient accrual. The baseline visit was not necessarily when the diagnosis was 
made. For example, newly referred patients may have managed their axSpA for many years 
in the community or by other centres. Conversely, patients may not be diagnosed until 
after a series of assessments. 
Data were obtained by manual review of each patient’s electronic health records, 
predominantly clinic letters (by rheumatology physicians and specialist nurses), scanned 
notes, and investigation results. To improve accuracy and validity, collection of each 
variable was checked in duplicate by two trained medical (Master of Research) students. 
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Any discrepancies were resolved through discussion. The data collection process is 
summarised in Figure 3.3. 
 
Figure 3. 3: Summary of data collection for the Aintree axial spondyloarthritis registry. 
 
 
For each consecutive patient attending the Aintree SpA service, three components of 
electronic health records were manually reviewed by the thesis author. All variables were 
validated by a trained medical student (duplicated extraction). Only patients who had 
records of their baseline assessment were eligible (e.g., follow-up patients whose baseline 
assessment predated available electronic records would not be eligible). Two patients, who 
had records missing all relevant components of clinical letters and notes, were excluded. 
No record was kept of the number of individuals failing to meet eligibility criteria, but the 
SpA service was estimated to have served 600 patients from 2014 to 2018, inclusive. BMI, 
body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hx, history; 





Box 3.1 shows the variables collected for each patient. In addition to basic demographics, 
socioeconomic status was approximated using Index of Multiple Deprivation (IMD) based 
on post-codes of England [158]. Decile 1 relates to the top 10% most deprived areas whilst 
decile 10 represents the least deprived areas. Height and weight were measured for each 
patient, from which body mass index (BMI) was calculated as weight (in kilograms) divided 
by height (metres) squared. 
 
Box 3. 1: Variables collected in the Aintree axSpA registry, organised into four linked 
datasets. 
1) Basic and demographic information 
• Age (at baseline, i.e., first clinic visit), gender, age at symptom onset, age at 
diagnosis, Index of Multiple Deprivation. 
• Clinical diagnosis, HLA-B27 status, CRP (mg/L), ESR (mm/hr) 
• Imagining (i.e., radiographic sacroiliitis, positive MRI) 
2) Detailed clinical history: 
• Peripheral joint involvement, uveitis, psoriasis, inflammatory bowel disease 
• Body mass index (BMI) 
• Medications 
• Smoking, pack-years; Alcohol, units/week; Illicit drug use 
3) Comorbidities (see Box 3.2) 
4) Questionnaire data: 
• BASDAI, Spinal pain, BASFI (described in Chapter 1) 
• EQ5D 3-level version [159]. Responses were converted into a single index value, 
which reflects the health state is according to the preferences of the UK general (1 
for ‘best health state’, and 0 for ‘worst health state equalling death’) 
• Fatigue visual analogue scale (VAS): How would you describe the level of 
fatigue/tiredness you have experienced in the past week? (0: no fatigue, 100: worst 
fatigue ever experienced) 
• Global health VAS: How would you describe your general state of health today? (0: 
best imaginable heath state, 100: worst imaginable health state) 
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The semi-structured clinical assessment routinely recorded age at symptom onset, CRP, 
ESR, and SpA features (Chapter 1, Box 1.2, page 35) as they are pivotal for diagnosis and 
classification. HLA-B27 was not always tested, for example, when the clinical picture was 
highly indicative of a diagnosis. All medications were recorded from clinic letters and 
confirmed against GP referral documents where available. Only summary-level results for 
imaging investigations were collected for the study, i.e., presence of radiographic sacroiliitis 
or bone marrow oedema without grading or further description.  
Routine clinic questionnaires were scanned into EDMS. Numerical rating scale (i.e., integers 
from 1 to 10) version of the BASDAI, spinal pain and BASFI were used. In addition, patients 
completed the 3-level version of the descriptive EQ-5D (i.e., without the visual analogue 
scale, EQ5D-VAS), and single questions on fatigue and general health. No additional 
questionnaires were given to patients specifically for the study. Data were stored in a 
Microsoft Access relational database, with the four datasets linked by a unique study 
identification number. 
3.2.4.4 Comorbidity ascertainment 
There are several indices commonly used to measure comorbidity burden. Among them, 
the multimorbidity index (MMI) by Radner et al [148] was selected for use in assessing 
comorbidities in this study for the following reasons: 1) it assesses the largest number of 
conditions, 2) it is unweighted and 3) it has been validated in patients with rheumatic 
diseases against health-related quality of life [148]. Weighted indices such as the Charlson 
[149] and Elixhauser [150] indices were validated for inpatients and mortality or inpatient-
related outcomes. They are less suitable for chronic diseases predominantly managed in 
outpatient settings. The rheumatic disease comorbidity index (RDCI) - although validated in 
rheumatic diseases - is also weighted and only includes 11 conditions [147]. 
Further adaptations to the original MMI were made for the Aintree axSpA registry, with 
discussion involving senior academic rheumatologists. Extra-articular manifestations - 
inflammatory bowel disease and psoriasis - were excluded. ‘Painful conditions’ was 
changed to fibromyalgia. Osteoporosis was added because of its importance in chronic 
rheumatic musculoskeletal diseases. The final list of 39 comorbidities is shown in Box 3.2. 
Body mass index (BMI) was systematically measured in all patients. Given this differential 
ascertainment of obesity (compared to other comorbidities) and the greater amount of 
information held by BMI as a continuous variable (compared to obesity), obesity was not 




Box 3. 2: List of 39 comorbidities in the Aintree axial spondyloarthritis registry. 
• Alcohol problems • COPD • Glaucoma • Peripheral vascular 
disease 




• Hearing loss • Prostate disorders 
• Anxiety and other 
neuroses 
• Constipation • Heart failure • Psychoactive 
substance misuse 
• Asthma • Coronary heart 
disease 
• Hypertension • Schizophrenia or 
bipolar 
• Atrial fibrillation • Dementia • Irritable bowel 
syndrome (IBS) 
• Stroke or TIA 
• Blind or low vision • Depression • Learning 
disability 
• Thyroid disorders 
• Bronchiectasis • Diabetes 
mellitus 
• Migraine • Viral hepatitis 
• Cancer • Diverticular 
disease 
• Multiple sclerosis • Fibromyalgia 
• Chronic kidney 
disease 
• Dyspepsia • Obesity • Osteoporosis 
• Chronic liver 
disease 




Comorbidity list based on the multimorbidity index (MMI) [148] with modifications 






Presence of each comorbidity was sought from each patient’s clinical records. The 
‘diagnosis’ list in each rheumatology clinic letter was the main source of comorbidity 
information. This was supported by GP records, which were provided in most referral 
documents. Some comorbidities were assumed to be present if the patient’s medication 
were highly suggestive of an underlying condition (Table 3.1). 
 
Table 3. 1: Comorbidities assumed to be present if history and medications were 
suggestive of the condition. 
Condition Suggestive medication 
Hypertension Prescribed anti-hypertensives in the absence of kidney or heart 
disease 
Dyspepsia Prescribed proton pump inhibitors or H2 receptor blockers in 
the absence of glucocorticoids or NSAIDs 
Coronary heart 
disease 
Prescribed antianginals (e.g. nitrates) or secondary prophylaxis 
combinations (e.g., statin, antiplatelet and beta-blocker/ACE 
inhibitor) in the absence of other indications. 
Diabetes Prescribed oral hypoglycaemics or insulin. 
Irritable bowel 
syndrome (IBS) 
Prescribed mebeverine in the absence of other intestinal 
diseases 
Constipation Prescribed laxatives without gastroenteric diseases such as 
chronic liver disease or IBS. 
Depression  Prescribed selective serotonin reuptake inhibitors, serotonin 
and norepinephrine reuptake inhibitors, or tricyclics in the 
absence of any neuropsychiatric conditions or chronic pain. 
Fibromyalgia  Prescribed duloxetine, pregabalin or gabapentin in the absence 
of neuropsychiatric conditions or neuropathic pain. 
Other psychoactive 
substance misuse 
Includes documented use of cannabis. 
Alcohol problems Includes documented weekly alcohol use of ≥50 units for men 
or ≥35 units for women. These thresholds are defined by UK 





3.2.4.5 Sample size considerations 
Sample size calculations are subtly different when describing data without invoking 
hypothesis testing, but nevertheless relevant for precision (i.e., standard error). The 
primary aim of the Aintree axSpA study was to describe the prevalence of comorbidities. 





Where p is the proportion (or prevalence), and N is the sample size. The 95% confidence 
interval (i.e., alpha=0.05) is p±1.96*SE. A correction (±0.5/N) is made for using a normal 
approximation for a discrete distribution, i.e., 95% CI = p±1.96*SE±0.5/N. The relationship 
between prevalence, sample size and precision are illustrated in Table 3.2; sufficient 
precision is where the ‘margin of error’ is smaller than the prevalence estimate. For 
example, a sample size of >1000 is required to provide sufficient precision (i.e., margin of 
error <0.5%) for a comorbidity with 0.5% prevalence.  
However, sample size is often not a decision in many observational studies; examples 
include secondary analysis of existing registries, or when the available patient population 
imposes a ceiling of sample size. Instead, investigators are recommended to estimate 
whether there is sufficient power (or in this case precision) to pursue their analysis, given 
the sample size [161]. 
Using the above described method of case identification, a sample of 421 axSpA patients 
was achieved at the time of analysis. This would allow conditions with >1.2% prevalence to 
be estimated with sufficient precision. It was therefore anticipated that 1) confidence 
intervals for the population prevalence estimate would include zero for rarer conditions, 
and 2) rarer comorbidities are likely to have zero cases in this study. In a study of RA using 
the same list of comorbidities, a sample size of 876 was able to capture at least one case of 
all but one comorbidity [148]. 
A once popular practice is to calculate post hoc power of an analysis. This is simply an 
alternative way of expressing the p-value and provides no additional information [162]. 
Instead, each chapter will begin by estimating whether there is sufficient power given the 




Table 3. 2: Relationship between sample size and precision for different prevalence 
estimates. 











10% 100 3.0% 0.5% 6.4% 3.6% 16.4% 
500 1.3% 0.1% 2.7% 7.3% 12.7% 
1000 0.9% 0.1% 1.9% 8.1% 11.9% 
5% 100 2.2% 0.5% 4.8% 0.2% 9.8% 
500 1.0% 0.1% 2.0% 3.0% 7.0% 
1000 0.7% 0.1% 1.4% 3.6% 6.4% 
1% 100 1.0% 0.5% 2.5% <0% 3.5% 
500 0.4% 0.1% 1.0% 0.0% 2.0% 
1000 0.3% 0.1% 0.7% 0.3% 1.7% 
0.5% 100 0.7% 0.5% 1.9% <0% 2.4% 
500 0.3% 0.1% 0.7% <0% 1.2% 
1000 0.2% 0.1% 0.5% 0.0% 1.0% 
0.1% 100 0.3% 0.5% 1.1% <0% 1.2% 
500 0.1% 0.1% 0.4% <0% 0.5% 
1000 0.1% 0.1% 0.2% <0% 0.3% 
P, proportion/prevalence; N, sample size; SE, standard error; 95% confidence interval = 





3.3 Boston axial spondyloarthritis study (Massachusetts, USA) 
3.3.1 Local population 
Boston is the capital of the state of Massachusetts, United States (US), with a population of 
695 thousand according to the 2018 census [163]. It is also the centre of the larger 
metropolitan area known as Greater Boston which, depending on the geographic definition, 
is home to 5 to 8 million people (Figure 3.4). Like Liverpool, the Boston population is 
relatively young, with half the population between 20 and 49 years of age. However, 
Boston has significantly greater ethnic diversity (44% white, 22% black, 20% Hispanic and 
9% Asian) and higher educational attainment (51% with university or higher degrees). 
 
Figure 3. 4: Boston city within Greater Boston. 
 
The Brigham and Women’s Hospital (blue) and Massachusetts General Hospital (green) 




There are no metrics of socioeconomic status equivalent to the UK’s Index of Multiple 
Deprivation. The Greater Boston area has the 6th largest economy in the US and 12th largest 
in the world (by 2008 estimates [164]). But there is great disparity in wealth [165]; 18% of 
Boston residents live below the poverty line (defined as minimum necessary to meet the 
basic needs of a family unit), compared to 10% for the state of Massachusetts. 
3.3.2 Health provision 
3.3.2.1 Healthcare in the United States (US) 
Unlike the UK’s NHS, healthcare facilities in the US are predominantly run by private sector 
businesses. A single clinic visit can cost several hundred dollars and an average three-day 
inpatient stay may cost tens of thousands of dollars depending on the type of care needed. 
Most Americans access healthcare through insurance, paid either privately or by their 
employer, to reduce such costs. The US government also provides state-managed, low-cost, 
public insurance: Medicare is eligible to people over the age of 65, disabled adults and 
those with end-stage renal disease. Medicaid provides health insurance to those who 
cannot afford it, to children in lower-income families, and sometimes to the disabled.  
The insurance premium is not the only cost; there are also deductibles (analogous to the 
‘excess’ in UK insurance), co-insurance (a proportion that individuals have to pay alongside 
the insurer), and/or ‘co-pays’ (co-payments; a fixed-amount payment each time care is 
accessed), the amount of each varies with different insurance policies. Furthermore, not all 
insurance plans cover all aspects of care; for example, until the Affordable Care Act 
(‘Obamacare’) in 2010 that standardised essential care, some plans did not cover 
prescriptions or non-emergency services. Not all plans provide access to all providers; that 
is, insurers may give access to certain physicians, hospitals, pharmacies, networks, etc., 
while another may not. These factors mean that there is great disparity in who can, or 
chooses to, access certain health services. 
3.3.2.2 Healthcare in Boston 
Partners HealthCare is a not-for-profit conglomerate of over 20 hospitals and primary care 
centres in the Greater Boston area. Around 1.5 million patients are seen each year in 
Partners hospitals [166]. It was founded in 1994 by two large tertiary care hospitals, the 
Brigham and Women’s Hospital and Massachusetts General Hospital (Figure 3.4). Both are 
academic tertiary hospitals affiliated with Harvard Medical School. Together, they run the 
largest hospital-based research program in the world. 
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There are around 30 rheumatologists in the Brigham and Women’s hospital, among whom 
SpA patients are dispersed. Although there is no dedicated SpA service, some 
rheumatologists do have it as a sub-specialty interest.  
The American College of Rheumatology guidance for axSpA management resembles those 
from the UK and Europe, but there are differences in routine practice. First, uptake of the 
term ‘axial spondyloarthritis’ (first defined by predominantly European researchers) came 
much later. Until March 2019 (when the first biologic was licenced for non-radiographic 
axSpA in the US), many continued to exclusively use ‘ankylosing spondylitis’. This is partly 
because the billing code system (International Classification of Diseases, ICD) was not 
updated to include axSpA until version 11 (to come into effect in 2022), and partly because 
of concerns in distinguishing non-radiographic axSpA from other differentials (namely 
fibromyalgia). Second, access to biologic drugs are at the discretion of the rheumatologist 
and the patient’s insurer. Unlike the UK (and much of Europe), there are no criteria 
required to commence or continue biologic therapy. Thus, many outcome measures, such 
as BASDAI or ASDAS, are not recorded. in the Partners’ electronic health records, the only 
consistently recorded patient-reported outcome is the pain visual analogue scale, which 
patients complete in the waiting room. 
3.3.3 Electronic Health Records (EHRs) and the Research Patient Data Registry 
(RPDR) 
 
Use of EHR started in 1996 for Brigham and Women’s Hospital and 1994 for Massachusetts 
General Hospital. An internally developed Longitudinal Medical Record (LMR) system was 
initially used. This was superseded by EHR from Epic Systems in 2015. This system provides 
a single platform where all aspects of healthcare records (e.g., prescriptions, clinic letters, 
investigation results) are entered and accessed. Together, LMR and Epic EHR have 
facilitated care for approximately 7 million patients. 
Partners HealthCare also has a Research Patient Data Registry (RPDR) – a centralised clinical 
data registry that gathers information from EHR and other hospital systems, as well as 
existing research data (Figure 3.5). 
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Figure 3. 5: The Research Patient Data Registry (RPDR). 
  




RPDR is not an inherent component of the Epic EHR. It is an online, self-service system that 
allows registered users to, for example, identify patients for clinical trials or audit care 
provision. It also controls and audits access to patient data for research, thereby ensuring 
security of patient information. The RPDR can be used to: 1) obtain aggregate numbers (i.e., 
no individual-level data) of patients that meet user-defined criteria (e.g., diagnosis, 
medication, investigations) to help assess study feasibility, without institute review board 
(IRB) approval, and 2) request detailed identifiable patient records from the 
aforementioned searches, but only with an IRB approved study protocol. 
3.3.4 Study design 
The Boston axSpA study was set up by the thesis author. The Partners HealthCare 
Institutional Review Board approved all aspects of this study (2018P001840/PHS) in August 
2018. Individual patient consent was not required. All data processing and analyses were 
completed in November 2018 and IRB approval ended in August 2020. It was a cross-
sectional observational study of axSpA patients identified from Partners EHR. Requests for 
data from all Partners sites were submitted to, and processed by, the RPDR. Patient data 
were identifiable (via unique hospital number and date of birth) and were stored and 
processed on secure drives held at the Division of Rheumatology, Immunology and Allergy, 
Brigham and Women’s Hospital.  
3.3.4.1 Eligibility  
The Partners EHR contains over 7 million patient-records. A feasible approach of identifying 
axSpA patients among this number was therefore necessary. There is no dedicated Partners 
SpA service from which potentially eligible patients could be identified. It was also not 
possible to restrict records to rheumatology departments. Potentially eligible patients were 
identified from the entirety of Partners EHR using automated searches in RPDR.  
Since the prevalence of axSpA was expected to be low (0.2 to 0.5% [167]), a search strategy 
with high specificity (at costs to sensitivity) was necessary to make subsequent manual 
review feasible. For example, using published criteria (at least 1 ICD code for AS [168]) 
returned tens of thousands of records with low prevalence of true axSpA. More stringent 
search criteria were therefore developed. Aggregate data provided by RPDR facilitated an 
iterative process to refine the search strategy. Ultimately, the search combined ICD codes 
with a simple text-search of radiology reports: ≥3 ICD-9 or 10 codes for AS (720.x or M45.x) 
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≥7 days apart and string-text mention of ‘sacroiliitis’, ‘ankylosis’ or ‘syndesmophyte’ 
(whether present or absent) in radiology reports, including plain X-rays, MRIs or CT scans. 
This created a population with higher prevalence of cases, which was then manually 
reviewed. Each adult (≥18 years of age) fulfilling classification criteria were eligible for the 
study. Patients with a clinical diagnosis of axSpA were classified as AS if they fulfilled the 
modified New York criteria [169], and as nr-axSpA if they fulfilled ASAS criteria for axSpA 
[170] but not the modified New York criteria.  
Since this was primarily a clinical rather than research cohort, investigations required for 
classification were not always available; for example, when patients attend with a 
previously established diagnosis. This was particularly true for imaging data. Patients 
incompletely fulfilling classification criteria were labelled as ‘Probable’ AS if they had 
imaging pathology consistent with AS (e.g. ankylosis of the vertebrae or sacroiliac joint 
fusion) on plain-film radiographs, CT or MRI; patients with less definitive changes on 
CT/MRI (e.g. sacroiliac joint sclerosis/irregularity) were labelled as ‘Probable’ nr-axSpA. 
Both Definite (fulfilling full criteria) and Probable cases of AS and nr-axSpA were eligible for 
inclusion. Patients with a clinical diagnosis of axSpA upon manual medical record review but 
no supportive imaging evidence or medical notes, and those with ICD codes but no formal 
clinical diagnosis of axSpA, were excluded. A flow-chart of the case selection process is 
shown in Figure 3.6. 
During the cohort development process, a probabilistic method of case-identification was 
developed using Natural Language Processing (i.e., of free-text records). These algorithms 
were able to identify a larger number of patients without imposing the strict eligibility 





Figure 3. 6: Classification process for axSpA patients. 
 
Severity of sacroiliitis was determined using a combination of radiology reports and scoring 
by a trained rheumatologist. Both Definite and Probable cases (in green) were included, 
while cases with insufficient/no evidence (in red) were not. ASAS: Assessment of 
Spondyloarthritis International Society; NY: New York; SIJ: sacroiliac joint; nr-axSpA: non-




The Boston cohort may differ in representability for several reasons. First, there is great 
disparity in wealth and access to healthcare. Patients with underlying axSpA may not 
present to healthcare services, or decline referral to rheumatology recommended by, for 
example, physiotherapists or primary care clinicians. AxSpA patients without insurance or 
those with plans that do not cover relevant tests, referrals, or treatments (i.e., those from 
lower socioeconomic groups), are unlikely to be represented unless they are eligible for 
Medicaid. In a similar Partners study of rheumatoid arthritis, 96% of the cohort were white 
[148], which does not reflect the local diversity. Second, the Partners group includes two 
large tertiary academic hospitals but also over 20 affiliated primary care centres. The latter 
may provide better representation of the general axSpA population in theory. However, in 
practice, most records came from rheumatology departments of the two academic 
hospitals. Third, the way in which eligibility was defined will likely restrict the study to 
patients with longer disease duration or more severe disease. 
3.3.4.3 Data collection 
Records of potentially eligible patient from all historical encounters with Partners 
HealthCare were downloaded, including in- and outpatient records, medication/pharmacy 
records, laboratory results (HLA-B27, ESR and CRP) and radiology reports. Records include 
all free-text documents and coded data (e.g., ICD and prescription codes); scanned records 
were not included. Patients’ unique identifiers were used to access their records on Epic 
EHR where review of radiological images was required. A summary of the data processing is 








An automated search was performed (using criteria adapted to balanced positive predictive 
value and feasibility) to identify 965 individuals with high probability of having axSpA. Their 
records were then manually reviewed by the thesis author (without validation) to assess 
eligibility (defined by classification criteria). 190 individuals were excluded because they did 
not have a clearly documented physician diagnosis of axSpA (thus classification criteria not 
applicable) or did not meet classification criteria. Imaging definitions were adapted (e.g., 
accepting ankylosis on CT); these individuals were labelled as partial or ‘Probable’ cases. 
ASAS, Assessment of SpondyloArthritis international Society; AS, ankylosing spondylitis; 
axSpA, axial spondyloarthritis; EHR, electronic health records; ICD-9, International 





To determine eligibility, data relevant to AS and axSpA classification criteria were manually 
extracted from all available free-text records prior to the date of the latest clinical record 
for each patient (i.e., the index date). Coded EHR data (e.g., medication) were also 
extracted from all historical data. Exceptions to this included ICD codes for comorbidity, 
smoking status, pain score and CRP/ESR results, which were extracted from the 1-year 
period prior to the index date (Figure 3.8). Smoking status was assumed as current and non-
current based on the presence of ICD codes for smoking. All ICD codes used for this study 
are shown in Appendix Table S3.1. A summary of variables collected are shown in Box 3.3. 
Data were stored in Microsoft Excel spreadsheets. 
 
Figure 3. 8: Time ranges from which data were obtained from electronic health records 
for the Boston axSpA study.  
 
All variables, whether by manual review or coded data, were obtained from all historical 
records prior to the date of the last clinic visit. The exceptions were comorbidity ICD codes, 
smoking status, pain score and inflammatory markers, which were from one year prior to 






3.3.4.4 Comorbidity ascertainment 
The same list of 39 comorbidities in were used for this study. In order to include only 
chronic and ongoing conditions, ICD codes within a year prior to the index date were 
extracted. The presence of one ICD code in this period was used to define presence of a 
comorbidity. The full list of ICD codes used for each of the 39 conditions are shown in the 
Appendix (Table S3.1). 
There are well-described limitations of using claims data for epidemiological research. One 
consideration at the time of data collection was the window in which to collect comorbidity 
ICD codes. Possible approaches included using: 1) all available historical codes, 2) codes 
within a defined window, or 3) codes in the most recent encounter. Prior studies in support 
of each approach were linked to specific comparisons and outcomes of interest that related 
poorly to the aims of this study [172,173]. We chose the above approach because 1) it was 
used to develop the MMI [148] and 2) preliminary trials using all historical codes led to 
Box 3. 3: Variables collected in the Boston study. 
Variables from manual review: 
• Relevant pathological findings from sacroiliac joint and/or spine radiograph, 
CT, MRI. 
• Onset <45 years, uveitis, psoriasis, inflammatory bowel disease (IBD), 
peripheral arthritis, enthesitis, dactylitis, response to NSAIDs, HLA-B27 status and 
family history (of AS, psoriasis, uveitis, reactive arthritis or IBD). 
Variables from coded EHR data: 
• Age at index date, gender, BMI, smoking status 
• HLA-B27, ESR, CRP 
• Pain VAS 
• Comorbidities in Box 4.4; psoriasis, IBD. 
• Medication: biologic DMARDs (Adalimumab, Etanercept, Infliximab, 
Golimumab, Certolizumab pegol, Secukinumab, Ustekinumab), conventional 
synthetic DMARDs (Sulfasalazine, Methotrexate, Leflunomide), NSAIDs (Ibuprofen, 




unrealistic prevalence estimates. For example, one prior episode of self-limited reactive 
depression, or irritable bowel syndrome that was included in a list of differential diagnoses 
several years before the index date, should not be included as a chronic comorbidity. The 
duration of available historical records would also vary between individuals and differ in a 
manner that risks introducing bias. 
3.3.4.5 Sample size considerations 
Sample size considerations mirror those of the Aintree axSpA study (Section 3.2.4.5). The 
required sample size to provide sufficiently precise prevalence estimates for most 
comorbidities (i.e., those with prevalence >0.5%) was 1000. However, identifying cases 
from such a large data source required an approach that had different limitations on 
sample size. Less restrictive criteria for identifying potentially eligible patients returned 
samples that were not feasible to manually review. For example, using one ICD code for AS 
returned over 10,000 cases with less than 10% having AS. The maximum prevalence that 
could be estimated with sufficient precision was 0.5%. It was again anticipated that rarer 









The British Society for Rheumatology (BSR), along with pharmaceutical partners and the 
University of Manchester, set up the first nationwide biologics register in 2001 when these 
therapies became available for the management of rheumatoid arthritis (RA). This registry 
provided a wealth of safety data for TNF inhibitors, which were subsequently licensed for 
treatment of axSpA. Transferring observed safety data to the axSpA population is 
problematic given the older age, higher comorbidity burden and concurrent csDMARD use 
in RA patients. The BSRBR-AS was therefore created to test the hypothesis that biologic 
therapy increases the risk of serious infections (i.e., those requiring hospitalisation or 
death). Secondary objectives of the BSRBR-AS were to examine the relationship between 
biologic therapy and incidence of malignancy, serious comorbidity, all-cause mortality, and 
impact on quality of life. 
The BSRBR-AS was set up by the University of Aberdeen as a five-year prospective 
pharmacovigilance study across the UK (Figure 3.9). Recruitment began in December 2012. 
Initially, the study recruited only patients who met classification criteria for AS. This was 
amended to include those fulfilling classification criteria for axSpA (i.e., to include nr-axSpA) 
in November 2014 [15,16]. The study population was recruited into two cohorts: 1) a 
‘biologic’ groups: participants newly exposed to an eligible biologic drug, and 2) a ‘non-
biologic’ group: participants unexposed to these therapies. The sample size was updated 
after the first year of study recruitment to reflect the number of serious adverse events 
reported; the study set out to recruit approximately 2000 participants. The final dataset of 





Figure 3. 9: Recruitment sites cross the UK for the BSRBR-AS.  
 
Colours indicate the number of participants per site as of 2017. (Used with permission from 
the BSRBR-AS newsletter.) 
 
3.4.2 Study design 
The BSRBR-AS was a prospective cohort study. Ethical approval was obtained from the 
National Research Ethics Committee (11/NE/0374) and written informed consent was 
obtained from all participants. Applications were made to the BSR to perform secondary 
analyses relating to comorbidities. Once approved, data were securely transferred, stored, 
and analysed on University of Liverpool computers. 
107 
 
3.4.2.1 Eligibility  
Inclusion and exclusion criteria are summarised in Box 3.4 and in the published protocol 
[14]. Potentially eligible patients were identified by participating hospitals and first 
informed about the study prior to their rheumatology clinic appointment by means of a 
letter from their consultant. Patients were then invited to take part upon clinic attendance 
and provided written informed consent if they accepted participation. 
 
Box 3. 4: Eligibility criteria for the British Society for Rheumatology Biologics Register for 
Ankylosing Spondylitis (BSRBR-AS) 
Inclusion: 
• Meeting either modified New York [48] or ASAS (imaging or clinical arm) 
classification criteria [174] 
• Age ≥16 
• Willing to give consent 
Exclusion: 
• Previously treated with biologic therapy 
• Unable to give consent 
• Unable to communicate in English 
• Starting biologic therapy which was not one of the following: Adalimumab 
(Humira), Etanercept (Enbrel or Benepali), Certolizumab pegol (Cimzia) 
 
3.4.2.2 Representativeness 
Participants were consecutively recruited from secondary and tertiary hospitals across 
England, Scotland, and Wales. This should provide a broad and nationally representative 
cohort of hospital axSpA patients. There are a number of caveats. It is likely that healthier 
patients in higher socioeconomic categories were more likely to consent to participate. 
Hospitals with the highest number of recruits tended to be tertiary centres or those with a 
specialist SpA service, which may bias towards more complex patients. Lastly, recruitment 
was stratified into two arms with a pre-determined ratio; while each arm may represent 
biologic treated and naïve patients (at 35:65 respectively), the overall sample may not 




3.4.2.3 Data collection 
Each participant was posted a set of questionnaires that collected information summarised 
in Table 3.3. A reminder letter and phone call or email were sent if necessary.  
 
Table 3. 3: Variables collected at baseline and follow-up in the BSRBR-AS that were 
requested for this thesis. 
 Baseline Follow-up 
 
Visit date ✓ ✓ 
Cohort indicator ✓  
Date of birth, gender, year of symptom onset, year first 
seen by a rheumatologist, BMI, Index of Multiple 
Deprivation 
✓  
AS and axSpA classification criteria components, 
including imaging, HLA-B27, SpA features 
✓  
bDMARD (name, start date, dose, stop date, reason for 
stopping) 
✓ ✓ 
NSAID and csDMARD use in the past 6 months ✓  
Uveitis, IBD, psoriasis confirmed physician diagnoses ✓ ✓ 
Peripheral articular involvement, dactylitis, enthesitis in 
the past 6 months 
✓ ✓ 
CRP, ESR, BASMI (date of measurement) ✓ ✓ 
Comorbidities: myocardial infarction, unstable angina, 
congestive cardiac failure, stroke, hypertension, diabetes, 
asthma, chronic bronchitis/emphysema (i.e., chronic 
obstructive pulmonary disease, COPD), peptic ulcer, liver 
disease, renal disease, tuberculosis, demyelination, 
depression and cancer. 
✓ ✓ 
 
Questionnaire date ✓ ✓ 
Smoking (status, frequency, cigarettes/day), alcohol 
status, education 
✓ ✓ 
BASDAI (including components), spinal pain, BASFI, 
patient global, BASG, AS quality of life questionnaire, 
EQ5D-5L, EQ5D-VAS, Chalder Fatigue Scale, Jenkins Sleep 
Evaluation Questionnaire, Hospital Anxiety and 
Depression Scale 
✓ ✓ 
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; BMI, body mass index; bDMARD, 
biologic DMARDs; csDMARD, conventional synthetic DMARDs; IBD, inflammatory bowel 


































Follow-up started at bDMARD commencement (which was not necessarily the baseline 
questionnaire date). For the biologic group, per protocol assessments were at 0, 3, 6, 12 
months and annually thereafter. The non-biologic group underwent annual assessments. 
Additional clinic visits and questionnaires were possible. When participants in the non-
biologic group started biologics, they were switched to the biologic group; that is, they 
contributed follow-up time to both cohorts. Discontinuation of biologics did not change 
their assigned group. At each follow-up, clinical (extracted from medical records) and self-
reported data (from questionnaires) were collected (Table 3.3). Socioeconomic status was 
approximated using post-code derived Index of Multiple Deprivation (IMD) for each country 
of the UK, with quintile 1 representing the top 20% most deprived areas and quintile 5 the 
least [17, 18].  
3.4.2.4 Comorbidity ascertainment 
Participating centres extracted physician-diagnosed comorbidity data from medical records. 
The source of this information was predominantly from patient-reported past medical 
history, supported by GP records, where available. The list of 14 comorbidities included in 
the BSRBR-AS registry are shown in Box 3.5. These conditions were selected through a 
consensus meeting of clinicians and researchers, based on commonly recorded 
comorbidities in routine practice. 
 
The registry protocol specified 15 comorbidities. There was some uncertainty between 
angina (which is categorised with ischaemic heart disease) and unstable angina (which is 
grouped with myocardial infarction as acute coronary syndrome) during the data entering 
process. Therefore, for this thesis, myocardial infarction and (unstable) angina were 
Box 3. 5: List of 14 comorbidities recorded in the British Society for 
Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) registry. 
1. Ischaemic heart disease 
2. Heart failure 
3. Stroke  
4. Hypertension 
5. Diabetes mellitus 
6. Asthma 
7. Chronic obstructive pulmonary disease 
(COPD) 
8. Peptic ulcer disease 
9. Liver disease 
10. Renal disease 








combined as ischaemic heart disease. The BSRBR-AS also assessed fibromyalgia using the 
survey criteria [175]. It was not included as a comorbidity in this thesis because 1) a 
different method of ascertainment was used, and 2) data were collected only from 
September 2015 onwards. 
3.4.2.5 Follow-up outcomes 
All indices used in the thesis are commonly referred to as ‘outcome measures’ in existing 
literature. This has potential to introduce ambiguity by implying longitudinal design, which 
is particularly relevant since the BSRBR-AS data were used in both cross-sectional and 
longitudinal analyses. To avoid the use of ‘outcome’ in cross-sectional designs, indices were 
referred to as measures of disease severity, including a subset that specifically measure 
disease activity (i.e., BASDAI, spinal pain, ASDAS, ESR, CRP). 
A summary of longitudinal outcome measures collected at each follow-up time point is 
summarised in Table 3.3 above. This section briefly summarises the properties of some 
indices that will be used in the thesis but were not previously described in Chapter 1. 
3.4.2.5.1 Hospital Anxiety and Depression Score (HADS) 
The Hospital Anxiety and Depression Score (HADS) was created to assess symptoms of 
anxiety and depression in a general medical population [176,177]. It comprises 14 
questions, 7 each for the anxiety and depression sub-scales; each item is scored from 0 to 
3, to give each sub-scale score a possible range from 0 (none) to 21 (indicating severe 
symptoms). Its strength includes the parallel assessment of both conditions, which 
commonly coexist. It excludes questions relating to somatic symptoms that may confound 
the diagnosis in hospital populations with physical illnesses. Additional details are provided 
in Chapter 7 – the only data analysis chapter that use the HADS. 
3.4.2.5.2 Jenkins Sleep Evaluation Questionnaire 
The Jenkins Sleep Evaluation Questionnaire comprises 4 questions, each scored 0 to 5. The 
total score ranges from 0 to 20 with higher scores indicating poorer sleep [178]. 
3.4.2.5.3 Chalder Fatigue Scale 
The Chalder Fatigue Scale comprises 11 questions scored 0 to 3. It ranges from 0 to 33 with 
higher scores indicating greater levels of fatigue [179]. 
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3.4.2.5.4 AS quality of life questionnaire 
The AS quality of life questionnaire (ASQoL) has 18 questions with the total score ranging 
from 0 to 18; higher scores indicate poorer health-related quality of life [180]. 
3.4.2.6 Sample size considerations 
Sample size for the BSRBR-AS was calculated to power the primary analysis - comparing the 
risks of serious infections using time-to-event analysis [181]. Investigators estimated the 
baseline risk of serious infection as 1.6 cases per 100 person-years and set out to detect a 
Hazard Ratio of 2 in the biologic cohort compared to the non-biologic cohort (i.e., event 
rate of 3.2 per 100 person-years), at a ratio of 35 biologic to every 65 non-biologic 
participants. This required 1184 and 2216 person-years of observation in the biologic and 
non-biologic cohorts respectively which, according to the protocol [181], could be provided 
by at least 720 and 1300 participants in each cohort. Power implications of this pre-
determined sample size were analysis-specific and discussed in respective chapters. 
3.4.3 Preparing data for analysis 
3.4.3.1 Assembling data files 
Data collection for the Aintree and Boston studies were informed by specific aims in this 
thesis. In contrast, the BSRBR-AS was created for a broad research agenda that did not 
include the research questions raised in this thesis. This is apparent from, for example, the 
comorbid conditions that were collected. Data collation from questionnaires and dataset 
generation were performed by other researchers, which, although to an incredibly high 
standard, was not tailored for analyses in this thesis. This section summarises the data 
structure and relevant assumptions made during general data cleaning. Details of data 
processing are summarised in Appendix 10.2.1. 
Data from clinic visits and questionnaires were each stored separately, contents of which 
are shown above in Table 3.3. The visit file was separated into 1) bDMARD data to create a 
‘treatment timeline’ (described in the next section), 2) outcome-related data (ESR, CRP, 
BASMI), and 3) baseline characteristics. Each questionnaire file was divided into 1) patient-
reported outcome measures and 2) data relating to smoking, alcohol, and education. This 
then allowed time-varying data from visit and questionnaire files to be combined (Figure 
3.10). For analyses of treatment response, the treatment timeline was used to inform 




Figure 3. 10: Preparation of the analysis file from data files provided by the BSRBR-AS. 
 
 
Assessments were rarely performed at exact per protocol time-points (Figure 3.11). 
Individuals could also contribute data (questionnaires or visits) in addition to the follow-up 
schedule. Questionnaires were not necessarily completed on the day of the clinic 
assessment. For each time-point, the assessment nearest to the protocol schedule was 
chosen; for example, if a participant completed questionnaires at months 10 and 13, and 
attended clinic at months 11 and 12.5, only the month 13 questionnaire and month 12.5 
visit were retained. Keeping data processing and analyses consistent with the protocol 
schedule helps to reduce bias [161] and improve assessment and handling of missing data 
[182].For example, a participant with one assessment at month 3 is likely different from 
another with numerous additional clinic visits around the same time (i.e., the number of 





Figure 3. 11: Categorisation of follow-up assessments for the BSRBR-AS registry. 
 
Questionnaires and clinic visits nearest to the per protocol schedule within the above 
windows were retained for longitudinal analyses. Time 0, or the baseline, was defined 
differently for analyses of treatment response (as date of treatment initiation date) and 
non-biologic participants (as baseline visit). 
 
 
Definition of the baseline (time 0 in the above figure) differed according to whether cross-
sectional or longitudinal analyses were performed. For longitudinal analyses of treatment 
response, baseline was defined as the date of biologic initiation. This date was not always 
the same as the ‘baseline visit’ as intended in the protocol due to delayed treatment 
initiation (e.g., delivery issues, holidays, illness, or personal preference). Baseline 
inflammatory markers and patient-reported outcomes were only included for analysis if 
within one year prior to and seven days after the treatment start date. These windows 
were chosen on the assumption that 1) on average, the disease remains relatively stable 
pre-treatment and 2) treatment response typically becomes apparent after one week and 
demonstrable by week 2 in trials [60,183]. Other non-time-varying variables in the visit 
(e.g., comorbidities, extra-articular manifestations) and questionnaire files (e.g., education) 
were taken from one year before or after the baseline. 
In cross-sectional analyses, ‘baseline’ was defined as per protocol for the non-biologic 
cohort and outcome measures from one year before or after the baseline were eligible, 
since they were not influenced by treatment. 
3.4.3.2 The treatment timeline 
Longitudinal analyses of treatment response required a clear definition of the treatment 
timeline, such that only assessments within the treatment period were considered. For 
example, if a participant permanently stopped treatment at month 6, his/her 9-month 
outcomes would not be considered. This is particularly relevant when separating response 
to different treatment courses. For this thesis, only data relating to the first TNF inhibitor 
were analysed. This decision was taken because 1) baseline data were most consistently 
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complete for the first drug (the follow-up schedule does not change with biologic switch, 
thus switch could be between two annual or longer assessments), and 2) it is not valid to 
combine treatment response in treatment-naïve and -experienced patients, since response 
is known to differ between them. 
Each participant’s biologic treatment history was provided in ‘wide’ format; that is, each 
individual had one row of data, with details of their first, second, third TNF inhibitor, etc., 
listed across the same row. This was converted to ‘long’ format; that is, each individual had 
multiple rows, each row corresponds to a new treatment course. A pause in treatment of 
>3 months (e.g., for a prolonged infection) was considered as treatment discontinuation, 
but a shorter duration was not. Switch to biosimilars (e.g., Enbrel to Benepali) or dose 
changes were not considered change in treatment; for example, an individual with one row 
for Enbrel and the next for Benepali would have a combined course of etanercept.  
3.4.3.3 Preparing and consolidating existing variables 
Once data files were assembled, further data processing and validation were performed. 
Some SpA features (uveitis, IBD and psoriasis) were recorded twice: once as components of 
eligibility/classification criteria, and again in the targeted medical history. The latter were 
physician-confirmed diagnoses specifically relating to the prior 6 months. These duplicates 
did not always match. If participants had physician-confirmed diagnoses, they were also 
assumed to fulfil the corresponding ASAS criteria components. HLA-B27 status was also 
recorded twice: as part of the ASAS criteria, and from the genetics sub-study. Positivity was 
defined as a positive result from either variable; there were no conflicts regarding positive 
and negative results from the two variables. Peripheral joint involvement and enthesitis 
were assumed to be present if swollen joint and enthesitis count, respectively, were 
recorded as >0. 
3.4.3.4 Exclusions 
Eligibility for the analysis population were unique to each analysis and will be described in 
respective chapters. For example, the cross-sectional design of Chapter 5 included all 
participants who had a valid assessment, which is defined differently for those who start 
bDMARDs and those who do not. Chapters 6 and 7 included only participants who start on 




Figure 3. 12: Summary of exclusions used for BSRBR-AS analyses. 
 
bDMARD, biologic disease modifying antirheumatic drugs; PROMs, patient-reported 




This section describes the common statistical methods used throughout the thesis, 
including basic descriptive statistics, linear and generalise linear regression, and 
longitudinal analyses (time-to-event and repeated measures). All datasets were imported 
into Stata version 13 (College Station, TX). 
3.5.1 Analysis approach 
Statistical approaches can be broadly considered to serve one of three purposes: 
description, prediction, or causal inference [184]. Description provides a quantitative 
summary of the data, ranging in complexity from mean/median to cluster analysis. 
Prediction links input to output, for example, correlation coefficients or ‘machine learning’ 
methods such as neural networks. Not all predictors are, or need to be, causative factors – 
factors that change the outcome if modified. Distinguishing causation from association has 
become an increasing focus for the data sciences [185]. Causal inference differs from 
prediction in that it requires expert knowledge to specify the question, relevant data 
sources and the underlying causal structure. The thesis follows the prevailing school of 
thought that causation can only be claimed for exposures that can be manipulated under a 
(hypothetical) experiment (‘no causation without manipulation’). Although analyses in this 
thesis were carefully considered, comorbidity status generally cannot be manipulated; 
therefore, conclusions should not be interpreted as strictly causal. Further discussions are 
provided in respective chapters. 
Regardless of the confidence with which causation can be claimed, this thesis focused on 
inference between comorbidities and outcomes. Thus, coefficients for other variables in 
multivariable models were not presented. This avoids the ‘Table 2 fallacy’ – derived from 
the practice of presenting effect estimates for all independent variables in ‘Table 2’ [186]. 
Many journals actively forbid this approach [187], since observed associations between 
these covariates and the outcome are not part of a priori aims, do not undergo 
consideration for confounding, and are thus subject to bias. Throughout this thesis, results 
– particularly from regression models – were presented primarily as graphs of effect 
estimates or predicted values to facilitate interpretation. Raw model outputs, including 




3.5.2 Exposure and outcome definitions 
The main ‘exposure’ or independent variable of interest in this thesis was comorbidity. For 
descriptive purposes, results for individual conditions and total count were presented. 
Chapter 2 showed that comorbidity could be included in different forms in regression 
modelling. Since each has strengths and limitations, all variable types were used where 
possible: 
1. Binary variable (i.e., presence or absence of comorbidity) provides results that are 
the simplest to interpret but has limited amount of information; 
2. Continuous variable captures more information, but assumes a linear relationship 
with the outcome; 
3. Categorical variable allows examination of the linear assumption. However, very 
few patients have high comorbidity count, thus necessitating grouping of higher 
counts (e.g., into 0, 1, 2 and ≥3 comorbidities); 
4. Comorbidities can also be examined as individual conditions, which provides 
granular information but at the cost of statistical power (e.g., due to the high 
number of comparisons and the low prevalence of some comorbidities) 
In longitudinal analyses, treatment response can be assessed using various definitions of 
change from baseline. Methodology research (that was performed in parallel but not 
included in the thesis) demonstrated the potential for very different conclusions to be 
drawn using different definitions [41,42]. For chapters on treatment response, three 
approaches were therefore used: 
1. Binary response at a specified time point. This is the commonest response 
definition used by existing studies and clinical trials. They fall into two categories 
that are described in the next section: a fixed reduction (e.g., 50% reduction in 
BASDAI) or a disease state (e.g., ASDAS inactive disease). There are many well-
described methodological issues with binary outcomes [188]. For example, binary 
response thresholds are harder to achieve for individuals with higher baseline 
disease activity. Adjustment for the baseline disease activity is necessary, but 
introduces bias [41]. However, binary outcomes are favoured for their ease of 
interpretation for clinicians and patients alike. Patients may also care more about 
achieving a certain disease state (e.g., ‘inactive disease’) rather than other outcome 
definitions. They are included in this thesis predominantly for consistency and 
comparability with existing literature. 
118 
 
2. Continuous response or absolute change from baseline over follow-up. The 
simplest approach is to measure change from baseline at a fixed time point, but 
assessing continuous change in repeated assessments over time is more 
informative and statistically efficient. 
3. Time to treatment discontinuation. This outcome is commonly used with real-world 
(particularly administrative claims) data where disease severity indices are often 
not available. It is, in effect, a composite outcome that captures ineffectiveness, 
intolerance, but also factors unrelated to treatment/disease (e.g., social 
circumstances, not attending follow-up). Data relating to causes of discontinuation 
were limited in the BSRBR-AS as shown in previous work [189] and discussed in 
greater detail in the relevant chapters. 
As alluded to above, there are a wide range of binary outcomes in widespread use. For this 
thesis, four binary outcomes were chosen: 
1. BASDAI 50/2: 50% or 2-units reduction in BASDAI from baseline. This outcome is 
used in routine clinical practice in the UK to determine response and eligibility to 
continue treatment [190]. 
2. BASDAI<4: This has been used to define ‘low disease activity’, deduced from the 
fact that BASDAI≥4 was defined as high disease activity for early trials of TNFi (and 
therefore implemented in policy), although the cut-off was not evidence-based and 
has never been validated. 
3. ASDAS major improvement (ASDAS-MI): ≥2-unit reduction in ASDAS. 
4. ASDAS<2.1: a validated threshold indicating ‘low disease activity’ (Chapter 1). 
BASDAI was chosen for its direct relevance to UK clinical practice, and ASDAS for its 
relevance to continental Europe. Clinical trial outcomes such as ASAS40 (≥40% 
improvement and an absolute improvement from baseline of ≥2 units in ≥3 of the following 
domains: back pain, patient global, BASFI and inflammation without any worsening in the 
remaining domain) were deliberately excluded because they were not designed for use in 
observational data. 
3.5.3 Descriptive statistics 
Throughout the thesis, simple descriptive statistics (Table 3.4) were used to describe and 
compare the appropriate types of data. It is common for analysts to apply statistical tests 
for ‘normality’ of a continuous variable’s distribution (e.g., Kolmogorov-Smirnov or 
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skewness-kurtosis tests). These tests are over-sensitive, particularly when sample sizes are 
large. Whether distributions were normally distributed - for the purposes of descriptive 
statistics (as well as for linear model residuals, see later) - was decided using visual 
inspection of kernel density plots juxtaposed against a normal distribution. 
 
Table 3. 4: Simple descriptive statistical tests used in the thesis. 






Chi-squared. Fisher’s exact when expected value of 
any cell is ≤5. Non-parametric test for trend when 

















3.5.4 Generalised linear regression models 
A simple regression model describes the relationship between a dependent variable, y, and 
an independent variable, x. In its simplest form, the association between two continuous 
variables are modelled. The regression line formula is yi = β0+ β1xi+Ɛi, where β1 gives the 
slope of the regression line, i.e., the change in y for one-unit change in x. The intercept, β0, 
is the value of y when x is zero. Due to potentially broad range of unmeasured 
determinants, y varies for any given value of x, which is combined in an error term Ɛ or 
‘residual’. The relationship between y and x are assumed to be linear, not unduly influenced 
by outliers, and correctly specified (i.e., model adequate) [191]. The model residuals and 
assumptions were tested for each linear model in this thesis, but not shown. 
The above simple linear regression model can be extended to a linear combination of 
multiple covariates – a multivariable model: yi = β0+ β1x1+ β2x2+…+ βpxp+Ɛi, where x 
represents a collection of p variables (x1, x2, … xp). Coefficient β1 is the change in y for one-
unit increase in x1, holding all other variables in the model constant. 
Linear models can be generalised to accommodate other outcome variable types; for 
example, logistic models for binary outcomes. In the logistic model, the log-odds of the 
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outcome is linearly related to x: log [
𝑃(𝑥)
1−𝑃(𝑥)
] = β0+ β1x. Exponentiating β1 gives the odds 
ratio associated with one-unit increase in x. Generalisation to multiple predictors is the 
same as for linear models. Unlike ordinal least square in linear models, logistic models use 
maximum likelihood to estimate parameters; that is, parameter are estimated to maximise 
the likelihood (or joint probability) for the observed data under the chosen model. Models 
were examined for adequacy (Hosmer-Lemeshow test), influential datapoints, and linearity 
(between log-odds and x) [191]. 
3.5.6 Mixed effects models and GEE (Generalised Estimating Equations) 
All tests and models discussed so far assume independent (i.e., non-clustered) data. When 
comparing effects of treatment on BASDAI over repeated follow-ups, each participant’s 
follow-up BASDAI would be related to values at the baseline and other time points. 
Different methods are required for such analyses. A brief summary of their principles 
relevant to this thesis are discussed here. 
Linear mixed effects (also known as random effects or multilevel) models accommodate 
non-independent data and, more importantly, examine effects between and within 
individuals. They differ from simple linear models in the way which variance (error) is 
partitioned. Each cluster, in this case each patient over time, can be given their own 




Figure 3. 13: Linear mixed models. 
 
 
Demonstration of three approaches to modelling repeated BASDAI of eight patients over 
time: simple linear model combining data points from all 8 patients (top); allowing different 
starting BASDAI (random intercept) for each patient assuming change overtime is constant 
(middle); or allowing different starting and change in BASDAI, i.e., random intercept and 
random slope (bottom). 
 
 
Generalised estimating equations (GEE) are also commonly used for repeated measure 
analyses. The syntax in Stata is not dissimilar to mixed models. However, there are key 
differences. Mixed models provide conditional estimates, or individual effects (hence 






      β0j = β0+uj  
Random intercept and slope 
yij=β0j+β1jxij+Ɛij 
      β0j = β0+u0j  




population and both have identical covariate values, the person with one comorbidity 
would have an outcome value which is, on average, β units higher’. GEE assess marginal 
effects, that is, population-level effects or ‘average change in outcome per unit change in 
exposure’. Results from marginal and conditional models coincide for continuous 
outcomes, but not necessarily for binary and time-to-event outcomes. Thus, marginal 
estimates should not be used to make inferences about individuals under these 
circumstances. For context, randomised controlled trials assess marginal effects (and so do 
observational emulations thereof [161], e.g., using inverse-probability weighting).  
GEE is robust against misspecification of the correlation structure (discussed in greater 
detail in Appendix 10.2.2). However, GEE requires stronger assumptions about missing data 
(Missing Completely At Random) than mixed models (Missing At Random) (Section 3.5.8) 
[192]. Marginal structural models (discussed in Chapter 7) can only be used with GEE. 
3.5.6.1 Interpretation of interaction terms  
For both mixed models and GEE, difference over time between ‘exposure’ groups were 
compared using interaction terms between the group and time. Clarifying the 
interpretation for interaction terms is essential for understanding the results. There is a not 
uncommon misconception that interaction terms are not required, and that the coefficient 
for the ‘exposure’ (i.e., here the dependent variable comorbidity) represents the difference 
in longitudinal change (e.g., as applied in reference [193]). The following explains why this is 
incorrect. Take for example the output shown in Table 3.5 when modelling BASDAI 
(repeated over time) against comorbidity (as binary) and follow-up time (as categorical). 
(For simplicity covariates are omitted; when they are included later in the results, 




Table 3. 5: Example output from mixed model with BASDAI as the outcome to explain the 
interpretation of interaction terms. 
 Coefficient 95% CI 





3.FU -2.20 (-2.42 to -1.98) 
6.FU -2.71 (-2.94 to -2.48) 
12.FU -2.65 (-2.90 to -2.41) 
24.FU -2.76 (-3.08 to -2.44) 
36.FU -3.03 (-3.48 to -2.57) 
Comorbidity present (no 
comorbidity as reference) 
0.50 (0.17 to 0.82) 
Interaction 
terms (month 
0 and no 
comorbidity 
omitted) 
3.FU#Comorbidity 0.37 (-0.02 to 0.76) 
6.FU#Comorbidity 0.22 (-0.18 to 0.62) 
12.FU#Comorbidity 0.05 (-0.38 to 0.48) 
24.FU#Comorbidity -0.21 (-0.75 to 0.32) 
36.FU#Comorbidity 0.45 (-0.26 to 1.16) 
FU, follow-up at numbered month. #, interaction term. 
 
Figure 3. 14: Demonstration of how coefficients from a mixed model with interaction terms 












On the left, Table 3.5 results are plotted as 5.38 vs. 5.88 (=5.38+0.50) at month 0, and 3.18 
(=5.38-2.20) vs. 4.05 (=3.18+0.50+0.37) at month 3. The right shows that this is analogous 
to comparing differences after balancing the baseline. 
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The mean BASDAI at baseline is 5.38 (the constant) in those without comorbidities; that is, 
when the follow-up time indicator and comorbidity both take the value of 0. Those with 
comorbidities have 0.50-units higher BASDAI (coefficient for comorbidity) when the follow-
up takes the value of 0. For those without comorbidities, month 3 BASDAI falls by a mean of 
2.20-units from baseline (month 3 coefficient). Those with comorbidities have 0.87 
(=0.37+0.50)-unit higher BASDAI at month 3 (interaction coefficient plus baseline 
difference). Note that the baseline difference in disease activity (0.50) is incorporated into 
the difference at month 3, thus the interaction term coefficient indicates the difference in 
change from baseline between groups at each follow-up; in this example, the difference 
(0.37) was not statistically significant (see below). Additional ‘adjustment’ for the baseline 
value is therefore not necessary. (This approach also avoids the causal conundrum of 
baseline adjustment). Had the model not used interaction terms, the two groups’ 
trajectories would be parallel, with the coefficient for comorbidity simply representing the 
baseline difference (carried over time). 
To make interpretation easier, predicted values (using -marginsplot- command in Stata) are 
shown graphically (Figure 3.14, left panel), with asterisks indicating statistical significance of 
the interaction term at the p<0.05 level. Note that statistical significance here does not 
relate to the difference between the two predicted values at month 3 (4.05 and 3.18), 
rather it is the departure from the baseline difference, or ‘difference accounting for the 
baseline’ (Figure 3.14, right panel). 
3.5.7 Survival analysis 
Survival analysis accounts for whether the event occurred as well as time to event (e.g., 
treatment discontinuation). Survival analysis allows ‘right-censored’ data (when follow-up is 
stopped before the event occurs) to be included in analyses. The probability of remaining 
event-free at time t (i.e., the survival function, S(t)) is estimated using the Kaplan-Meier 
estimator. The Kaplan-Meier curve ‘drops’ at observed event times and is flat in the 
intervening period. Curves can be compared using the log-rank test, that tests the 
hypothesis that the survival distribution is equal at all times. 
S(t) is related to the hazard function, h(t), which is the short-term event rate for individuals 
who have not yet experienced the outcome event. The hazard ratio HR(t) is simply a ratio of 
h(t) between two groups. In their simplest form, proportional hazards models assume that 
the hazard ratio does not vary with time, i.e., HR(t)=HR. In these models, the linear 
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predictor is linked through log-transformation to the HR: log[HR(x)] = log [
ℎ(𝑡|𝑥)
ℎ0(𝑡)
] = βx, 
where h(t|x) is the hazard at time t for an observation with predictor value x, and h0(t) is 
the baseline hazard (hazard at time t with predictor at zero). This equation solves to: 
log[h(t|x)] = log[h0(t)] + βx, where log[h0(t)] is analogous to the intercept in linear 
models. This log-linear model implies that the log of the hazard changes linearly with each 
unit change in x. The Cox proportional hazards model was used in this thesis. There are 
many other approaches, including pooled logistic regression (used with marginal structural 
models, described in Chapter 7). 
Four main diagnostics were performed for each Cox model: model specification, outliers, 
log-linearity, and proportional hazards [191]. For model specification, Cox-Snell residuals 
(compared to the cumulative hazard) were used to examine model fit. For log-linearity, 
higher-order forms of each variable (polynomials) were added to assess model 
improvement. Proportional hazards were tested by inspecting the Kaplan-Meier estimator 
and Schoenfeld residuals. Where covariates violated the proportional hazards assumption, 
the variable was stratified (using the -strata()- option of the -stcox- command in Stata); i.e., 
allowing equal coefficients across strata but with a baseline hazard unique to each stratum. 
3.5.8 Missing data and multiple imputation 
Missing data are problematic because most statistical analyses require a value for each 
variable. The simplest and commonest approach is to analyse only the cases with complete 
data; individuals with data missing on any variable are excluded. This can reduce the 
sample size, power, and introduce bias. Types of missing data can be considered according 






Complete case analysis with MCAR data produces the same result had there been no 
missing; this is true of cross-sectional or longitudinal data. MAR data can be imputed based 
on, or weighted to be represented by, observed data to provide unbiased estimates. In 
longitudinal data, complete case analysis with MAR data can introduce bias when using 
with some approaches (GEE) but not others (mixed models). MNAR is particularly 
problematic and requires sophisticated methods that are beyond the scope of this thesis. 
Complete case analysis in GEE/mixed models – used throughout this thesis – do not ‘drop’ 
individuals who do not have complete follow-up at all time points. No imputation was 
performed for longitudinal analyses. The only exception was when deriving inverse-
probability of censoring weights, where the derivation procedure creates a row of data for 
each person-month (Chapter 7). Values of time-varying variables were carried forward until 
the next available time point. 
The proportion of missing for each relevant variable is described in respective chapters. All 
primary analyses used complete case only. Sensitivity analysis using multiple imputation 
was performed for each regression model that used cross-sectional data; only clinically 
meaningful differences were reported. Models for inverse-probability weights used MICE 
by default. Multiple imputation by chained equations (-mi- command in Stata) handles 
MAR/MCAR data by creating multiple copies of the dataset (30 used in this thesis) and 
using the distribution of the observed data and relationships with ‘auxiliary variables’ to 
impute missing values (i.e., using them to predict the missing values) of each variable in 
Box 3.6. Missing data mechanisms. 
Missing Completely at Random (MCAR): the propensity for missingness is completely 
random; i.e., there is no relationship between whether a data point is missing and any 
values in the dataset (missing or observed). 
Missing at Random (MAR): systematic relationship between the propensity for 
missingness and the observed data (but not the missing data); i.e., missingness can be 
made random by conditioning on certain observed variables. 
Missing Not at Random (MNAR): missingness that is explained by the missing data. For 
example, missing disease activity data after loss of treatment response because 




turn. Outcome regression was performed on all 30 datasets and combined. Using multiple 
imputed values reflect the uncertainty around the true value. All covariates in the model of 
interest were used as auxiliary variables (i.e., variables that are correlated or believed to be 
associated with missingness). 
 
3.6 Summary 
Data used in this thesis were derived from three sources: 
• Aintree axSpA registry: cross-sectional data from routine clinical records and 
questionnaires, from 2010 to 2018. This tertiary care dataset included rich and 
validated comorbidities (39 diseases derived from multiple sources of data by 
manual review). 
• Boston axSpA study: cross-sectional data from electronic health records extracted 
by manual review and using coded data, from 2001 to 2018. This was one of the 
biggest axSpA cohorts in the US at the time of creation. The same list of 39 
comorbidities were derived from ICD codes. 
• BSRBR-AS: a longitudinal pharmacovigilance study from 2012 to 2017. It contained 
a wealth of outcomes data for biologic treated and biologic naïve axSpA 
participants, which allowed examination of treatment response. The list of 15 
comorbidities were already collected by the study and provided for secondary 
analysis for this thesis. 




Chapters and Aims Dataset used 
Aintree Boston BSRBR-AS 
Chapter 4: Comorbidities in radiographic vs. non-
radiographic axSpA and clustering of comorbidities in 
axial spondyloarthritis 
• To describe prevalence of comorbidities among the 
Boston and Aintree axSpA cohorts. 
• To compare the prevalence and patterns of 
comorbidities between AS and nr-axSpA patients, 
separately in each of the two populations.  
• To describe axSpA patients according to clusters of 
comorbidities in the Aintree cohort, and validate 
results using the Boston data. 
• To examine whether comorbidity clusters are 
associated with axSpA disease severity using the 
Aintree cohort. 
   
Chapter 5: Comorbidities and disease severity  
• To compare whether measures of disease activity 
(BASDAI, spinal pain, ASDAS) and inflammation 
(CRP/ESR) are differentially influenced by 
comorbidities. 
• To replicate these comparisons for other important 
measures of disease severity (fatigue, function, and 
health-related quality of life).  
• To examine whether the patient global component of 
ASDAS is influenced by comorbidities independent of 
the other components. 
  Cross-
sectional 
Chapter 6: Comorbidities and response to TNF inhibitors 
• To examine the association between baseline 
comorbidity status and binary response definitions 
among those using TNFi. 
• To examine the association between baseline 
comorbidity status absolute change in disease activity 
(BASDAI, spinal pain, ASDAS) and other measures of 
disease severity. 
• To examine the association between baseline 
comorbidity status and TNFi discontinuation. 
  Longitudinal 
Chapter 7: Mental health and response to TNF inhibitors 
• To describe correlations between depression 
diagnosis and symptom. 
• To examine the association between history of 
depression at baseline and response to TNFi. 
• To examine the association between baseline 
symptoms of depression or anxiety and response to 
TNFi. 





Chapter 4: Comorbidities in radiographic vs. non-radiographic 
axSpA and clustering of comorbidities in axial 
spondyloarthritis 
 
This chapter describes the prevalence and pattern of comorbidities and compares them 
between radiographic (i.e., ankylosing spondylitis) and non-radiographic axial 
spondyloarthritis, using cross-sectional data from both the Aintree and Boston studies. The 
same datasets were used to examine how comorbidities co-occur and whether axSpA 
disease severity differs between these patient-clusters. 
 
4.1 Introduction 
AS and non-radiographic axSpA (nr-axSpA) have similar symptom burdens and clinical 
features [56,57]. AS cohorts differ from their nr-axSpA counterparts in being older, more 
frequently male and having higher levels of CRP [56,57]. Each of these factors can influence 
the likelihood of developing comorbidities; for example, comorbidity burden generally 
increases with age, while some conditions are unique to (e.g., prostate disorders), or are 
much more prevalent in, one gender (osteoporosis in females) [140]. Systemic 
inflammation is also a risk factor for many comorbidities, e.g., cardiovascular diseases 
[141]. Whether comorbidities differ between AS and nr-axSpA groups has not been 
examined. Characterising their respective comorbidity burden is important since it is 
associated with several adverse disease outcomes [142]. 
Prior studies of comorbidities have either examined individual conditions or comorbidity 
count, which does not account for relationships between diseases (e.g., between 
hypertension and cardiovascular disease). This chapter addresses this gap in the literature 
using cluster analysis. Cluster analysis is a set of exploratory statistical techniques that can 
be used to describe which comorbidities commonly co-occur. It also helps identify patient-
groups with disease clusters most associated with disease activity and other outcome 
measures, who may benefit from additional intervention. 
Cross-sectional data from two tertiary centres in Boston (USA) and Aintree (UK), that differ 
in both socioeconomic context and clinical approaches, will be used to complement each 
other in all analyses. The Results section will begin with a description of comorbidity 




1. To describe prevalence of comorbidities among the Boston and Aintree axSpA 
cohorts. 
2. To compare the prevalence and patterns of comorbidities between AS and nr-
axSpA patients, separately in each of the two populations. 
3. To describe axSpA patients according to clusters of comorbidities in the Aintree 
cohort, and validate results using the Boston data. 
4. To examine whether comorbidity clusters are associated with axSpA disease 
severity using the Aintree cohort. 
4.3 Methods 
4.3.1 Patient populations 
4.3.1.1 Boston axial spondyloarthritis study 
The Boston axSpA data was extracted from electronic health records (EHR) specifically to 
address Aim 2 of this chapter. Its sample size is larger than the Aintree study (n=775 vs. 
n=419); therefore, the primary analyses for Aim 2 focus on the Boston data (for which 
power calculations were performed), with the Aintree data serving to validate the results. 
The Boston study holds data on a list of 39 comorbidities (see Chapter 3 Box 3.2, page 88), 
selected according to their importance to general health, i.e., without assumptions of what 
might be relevant for axSpA. The accuracy of ICD codes in any study using EHR is a potential 
limitation, but is unlikely to differ systematically between AS and nr-axSpA groups. 
4.3.1.2 Aintree axial spondyloarthritis study 
The Aintree axSpA cohort included the same list of 39 comorbidities. Obesity was 
systematically assessed (all patients were weighed and measured), which makes its 
ascertainment different from all other comorbidities. The Aintree study has more reliable 
comorbidity data (from several data sources, cross-checked against medication), in contrast 
to ICD codes only which were used in the Boston study. It also included a broad selection of 
disease severity measures relevant to routine practice: axSpA-specific indices (BASDAI, 
spinal pain, BASFI), ESR, CRP, health-related quality of life (3-level version of EuroQol, 
EQ5D-3L), global health, and fatigue (see Chapter 3, Box 3.1, page 85). These unique 
strengths make the Aintree data well-suited for Aims 3 and 4. By contrast, the Boston data 
only include pain assessment in half of the population. 
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The two datasets could not be merged for this Chapter due to fundamental differences in 
which the data were collected. The BSRBR-AS is not suitable for cluster analysis due to the 
small number of comorbidities recorded (Chapter 3 box 3.5, page 107),  
4.3.2 Definition of AS and nr-axSpA 
Definitions of AS and nr-axSpA in the Boston data were detailed in Chapter 3 (page 98). In 
brief, the Boston EHR did not always include imaging data required by the modified New 
York or ASAS classification criteria. Individuals partially fulfilling these criteria (e.g., 
sacroiliitis on CT where radiographs were not available) were also included. By contrast, 
prescribing regulations in the UK require complete assessment of classification criteria 
components; therefore, AS was defined using the modified New York criteria in the Aintree 
data, and nr-axSpA defined by meeting the ASAS but not the modified New York criteria. 
4.3.3 Statistics 
Simple descriptive statistics were used to compare patient characteristics and comorbidities 
between AS and nr-axSpA groups. Mean, rather than median, comorbidity count was 
compared; comparison of median and interquartile range (IQR) provides limited 
information with zero-inflated counts (e.g., median of 1 (IQR 0 to 2) vs. 1 (IQR 0 to 2)). 
Prevalence of individual comorbidities were compared using Fisher’s exact test. Prevalence 
were displayed as juxtaposing bar-charts to facilitate interpretation. No corrections were 
made for multiple comparisons, since many comorbidities co-occur and comparisons were 
not independent. 
4.3.3.1 Cluster analysis 
For the cluster analysis, obesity was removed from the list of 39 comorbidities for two 
reasons: 1) BMI was systematically recorded thus ascertainment of this comorbidity 
differed from all other conditions, and 2) BMI was included in regression models as a 
continuous variable, which holds more information than a dichotomised variable. 
Cluster analysis generates groups of individuals according to their ‘similarity’ with respect 
to selected variables, in this case comorbidities. Many different approaches, and 
combinations thereof, are available [194]. It has been described by some as an 
‘unsupervised machine learning’ method, implying input (or ‘supervision’) from domain 
experts is not necessary. However, selection of the analysis method and interpretation of 
the output both require clinical insight, as discussed below. 
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There are many ways to define ‘similarity’. One example is correlation: one can calculate 
correlation coefficients for each of the many pairs of variables, where sizes of the 
coefficient indicates the degree of similarity. Doing so with comorbidities presents two 
problems: first, comorbidities are binary variables (either present or absent in this data); 
second, patients can ‘correlate’ according to absence of comorbidities. A more appropriate 
similarity measure is the Jaccard coefficient [194]. It is conceptually simple (Figure 4.1), 
suitable for binary variables, and does not lend weight to negative matches. Once the 
similarity measure is chosen, different clustering algorithms are available, for example, 
single, complete or average linkage. The latter is the most commonly used for its desirable 
properties (Figure 4.2). 
 
Figure 4. 1: Principle of the Jaccard coefficient. 
 
 Disease A absent (0) Disease A present (1) 
Disease B absent (0) M00 M10 
Disease B present (1) M01 M11 


























Cluster analysis can be hierarchical or non-hierarchical. The former is more exploratory, 
while the latter pre-specifies the number of clusters to find when analysts have reason to 
assume an underlying data structure. The graphical output of hierarchical cluster analyses is 
like branches of a (upside down) tree, or ‘dendrogram’ (Figure 4.3). Hierarchical clustering 
can be agglomerative or divisive; the former starts with individual patients and successively 
clusters them until the final group contains all patients, while the latter starts with one 
cluster and separate individuals according to their ‘dis-similarity’. Whether using the top-
down or bottom-up approach, the analyst needs to decide at what level of similarity to 
create clusters; ‘cutting’ the branches near the top will provide fewer clusters and the 
bottom more (Figure 4.3). The decision can be made according to which makes the most 
clinical sense or is the most practical (e.g., avoiding hundreds of small clusters or clusters 
with very few individuals). It can also be based on a more objective measure. Several 
statistics are available to determine the ‘optimum’ number of clusters for separation in the 
Stata software; the default is the pseudo-F statistic. 
 
Single linkage: minimum distance; sensitive to 
outliers and can form clusters where observations 
between clusters are closer together than within 
clusters. 
 
Complete linkage: maximum distance; less 
sensitive to outliers but forms tight clusters that 
are resistant to merging. 
 
Average linkage: average of all pairwise distances; 




Figure 4. 3: Example of tree ‘dendrogram’ from hierarchical cluster analysis. 
 
 
‘Cutting’ branches at different levels of similarity will produce different numbers of clusters. 
 
Agglomerative hierarchical analysis was chosen to match the explorative nature of Aim 3, 
using Jaccard similarity coefficient and average linkage. The optimum number of clusters 
was determined by the pseudo-F statistic [195]. All prevalent conditions in this cohort were 
included in the cluster analysis. Small clusters (less than 5 patients) were combined for 
description and regression. Patient characteristics of, and dominant comorbidities in, each 
cluster were then described. 
4.3.3.1.1 Validating clusters 
A common practice when using ‘machine learning’ methods (including cluster analysis) is to 
examine the robustness of results using cross-validation; that is, performing the clustering 
(‘training’) in a random subset of the data and ‘testing’ in the remainder, repeatedly. This 
was not possible in the current dataset due to the limited sample size and power. Other 
approaches were therefore used to assess robustness of the results. First, the optimal 
number of clusters were also tested using an alternative method – the Duda-Hart pseudo T-
squared statistic (as this is the only other option available in Stata v14). Second, cluster 
formation may be influenced by rare comorbidities. To test the stability of clustering, the 
analysis was repeated using the same number of patients, but restricted to comorbidities 
that were prevalent in ≥2 patients. Third, the cluster analysis was externally validated using 
the Boston dataset. The aim of the external validation was to test whether main clusters 
were reproducible; clusters were not anticipated to match that of the main analysis exactly, 
since the comorbidity burden and its ascertainment were distinctly different.  
C1                                    C2 
Increasing similarity 




Each cluster was compared to patients with isolated axSpA (i.e. no comorbidity) using 
multivariable linear models for each outcome measure as the dependent variable, and 
cluster as a dummy independent variable. All models were adjusted for age, gender, 
symptom duration, smoking status, BMI, social deprivation, and current NSAID-use. ESR and 
CRP were log-transformed prior to regression. There was no correction for multiple 
comparisons since the outcome variables were closely related constructs that measure 
underlying severity of disease (i.e., not independent). 
4.3.3.3 Power considerations 
4.3.3.3.1 Power considerations for comorbidity prevalence between AS and nr-axSpA 
As discussed in Chapter 3, pre-determined sample sizes of both the Boston and Aintree 
studies were unable to provide sufficiently precise prevalence estimates for rarer 
conditions. The following power calculations were for the larger Boston study. For Aim 1, a 
sample of 775 would give insufficiently precise prevalence estimates for rarer 
comorbidities; that is, the ‘margin of error’ (95% CI divided by 2) would be larger than the 
prevalence estimate for conditions with ≤0.5% prevalence.  
Aim 2 hypothesises a difference between comorbidities in AS and nr-axSpA patients. This 
should be a comparison of counts (which is non-normally distributed, thus appropriate for 
Wilcoxon rank-sum test). T-tests were used instead, given 1) the robustness of the t-test for 
non-normal distributions [196], and 2) the excess of zero-count (no comorbidity; reporting 
medians of 0 vs. 0 is uninformative). The two-tailed t-test has 99% power, assuming a 
meaningful difference in comorbidity count of 1 and standard deviation of 2, known sample 
sizes in each group (669 vs. 135), beta:alpha ratio of 1 (i.e., both types of error equally 
prioritised); the equivalent power for the rank-sum test is similar (99%). Power for probable 




Table 4. 1: Examples of statistical power for t-tests. 
Mean group 1 Mean group 2 Standard 
deviation 
Power, % 
1 2 1 ~100 
1 1.5 1 99 
0.5 0.75 1 86 
1 2 2 99 
1 1.5 2 86 
0.5 0.75 2 65 




Pairwise comparisons of individual comorbidity prevalence using Fisher’s exact test are 
sufficiently powered (beta=0.2, alpha=0.05) to detect the differences shown in Table 4.2, 
without accounting for multiple testing. For example, if a condition has 0.5% prevalence in 
the AS group, the sample size provides 80% power to detect a difference of 3.9% but no 
smaller. 
 
Table 4. 2: Relationship between prevalence and difference that can be detected with 
sufficient power. 
Prevalence in the AS 
group 
Difference in prevalence that can be 









4.3.3.3.2 Power considerations Cluster analysis 
As discussed in Chapter 4, the Aintree study sample size was limited by the local patient 
population and study duration. Approaches to cluster analysis are legion and there are no 
widely accepted sample size estimation methods. One recent recommendation arising from 
mathematical simulations [197] suggested 70 observations for each variable (70*39=2730). 
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The main concern was that insufficient sample sizes could produce unstable clusters – this 
was addressed using approaches described in Section 4.3.3.1.1. 
For the regression model, patient-clusters were entered as dummy variables (i.e., each 
cluster required one additional degree of freedom) resulting in 18 variables in total. Power 
depends on the amount of variance explained by each variable. Using an alpha of 0.05, a 
sample size of 419 provides 80% power (i.e., beta of 0.2) for a cluster explaining ≥2% of 
total variance. This value is difficult to conceptualise; to illustrate, the proportion of 
variance (i.e., R2) in BASDAI explained by age is 0.2%, depression 0.5%, and hypertension 
0.02%. For a binary variable such as cluster-membership, a very low prevalence will 
contribute to a small R2, although their relationship is not easily predictable. 
4.3.3.4 Sensitivity analyses 
For the AS vs. nr-axSpA comparison and bDMARD-prescription analysis using Boston data, 
sensitivity analyses were conducted restricting to only individuals meeting full classification 
criteria to increase robustness of eligibility. Sensitivity analysis was also performed for the 
Aintree study by excluding obesity from the comorbidity count. Sensitivity analysis for 





4.4.1 Prevalence of comorbidities 
4.4.1.1 Boston axSpA study 
Among 965 patients who fulfilled the initial inclusion criteria, 775 patients (80%) were 
classified as axSpA and the remainder were excluded. 641 (83%) patients were classified as 
AS (553 Definite, 88 Probable) and 134 (17%) as nr-axSpA (93 Definite, 41 Probable). The 
cohort was predominantly male (74%) with a mean age of 53 years (SD 17). HLA-B27 was 
tested in 58% of patients, among whom 80% were positive. 91% of patient-records were 
from 2012 to 2018, 63% from 2018. 
Patient characteristics according to diagnosis are shown in Table 4.3. AS patients were 
significantly older (54 (SD 17) vs. 46 (SD 17) years) and more frequently male (77% vs. 64%). 
HLA-B27 was more frequently tested in nr-axSpA patients, although the proportion of 
positive results were similar between the two groups. There were no differences in extra-
axial manifestations except psoriasis, which was more frequently recorded in AS patients 
(13% vs. 6%, P=0.035). AS patients also had higher ESR and CRP levels, but pain VAS was 
similar to the nr-axSpA group. Sensitivity analysis restricting to those with AS and nr-axSpA 
meeting full classification criteria (i.e., Definite) did not significantly change results 




Table 4. 3: Characteristics of 775 patients in the Boston axial spondyloarthritis study, 











Age, years 52.5 (16.8) 53.8 (16.6) 46.3 (16.5) <0.001 
Male 575 (74%) 490 (77%) 85 (64%) 0.002 
BMI, kg/m2 28.0 (6.1) 28.0 (6.2) 28.0 (5.9) 0.95 
Current smoking 88 (11%) 71 (11%) 17 (13%) 0.59 
HLA-B27 tested 447 (58%) 359 (56%) 88 (66%) 0.039 
HLA-B27 positive 356 (80%) 287 (80%) 69 (78%) 0.75 
Family history 103 (14%) 81 (13%) 22 (17%) 0.17 
Uveitis 201 (27%) 165 (26%) 36 (29%) 0.57 
Psoriasis 90 (12%) 82 (13%) 8 (6%) 0.035 
Inflammatory bowel 
disease 
80 (11%) 70 (11%) 10 (8%) 0.29 
Peripheral arthritis 136 (18%) 114 (18%) 22 (17%) 0.87 
Enthesitis 31 (4%) 24 (4%) 7 (6%) 0.36 
Dactylitis 17 (2%) 16 (3%) 1 (1%) 0.23 
ESR tested 305 (39%) 255 (40%) 50 (37%) 0.59 
ESR result (mm/hr), 
median (IQR) 
13.0 (6.0 to 
25.0) 
13.0 (6.0 to 
27.0) 
9.5 (5.0 to 
21.0) 
0.042 
CRP tested 386 (50%) 323 (50%) 63 (47%) 0.48 
CRP result (mg/dl), 
median (IQR) 
3.0 (1.1 to 10.4) 3.4 (1.2 to 11.0) 2.2 (0.7 to 5.3) 0.007 
Pain VAS available 280 (36%) 227 (35%) 53 (40%) 0.36 
Pain VAS 2.4 (3.1) 2.2 (3.0) 3.0 (3.3) 0.12 
Comorbidity count*, 
mean (SD) 
1.5 (2.2) 1.5 (2.2) 1.3 (2.2) 0.29 
Data are shown as mean (SD) and n (%) unless otherwise specified.  
*number of comorbidities among a list of 39 chronic conditions. 
BMI, body mass index; IBD, inflammatory bowel disease; IQR, interquartile range; SD, 





Overall, a history of bDMARD-use was seen in 55% of Boston patients, csDMARDs in 25%, 
NSAIDs in 76%, and prednisone in 35% of patients. Ever-prescriptions of each bDMARD was 
similar between AS and nr-axSpA groups (Table 4.4). NSAID prescription was also similar 
between the two groups, except meloxicam which was significantly more frequently 
prescribed in patients with nr-axSpA. Sensitivity analysis restricting to those with AS and nr-
axSpA meeting full classification criteria (i.e., Definite) did not significantly change the 
results (Appendix Table S4.2). 
 








bDMARDs 353 (55%) 70 (52%) 0.55 
Adalimumab 205 (32%) 39 (29%) 0.51 
Etanercept 190 (30%) 36 (27%) 0.52 
Infliximab 85 (13%) 17 (13%) 0.86 
Golimumab 26 (4%) 7 (5%) 0.54 
Certolizumab pegol 20 (3%) 3 (2%) 0.78 
Secukinumab 21 (3%) 4 (3%) 1.00 
Ustekinumab 12 (2%) 0 0.24 
csDMARDs 158 (25%) 35 (26%) 0.72 
Sulfasalazine 81 (13%) 18 (13%) 0.80 
Methotrexate 101 (16%) 23 (17%) 0.69 
Leflunomide 4 (1%) 3 (2%) 0.10 
NSAIDs 480 (75%) 106 (79%) 0.30 
Ibuprofen 234 (37%) 61 (46%) 0.051 
Naproxen 204 (32%) 49 (37%) 0.29 
Indomethacin 157 (24%) 28 (21%) 0.37 
Celecoxib 116 (18%) 19 (14%) 0.28 
Diclofenac 86 (13%) 23 (17%) 0.26 
Meloxicam 58 (9%) 20 (15%) 0.04 
Prednisone 223 (35%) 51 (38%) 0.47 
bDMARD, biologic disease modifying anti-rheumatic drugs; csDMARD, 





The median number of comorbidities was 1 (IQR 0 to 2). The mean comorbidity count was 
1.5 (SD 2.2) and not statistically different between AS and nr-axSpA groups. Half of all 
patients had at least one comorbidity. Figure 4.4 shows the distribution of comorbidity 
count. The prevalence of each comorbidity is shown in Figure 4.5 in order of prevalence. 
The common comorbidities were anxiety (7.9%), coronary heart disease (7.7%), cancer 
(7.2%), hypertension (6.1%) and depression (5.2%). Twelve of the 39 conditions had a 
prevalence of 5% or higher, while 9 diseases had a prevalence of 1% or lower. 
 













Compared to those with isolated axSpA, patients with comorbidity were significantly older 
and had higher mean BMI (Table 4.5). Patients with comorbidities were more likely to be 
current smokers than those without (18% vs. 4%). These patients were also more likely to 
have IBD, but not other extra-articular manifestations. Comorbid patients reported similar 
levels of pain, but had significantly higher ESR and CRP levels. 
 
Table 4. 5: Patient characteristics of the Boston axial spondyloarthritis study according to 









Age, years 46.7 (15.4) 58.0 (16.3) <0.001 
Male 287 (76%) 288 (73%) 0.34 
BMI, kg/m2 27.1 (6.1) 28.7 (6.1) 0.017 
Current smoking 15 (4%) 73 (18%) <0.001 
HLA-B27 tested 241 (63%) 206 (52%) 0.002 
HLA-B27 positive 194 (80%) 162 (79%) 0.63 
Family history 45 (12%) 58 (15%) 0.25 
Uveitis 98 (26%) 103 (27%) 0.93 
Psoriasis 37 (10%) 53 (14%) 0.11 
Inflammatory bowel disease 25 (7%) 55 (14%) <0.001 
Peripheral arthritis 70 (19%) 66 (17%) 0.53 
Enthesitis 14 (4%) 17 (4%) 0.66 
Dactylitis 9 (2%) 8 (2%) 0.74 
ESR tested 122 (32%) 183 (46%) <0.001 
ESR result (mm/hr), median (IQR) 8.5 (4.0, 18.0) 16.0 (7.0, 33.0) <0.001 
CRP tested 168 (44%) 218 (55%) 0.002 
CRP result (mg/dl), median (IQR) 2.2 (0.8, 6.8) 5.1 (1.8, 13.6) <0.001 
Pain VAS available 108 (28%) 172 (44%) <0.001 
Pain VAS 2.2 (3.0) 2.5 (3.1) 0.44 
Data are shown as mean (SD) and n (%) unless otherwise specified.  
BMI, body mass index; VAS, visual analogue scale; IQR, interquartile range; SD, 






4.4.1.2 Aintree axSpA registry 
The Aintree axSpA registry included 421 patients with established axSpA. Sufficient clinical 
data were available for 419 patients (2 patients had no accessible electronic health 
records). The cohort was predominantly male (69%) with a mean age of 46 (SD 14) years. 
82% fulfilled the modified New York criteria for AS. HLA-B27 was available in 269 and of 
these 59% were positive. Two patients were prescribed TNF inhibitors and 17% were 
currently using NSAIDs at baseline. 
Patient characteristics according to diagnosis are shown in Table 4.6. AS patients were 
significantly older (46 (SD 14) vs. 41 (SD 14) years) and more frequently male (73% vs. 53%). 
HLA-B27 was more frequently positive among AS patients (66 vs. 30%). AS patients more 
frequently had EAMs, which was significant for uveitis and psoriasis but not IBD. AS patients 
had (numerically but not statistically) higher median ESR (12.0 vs. 10.0mm/hr) and CRP (5.0 
vs. 3.0mg/dl) levels. All patient reported measures were similar in the AS and nr-axSpA 
groups. The mean number of comorbidities was 1.3 (SD 1.3) and not statistically different 




Table 4. 6: Characteristics of 419 patient in the Aintree axial spondyloarthritis registry, 
overall and according to diagnosis. 
 









Age, years  45.5 (14.3) 46.4 (14.2) 41.0 (13.8) 0.003 
Male  291 (69%) 252 (73%) 39 (53%) <0.001 
Modified New York 
criteria for AS 
345 (82%) 345 (100%) 0 (0%) <0.001 
HLA-B27 positive* 158 (59%) 141 (66%) 17 (30%) <0.001 
Age at symptom 
onset, years 
27.6 (11.1) 27.0 (10.6) 30.3 (12.4) 0.026 
Symptom duration, 
median (IQR) years 
14.6 (6.2, 26.7) 17.0 (8.2, 27.9) 5.9 (2.2, 13.7) <0.001 
BMI, kg/m2 28.2 (5.7) 28.3 (5.4) 28.1 (7.0) 0.78 
Deprivation index**, 
median (IQR) 
2.0 (1.0, 5.0) 2.0 (1.0, 5.0) 2.0 (1.0, 6.0) 0.96 
Current smoker 137 (35%) 114 (36%) 23 (32%) 0.30 
Ex-smoker 69 (18%) 60 (19%) 9 (13%) 
Never smoked 186 (47%) 147 (46%) 39 (55%) 
Current NSAID use 71 (17%) 54 (16%) 17 (23%) 0.13 
Peripheral joint 
involvement 
113 (29%) 75 (23%) 38 (54%) <0.001 
Uveitis 100 (25%) 96 (29%) 4 (6%) <0.001 
Psoriasis 73 (18%) 46 (14%) 27 (38%) <0.001 
Inflammatory bowel 
disease 
40 (10%) 35 (11%) 5 (7%) 0.35 
EuroQoL, median 
(IQR) 
0.5 (0.1, 0.7) 0.5 (0.1, 0.8) 0.5 (0.0, 0.7) 0.46 
Global health, median 
(IQR) 
5.0 (2.9, 6.8) 5.0 (2.9, 6.9) 5.0 (3.2, 6.3) 0.85 
Fatigue, median (IQR) 6.0 (3.3, 7.5) 6.0 (3.2, 7.5) 6.1 (4.2, 7.6) 0.28 
BASDAI, median (IQR) 6.1 (3.8, 7.7) 6.0 (3.6, 7.8) 6.6 (4.8, 7.5) 0.29 
Spinal pain, median 
(IQR) 
6.7 (4.0, 8.0) 6.0 (3.0, 8.0) 7.0 (5.0, 8.0) 0.31 
BASFI, median (IQR) 6.0 (3.2, 8.1) 6.0 (3.1, 8.1) 6.1 (3.9, 7.8) 0.89 
ESR (mm/hr) 11.5 (5.0, 28.0) 12.0 (5.0, 28.0) 10.0 (5.0, 29.0) 0.51 
CRP (mg/L) 5.0 (1.0, 15.0) 5.0 (1.0, 16.0) 3.0 (1.0, 8.0) 0.14 
Comorbidity count, 
mean (SD) 
1.3 (1.3) 1.4 (1.4) 1.3 (1.3) 0.69 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
*HLA-B27 available for 269 patients. 
**Index of multiple deprivation deciles, with 1 representing the top 10% most deprived 
areas and 10 the most affluent. 
Fatigue and global health were single-question visual analogue scales, ranging from 0 




At least one comorbidity was seen in 286 (68%) axSpA patients. Figure 4.6 shows the 
distribution of comorbidity count. The median number of comorbidities was 1 (IQR 0 to 2). 
The mean was 1.3 (SD 1.3). Excluding obesity, the median and IQR of comorbidities 
remained unchanged, but mean was 1.1 (SD 1.2). 
 




The prevalence of each comorbidity is shown in Figure 4.7, in order of prevalence. Obesity 
was present in 23% (derived from systematically assessed BMI). Excluding obesity, the most 
common comorbidities were hypertension (14.3%), depression (11.7%) and dyspepsia 
(8.5%). Only six of the 38 conditions had a prevalence of over 5%, while 16 diseases had a 




Figure 4. 7: Prevalence of individual comorbidities in the Aintree axial spondyloarthritis registry. 
 
*Currently treated. **New diagnosis in last 5 years. ***Obesity was defined through systematic assessment of BMI. TIA, transient ischaemic attack.
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Compared to those with isolated axSpA, Aintree patients with comorbidities were 
significantly older (mean 49 (SD 14) vs. 40 (SD 13) years) and had higher mean BMI. 
Comorbid patients reported significantly worse disease activity (BASDAI and spinal pain), 
functional impairment, health-related quality of life, global health, and fatigue. There were 
no significant differences in ESR or CRP levels (Table 4.7). These comparisons were 
repeated with obesity excluded from the comorbidity count (Appendix 10.3: Table S4.3); 
results were not significantly different. 
 
Table 4. 7: Patient characteristics the Aintree axial spondyloarthritis registry according to 
the presence of comorbidities. 







Age, years  39.5 (13.0) 48.3 (14.1) <0.001 
Male  94 (71%) 197 (69%) 0.71 
Modified New York criteria for AS 111 (83%) 234 (82%) 0.68 
HLA-B27 positive* 51 (60%) 107 (58%) 0.77 
Symptom duration, median (IQR) years 10.6 (4.6, 20.0) 17.5 (7.1, 30.1) <0.001 
BMI***, kg/m2 27.4 (5.2) 28.7 (5.9) 0.045 
Deprivation index**, median (IQR) 3.0 (1.0, 6.0) 2.0 (1.0, 5.0) 0.08 
Current smoker 42 (34%) 95 (35%) 0.32 
Ex-smoker 17 (14%) 52 (19%) 
Never smoked 64 (52%) 122 (45%) 
NSAIDs 21 (16%) 50 (17%) 0.67 
Peripheral joint involvement 34 (28%) 79 (29%) 0.95 
Uveitis 33 (27%) 67 (24%) 0.56 
Psoriasis 27 (22%) 46 (16%) 0.19 
Inflammatory bowel disease 14 (11%) 26 (9%) 0.49 
EuroQoL, median (IQR) 0.6 (0.1, 0.8) 0.5 (-0.02, 0.7) 0.012 
Global health, median (IQR) 4.9 (2.1, 6.5) 5.1 (3.3, 7.0) 0.041 
Fatigue, median (IQR) 5.5 (3.2, 7.1) 6.1 (3.6, 7.6) 0.15 
BASDAI, median (IQR) 5.6 (3.5, 7.2) 6.3 (4.0, 8.1) 0.014 
Spinal pain, median (IQR) 6.0 (3.0, 8.0) 7.0 (4.0, 8.0) 0.014 
BASFI, median (IQR) 4.2 (2.1, 6.2) 6.7 (3.9, 8.3) <0.001 
ESR (mm/hr) 8.0 (5.0, 23.5) 13.0 (6.0, 30.0) 0.006 
CRP (mg/L) 3.0 (0.0, 16.0) 5.0 (1.0, 15.0) 0.21 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
*HLA-B27 available for 269 patients. 
**Index of multiple deprivation deciles, with 1 representing the top 10% most 
deprived areas and 10 the most affluent. 
***comparison excluding obesity. 
Fatigue and global health were single-question visual analogue scales, ranging from 0 
(worst) to 10 (best). EuroQoL, 5-domain quality of life measure; BASDAI, Bath AS 
disease activity index; BASFI, Bath AS Functional index. 
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4.4.2 Comorbidities in AS vs. nr-axSpA  
4.4.2.1 Comparison of comorbidities in AS and nr-axSpA among Boston patients 
There were no statistically significant differences in prevalence of the 39 chronic conditions 
between AS and nr-axSpA groups, except chronic kidney disease which was higher in AS 
patients (3% vs. 0%, p=0.035) (Figure 4.8). Sensitivity analysis restricting to those with AS 
and nr-axSpA meeting full classification criteria did not significantly change results 
(Appendix 10.3: Table S4.4). 
4.4.2.2 Comparison of comorbidities in AS and nr-axSpA among Aintree patients 
There were no statistically significant differences in prevalence of the 39 chronic conditions 
between AS and nr-axSpA groups, except irritable bowel syndrome (2% in AS vs. 9% in nr-
axSpA, p=0.008) (Figure 4.9). The prevalence of hypertension was higher in AS patients with 
borderline significance (21% vs. 11%, p=0.05). Depression and fibromyalgia prevalence 















4.4.3 Comorbidity clusters in the Aintree axSpA registry 
No patients had dementia, hearing loss, bronchiectasis or anorexia; therefore, these 
conditions were excluded from the cluster analysis. The diagram from cluster analysis of the 
remaining 34 conditions is shown in Figure 4.10. The pseudo-F statistic (Appendix 10.3: 
Table S4.5) identified 15 as the optimum number of clusters, labelled in numerical order 
from left to right. Clustering generally occurred at low levels of similarity. 
 
Figure 4. 10: Diagram (‘dendrogram’) from cluster analysis of 419 Aintree patients and 34 
comorbidities. 
 
Zero on the y-axis indicates no similarity between clusters. From the bottom, clusters 
progressive joined (at levels of similarity shown at their union) until a single cluster is 
formed at the top. The pseudo-F statistic determined the optimum number of clusters, 
indicated by where the dotted horizontal line intersects with the branches. Clusters are 





Six clusters were formed at near-zero similarity, indicating relative distinctness. Cluster 1 
(C1, n=164) consisted of patients with isolated axSpA with no comorbidities. C11 had two 
patients with atrial fibrillation, one of whom also had Parkinson’s disease. C12 to C15 
contained only one patient each with the following conditions: chronic sinusitis, blindness 
or low vision, multiple sclerosis, and learning disability. 
All other clusters were generally dominated by one to two comorbidities with varying 
number of other less frequent conditions (Table 4.8). C2 (n=40) was predominantly 
characterised by patients with concurrent dyspepsia (94%). Clusters 3, 4 and 5 were similar: 
C3 (n=84) patients most commonly had depression (83%) and anxiety (14%); C4 (n=35) 
patients frequently had fibromyalgia (72%) and irritable bowel syndrome (IBS, 56%); C5 had 
only four patients, all with anxiety. Clusters 3 and 5 were combined for further analysis 
since they both included anxiety and would merge in the next clustering (Figure 4.10). 
C6, the largest comorbidity cluster (n=88), was predominantly characterised by 
hypertension (82%) and coronary heart disease (CHD, 24%). C7 (n=38) commonly had 
osteoporosis (74%) and alcohol problems (47%). CHD and other cardiovascular diseases 
feature in both groups, explaining their proximity in Figure 4.10. 
C8 (thyroid disease), C9 (other psychoactive substance misuse) and C10 (asthma) were 
largely unrelated to other clusters and each was dominated by a single disease. 
The fibromyalgia-IBS cluster and thyroid disorders cluster were predominantly female and 
least frequently had positive HLA-B27 status or met classification criteria for AS (Table 4.9). 
Patients in the hypertension-CHD cluster and alcohol problems-osteoporosis cluster were 
the oldest and had a higher prevalence of uveitis. Current NSAID use was lowest among 
those in the dyspepsia and other substance misuse clusters. Current smoking was highest 
among those with other substance misuse and lowest among asthma clusters. 
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Table 4. 8: Prevalence of comorbidities in each of the 11 patient clusters with more than one patient. 
Cluster 1 2 3 4 5 6 7 8 9 10 11 
Number of patients 164 31 50 18 4 88 19 9 16 14 2 
Hypertension   1 (2) 3 (17)  72 (82) 4 (21) 1 (11)    
Depression  3 (10) 42 (84) 4 (22)  15 (17)   1 (6) 1 (7)  
Anxiety and other neuroses  2 (6) 7 (14)  4 (100) 2 (2)      
Schizophrenia or bipolar      3 (3)   1 (6) 1 (7)  
Osteoporosis  1 (3) 5 (10)    14 (74)   1 (7)  
Alcohol problems  1 (3) 1 (2) 1 (6)  6 (7) 9 (47)     
Other psychoactive substance 
misuse 
     1 (1) 1 (5)  16 (100)   
Chronic liver disease    1 (6)  1 (1) 1 (5)     
Viral hepatitis   1 (2)   1 (2)   1 (6)   
Migraine   6 (12)     1 (11)  1 (7)  
Epilepsy*  1 (3) 3 (6)       1 (7)  
Thyroid disorders   1 (2)   3 (3)  9 (100)    
Diabetes   4 (8)   15 (17) 2 (11)     
Atrial fibrillation      3 (3)     2 (100) 
Coronary heart disease   1 (2)   21 (24) 1 (5)   1 (7)  
Heart failure      2 (2) 1 (5)     
Stroke and TIA   1 (2)   4 (5) 1 (5)     
Peripheral vessel disease       1 (5)     
COPD   3 (6)   12 (14) 1 (5)     
Asthma*      3 (3) 1 (5)   14 (100)  
Chronic sinusitis      1 (1)      
Prostate disorders      5 (6)      
Fibromyalgia   2 (4) 13 (72) 1 (25) 2 (2)  1 (11)    
Irritable bowel syndrome   1 (2) 10 (56)  3 (3)    1 (7)  
Diverticular disease   1 (2)   4 (5)      
Constipation*   1 (2)   3 (3)      
Cancer   4 (8)         
Chronic kidney disease  3 (10)    6 (7) 1 (5)     
Dyspepsia*  29 (94) 1 (2) 3 (17)     2 (13)   
Glaucoma      13 (15)      
Parkinson's disease           1 (50) 
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*Currently treated. **Cancer diagnoses in the past 5 years. Cells with zero prevalence were left empty for clarity. Bold text highlights dominant 
morbidities in each cluster. Clusters 12, 13, 14 and 15 were omitted: each had only 1 patient (chronic sinusitis, blind or low vision, multiple sclerosis, and 





Table 4. 9 Baseline characteristics compared across comorbidity clusters in the Aintree registry. 

















Asthma Other rare 
conditions 
n 164 31 54 18 88 19 9 16 14 6 
Age, years  40.0 (12.9) 47.9 (13.8) 44.1 (11.1) 45.9 (10.6) 56.5 (12.2) 58.0 (8.6) 50.6 (14.7) 31.6 (8.1) 37.7 (12.0) 38.3 (19.4) 
Male  114 (70%) 21 (68%) 36 (67%) 7 (39%) 64 (73%) 16 (84%) 2 (22%) 16 (100%) 9 (64%) 6 (100%) 
Modified New York 
criteria for AS 
135 (82%) 26 (84%) 41 (76%) 12 (67%) 81 (92%) 15 (79%) 5 (56%) 14 (88%) 11 (79%) 5 (83%) 
HLA-B27 positive* 66 (62%) 8 (44%) 17 (47%) 6 (43%) 31 (66%) 7 (70%) 2 (33%) 9 (64%) 6 (50%) 6 (100%) 
BMI 27.4 (5.2) 28.2 (4.6) 29.2 (6.3) 29.7 (8.9) 29.2 (5.7) 30.0 (4.7) 28.4 (2.2) 24.4 (5.0) 29.9 (5.8) 24.5 (6.0) 
Deprivation 
index** 
2.0 (1.0, 6.0) 2.0 (1.0, 5.0) 2.0 (1.0, 4.0) 1.5 (1.0, 6.0) 2.0 (1.0, 5.0) 5.0 (1.0, 6.0) 3.5 (1.0, 7.5) 1.5 (1.0, 4.0) 1.0 (1.0, 5.0) 3.5 (1.0, 7.0) 
Smoking Current 53 (34%) 12 (44%) 23 (43%) 4 (25%) 22 (27%) 6 (33%) 1 (13%) 15 (94%) 1 (8%) 0 
Ex 23 (15%) 5 (19%) 8 (15%) 4 (25%) 22 (27%) 4 (22%) 1 (13%) 0 1 (8%) 1 (20%) 
Never 78 (51%) 10 (37%) 22 (42%) 8 (50%) 39 (47%) 8 (44%) 6 (75%) 1 (6%) 10 (83%) 4 (80%) 
NSAIDS 31 (19%) 2 (6%) 12 (22%) 3 (17%) 13 (15%) 4 (21%) 2 (22%) 1 (6%) 2 (14%) 1 (17%) 
Peripheral joint 
involvement 
40 (26%) 10 (34%) 15 (28%) 7 (41%) 19 (23%) 7 (37%) 4 (44%) 3 (20%) 6 (43%) 2 (33%) 
Uveitis 39 (25%) 4 (14%) 6 (11%) 6 (35%) 33 (38%) 8 (42%) 1 (11%) 1 (6%) 2 (14%) 0 
Psoriasis 33 (21%) 5 (17%) 11 (21%) 2 (12%) 12 (14%) 2 (11%) 3 (33%) 3 (19%) 2 (14%) 0 
IBD 19 (12%) 3 (10%) 5 (9%) 3 (18%) 7 (8%) 1 (5%) 0 0 1 (7%) 1 (17%) 
Data shown as mean (SD), median (interquartile range) or n (%). 
*HLA-B27 available for 269 patients. 




4.4.3.1 Validation of cluster analysis results  
4.4.3.1.1 Cluster number using an alternative algorithm  
The optimal number of clusters determined using the pseudo T-squared statistic was 12 
(Appendix 10.3: Table S4.5). The only difference compared to the main analysis was that 
Clusters 3 (depression/anxiety), C4 (fibromyalgia/IBS) and C5 (anxiety) were combined into 
one cluster. 
4.4.3.1.2 Excluding rare comorbidities  
Cluster analysis using the 28 comorbidities that were prevalent in at least two patients 
showed the same clusters (Appendix 10.3: Table S4.6).  
4.4.3.1.3 Externally validation of clusters using the Boston data  
Repeating the cluster analysis using the Boston data (n=775, mean number of comorbidities 
1.5 (SD 2.2)) revealed broadly similar patient-clusters. The dendrogram is shown in Figure 
4.11. 




Zero on the y-axis indicates no similarity between clusters. Red line indicating 





Ten clusters (C) were identified (Table 4.10); the corresponding pseudo-F and pseudo T-
squared statistics are shown in Appendix 10.3: Table S4.7. The right-most three clusters in 
Figure 4.11 were most distinct from (i.e., least similar to) other clusters: C10, the largest 
cluster was formed by patients with no comorbidities; C9 (fibromyalgia) and C8 (dementia) 
had only three patients between them. 
C1 to C3 were closely related. C1 (n=118) was dominated by cardiometabolic comorbidities 
(atrial fibrillation, coronary heart disease, heart failure, hypertension, diabetes, obesity) 
and cancer. C2 (n=58) was dominated by cancer. C3 (n=42) by gastrointestinal (dyspepsia, 
chronic liver disease, diverticular disease) and prostate diseases. The second largest cluster, 
C4 (n=127), was dominated by anxiety, depression, other substance misuse, and also 
constipation. C5 (osteoporosis, n=17) and C6 (glaucoma and blindness, n=4) were small, 
closely related clusters. C7 (n=26) was dominated by asthma and migraine. 
As in the main analysis using the Aintree axSpA dataset, patients with no comorbidities 
were generally younger (47 (SD 15) years) and less frequently current smokers (4%) (Table 
4.11). Patients in the cardiometabolic cluster were older (64 (SD 15) years) and had higher 
BMI (31 vs. 27 in the no comorbidity cluster). The mental health and substance misuse 
cluster had the highest prevalence of smoking (31%) – almost twice that of the group with 
the next highest prevalence. 
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Table 4. 10: Prevalence of comorbidities in each cluster with in the Boston axSpA study as external validation. 
 
Cluster 1 2 3 4 5 6 7 8 9 10 
Number of patients 118 58 42 127 17 4 26 1 2 380 
Atrial fibrillation 33 (28) 2 (3)  9 (7)       
Alcohol 2 (2)  1 (2) 13 (10)       
Anorexia and other neuroses 2 (2)   4 (3)  1 (25) 1 (4)    
Anxiety 5 (4) 4 (7) 2 (5) 77 (61)       
Asthma 4 (3)  3 (7) 11 (9)   17 (65)    
Blind or low vision 8 (7)   6 (5)  2 (50)     
Bronchiectasis    1 (1) 2 (12)  1 (4)    
Cancer 30 (25) 35 (60) 6 (14) 10 (8) 1 (6)      
Coronary heart disease 59 (50)  5 (12) 22 (17)   1 (4)    
Chronic liver disease 5 (4)  14 (33) 9 (7)       
Chronic sinusitis 1 (1) 3 (5) 1 (2) 3 (2)       
Chronic kidney disease 16 (14) 2 (3) 1 (2) 2 (2)       
COPD 7 (6)  3 (7) 1 (1) 1 (6) 1 (25)     
Dementia 3 (3)   1 (1)    1 (100)   
Depression 7 (6) 3 (5) 5 (12) 44 (35)       
Diabetes mellitus 39 (33)  2 (5) 12 (9) 1 (6) 1 (25) 2 (8)    
Diverticular disease 5 (4)  14 (33) 6 (5)       
Epilepsy 2 (2)   3 (2)       
Fibromyalgia    1 (1)     2 (100)  
Glaucoma 2 (2)  1 (2) 2 (2)  4 (100)     
Hearing loss 4 (3) 9 (16) 5 (12) 5 (4)       
Heart failure 26 (22)   5 (4)   1 (4)    
Hypertension 45 (38) 1 (2) 4 (10) 13 (10) 3 (18)  3 (12)    
Irritable bowel syndrome 3 (3)  2 (5) 39 (31)   1 (4)    
Learning disability 1 (1) 3 (5) 1 (2) 3 (2)  1 (25)     
Migraine 2 (2)  1 (2) 9 (7)   11 (42)    
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Cluster 1 2 3 4 5 6 7 8 9 10 
MS  1 (2)         
Obesity 26 (22) 3 (5) 2 (5) 7 (6)   1 (4)    
Osteoporosis 9 (8) 2 (3) 1 (2) 10 (8) 17 (100) 1 (25)     
Other psychoactive substance 
misuse 
1 (1)  1 (2) 35 (28)       
Parkinson’s disease 1 (1)          
Prostate disorders 16 (14) 3 (5) 20 (48) 14 (11)  1 (25)     
Peripheral vessel disease 6 (5) 4 (7)  4 (3)       
Schizophrenia or bipolar 2 (2)  1 (2) 4 (3)  1 (25)     
Stroke 17 (14) 8 (14)  12 (9)       
Thyroid disorders 8 (7) 10 (17)  18 (14) 4 (24)  1 (4)    
Constipation 1 (1)  1 (2) 33 (26)       
Dyspepsia 4 (3)  11 (26) 3 (2)   2 (8)    
Viral hepatitis 2 (2) 1 (2) 1 (2) 2 (2)       
*Currently treated. **Cancer diagnoses in the past 5 years. Cells with zero prevalence were left empty for clarity. Bold text highlights dominant 
morbidities in each cluster. Clusters 12 (2 patients with AF) and 13 (1 with sinusitis) were omitted. 





Table 4. 11 Baseline characteristics compared across comorbidity clusters in the Boston study. 
 
Cluster 10 1 2 3 4 7 5, 6, 8, 9 
Disease(s) Isolated 
axSpA 










n 380 118 58 42 127 26 24 
Age, years  46.7 (15.4) 63.5 (14.5) 58.3 (16.4) 60.3 (15.5) 53.3 (15.7) 47.1 (18.4) 63.0 (14.8) 
Male  287 (76%) 100 (85%) 40 (69%) 38 (90%) 88 (69%) 9 (35%) 13 (54%) 
AS* 309 (81%) 103 (87%) 49 (84%) 38 (90%) 103 (81%) 21 (81%) 18 (75%) 
HLA-B27 
positive** 
194 (80%) 44 (75%) 20 (77%) 21 (84%) 56 (81%) 11 (73%) 10 (83%) 
BMI 27.1 (6.1) 30.7 (5.8) 27.9 (6.5) 28.4 (4.2) 28.1 (6.1) 29.1 (8.2) 23.6 (3.9) 
Current smoking 15 (4%) 16 (14%) 4 (7%) 7 (17%) 40 (31%) 4 (15%) 2 (8%) 
NSAIDS 98 (26%) 28 (24%) 15 (26%) 15 (36%) 30 (25%) 6 (23%) 9 (39%) 
Peripheral joint 
involvement 
37 (10%) 21 (18%) 9 (16%) 7 (17%) 10 (8%) 1 (4%) 5 (22%) 
Uveitis 25 (7%) 18 (16%) 8 (14%) 9 (21%) 12 (10%) 6 (23%) 2 (9%) 
Psoriasis 70 (19%) 18 (16%) 13 (23%) 11 (26%) 17 (14%) 4 (15%) 3 (13%) 
IBD 14 (4%) 8 (7%) 2 (4%) 2 (5%) 4 (3%) 0 (0%) 1 (4%) 
Data shown as mean (SD), median (interquartile range) or n (%). 
*modified New York criteria adapted for the Boston study to include sacroiliitis by other imaging modalities. 




4.4.4 Associations between patient-clusters and disease indices in the Aintree study 
Aintree axSpA patients in the depression-anxiety clusters (C3 and C5), and fibromyalgia-IBS 
cluster (C4) reported poorer health-related quality of life, global health, fatigue, and axSpA-
specific indices, compared to patients with isolated axSpA (Table 4.12). To facilitate 
interpretation, model coefficients and confidence intervals are also displayed graphically in 
Figure 4.12. For example, EQ5D-3L was lower by 0.25 units in both clusters compared to 
patients with isolated axSpA. Disease activity was higher by 0.9 units in the depression-
anxiety cluster and 1.8 units in the fibromyalgia-IBS cluster. There were no overall 
differences in ESR or CRP, except patients with concurrent dyspepsia had 0.5mg/dl lower 
CRP than those with isolated axSpA (P=0.008). 
Patients in the largest cluster (hypertension-CHD) had statistically similar axSpA severity as 
those without comorbidity across all patient-reported measures. Patients in C7 (alcohol 
problems-osteoporosis) reported worse global health and function with similar effect sizes 
to the depression-anxiety cluster, although this was not statistically significant. Patients 
with other psychoactive substance misuse reported significantly worse global health by 1.5 
units; they also showed a trend of having higher BASDAI. 






Table 4. 12: Disease indices compared between each comorbidity cluster and axial spondyloarthritis patients with no comorbidity. 

















Asthma Other rare 
conditions 
n 164 31 54 18 88 19 9 16 14 6 




















































































































































Data shown as regression coefficients (95% confidence interval). For EuroQol, higher values indicate better health-related quality of life (e.g. cluster 4 had 0.25-unit 
poorer QoL). For all other measures, higher values indicate more severe disease (e.g. cluster 4 had 1.5-unit poorer global health). 
Coefficients derived from models using each outcome measure as independent variable, and cluster as a dummy variable with isolated axSpA as the reference group. 
Models adjusted for age, gender, symptom duration, deprivation, current NSAID-use, and smoking status. 
Global health and fatigue were measured by single-item questions with 0 as best/no fatigue and 10 as worst. 
*ESR and CRP were log-transformed using Ln(ESR) and Ln(CRP+1). 
EQ5D-3L, 5-domain 3-level version of the EuroQoL quality of life measure; BASDAI, Bath AS disease activity index; BASFI, Bath AS Functional index; IBS, irritable bowel 





Figure 4. 12: Disease indices compared between each comorbidity cluster and axial spondyloarthritis patients with no comorbidity, show 
graphically. 
Data shown as 
regression coefficients 
(95% confidence 
interval). For EQ5D-3L, 
higher values indicate 
better quality of life. 
For all other 
measures, higher 
values indicate more 
severe disease.  







Bath AS disease 
activity index; BASFI, 
Bath AS functional 
index; QoL, quality of 





This chapter used two cross-sectional axSpA populations to describe comorbidity 
prevalence and patterns. In both populations, over half of all patients had at least one 
comorbid condition. Overall pattern and burden of comorbidity were similar between 
patients with AS and nr-axSpA. Several comorbidity clusters were identified, each with only 
a small number of predominant conditions. Depression-anxiety and hypertension-coronary 
heart disease were the most common disease clusters in both axSpA cohorts. Patients in 
the depression-anxiety clusters and fibromyalgia-IBS clusters had more severe disease 
consistent across all patient-reported outcomes.  
4.5.1 Prevalence of comorbidities 
Differences in demography and socioeconomic context between Boston and Aintree 
cohorts offer interesting comparisons. Boston patients were, on average, older (mean age 
53 vs. 46 years) and less likely to be current smokers (11 vs. 35%) compared to Aintree 
patients. BMI, extra-articular manifestations, and inflammatory makers between the two 
cohorts were virtually identical. Patients with comorbidities had higher inflammatory 
markers in both studies, but statistical significance was reached only in the Boston analysis; 
this could be due to selective testing (comorbid patients were more likely to be tested) or 
greater statistical power. Interestingly, the prevalence of IBD was higher in Boston patients 
with comorbidities than without, which was not observed in the Aintree data. This 
difference may be due to limitations of ICD codes used in the Boston data.  
The mean (1.5 vs. 1.3) and range (0 up to 13 vs. 6) of comorbidity count differed between 
the Boston and Aintree studies. Direct comparison of comorbidity prevalence has limited 
meaning given differences in age and methods of data collection. Manual chart review 
supported by GP and medication records (Aintree) is more likely to capture comorbidities 
than diagnostic codes (Boston). Clinical practice may also explain some key discrepancies, 
for example, systematic recording of BMI (obesity in 17% of Aintree vs. 3.4% of Boston 
patients) and blood pressure (hypertension in 14% of Aintree vs. 6.1% of Boston patients). 
Boston patients had higher prevalence of anxiety (7.9 vs. 2.7%), coronary heart disease (7.7 
vs. 4.2%), and cancer (7.2 vs. 0.7%) than Aintree patients. These differences are more 
challenging to explain without knowing the validity of ICD codes for these conditions, but 
may partly be explained by the older age of the Boston cohort. 
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The mean number of comorbidities (1.5) in the Boston axSpA study was similar to the 1.6 
conditions reported among rheumatoid arthritis patients, using the same index and ICD 
codes in the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study (BRASS) 
[198]. The BRASS cohort was older (mean age 58 years) than this axSpA group (mean age 53 
years). Notably, axSpA subjects had a higher prevalence of anxiety (11% vs. 4% of BRASS); 
this adds to an increasing body of literature highlighting the importance of mental health in 
these patients [199]. 
The prevalence of individual morbidities in the Aintree cohort were consistent with those 
reported in the worldwide ASAS-COMOSPA cohort which had similar age and gender 
distributions, although ASAS-COMOSPA included patients with both axial and peripheral 
SpA [200]. The proportion with at least one comorbidity was higher in the Aintree cohort 
(61% vs. 51%), but this is likely due to the larger number of conditions included. The Aintree 
cohort had a greater proportion of current smokers (35% vs. 29% of ASAS-COMOSPA), 
which is compatible with the relative deprivation in this area of Liverpool (see Chapter 3, 
Section 3.2.1). This may also explain the higher prevalence of coronary heart disease (6% 
vs. 1%) in the Aintree cohort. Interestingly, the prevalence of hypertension in the Aintree 
data was lower (19% vs. 34% in ASAS-COMOSPA). The ASAS-COMOSPA study used single-
measurement blood pressure thresholds in their definition of hypertension, which may lead 
to over-diagnosis [201]. Osteoporosis was also less common (6% vs. 13%), which may be 
under-documented since a previous study [202] found a higher (9%) prevalence of 
osteoporosis in a subgroup of this cohort (defined by T-score≤-2.5, as was in ASAS-
COMOSPA). 
Some comorbidities are likely under-represented in both cohorts. For example, 
fibromyalgia prevalence (0.1% in Boston and 3.4% in Aintree) were much lower than the 
prevalence reported using meta-analysis (13%) and found by screening questionnaire in the 
British Society for Rheumatology Biologics Register for AS (21%) [203,204].  
4.5.2 Comorbidities in AS vs. nr-axSpA 
There were no differences in the prevalence of HLA-B27 positivity between AS and nr-
axSpA groups in the Boston study, while the difference was marked in the Aintree data 
(66% positive in AS and 30% positive in nr-axSpA). Similar discrepancies exist in existing 
literature and may be explained by different approaches to the diagnostic work-up. AS 
subgroups in both populations had higher inflammatory markers and greater proportion of 
males [205,206]. These results support the hypothesis that both diagnoses belong to the 
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same disease spectrum, and that males and those with higher inflammatory markers are 
more likely to progress to radiographic damage [207]. Although data on disease severity 
measures were limited in the Boston data, subjective measures of pain were similar 
between diagnoses. All patient-reported disease measures were similar between AS and nr-
axSpA in the Aintree data. This is consistent with more detailed outcome measures from 
the Corrona SpA registry, where the two groups had similar disease activity, functional 
impairment, and health-related quality of life [205]. These results are supportive of 
guidelines that recommend a unified treatment approach for all axSpA patients [61]. 
The only statistically significant differences in prevalence of individual morbidities between 
AS and nr-axSpA patients were chronic kidney disease (in Boston cohort) and IBS (in Aintree 
cohort). Higher prevalence of chronic kidney disease in AS patients may be related to their 
older age and longer exposure to NSAIDs. Higher IBS (along with fibromyalgia and 
depression) prevalence in nr-axSpA may be due to higher psychosomatic burden due to 
more challenging (and therefore likely delayed) diagnosis, or from misdiagnosis of 
fibromyalgia as nr-axSpA. These differences should not be over-interpreted in the context 
of multiple comparisons. 
Results from the Boston study confirms those from the Corrona SpA registry that bDMARDs 
are widely used for nr-axSpA in clinical practice [205]. This is consistent with the 
ACR/SAA/SPARTAN treatment recommendations for AS and axSpA [208], although 
bDMARDs were not licensed for this indication in the US when this study was conducted. 
Clinicians were likely relying on a clinical diagnosis rather than classification criteria for 
making treatment decisions. The proportions of patients prescribed bDMARDs and 
csDMARDs (55% and 25%, respectively) were similar to those reported in Corrona SpA 
registry (67% and 36%) [205]. A history of bDMARD-use was seen in 55% of Boston patients, 
csDMARDs in 25%, NSAIDs in 76%, and prednisone in 35% of patients. 
4.5.3 Comorbidity clusters and associations with disease severity 
In the main analysis using the Aintree cohort, each comorbidity cluster had only a small 
number of predominant conditions reflecting the low number of conditions among those 
with comorbidity. All comorbidities within each cluster had shared patho-aetiological 
mechanisms. Depression-anxiety and hypertension-coronary heart disease formed the 
most common disease clusters, which were externally validated in the Boston axSpA study. 
The higher comorbidity burden in the Boston cohort resulted in clusters dominated by a 
higher number of conditions; for example, the cardiometabolic cluster additionally included 
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atrial fibrillation, heart failure and obesity, compared to results from the Aintree cohort. 
Another notable difference was the clustering of mental health and other substance misuse 
disorders. The latter was shown to be associated with disease severity indices with clinically 
important (but statistically non-significant) effect sizes. It also highlights the intimate link 
between mental and physical health. 
Differences in patient characteristics across the Aintree comorbidity clusters were 
consistent with the existing literature. Both fibromyalgia [209] and thyroid disorders [210] 
are generally more prevalent among females, which explains the high proportion of female 
patients in these clusters and also the higher prevalence of peripheral joint involvement 
and lower prevalence of radiographic disease and HLA-B27 positivity [211]. The prevalence 
of uveitis increases with age [16], which explains its higher prevalence in the older 
hypertension-CHD and alcohol problems-osteoporosis clusters.  
In the Aintree cohort, patients in the depression-anxiety clusters and fibromyalgia-IBS 
clusters reported worse health-related quality of life, global health, fatigue, disease activity, 
pain, and functional impairment. Associations between these two clusters and patient-
reported outcome measures were similar in magnitude to those reported in other studies 
[199,203,204,142]. However, none of the comorbidity clusters were significantly associated 
with ESR or CRP in the present study. In a previous meta-analysis, depression was 
additionally associated with objective measures such as ESR and BASMI [199]. Severe axSpA 
is likely to increase the risk of depression, and depression is known to impact the 
experience and reporting of pain [199,212]. Direction of causation could not be determined 
due to the cross-sectional design of this study. This is less relevant when the aim is to 
identify patient-clusters that may benefit from additional management. Baseline 
depression has been shown to reduce treatment response in longitudinal studies of RA 
[213], but whether this is true for axSpA patients is not yet known. 
Although consistent associations across several outcomes are reassuring, care should be 
taken when interpreting isolated significant results (such as the association between global 
health and other substance misuse). Several clusters (e.g., asthma, thyroid and other rare 
diseases) had low prevalence, which partly contributed to the lack of precision in their 
effect estimate. For example, the cluster for other rare conditions was associated with 
clinically significant effect sizes in BASDAI, pain and BASFI, but these were not statistically 
significant. Larger studies using standardised recording of comorbidities and disease indices 
are needed to study them in greater detail. 
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4.5.4 Strengths and limitations 
A key strength of this study was the range and number of comorbidities, selected based on 
their importance in the general population rather than their relationship to the index 
disease. The latter approach is common among studies of comorbidity, many of which 
include diseases based on prevalence or availability of data and may overlook other 
important conditions. Analyses of the two axSpA cohorts complemented and strengthened 
each other. In the Aintree axSpA study, comorbidity data were extracted from diagnoses 
documented in clinical notes, which are likely more accurate than those obtained from 
patient-recall or administrative diagnostic codes alone. Several sources of clinical 
information were reviewed to reduce the possibility of missing diagnoses.  
There were several limitations. For the Boston study, identifying cases from historical EHR 
data is challenging in the context of evolving terminology and classification criteria. There 
are no ICD-9 or -10 codes for axSpA, and using ICD code alone to classify AS has limited 
accuracy [168]. The high positive predictive value (80%) of the search strategy likely came 
at the cost of reduced sensitivity, in particular the ability to identify nr-axSpA cases. 
Requiring three or more ICD codes and radiological keywords may have selected individuals 
with more advanced disease, which may explain the older age of the cohort. Nevertheless, 
the proportion of AS cases (83%) was similar to that of the Corrona SpA registry (76%) 
[205]. 
In the US, patients can, and do, change their hospitals and care-providers such that 
diagnoses are often made at prior institutions and by different providers; therefore, data 
may not be consistently available for variables such as disease or symptom duration. 
Disease severity indices were not systematically collected. Treatment decisions in the US 
are made by the provider together with the patient; insurance companies do not require 
documentation of BASDAI to prescribe biologics. However, the available pain data was 
consistent with analyses of other disease indices in the Aintree axSpA and Corrona SpA 
registries [205].  
Using ICD codes to derive comorbidities may have limited accuracy for certain diseases. 
However, any inaccuracies with ICD codes are likely to be the same for both AS and nr-
axSpA groups and would not result in directional bias. Coded EHR medication data could 
not be used to determine current use of individual drugs. Furthermore, NSAIDs might be 
bought over the counter, and infliximab could be prescribed on infusion charts and not 
coded. It is also possible for patients to consult and receive treatment from 
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rheumatologists outside of Partners HealthCare, which would not be coded. The proportion 
of patients who had ever used prednisone was high. This could be explained by short 
courses prescribed for symptom flares or for other co-existing conditions.  
The main methodological limitation for the cluster analysis was the lack of internal (e.g., 
cross-) validation of the cluster analysis. Clustering results were, however, supported by a 
range of sensitivity analyses, including the use of an independent, external dataset.  
Results from these analyses may have limited generalisability to all axSpA cohorts, since 
both studies were conducted at tertiary centres. Lastly, some important disease indices 
were lacking in both studies, namely ASDAS and BASMI. This precluded comparison of 
whether associations with subjective and more objective measures of disease activity. 
 
4.6 Summary 
Comorbidities were common in both axSpA populations and similar between AS and nr-
axSpA. These findings highlight the importance of identifying and managing comorbidities 
in these patients and support a unified management approach for the full spectrum of 
axSpA. Comorbidity co-existed in clusters, which consisted mostly of concurrent 
cardiovascular or mental-health disorders. Patients with comorbid depression-anxiety and 
fibromyalgia-IBS reported worse overall health-related quality of life, global health, fatigue 
and axSpA disease activity. These results highlight the importance of identification and 
optimisation of comorbidities, particularly mental health, and holistic patient-centred 




Chapter 5: Comorbidities and disease assessment in axSpA 
 
This chapter examines whether assessment of axSpA disease activity and other measures of 
disease severity are influenced by the presence of comorbidities, using cross-sectional data 
from the BSRBR-AS registry. 
 
5.1 Introduction 
The previous chapter showed that axSpA patients with comorbidities reported more severe 
disease (including disease activity, functional impairment, fatigue, etc.) than those without. 
This may be explained, at least in part, by the subjectivity of patient-reported outcome 
measures. Prior studies have shown that patient perspectives of disease activity are more 
associated with function and fatigue, whereas physician assessments are more related to 
metrology and CRP [214]. Patients’ experience of axSpA symptom severity may be 
influenced by coexisting conditions; for example, cardiorespiratory diseases can 
significantly reduce physical function [90,215], while concurrent depression and 
fibromyalgia influence fatigue [216]. Many treatment decisions depend on patient-reported 
disease activity despite these limitations; for example, eligibility to commence and continue 
biologics are defined using thresholds of BASDAI and spinal pain in the UK [190]. 
The AS disease activity score (ASDAS) was developed to address some of these concerns 
around disease activity assessment [217,218]. ASDAS combines three questions from 
BASDAI with CRP/ESR and the patient global score (see Chapter 1, Box 1.5, page 39), 
analogous to the disease activity score – 28 joints (DAS28) for rheumatoid arthritis (RA). 
Unlike BASDAI, it has been shown to associate with radiographic progression [219]. 
However, whether ASDAS is robust to the influence of comorbidities compared to patient-
reported disease activity has not been examined. In RA, comorbidity count inflates DAS28 
through the patient global score, independently of swollen/tender joints and inflammatory 
markers [220]. The patient global score is given more weight than all other patient-reported 
components in the ESR-based ASDAS formula and surpassed only by the ‘back pain’ 
component in the CRP-based formula. It is unknown whether the same vulnerability exists 
for ASDAS. Understanding whether and how comorbidities influence assessment of disease 
activity is crucial given their high prevalent [84,221]. This chapter addresses these unmet 
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research needs, namely how comorbidities influence the assessment of disease activity and 
other disease indices. 
5.2 Aims 
1. To compare whether measures of disease activity (BASDAI, spinal pain, ASDAS) and 
inflammation (CRP/ESR) are differentially influenced by comorbidities. 
2. To replicate these comparisons for other important measures of disease severity 
(fatigue, function, and health-related quality of life).  
3. To examine whether the patient global component of ASDAS is influenced by 
comorbidities independent of the other components. 
 
5.3 Methods 
The BSRBR-AS was used to address these aims as it includes a wealth of axSpA disease 
severity measures. Sufficient data was collected from which ASDAS could be derived, which 
was not possible in the Aintree and Boston cohorts. Cross-sectional baseline data were 
used from both biologic (i.e., pre-treatment data) and non-biologic groups.  
5.3.1 Comorbidity  
The count of 14 comorbidities was considered in three ways (as described in Chapter 3, 
Section 3.5.2) as: binary (no comorbidity vs. at least one), continuous, categorical (0, 1, 2, 
≥3) and individual conditions. 
5.3.2 Assessment of disease activity and severity  
Disease severity is a multifaceted concept. For this thesis, ‘severity’ included disease 
activity and other indices such as functional impairment. Disease activity was assessed 
using BASDAI, ASDAS, spinal pain, CRP (mg/dl) and ESR (mm/hr) [180]. ASDAS was 
calculated using the following: ASDAS-CRP = 0.12 x Back Pain + 0.06 x Duration of Morning 
Stiffness + 0.07 x Peripheral Pain/Swelling + 0.11 x Patient Global + 0.58 x Ln(CRP+1), or 
ASDAS-ESR = 0.08 x Back Pain + 0.07 x Duration of Morning Stiffness + 0.09 x Peripheral 
Pain/Swelling + 0.11 x Patient Global + 0.29 x √ESR [218]. 
Functional impairment was assessed using BASFI and BASMI [180]. Fatigue was measured 
using the Chalder Fatigue Scale Likert scale (CFQ) and health-related quality of life using the 
AS quality of life questionnaire (ASQoL) [179,222]. 
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5.3.3 Covariates  
Covariates were determined a priori including age, gender (female as referent), BMI, 
smoking status (ever/never), socioeconomic status (as continuous variable) and educational 
attainment (as dummy variables). Socioeconomic status was approximated using post-code 
derived Index of Multiple Deprivation, with quintile 1 representing the top 20% most 
deprived areas and quintile 5 the least deprived [158,223]. Smoking was categorised as ever 
and never, since comorbidities will influence smoking cessation behaviour (see causal 
diagram in Figure 5.1). Similarly, use of NSAIDs in the past 6 months is an intermediate 
variable rather than confounder (Figure 5.1) 
 
Figure 5. 1. Causal diagrams to justify covariate selection. 
 
 




Ever-use of NSAIDs → Comorbidity → NSAID-use in the past 6 months → Disease activity 
Smoking is directly causal for several comorbidities, thus ever-exposure to smoking will be 
associated with increased risk of developing certain comorbidities. However, those with 
comorbidities will be more likely to stop smoking. Adjusting for current/past smoking status 
(an intermediate variable) would attenuate effect of comorbidity on outcomes, while 
adjusting for ever-smoking would not.  
Historical use of NSAIDs will likely impact development of comorbidities such as peptic ulcer 
disease. However, NSAID use was only captured for the preceding 6 months. It is likely that 
comorbidity onset pre-dated this. Adjusting for NSAID-use in the past 6 months (an 
intermediate variable) would attenuate effect of comorbidity on outcomes. 
 
Age, gender, and BMI are associated with both comorbidity and axSpA disease severity. 
Deprivation and education are causal factors for lifestyle, which is a latent variable 
associated with both comorbidity and disease severity. These hypothesised confounding 
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relationships were tested in the data: education was strongly associated with comorbidity 
count and BASDAI; deprivation was strongly associated with BASDAI but not comorbidity 
count. Potential confounders strongly associated with the outcome should be included, 
even if only weakly associated with the ‘exposure’ [224]. These variables were therefore 
included as covariates. 
5.3.4 Statistics 
Descriptive statistics were used to summarise comorbidity prevalence and compare 
participants with and without comorbidities. CRP and ESR were transformed using 
ln(CRP+1) and ln(ESR) in regression models. 
In addition to three variable-types for comorbidity count, the independent contribution of 
individual comorbidities to each disease activity and other disease severity measures was 
also examined, by adding all 14 comorbidities into linear models, and adjusting for the 
same covariates. Individual conditions may be closely related to others (e.g., hypertension 
and ischaemic heart disease shown in Chapter 4); variance inflation factor [191] was used 
to check for multicollinearity. Correction for multiple testing was not performed since 
dependent variables measure a shared underlying construct of disease severity; that is, 
tests were not independent [225]. 
To examine whether comorbidity count or individual comorbid conditions independently 
inflated the patient global score, the above analyses were repeated for patient global and 
comorbidity count or individual comorbidities, but additionally adjusting for other 
components of the ASDAS (three BASDAI questions and CRP). Throughout, model 
coefficients and 95% confidence intervals were displayed graphically with detailed results 
provided in the Appendix 10.4. 
5.3.4.1 Power considerations 
The primary analysis examined the association between the number of comorbidities 
against BASDAI using multivariable linear regression. Education was entered as a dummy 
variable (i.e., as 5 variables), giving a total of 11 variables. Using alpha of 0.05, a sample size 
of 2043 provides 80% power (i.e., beta of 0.2) if comorbidity count explains ≥0.4% of the 
total variance. These power estimates remain practically unchanged for secondary analyses 
that examine individual comorbidities (i.e., 14 additional variables, total 25 variables). 
Statistical power was reduced for analyses of other disease severity outcomes where the 
proportion missing was greater. 
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7.3.4.2 Sensitivity analyses 
Some comorbidities, including heart failure, cancer, TB and demyelinating diseases, are 
routinely sought for during the workup for TNF inhibitor therapy. These comorbidities may 
therefore be more prevalent in the biologic cohort due to differential ascertainment alone. 
Equally, presence of certain comorbidities may channel patients into (e.g., renal/peptic 
ulcer disease and inability to use NSAIDs) or away from (e.g., cancer) the biologic group. All 
analyses were repeated in the non-biologic cohort only.  
For analyses of comorbidity and the patient global score, successful adjustment for other 
components of ASDAS required adequate covariate overlap between comparison groups; 
extrapolating beyond overlap can introduce bias. Patients were therefore matched on all 
covariates (gender, ever-smoking, education, deprivation index, quintiles of age and BMI, 
and tertiles of the three ASDAS questions and ln(CRP+1)) in sensitivity analyses, using 





Among a total of 2687 participants, 2043 (76%) were included for analysis; exclusions were 
due to missing questionnaires (n=364, 14%), missing comorbidity data (n=6, 0.2%) and 
questionnaires completed outside the eligible window (n=274, 10%). Included and excluded 
participants were generally similar (Appendix 10.4: Table S5.1), except the latter were 
younger (mean 44 (SD 13) vs. 49 (SD 15) years, p<0.001) and had younger age of symptom 
onset (mean 28 (SD 13) vs. 29 (SD 14) years, p=0.015) and clinically non-significantly lower 
ESR (median 9 vs. 13 mm/hr, p=0.035) and BASMI (median 3.2 vs. 3.8, p=0.022). 
The population included in the analyses were predominantly male (67%) with mean age of 
49 (SD 15) years (Table 5.1). Classification criteria for AS was fulfilled by 1316 (65%). HLA-
B27 status was available for 74% of participants and was positive in 79% of these cases. 
Thirty one percent were in the biologic group but had not yet commenced treatment. 
Those with comorbidities were significantly older (54 (SD 15) vs. 45 (SD 14) years), had 
higher BMI (29 (SD 6) vs. 27 (SD 5) kg/m2) and lower educational attainment. Although 
there were more ever-smokers in the group with comorbidities (63 vs. 50%), a larger 
proportion had quit (43 vs. 32%). NSAID use in the preceding 6 months was less common 
among those with comorbidities. Participants with comorbidity also had higher disease 




Table 5. 1: Baseline characteristics of 2043 participants from the BSRBR-AS registry. 
 









Age, years 49.1 (14.7) 45.3 (13.5) 53.9 (14.8) <0.001 
Males 1382 (68%) 742 (66%) 615 (69%) 0.078 
Meeting modified New York 
criteria 
1340 (66%) 703 (62%) 613 (69%) 0.001 
Age at symptom onset, years 29.1 (11.8) 28.4 (11.3) 30.1 (12.3) 0.001 
Symptom duration, years 20.0 (14.6) 16.9 (13.4) 23.8 (15.3) <0.001 
HLA-B27 positive* 1193 (79%) 702 (80%) 471 (76%) 0.11 
BMI, kg/m2 27.7 (5.5) 26.7 (4.9) 28.9 (6.0) <0.001 
Smoking 
status 
Never smoked 900 (44%) 563 (50%) 323 (37%) <0.001 
Ex-smoker 743 (36%) 355 (32%) 379 (43%) 
Current smoker 394 (19%) 207 (18%) 181 (20%) 
Education Secondary 
school 
648 (32%) 335 (30%) 308 (35%) <0.001** 




620 (30%) 318 (28%) 289 (33%) 
University 
degree 
417 (21%) 275 (25%) 134 (15%) 
Further degree 157 (8%) 102 (9%) 53 (6%) 
Deprivation index, median 
(IQR) 
3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 0.26 
NSAID use in past 6 months 1486 (73%) 865 (77%) 596 (68%) <0.001 
DMARD use in past 6 months 201 (13%) 103 (12%) 96 (15%) 0.13 
BASDAI, median (IQR) 4.9 (2.6, 6.8) 4.4 (2.3, 6.6) 5.5 (3.3, 7.3) <0.001 
Spinal pain, median (IQR) 5.0 (2.0, 7.0) 3.0 (1.0, 7.0) 5.0 (2.0, 8.0) <0.001 
ASDAS* 2.3 (1.1) 2.2 (1.1) 2.4 (1.1) <0.001 
CRP (mg/dL), median (IQR)* 0.6 (0.2, 1.9) 0.6 (0.2, 1.8) 0.6 (0.2, 2.0) 0.50 
ESR (mm/hr), median (IQR)* 11.0 (5.0, 23.0) 10.5 (5.0, 23.0) 11.5 (5.0, 
24.0) 
0.28 





ASQoL, median (IQR) 8.0 (3.0, 13.0) 7.0 (3.0, 12.0) 10.0 (5.0, 
15.0) 
<0.001 
BASFI, median (IQR) 4.4 (2.0, 7.0) 3.6 (1.5, 6.1) 5.7 (2.9, 7.9) <0.001 
BASMI, median (IQR)* 3.8 (2.2, 5.4) 3.2 (2.0, 4.8) 4.4 (2.8, 6.0) <0.001 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
*Not all variables had complete data; HLA-B27 was available for 74% of participants, BASMI 
75%, ASDAS 78%, CRP 78%, ESR 39%. 
**non-parametric test for trend. 
ASDAS, AS disease activity score; ASQoL, AS quality of life; BASDAI, Bath AS disease activity 
index; BASFI, Bath AS functional index; BASMI, Metrology Index; questionnaire; BMI, body 




The distribution of comorbidity count is shown in Figure 5.2; 44% of participants had at 
least one of the 14 comorbidities. The median number of comorbidities was 0 (IQR 0 to 1) 
and the mean was 0.7 (SD 0.9). The prevalence of each comorbidity is shown in Figure 5.3. 
The most common comorbidities were hypertension (28%), depression (23%), and asthma 
(15%). Only four of the 14 conditions had a prevalence of ≥5%, while five diseases had a 
prevalence of 1% or lower. 
 







Figure 5. 3: Prevalence of comorbidities among 2043 participants of the BSRBR-AS. 
 
 
5.4.1 Comorbidities and disease activity 
With comorbidity count as a continuous variable, each additional comorbidity was 
associated with higher BASDAI by 0.40 units (95% CI 0.27 to 0.52) and spinal pain by 0.53 
(95% CI 0.37 to 0.68). Figure 5.4 shows these relationships with comorbidity count as a 
categorical variable (with full model coefficients shown in Appendix 10.4: Table S5.2). For 
each additional comorbidity, ASDAS was higher by 0.09 units (95% CI 0.03 to 0.15). Those 
with 1 or 2 comorbidities did not have higher ASDAS than those with no comorbidities in 
terms of statistical or clinical significance. Comorbidity count was not associated with log-
transformed CRP (β=-0.03 (back-transformed effect size -0.03mg/dL); 95% CI -0.07 to 0.02) 
or log-transformed ESR (β=-0.03 (i.e., 0.97mm/hr); 95% CI -0.12 to 0.06). 
Independent associations between each comorbid condition and disease activity are shown 
in Figure 5.5. Participants with depression, heart failure and peptic ulcer diseases had 
consistently higher disease activity than those without each of these conditions. For 
example, participants with depression had 0.9-unit higher BASDAI and spinal pain than 
those without, after accounting for covariates and all other comorbidities. Effect sizes were 
smaller for ASDAS. The only comorbidities associated with CRP and ESR were COPD and 
asthma, respectively; the back-transformed effect sizes for CRP (0.5mg/dL) and ESR 




Figure 5. 4: Association between comorbidity count and disease activity. 
 
Results shown as adjusted model coefficients 
(95% confidence interval) using participants with 
no comorbidities as the reference group.  
For example, participants with ≥3 comorbidities 
had 1.5-unit higher BASDAI and 0.38-unit higher 
ASDAS than those without comorbidities. Full 
model results shown in Appendix Table S7.2. 
ASDAS, AS disease activity score; BASDAI, Bath AS 
disease activity index.  
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Figure 5. 5: Association between each comorbid condition and disease activity. 
 
 
Results shown as adjusted model coefficients (95% confidence interval) compared to participants without each condition. For example, participants with 
heart failure (HF) had 1.7-unit higher BASDAI and 0.59-unit higher ASDAS than those without HF. Full model results shown in Appendix 10.4: Table S5.3.  
ASDAS, AS disease activity score; BASDAI, Bath AS disease activity index; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HF, heart 
failure; HTN, hypertension; IHD, ischaemic heart disease; PUD, peptic ulcer disease. 
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5.4.2 Comorbidities and other measures of disease severity 
Comorbidity count (as a continuous variable) was associated with significantly worse 
fatigue (β=1.05; 95% CI 0.76 to 1.33), health-related quality of life (β=1.18; 95% CI 0.90 to 
1.46) and functional impairment (β=0.55; 95% CI 0.41 to 0.69). The effect size was smaller 
for BASMI (β=0.22; 95% CI 0.12 to 0.33) than BASFI. Figure 5.6 shows these relationships 
with comorbidity count as a categorical variable.  
Independent associations between each comorbid condition and the four disease severity 
measures are shown in Figure 5.7. Participants with heart failure, depression and peptic 
ulcer disease had consistently worse fatigue, quality of life and functional impairment than 
those without, accounting for covariates and all other comorbidities. Diabetics had poorer 
function and quality of life, while participants with stroke had greater fatigue.  
 




Results shown as adjusted model coefficients (95% confidence interval) using participants 
with no comorbidities as the reference group. For example, participants with ≥3 
comorbidities had 2.0-unit higher BASDAI and 0.79-unit higher BASMI than those without. 
Full model results shown in Appendix 10.4: Table S5.4. ASQoL, AS quality of life 
questionnaire; BASFI, Bath AS functional index; BASMI, Bath AS metrology index. 
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Results shown as adjusted model coefficients (95% confidence interval) compared to 
participants without each condition. Full model results shown in Appendix 10.4: Table S5.5. 
ASQoL, AS quality of life questionnaire; BASFI, Bath AS functional index; BASMI, Bath AS 
metrology index; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HF, 





5.4.3 Independent influence of comorbidity on the patient global score 
Patient global score increased (suggesting an increase in disease severity) with the number 
of comorbidities, but not independently of other ASDAS components (Figure 5.8). 
Depression, peptic ulcer, and renal diseases were significantly associated with patient 
global score, but not when additionally adjusting for other ASDAS components. 
 
Figure 5. 8: Association between comorbidities and the patient global score. 
 
 
Top panels show comorbidity count vs. PG without (top left) and with adjustment for other 
components of ASDAS (top right). Bottom panels show associations between PG and 
individual comorbid conditions. Results shown as model coefficients (95% confidence 
interval). ASDAS, AS disease activity score; COPD, chronic obstructive pulmonary disease; 
DM, diabetes mellitus; HF, heart failure; HTN, hypertension; IHD, ischaemic heart disease; 





5.4.4 Sensitivity analysis 
There were some differences when biologic and non-biologic cohorts were compared 
(Appendix 10.4: Table S5.6). Participants in the biologic arm of the BSRBR-AS registry were 
younger, less frequently HLA-B27 positive or met the classification criteria for AS, more 
often current smokers, and resided in more deprived areas. They also had significantly 
more severe disease across all indices. Participants in the biologic cohort had an overall 
similar comorbidity burden (mean number 0.7 (SD 0.9) vs. 0.7 (SD 0.9)) to those in the non-
biologic cohort. However, they less frequently had stroke (1 vs. 2%, p=0.04), hypertension 
(15 vs. 21%, p=0.003), cancer (2 vs. 5%, p<0.001), and more often had peptic ulcer (4 vs. 2% 
p=0.006) and depression (21 vs. 13% p<0.001). Despite these differences, results from the 
sensitivity analysis restricted to the non-biologic cohort did not meaningfully change effect 
estimates, although precision was reduced (i.e., confidence intervals widened) with smaller 
sample sizes (Appendix 10.4: Figure S5.1 and S5.2). Results using coarsened exact matching 






This chapter used cross-sectional, pre-treatment data from the BSRBR-AS to examine 
associations between comorbidity and measures of disease severity. Unlike BASDAI and 
spinal pain (subjective measures of disease activity), ASDAS was not associated with 
comorbidity count or individual comorbidities at a clinically meaningful effect size. Although 
the patient global component of ASDAS was influenced by coexisting morbidities, they did 
not inflate ASDAS through the patient global score independently of other ASDAS 
components. Other patient-reported measures of disease severity (function, fatigue, and 
health-related quality of life) were significantly associated with comorbidity count and 
individual comorbidities. When making treatment decisions, clinicians should be mindful of 
the potential impact of comorbidities on patient reported measures of disease activity, and 
consider additionally assessing disease activity using ASDAS when comorbidities are 
present.  
These results complement those from the ASAS-COMOSPA study, where comorbidity 
burden (assessed using RDCI) was associated with poorer BASFI, health-related quality of 
life (EuroQol) and work-related outcomes, despite using a slightly different list of comorbid 
conditions [90]. The current analyses additionally demonstrated that BASMI – a physician 
derived outcome often considered objective – is also significantly associated with 
comorbidity count, albeit with smaller effect sizes than BASFI. Importantly, ASDAS was 
found to be comparatively robust to the impact of coexisting morbidities. Unlike BASDAI 
and spinal pain, the relationship between comorbidity count and ASDAS was not 
completely linear, which may be explained by the weighting of ASDAS components. ASDAS 
was not significantly different between participants without comorbidities and those with 
one or two. There was a statistically significant difference in ASDAS between those with ≥3 
and no comorbidities, but the mean difference of 0.38 is not clinically significant 
(meaningful change = 1.1). Using an unweighted comorbidity count was preferable, since 
RCDI was weighted for inpatient outcomes (mortality, hospitalization, disability, and costs) 
that may not be appropriate to study axSpA-specific measures. It also allowed examination 
of the relationship between comorbidity and outcomes in more detail: depression, 
diabetes, heart failure, peptic ulcer, and renal diseases (and to a smaller and less consistent 
extent stroke) were the most significant contributing conditions. Most of these conditions 
are relative (or potentially absolute depending on severity) contra-indications for NSAIDs – 
the first and only line of pharmacological therapy before bDMARDs. Patients with high 
cardiovascular risk, renal or peptic ulcer diseases, who cannot use NSAIDs, are more likely 
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to experience more severe symptoms of axSpA and their impact on other aspects such as 
fatigue. This channelling away from NSAIDs and towards bDMARDs was supported by the 
higher prevalence of peptic ulcer disease in the biologic than non-biologic cohort of the 
BSRBR-AS (Appendix 10.4: Table S5.6). Equally, cardiovascular, renal, and peptic ulcer 
disease may also result from long-term exposure to NSAIDs due to severe symptoms. These 
are limitations arising from the cross-sectional design and lack of historical NSAID data. The 
data does, however, suggest that more objective measures such as ASDAS and BASMI are 
influenced by comorbidities to a lesser extent than patient-reported indices.  
In RA, patient global score increased with the number of comorbidities, independently of 
tender/swollen joint count, CRP and physician global [220]. Among axSpA participants in 
these analyses, patient global score was significantly associated with comorbidity count. 
This is potentially concerning since it is given more weight than almost all patient-reported 
components of the ASDAS. Reassuringly, the patient global score did not appear to inflate 
ASDAS independent of its other components. These observations support the use of ASDAS 
particularly when comorbidities are present and likely to influence other patient-reported 
outcome measures. Further longitudinal studies are needed to assess whether 
comorbidities influence treatment response as measured by different outcomes (e.g., 
BASDAI vs. ASDAS). Longitudinal studies on comorbidities as ‘exposure’ (rather than 
outcome) in axSpA are scarce. Preliminary results from the BSRBR-AS suggests that 
comorbidity may be one of very few potentially modifiable predictors of treatment 
response [134]. 
5.5.1 Strengths and limitations 
A key strength of this study is its large sample size representative of a national axSpA 
population, for whom a wide range of disease measures were collected. Ascertainment of 
comorbidities was robust, using physician diagnoses from medical records. There were also 
some limitations. Cross-sectional data do not inform causal direction; however, it is more 
plausible that comorbidity burden influences experience and reporting of disease activity, 
rather than vice versa. First, baseline disease activity is less likely to influence past medical 
history (albeit baseline may reflect disease activity history). Second, the difference between 
subjective and more objective indices suggest subjectivity is relevant. Comorbidities were 
selected through a consensus meeting of clinicians and researchers to support the primary 
drug safety aims; therefore some (e.g., neurological) comorbidities were not compared. 
However, included comorbidities were broadly representative of important diseases when 
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compared to prior axSpA research [84]. Low prevalence of some conditions (e.g., heart 
failure, liver, and demyelinating diseases) meant that their effect estimates had significant 
uncertainty. Severity (e.g., for heart failure) and more granular descriptions (e.g., cancer 
type) for comorbidities were not available but would have provided useful information. 
Some comorbidities (TB, heart failure, cancer, and demyelinating diseases) are of special 
interest when considering TNF inhibition therapy; they may be recorded more 
systematically in patients. However, restricting analyses to the non-biologic cohort did not 
meaningful change results. Lastly, the wording of the patient global question can be highly 
variable [227]. For example, the patient global question in DAS28 can be worded to assess 
arthritis-related disease activity or global health (the recommended phrasing in RA is 
‘Considering all the ways your arthritis has affected you, how do you feel your arthritis is 
today?’). The patient global question in the BSRBR-AS was specific to spondyloarthritis 
activity in the past week; therefore, other versions may not be equally robust in the 
presence of comorbidities.  
 
5.6 Summary 
Patient-reported axSpA measures are influenced by comorbidities. This is important for 
routine practice as around half of all patients have at least one comorbidity. ASDAS seems 
to be less influenced by the presence of comorbidities. ASDAS was not disproportionately 
inflated by the effect of comorbidities on the patient global score, as was shown for DAS28 
in rheumatoid arthritis. In routine clinical practice, clinicians should consider additionally 
collecting ASDAS to assess disease activity in patients with multiple comorbidities, including 
but not limited to depression. Additional studies are needed to examine the impact of 
comorbidity burden on longitudinal disease severity and response to treatment. This will be 





Chapter 6: Comorbidities and response to TNF inhibitors 
 
This chapter uses longitudinal data from the BSRBR-AS to examine whether the presence of 
comorbidities at baseline is associated with response to TNF inhibition treatment. Analyses 
will approach response using common binary definitions, change in continuous outcome 
indices over time, and time to treatment discontinuation. 
 
6.1 Introduction 
Previous chapters showed that comorbidities are common and are associated with greater 
axSpA severity. Comorbidities may also impact management (e.g., eligibility for treatment 
escalation) through the way in which axSpA disease activity is assessed. Despite this, 
research into the impact of comorbidities on treatment response are scarce. This is an 
important unmet need for two reasons: First, up to half of patients do not respond to their 
first TNF inhibitor (TNFi) [228], thus identifying potentially modifiable factors are important 
for clinical practice. Second, if some axSpA disease indices are inflated in the presence of 
comorbidities, comorbid patients may have persistently high scores – thereby at risk of 
having treatment discontinued – despite successfully supressing axSpA inflammation. 
Of the three existing studies [114,118,134], most rely on binary response definitions, such 
as a certain degree of improvement (e.g., 50% improvement in BASDAI) or disease state 
(e.g., ASDAS low disease activity, <2.1). These outcomes are problematic in observational 
data where starting disease activity differ between groups under comparison: those with 
higher baseline disease activity are simultaneously more able to achieve the former 
(because there is more ‘room’ for improvement) and less able to achieve the latter 
(because greater absolute improvement is required), compared to those with lower disease 
activity. Consider a participant with ASDAS of 3.6 at baseline and another with ASDAS 2.2; 
an identical reduction by 1 unit in both would achieve ‘inactive disease’ status for the latter 
while the former would still have ‘high disease activity’. This is true regardless of the 
‘exposure’ of interest; smokers, those from more deprived areas or with lower education 
attainment, or any group with high disease activity at baseline, would all be less likely to 
achieve binary response. Thus, absolute improvement in disease activity is likely to differ 
from the binary response derived from the same index. (These limitations have been 
examined in detail in publications related to the thesis project [41,42].) Adjustment for the 
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baseline disease activity is necessary, but controversial [41], since it is unlikely a confounder 
(i.e., baseline disease activity will not cause comorbidities) and more likely a mediator (i.e., 
comorbidities influence baseline disease activity as a causal intermediate to response, as 
shown in the previous chapter). 
Untangling the role of comorbidities on the treatment response is important for clinical 
practice, which requires more than one approach to defining response. This chapter 
addresses this unmet research need using binary response definitions, change in 
continuous outcome indices over time, and time to treatment discontinuation. 
 
6.2 Aims 
1. To examine the association between baseline comorbidity status and binary 
response definitions among those using TNFi. 
2. To examine the association between baseline comorbidity status absolute change 
in disease activity (BASDAI, spinal pain, ASDAS) and other measures of disease 
severity. 




6.3.1 Patient population 
Participants in the BSRBR-AS who started on their first TNFi (including those who switched 
from the non-biologic group) were eligible for inclusion in this analysis. Eligible individuals 
were required to have a clinic visit or questionnaire within 1 year before, or 7 days after, 
the TNFi start date, from which the baseline value of time-varying data (i.e., measures of 
disease activity and severity) was obtained. Time-invariant data could come from any 
assessment time if missing at baseline; all variables except disease activity indices were 
considered time-invariant in this analysis. 
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6.3.2 Comorbidity  
The count of 14 comorbidities was analysed as three variable types: binary (comorbidity vs. 
none), continuous, and categorical (0, 1, ≥2; or 0, 1, 2 ≥3 where possible) (see Chapter 3, 
Section 3.5.2). Many existing studies select one approach often without justification; 
performing analyses using all three can reveal comparative merits or deficiencies of each. 
This subpopulation of TNFi initiators in the BSRBR-AS was not sufficient in size to explore 
individual comorbidities as was performed in the previous chapter. 
6.3.3 Outcomes 
6.3.3.1 Binary response definitions 
The first aim used the following common binary response definitions at 6 months: BASDAI 
50/2 (50% or 2-unit reduction), ASDAS major improvement (ASDAS-MI, ≥2-unit reduction), 
low disease activity defined as BASDAI<4 or ASDAS<2.1 (see Chapter 3, Section 3.5.2). 
Participants with missing baseline BASDAI or ASDAS were excluded. Where the 6-month 
assessment was missing but participants remained on the drug, they were considered as 
having responded if they demonstrated response at 3 or 12 months. Both assumptions are 
justifiable since participants were unlikely to remain on the drug if they lost or did not have 
a response, as per prescribing guidelines in the UK [190]. Participants who discontinued 
treatment within 6 months for any reason were considered as non-responders. 
Using the above definitions for the binary response, individuals who stayed on treatment 
(i.e., no stop date) but did not have assessments recorded at 3, 6 or 12 months would have 
missing response values. In sensitivity analyses, these individuals were assumed to have 
responded at 6 months if they remained on treatment beyond 12 months. This was not 
included in the main analysis because patients without a documented stop date could be 
on treatment or lost to follow-up. 
The first two response definitions are derivatives (in part for BASDAI 50/2) of absolute 
reductions. They should be less effected by baseline disease activity except through a ‘floor 
effect’ of the index (e.g., someone starting with BASDAI of 2 cannot possibly decrease by 
more than 2). The low disease activity definitions would be affected by issues relating to 
differing baseline values, as discussed above. 
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6.3.3.2 Change in continuous outcome indices over time 
The second aim examines the absolute change in disease activity (BASDAI, spinal pain, 
ASDAS); that is, change from baseline over follow-up time. Assessing continuous change in 
repeated assessments made over time is more efficient and informative than imposing one 
time point.  
These analyses were repeated for other disease outcomes including functional impairment, 
health-related quality of life, fatigue, and sleep (see Chapter 3 for descriptions of these 
indices). Response was assessed only in the first 3 years (up to 36 months + 6 months’ 
window = 42 months) because the number at each sequential follow-up dropped 
dramatically (see Results below). 
For continuous change in disease indices, mixed effects models are able to handle data 
Missing At Random (i.e., systematic relationship between the propensity for missingness 
and the observed data, but not the missing data [192]). No imputation for baseline or 
longitudinal values were required. 
6.3.3.3 Time to treatment discontinuation 
The final aim examines time to any-cause discontinuation. Treatment duration was 
analysed as continuous time from start to discontinuation of treatment was derived from 
respective dates. Censoring was defined by the last visit for those who did not discontinue 
treatment. 
A small number of participants were commenced on TNFi but did not have any subsequent 
assessments by visit or questionnaire, thus their time on-drug were unknown. These 
individuals with zero follow-up time would, by definition, be excluded from all time-to-
event analyses. They can contribute (their baseline characteristics) to the analysis by having 
an arbitrarily small time assigned. In the primary analysis, each were assigned 0.001 days’ 
follow-up (approximately 1.5 minutes) which does not affect the overall person-time. 
Cause-specific discontinuation was not assessed as part of the primary aims because 
previous work using the BSRBR-AS showed limitations in this data [189]. There is often 
overlap between how inefficacy and adverse events are defined and reported. For example, 
therapy is more likely to continue in the face of mild adverse events if they are highly 
effective for symptom control; inflammation in previously unaffected peripheral joints may 
be reported as an adverse event, when it would more appropriately reflect lack of disease 
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control and efficacy. Before 2016 – that is, most of the study period (2012-2017) – NICE 
stipulated that patients who did not demonstrate initial or maintained response to 
treatment would not be funded to use a second TNFi [17, 18]. However, switching to a 
second TNFi was allowed if discontinuation was due to the development of a treatment-
related adverse event. This may have influenced labelling of discontinuation as adverse 
events or other reasons. These errors would not affect the analysis of all-cause 
discontinuation. 
6.3.4 Covariates 
The following covariates were determined a priori: age, gender (female as reference), BMI, 
Index of Multiple Deprivation (IMD, as a continuous variable) and educational attainment 
(as dummy variables). Smoking was not included since analyses performed in parallel to this 
thesis did not demonstrate a convincing causal role with treatment-related outcomes 
[42,189]. 
Baseline disease activity is a controversial covariate. Existing literature have both justifiably 
included and excluded it as a covariate. Debate on this topic necessitates the distinction 
and definition of causation, as discussed in Chapter 3; a summary is given in this section. 
Part of the definition for a confounder is that it is a cause for the exposure (here 
comorbidity) and outcome. High disease activity at baseline does not cause comorbidity. It 
is more likely that comorbidities influence baseline assessment, in which case adjusting for 
a causal intermediate (a mediator) would be inappropriate. However, not accounting for 
baseline disease activity is problematic for some binary definitions of response (see above) 
and does not give the effect of the exposure independent of baseline disease activity.  
6.3.5 Statistics 
Descriptive statistics were used to describe comorbidity prevalence in this analysis cohort 
and compare participant with and without comorbidities. 
6.3.5.1 Logistic regression 
Each of the four binary response variables were used in turn as the dependent variable. 
Comorbidity count was modelled as the independent variable, adjusting for covariates. 
Odds ratios were reported without, then with, adjustment for baseline values of the 
disease index of interest; the latter were displayed graphically to aid interpretation. 
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Interactions between the comorbidity variable and each covariate (i.e., effect modification 
age, gender, etc.) were tested. 
6.3.5.2 Mixed effect model  
The principles of mixed effect models and interaction terms were discussed in Chapter 3. In 
summary, differences in baseline values of each index is accounted for by the intercept and 
does not require additional adjustment. Comparison instead focuses on the interaction-
term coefficients, which represents the additional difference in change from baseline. To 
facilitate interpretation, predicted values are shown graphically, with an asterisk indicating 
statistical significance of the interaction term at the p<0.05 level. Note that statistical 
significance refers to the departure from the baseline difference, or ‘difference accounting 
for the baseline’ (see Chapter 3, Figure 3.14). 
6.3.5.3 Time-to-event analyses 
TNFi discontinuation is equivalent to drug ‘survival’. Kaplan-Meier curves were used to 
show the shape of the survival function for each group (comorbidity was used as binary and 
categorical). The log-rank test was used to test whether their survival distributions are 
equal. The relationship between comorbidity history at baseline (binary and categorical) 
and discontinuation was then modelled using Cox models, adjusting for covariates. 
Interaction between comorbidity and all covariates were tested. Where covariates violated 
the proportional hazards assumption, non-proportional variables were stratified (see 
Chapter 3, Section 3.5.7). 
6.3.5.4 Power considerations 
Power calculation for logistic regression remains an active area of research. The 
commonest ‘rule-of-thumb’ is to have at least 10 ‘events’ (i.e., responders) per 
independent variable. The number of events would therefore need to be 90 for models of 
binary comorbidity and 100 for categorical (assuming 3 categories). Adjusting for baseline 
disease activity would require 10 additional events. Assuming a 50% response, a sample of 
994 would provide sufficient events per variable. There are two caveats. First, this rule-of-
thumb is not based on robust mathematics nor does it perform well in simulations [229]. 
Alternatives were developed mainly for prediction models (using metrics related to out-of-
sample prediction performance) that are difficult to apply here [229]. Second, the number 
of events will be very small when categorising comorbidity count; for example, around 150 
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participants have just one comorbidity (thus 75 events) and 60 have two or more (thus 30 
events). These analyses will be underpowered. 
Power calculations for mixed models are extremely complex, many of which are simulation-
based, and are not available in software such as Stata and G*Power. They also require a 
range of assumptions that, if taken from the output of an already performed model, 
essentially become a transformation of its p-value (i.e., post-hoc power). 
For a Cox model with none:≥1 comorbidities ratio of 2:1, alpha 0.05 and power 0.8, the 
number of events (TNFI discontinuation) needed is 3198 for a 10% reduction in hazard (i.e., 
HR 0.9), 713 for 20%, and 279 for 30% [230]. There were approximately 300 
discontinuations in the analysis population. Therefore, the present analyses will be 
underpowered to detect an effect size smaller than 30% risk of discontinuation in those 
with compared to without comorbidities. As above, power will be further reduced when 
comorbidity count is categorised. 
6.3.5.5 Sensitivity analyses 
The UK prescribing guidelines should mean that all participants have BASDAI ≥4 at TNFi 
initiation. Some participants had lower values; the commonest example is a participant who 
had BASDAI<4 within a year before TNFi initiation but did not have any other assessments 
recorded prior to (or within 7 days of) starting treatment. It is also possible that the 
initiation date was recalled with error. In the first set of sensitivity analyses, these 
individuals were excluded from the analysis set. 
Second, missing binary outcomes were imputed as response if patients remained on drug 
for longer than one year (see Section 6.3.3.1). 
The third set of sensitivity analyses additionally adjusted for smoking status (ever/never) 
and alcohol status (ever/never) in turn. These are potential confounders, although evidence 
of their causal link with the outcome (required for confounder definition) are equivocal. 
Baseline employment status was reported as a predictor in a subsequent BSRBR-AS 
publication [134], but this data was not available for this thesis. Note that employment 
status – a time-varying covariate – is unlikely to serve as a confounder. 
The final sensitivity analysis, other variance-covariance structures were tested for one 
outcome, BASDAI, in linear mixed models. Three are available in Stata: ‘independent’, one 
variance parameter per random effect and all covariances 0; ‘exchangeable’, equal 
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variances for random effects and one common pairwise covariance; and ‘unstructured’, all 
variances and covariances to be distinctly estimated (Appendix 10.2.2). 
 
6.4 Results 
Among 2687 participants in the BSRBR-AS, 1145 (43%) started on biologics. Of this group, 
17 (1.5%) were excluded for using non-TNFi bDMARD, and 134 (12%) for having no valid 
baseline assessment within the accepted time window. Thus 994 (87%) were eligible for the 
current analysis. TNFi initiators included and excluded from the analysis set were similar in 
all baseline characteristics except the former were more often male (68 vs. 60%) (Appendix 
10.5:Table S6.1). Sample sizes for individual analyses in the subsections below vary 
according to the amount of missing data for each variable. The analysis cohort was 
predominantly (68%) male with a mean age of 45 (SD 13) years (Table 6.1). Participants 
with comorbidities were significantly older, had higher BMI, and less frequently had 
university education than those without; they also used NSAIDs less frequently in the past 6 


















Age, years 44.7 (13.4) 43.0 (12.7) 48.3 (14.2) <0.001 
Males 679 (68%) 468 (70%) 211 (65%) 0.17 
Meeting modified New York 
criteria 
597 (60%) 394 (59%) 203 (63%) 0.24 
Age at symptom onset, 
years 
28.6 (11.3) 28.3 (10.9) 29.4 (12.1) 0.13 
Symptom duration, years 16.0 (12.6) 14.7 (12.0) 18.9 (13.4) <0.001 
HLA-B27 positive* 540 (74%) 382 (76%) 158 (71%) 0.12 
BMI, kg/m2 28.1 (5.8) 27.5 (5.6) 29.2 (6.1) <0.001 
Smoking 
status 
Never smoked 351 (40%) 251 (42%) 100 (35%) 0.093 
Ex-smoker 291 (33%) 188 (32%) 103 (36%) 
Current smoker 241 (27%) 155 (26%) 86 (30%) 
Education Secondary 
school 
289 (33%) 184 (31%) 105 (36%) 0.022** 




276 (31%) 175 (30%) 101 (35%) 
University 
degree 
178 (20%) 138 (23%) 40 (14%) 
Further degree 53 (6%) 36 (6%) 17 (6%) 
Deprivation index, median 
(IQR) 
3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 0.12 
NSAID use in past 6 months 734 (75%) 509 (77%) 225 (70%) 0.023 
DMARD use in past 6 
months 
146 (15%) 104 (16%) 42 (13%) 0.29 
BASDAI, median (IQR) 6.7 (5.3, 7.8) 6.5 (5.1, 7.7) 7.2 (6.0, 8.2) <0.001 
Spinal pain, median (IQR) 7.0 (5.0, 8.0) 7.0 (5.0, 8.0) 7.0 (6.0, 8.0) <0.001 
ASDAS* 2.9 (0.8) 2.8 (0.8) 3.0 (0.8) <0.001 
BASFI, median (IQR) 6.5 (4.5, 8.1) 6.1 (4.1, 7.7) 7.1 (5.4, 8.6) <0.001 





















Data shown as mean (SD) and n (%) unless otherwise indicated. 
**non-parametric test for trend. 
IQR, interquartile range; BMI, body mass index; BASDAI, Bath AS disease activity index; 





Prevalence of individual comorbidities are shown in Figure 6.1. Again, there were no 
difference between those included and excluded from analysis (Appendix 10.5: Table S6.1).  
 





The distribution of comorbidity count is shown in Figure 6.2. The proportion with any 
comorbidity in this subgroup of TNFi initiators was lower than the whole BSRBR-AS cohort 
(32 vs. 44%); the mean number of comorbidities was 0.5 (SD 0.8) in this subgroup 
compared to 0.7 in the entire study population (see Chapter 5). Only around 1 in 5 had one 
comorbidity and 1 in 10 had two or more comorbidities.  
 
Figure 6. 2: Histogram showing comorbidity count among 944 participants initiating TNF 






When comorbidity count was categorised, the most prevalent condition was depression 
among those with only one comorbidity (Figure 6.3). 
 
Figure 6. 3 Prevalence of individual comorbidities among those with only one 
comorbidity, and in two other comorbidity count categories. 
  
COPD, chronic obstructive pulmonary disease. 
 
To facilitate navigation of the following results, combinations of comorbidity and outcome 
variable-types will be reported in sections as indicated: 
 Binary comorbidity 






Aim 1: Binary response  6.4.1.1 6.4.1.1 6.4.1.2 
Aim 2: Change in 
continuous outcome 
6.4.2.1 6.4.2.2 6.4.2.3 
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6.4.1 Binary response outcome 
6.4.1.1 Binary and continuous comorbidity variables vs. binary outcome 
The proportion of participants achieving binary responses varied from 26% to 52% 
depending on the definition (Table 6.2). There were no significant interactions in any of the 
models. Models for BASDAI<4 and ASDAS<2.1 showed reduced effect sizes for comorbidity 
after adjusting for baseline values of BASDAI and ASDAS, respectively. For example, 
participants with comorbidity (vs. none) had 30% lower odds of achieving BASDAI<4, but 
this reduced to 19% when accounting for baseline differences in BASDAI between the two 
groups. In contrast, comorbidity effect sizes increased after such adjustment for models of 
BASDAI 50/2 and ASDAS-MI. For example, participants with comorbidity (vs. without) had 
4% lower odds of achieving BASDAI 50/2, but this increased to 13% when adjusting for 
baseline differences in BASDAI. 
 















BASDAI 50/2 312 (51%) Binary 0.96 (0.65 to 1.40) 0.87 (0.59 to 1.28) 
Continuous 
count 
0.88 (0.70 to 1.10) 0.81 (0.64 to 1.02) 
ASDAS-MI 130 (26%) Binary 0.94 (0.57 to 1.55) 0.69 (0.39 to 1.22) 
Continuous 
count 
0.88 (0.63 to 1.21) 0.66 (0.46 to 0.94) 
BASDAI<4 316 (52%) Binary 0.70 (0.47 to 1.03) 0.81 (0.54 to 1.22) 
Continuous 
count 
0.73 (0.57 to 0.92) 0.82 (0.64 to 1.05) 
ASDAS<2.1 168 (34%) Binary 0.95 (0.59 to 1.51) 0.98 (0.62 to 1.57) 
Continuous 
count 
0.84 (0.62 to 1.14) 0.87 (0.64 to 1.18) 
Binary comorbidity variable compared 0 (reference) vs. ≥1 comorbidities. 
Bold text highlights statistically significant results. 
BASDAI 50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, major improvement i.e. 
≥2-unit reduction. 






The following results refer to models adjusted for baseline disease activity. Participants 
with comorbidity (vs. none) had a 2% to 31% reduced odds of achieving a binary response 
at 6 months (Table 6.2), but none were statistically significant. Using comorbidity count as a 
continuous variable showed a 13% to 34% reduced odds of achieving a binary response at 6 
months for each additional comorbidity. 
Effect sizes were not dissimilar when using binary and continuous comorbidity in Table 6.2, 
suggesting that the relationships between comorbidity count and outcome were not linear. 
For example, odds of BASDAI 50/2 were reduced by 19% per additional comorbidity yet the 
presence of any comorbidity reduced it by 13%. 
6.4.1.2 Categorical comorbidity count vs. binary outcome 
No participants with ≥3 comorbidities achieved ASDAS-MI or ASDAS<2.1 and very few 
achieved BASDAI 50/2 or BASDAI<4; therefore, the top category was replaced as ≥2 
comorbidities. Figure 6.4 shows that the odds of achieving each binary response was not 
statistically significantly different with increasing number of comorbidities, without 
adjusting for baseline values of each index. Effect sizes for BASDAI<4 (43% reduction) and 





Figure 6. 4: Associations between comorbidity count categories and binary responses at 6 
months.  
 
Model coefficients shown in Appendix 10.5: Table S6.4. BASDAI 50/2, 50% or 2-unit 




Results from the same models, additionally adjusting for the baseline values of each index, 
showed analogous changes in effect sizes as described above for binary comorbidity (that 
is, increased effect estimates of BASDAI 50/2 and ASDAS-MI, but decreased for low disease 
activity states). Equivalent plots are shown in Figure 6.5. 
 
Figure 6. 5: Associations between comorbidity count categories and binary responses at 6 
months, additionally adjusting for baseline values of respective indices. 
 
Model coefficients shown in Appendix 10.5: Table S6.4. BASDAI 50/2, 50% or 2-unit 




6.4.2 Change in continuous outcome indices over time 
The number of participants with follow-up declined over time (Figure 6.6); therefore, 
analyses were restricted to the first 3 years (as discussed in the Methods section).  
 
Figure 6. 6: Number of participants with follow-up at each per protocol assessment time, 








The average trajectories of BASDAI, ASDAS, and spinal pain disease indexes are shown in 
Figure 6.7. Other disease severity measures followed a similar trajectory (Figure 6.8) 
 
Figure 6. 7: Change in average disease activity after starting TNF inhibitors in the analysis 
sample. 
 




 Figure 6. 8: Change in average disease severity indices after starting TNF inhibitors in the 
analysis sample. 
 




6.4.2.1 Binary comorbidity status vs. continuous outcome 
Figure 6.9 compares model-predicted values of each disease activity measure between 
participants with and without comorbidity at baseline. Participants with comorbidity (red) 
had higher disease activity at baseline than those without (dashed blue), but the absolute 
change in disease activity was similar (i.e., lines are parallel) between the two groups. Each 
of the three disease activity indices decreased significantly over follow-up, compared to the 
baseline. 
 
Figure 6. 9: Change in disease activity in response to TNF inhibitors, in participants with 
and without comorbidities. 
 
 




The model coefficients for Figure 6.9 are shown in Table 6.3 (interpretation discussed in 
Chapter 3, Section 3.5.6). For example, using the BASDAI, 734 participants with complete 
covariate data contributed 1998 follow-up assessments to the model; the baseline BADSAI 
was 6.4 among those with no comorbidities (derived from the constant, plus model-
prediction at mean age (44 years), deprivation index (2.9), BMI (27), and weighted gender 
and education such that comparison groups had balanced categories) and 7.0 among those 
with ≥1 comorbidities. BASDAI changed by -2.2 units after 3 months of treatment in the 
group with no comorbidities, and -1.8 units (-2.2 plus the interaction term 
3.FU#Comorbidity coefficient 0.4) in those with ≥1 comorbidities (contribution from 
covariates omitted for simplicity). The interaction term coefficient has a confidence interval 
that includes the null, indicating that the difference in change between the comparison 
groups were not statistically significant. All coefficients for each categorical time in Table 
6.3 (i.e., improvement after treatment) were statistically significant, but the interaction 
term coefficients were not. Note that difference in ASDAS at baseline between those with 
and without comorbidity (0.12 units) was not statistically significant.  
 
Table 6. 3: Coefficients from mixed effects models of baseline comorbidity status vs. 




BASDAI ASDAS Spinal pain 
N, participants 
(follow-ups) 
734 (1998) 707 (1872) 734 (2009) 
Constant 5.38 (4.48 to 6.28) 2.12 (1.75 to 2.50) 5.39 (4.35 to 6.42) 
3.FU -2.20 (-2.43 to -1.97) -1.06 (-1.17 to -0.95) -2.49 (-2.78 to -2.20) 
6.FU -2.71 (-2.94 to -2.47) -1.26 (-1.37 to -1.15) -3.09 (-3.39 to -2.80) 
12.FU -2.66 (-2.91 to -2.41) -1.29 (-1.41 to -1.17) -2.99 (-3.30 to -2.67) 
24.FU -2.78 (-3.09 to -2.47) -1.35 (-1.50 to -1.20) -3.28 (-3.67 to -2.89) 
36.FU -3.04 (-3.46 to -2.63) -1.43 (-1.64 to -1.22) -3.31 (-3.84 to -2.78) 
Comorbidity* 0.50 (0.17 to 0.83) 0.12 (-0.03 to 0.26) 0.74 (0.35 to 1.13) 
3.FU#Comorbidity 0.37 (-0.03 to 0.77) 0.15 (-0.04 to 0.33) 0.16 (-0.34 to 0.66) 
6.FU#Comorbidity 0.22 (-0.18 to 0.62) 0.06 (-0.13 to 0.25) 0.15 (-0.35 to 0.66) 
12.FU#Comorbidity 0.05 (-0.39 to 0.48) 0.03 (-0.17 to 0.24) -0.38 (-0.93 to 0.17) 
24.FU#Comorbidity -0.21 (-0.73 to 0.30) 0.05 (-0.20 to 0.30) -0.30 (-0.95 to 0.36) 
36.FU#Comorbidity 0.44 (-0.22 to 1.09) 0.18 (-0.13 to 0.49) -0.01 (-0.84 to 0.82) 
*≥1 comorbidity vs. none. Covariate coefficients omitted.  
Bold text highlights statistically significant results. 




The analogous comparisons for other disease severity indices are shown in Figure 6.10 and 
Table 6.4. Participants without comorbidities at baseline had significantly greater 
improvement in BASFI at the 3- and 6-month assessments, by approximately 0.5 units. 
Interaction terms for health-related quality of life, fatigue and sleep were not overall 
significant. Note that the asterisks for fatigue at 12 and 24-month show a significant 
deviation in the opposite direction; that is, difference at baseline was significantly reduced 
(by around 1.5 units) at months 12 and 24. 
 
Figure 6. 10: Change in other measures of disease severity in response to TNF inhibitors, 
in participants with and without comorbidities. 
 
 








BASFI Quality of life Fatigue Sleep 
N, participants 
(follow-ups) 
736 (2013) 732 (1989) 735 (2010) 736 (2003) 
Constant 2.10 (0.99 to 3.20) 9.47 (7.30 to 11.63) 16.5 (14.1 to 19.0) 9.46 (6.87 to 12.05) 
3.FU -1.83 (-2.04 to -1.62) -3.61 (-4.08 to -3.13) -3.03 (-3.65 to -2.41) -2.79 (-3.39 to -2.18) 
6.FU -2.26 (-2.49 to -2.04) -4.31 (-4.80 to -3.82) -3.79 (-4.43 to -3.15) -3.91 (-4.54 to -3.29) 
12.FU -2.23 (-2.46 to -1.99) -4.35 (-4.88 to -3.82) -3.16 (-3.85 to -2.47) -3.74 (-4.40 to -3.07) 
24.FU -2.24 (-2.53 to -1.95) -4.82 (-5.47 to -4.17) -3.43 (-4.27 to -2.58) -3.80 (-4.61 to -2.98) 
36.FU -2.42 (-2.81 to -2.02) -5.70 (-6.57 to -4.82) -3.05 (-4.20 to -1.90) -4.30 (-5.42 to -3.18) 
Comorbidity* 0.49 (0.11 to 0.87) 1.56 (0.79 to 2.33) 2.07 (1.17 to 2.96) 0.98 (0.05 to 1.91) 
3.FU#Comorbidity 0.49 (0.12 to 0.87) 1.05 (0.22 to 1.88) 0.05 (-1.03 to 1.14) 0.75 (-0.31 to 1.80) 
6.FU#Comorbidity 0.52 (0.14 to 0.91) 0.66 (-0.19 to 1.51) -0.42 (-1.52 to 0.69) 1.24 (0.17 to 2.32) 
12.FU#Comorbidity 0.36 (-0.05 to 0.77) 0.37 (-0.54 to 1.28) -1.35 (-2.54 to -0.16) 0.78 (-0.38 to 1.93) 
24.FU#Comorbidity 0.39 (-0.10 to 0.87) 0.18 (-0.89 to 1.26) -1.49 (-2.89 to -0.08) 0.37 (-1.00 to 1.74) 
36.FU#Comorbidity 0.58 (-0.03 to 1.20) 1.41 (0.05 to 2.78) -0.32 (-2.11 to 1.48) 0.91 (-0.84 to 2.66) 
*≥1 comorbidity vs. none. Covariate coefficients omitted.  
Bold text highlights statistically significant results. 
FU, follow-up at numbered month. #, interaction term. 
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6.4.2.2 Continuous comorbidity count vs. continuous outcome 
Comorbidity count was also modelled as a continuous variable, but results could not be 
shown graphically. Coefficients are shown in Table 6.5. Using BASDAI as the example: 
model-predictions show that for each additional comorbidity, the BASDAI response was 
approximately (since covariate contributions unaccounted) 0.2 units smaller at 3 and 6 
months, although these interaction coefficients were not statistically significant. The same 
model for BASFI showed 0.3 units reduced response at 3 months for each additional 









BASDAI ASDAS Spinal pain BASFI Quality of life Fatigue Sleep 
N, participants 
(follow-ups) 
734 (1998) 707 (1872) 734 (2009) 736 (2013) 732 (1989) 735 (2010) 736 (2003) 
Constant 5.59 
(4.69 to 6.49) 
2.2 
(1.83 to 2.58) 
5.69 
(4.66 to 6.72) 
2.37 
(1.27 to 3.47) 
10.1 
(7.96 to 12.2) 
17.1 
(14.7 to 19.5) 
9.79 
(7.18 to 12.3) 
3.FU -2.19 
(-2.40 to -1.97) 
-1.06 
(-1.16 to -0.95) 
-2.48 
(-2.76 to -2.21) 
-1.81 
(-2.02 to -1.61) 
-3.61 
(-4.07 to -3.16) 
-3.10 
(-3.69 to -2.51) 
-2.75 
(-3.33 to -2.18) 
6.FU -2.74 
(-2.97 to -2.52) 
-1.28 
(-1.39 to -1.17) 
-3.16 
(-3.44 to -2.88) 
-2.29 
(-2.50 to -2.08) 
-4.45 
(-4.92 to -3.98) 
-3.93 
(-4.55 to -3.32) 
-3.94 
(-4.54 to -3.35) 
12.FU -2.66 
(-2.90 to -2.42) 
-1.31 
(-1.42 to -1.19) 
-3.06 
(-3.36 to -2.75) 
-2.22 
(-2.45 to -2.00) 
-4.48 
(-4.98 to -3.97) 
-3.25 
(-3.91 to -2.59) 
-3.69 
(-4.33 to -3.04) 
24.FU -2.85 
(-3.14 to -2.55) 
-1.38 
(-1.52 to -1.24) 
-3.33 
(-3.70 to -2.96) 
-2.24 
(-2.52 to -1.96) 
-4.97 
(-5.58 to -4.35) 
-3.52 
(-4.33 to -2.72) 
-3.82 
(-4.60 to -3.04) 
36.FU -2.99 
(-3.39 to -2.59) 
-1.42 
(-1.62 to -1.22) 
-3.33 
(-3.84 to -2.82) 
-2.42 
(-2.80 to -2.04) 
-5.79 
(-6.63 to -4.96) 
-3.07 
(-4.17 to -1.98) 
-4.25 




(0.17 to 0.55) 
0.10 
(0.01 to 0.18) 
0.53 
(0.30 to 0.75) 
0.40 
(0.18 to 0.62) 
1.00 
(0.55 to 1.44) 
1.22 
(0.70 to 1.74) 
0.57 




(-0.01 to 0.46) 
0.09 
(-0.01 to 0.20) 
0.09 
(-0.19 to 0.38) 
0.30 
(0.08 to 0.53) 
0.71 
(0.23 to 1.20) 
0.17 
(-0.45 to 0.80) 
0.44 




(-0.01 to 0.50) 
0.08 
(-0.04 to 0.20) 
0.27 
(-0.04 to 0.59) 
0.44 
(0.20 to 0.67) 
0.81 
(0.27 to 1.35) 
0.03 
(-0.66 to 0.71) 
0.99 




(-0.24 to 0.34) 
0.06 
(-0.07 to 0.19) 
-0.11 
(-0.47 to 0.25) 
0.27 
(-0.001 to 0.54) 
0.58 
(-0.03 to 1.18) 
-0.8 
(-1.60 to 0.01) 
0.49 




(-0.36 to 0.32) 
0.11 
(-0.06 to 0.27) 
-0.11 
(-0.52 to 0.29) 
0.29 
(-0.03 to 0.62) 
0.45 
(-0.23 to 1.13) 
-0.86 
(-1.75 to 0.02) 
0.34 




(-0.20 to 0.69) 
0.13 
(-0.08 to 0.35) 
0.05 
(-0.51 to 0.61) 
0.45 
(0.03 to 0.87) 
1.31 (0.39 to 
2.24) 
-0.12 
(-1.33 to 1.10) 
0.62 
(-0.57 to 1.80) 
*as a continuous variable, i.e., change with each additional comorbidity. Covariate coefficients omitted.  
Bold text highlights statistically significant results. 
FU, follow-up at numbered month. #, interaction term. 
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6.4.2.3 Categorical comorbidity count vs. continuous outcome 
Figure 6.11 shows the differences in disease activity change according to comorbidity count 
categories (model coefficients shown in Table 6.6). The top category was combined into ≥2 
comorbidities due to the small number of participants with ≥3 comorbidities. In summary, 
there were no statistically significant differences in the absolute change from baseline (i.e., 
the lines are not statistically different from parallel). Participants with no and one 
comorbidity had similar graphically depicted trajectories, confirmed by no statistically 
significant difference in baseline BASDAI (β=0.31; 95% CI -0.06 to 0.68) or ASDAS (β=0.05; 
95% CI -0.11 to 0.21). Participants with ≥2 comorbidities had higher BASDAI and ASDAS 
throughout follow-up. Spinal pain compared between 1 vs. 0 (β=0.47; 95% CI 0.03 to 0.91) 
and 2 vs. 0 comorbidities (β=1.32; 95% CI 0.74 to 1.91) were significantly different, but 
changes over time were not. 
Figure 6. 11: Change in disease activity according to comorbidity count categories.  
 
 
ASDAS, AS disease activity score; 




 Table 6. 6: Coefficients from mixed effect models of baseline comorbidity count 
categories vs. disease activity over time. 
 
 
BASDAI ASDAS Spinal pain 
N, participants 
(follow-ups) 
734 (1998) 707 (1872) 734 (2009) 
Constant 5.54 (4.64 to 6.44) 2.19 (1.81 to 2.57) 5.64 (4.60 to 6.67) 
3.FU -2.20 (-2.43 to -1.97) -1.06 (-1.16 to -0.95) -2.49 (-2.77 to -2.20) 
6.FU -2.71 (-2.94 to -2.47) -1.26 (-1.37 to -1.15) -3.09 (-3.39 to -2.80) 
12.FU -2.66 (-2.91 to -2.41) -1.29 (-1.41 to -1.17) -2.99 (-3.30 to -2.67) 
24.FU -2.78 (-3.09 to -2.47) -1.35 (-1.50 to -1.20) -3.29 (-3.67 to -2.90) 
36.FU -3.04 (-3.46 to -2.63) -1.43 (-1.64 to -1.22) -3.32 (-3.85 to -2.79) 
1.comcat 0.31 (-0.06 to 0.69) 0.05 (-0.11 to 0.21) 0.47 (0.03 to 0.92) 
2.comcat 0.90 (0.40 to 1.40) 0.26 (0.04 to 0.48) 1.32 (0.74 to 1.91) 
3.FU#1.comcat 0.32 (-0.15 to 0.78) 0.14 (-0.07 to 0.36) 0.13 (-0.45 to 0.72) 
6.FU#1.comcat 0.11 (-0.35 to 0.57) 0.03 (-0.19 to 0.24) -0.02 (-0.60 to 0.55) 
12.FU#1.comcat 0.02 (-0.46 to 0.50) -0.02 (-0.25 to 0.20) -0.50 (-1.11 to 0.10) 
24.FU#1.comcat -0.28 (-0.85 to 0.30) -0.05 (-0.33 to 0.23) -0.30 (-1.04 to 0.43) 
36.FU#1.comcat 0.49 (-0.24 to 1.21) 0.15 (-0.19 to 0.49) -0.06 (-0.97 to 0.85) 
3.FU#2.comcat 0.44 (-0.15 to 1.03) 0.15 (-0.13 to 0.42) 0.17 (-0.56 to 0.90) 
6.FU#2.comcat 0.51 (-0.13 to 1.15) 0.16 (-0.14 to 0.46) 0.63 (-0.17 to 1.43) 
12.FU#2.comcat 0.16 (-0.58 to 0.91) 0.23 (-0.12 to 0.57) 0.13 (-0.81 to 1.08) 
24.FU#2.comcat 0.00 (-0.84 to 0.84) 0.32 (-0.08 to 0.72) -0.20 (-1.24 to 0.84) 
36.FU#2.comcat 0.35 (-0.70 to 1.40) 0.29 (-0.23 to 0.82) 0.24 (-1.09 to 1.57) 
Comcat, comorbidity category 0 (reference), 1, ≥2. FU, follow-up at numbered month.  
Bold text highlights statistically significant results. 
#, interaction term.; ASDAS, AS disease activity score; BASDAI, Bath AS disease activity index. 
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Figure 6.12 shows the differences in change in other measures of disease severity according 
to comorbidity count categories (model coefficients shown in Table 6.7). Change over time 
in all four indices were parallel for participants with no and one comorbidity. BASFI was 
significantly higher at baseline by 1.03 (0.46 to 1.60) in those with ≥2 comorbidities. 
Moreover, their improvement (i.e., absolute change) over the first 6 months was also 
significantly smaller than those with no comorbidities (i.e., the gradient of the green line is 
less ‘steep’ in the first 6 months). This was also observed for health-related quality of life, 
which was poorer at baseline and improvement was also smaller. 
 
Figure 6. 12: Change in other measures of disease severity according to comorbidity count 
categories. 
 
ASQoL, AS quality of life questionnaire; 
BASFI, Bath AS functional index. 
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Table 6. 7: Coefficients from mixed effect models of baseline comorbidity count categories vs. disease severity measures over time. 
 
 
BASFI ASQoL Fatigue Sleep 
N, participants 
(follow-ups) 
736 (2013) 732 (1989) 735 (2010) 736 (2003) 
Constant 2.33 (1.23 to 3.43) 9.90 (7.73 to 12.07) 16.8 (14.4 to 19.3) 9.69 (7.09 to 12.30) 
3.FU -1.83 (-2.04 to -1.62) -3.61 (-4.08 to -3.13) -3.03 (-3.65 to -2.41) -2.79 (-3.39 to -2.18) 
6.FU -2.26 (-2.48 to -2.04) -4.31 (-4.80 to -3.82) -3.79 (-4.43 to -3.15) -3.91 (-4.53 to -3.29) 
12.FU -2.23 (-2.46 to -1.99) -4.35 (-4.87 to -3.82) -3.16 (-3.84 to -2.47) -3.73 (-4.40 to -3.06) 
24.FU -2.24 (-2.53 to -1.95) -4.82 (-5.47 to -4.18) -3.43 (-4.27 to -2.59) -3.80 (-4.61 to -2.98) 
36.FU -2.42 (-2.81 to -2.03) -5.70 (-6.57 to -4.83) -3.05 (-4.20 to -1.90) -4.30 (-5.42 to -3.18) 
1.comcat 0.23 (-0.20 to 0.66) 1.26 (0.39 to 2.13) 1.76 (0.75 to 2.78) 0.72 (-0.34 to 1.78) 
2.comcat 1.03 (0.46 to 1.60) 2.25 (1.09 to 3.40) 2.72 (1.38 to 4.07) 1.54 (0.14 to 2.94) 
3.FU#1.comcat 0.41 (-0.02 to 0.85) 0.77 (-0.19 to 1.74) -0.14 (-1.41 to 1.12) 0.76 (-0.48 to 1.99) 
6.FU#1.comcat 0.33 (-0.10 to 0.76) 0.01 (-0.94 to 0.97) -0.72 (-1.98 to 0.53) 0.94 (-0.28 to 2.16) 
12.FU#1.comcat 0.28 (-0.18 to 0.73) -0.19 (-1.19 to 0.81) -1.34 (-2.66 to -0.03) 0.88 (-0.40 to 2.16) 
24.FU#1.comcat 0.32 (-0.22 to 0.86) -0.30 (-1.50 to 0.90) -1.47 (-3.05 to 0.11) 0.26 (-1.27 to 1.79) 
36.FU#1.comcat 0.46 (-0.22 to 1.14) 0.80 (-0.70 to 2.30) -0.39 (-2.36 to 1.59) 0.99 (-0.95 to 2.93) 
3.FU#2.comcat 0.62 (0.06 to 1.18) 1.55 (0.33 to 2.78) 0.38 (-1.23 to 1.98) 0.72 (-0.84 to 2.28) 
6.FU#2.comcat 1.00 (0.40 to 1.60) 2.29 (0.94 to 3.65) 0.33 (-1.41 to 2.06) 2.02 (0.31 to 3.72) 
12.FU#2.comcat 0.65 (-0.06 to 1.36) 2.10 (0.54 to 3.67) -1.33 (-3.42 to 0.75) 0.49 (-1.51 to 2.48) 
24.FU#2.comcat 0.59 (-0.21 to 1.39) 1.48 (-0.24 to 3.20) -1.49 (-3.75 to 0.77) 0.73 (-1.51 to 2.97) 
36.FU#2.comcat 0.95 (-0.05 to 1.94) 3.16 (0.97 to 5.34) -0.08 (-2.96 to 2.81) 0.74 (-2.06 to 3.54) 
Comcat, comorbidity category 0 (reference), 1, ≥2. FU, follow-up at numbered month.  
Bold text highlights statistically significant results. 
#, interaction term. ASDAS, AS disease activity score; BASDAI, Bath AS disease activity index. 
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6.4.3 Time to treatment discontinuation 
Of the 994 participants that started TNFi, 18 (1.8%) did not have any post-baseline data and 
were each assigned one minute of follow-up time. The remaining 976 subjects had 1441 
person-years of follow-up, with a mean of 17 (SD 15) months and median of 12 (IQR 6 to 
27) months. Thirty one percent of the cohort stopped treatment over the whole study 
follow-up: 29% of those with no comorbidities, 30% of those with one, 42% two and 68% 
with ≥3 comorbidities. 
The top panel of Figure 6.13 shows overall poorer drug survival in those with comorbidity at 
baseline than without. The lines are approximately parallel except at around 3 years, 
suggesting violation of the proportional hazards assumption required for further modelling. 
(Kaplan-Meier curves were not possible for continuous comorbidity count.) The right panel 
compares drug survival according to categories of comorbidity count. Log-rank test 











6.4.3.1 Cox models 
Modelling for presence vs. absence of comorbidity was not performed due to violation of 
the proportional hazards assumption indicated by the above Kaplan-Meier curve. 
Comorbidity count as a single continuous variable was performed for completeness; each 
additional comorbidity increased the hazard rate of discontinuation by 17% (95%CI 1.02, 
1.36). However, this has limited meaning as the relationship with comorbidity count is non-
linear (Figure 6.13). 
Results from the Cox model of categorical comorbidity count vs. drug discontinuation are 
shown in Figure 6.14 (model coefficients shown in Appendix Table S6.5). Education was 
stratified in the model since it was significant in tests for proportional hazards violation. 
Participants with one comorbidity were not more or less likely to discontinue TNFi 
compared to those with no comorbidities. The hazard rate of TNFi discontinuation was 32% 
higher (95%CI 0.88 to 2.00) for those with two comorbidities, but not statistically significant 
to those without comorbidities. Participants with ≥3 comorbidities had 2.2-fold higher 
hazard rate (95%CI 1.20 to 3.93) of discontinuation compared to those without 
comorbidities at baseline (i.e., 2.2 times as many individuals discontinued at any one time, 
assuming rates are proportional). 





Interaction between gender and comorbidity categories were significant across all 
categories. To aid interpretation, analysis was performed separately in males and females 
with results plotted in Figure 6.15 (model coefficients shown in Appendix 10.5: Table S6.5). 
The association between comorbidity and drug survival was present among males, but not 
females. Males with one comorbidity did not differ in hazard of drug discontinuation 
compared to those with no comorbidities, but those with 2 comorbidities had 68% higher 
and ≥3 had over 5-fold higher hazard rates. 
 
Figure 6. 15: Hazard rate of TNF inhibitor discontinuation according to the number of 






6.4.4 Sensitivity analyses 
6.4.4.1 Excluding individuals with baseline BASDAI<4 
Participants with baseline BASDAI<4 would not ordinarily be eligible for TNFi according to 
NICE guidance. One explanation is imputation of missing baseline BASDAI from up to a year 
before TNFi initiation. After excluding these patients, results for the binary outcome, 
absolute response, and treatment discontinuation analyses were not meaningfully different 
from the primary analysis (data not shown).  
6.4.4.2 Missing binary outcome imputation 
Analyses of binary outcomes with imputation significantly changed the proportion of 
responders, particularly for ASDAS-based variables (due to more missing data with ASDAS). 
However, analyses of binary, continuous or categorical comorbidity count definitions 
showed no meaningful differences in results (Appendix 10.5: Table S6.6 and Figure S6.1). 
6.4.4.3 Adjusting for additional potential confounders 
Results from all models additionally adjusting for ever/never smoking and ever/never use of 
alcohol were not meaningfully different (data not shown). 
6.4.4.4 Testing other variance-covariance structures 
Mixed effects models of comorbidity vs. BASDAI using three other variance-covariance 





In this longitudinal study of response to the first TNF inhibitor, participants with greater 
comorbidity burden had higher disease activity at baseline that persisted throughout 
follow-up. Participants with multiple (≥2) comorbidities had significantly poorer absolute 
improvements in function and health-related quality of life. These individuals also had 
significantly increased TNFi discontinuation compared to those without comorbidities. 
Three studies have previously examined the same topic. Iannone et al showed that mRCDI 
was significantly correlated (by Spearman’s rank) with the number of biologic switches 
[114]. Kaplan Meier curves showed no difference between mRDCI of 1 and 0, while the 
mRDCI≥2 group separated after approximately 1 year. These curves were difficult to 
interpret as they suggested: 1) discontinuation was assessed at large intervals of discrete 
time, and 2) >90% of those with mRDCI 0 or 1, but 0% of those with mRDCI≥2, remained on 
treatment at end of follow-up (approximately 60 months). The second study, by Lindström 
et al [118], examined risk of TNFi discontinuation in unadjusted Cox models for each of: 
cardiovascular disease (HR 1.24; 1.08 to 1.43), affective disorder (HR 1.81; 1.54 to 2.13), 
chronic lung disease (HR 1.49; 1.22 to 1.82), malignancy (HR 1.36; 1.06 to 1.74), diabetes 
(HR 1.36; 0.99 to 1.87) and chronic kidney disease (HR 0.79; 0.41 to 1.52). The third study 
used an earlier sample of 335 BSRBR-AS participants to show continuous comorbidity count 
as a predictor of binary response [134]. The investigators showed each additional 
comorbidity to reduce odds of achieving clinically important improvement in ASDAS (≥1.1) 
by 43% (95%CI 0.37 to 0.88) and ASDAS<2.1 by 40% (95%CI 0.38 to 0.95) within 10 weeks to 
9 months of treatment initiation. These prediction models assumed a log-linear relationship 
between outcomes and each additional comorbidity, which was shown not to be the case in 
this study. 
Another limitation of these prior studies is that they used only binary definitions of 
response. To summarise, the decision to adjust for baseline disease activity or not are both 
fraught with potential bias. By analysing three types of outcomes, this chapter highlights 
the importance of interpreting each result in the context of the others. For example, it is 
reasonable to tell patients with comorbidities that they may have lower odds of achieving 
‘low disease activity’ states, but the absolute degree of improvement from pre-treatment 
disease activity is comparable to those with no comorbidities. Communicating the influence 
of comorbidities to patients should be more nuanced, depending on whether degree of 
improvement or a fixed low level of disease activity is more important to the individual. 
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Existing definitions of response as used for prescribing guidelines, for example in the UK, 
may need to be reconsidered: a patient starting TNFi with BASDAI of 7 will have higher odds 
(by 25% in this data) of achieving BASDAI 50/2, while simultaneously having lower odds of 
BASDAI<4 (by 32%), than an identical individual with starting BASDAI of 6. Which definition 
of response is more relevant for health-economics remains to be determined. Lastly, many 
comorbid patients would have been ineligible for randomised controlled trials; this study 
provided unique insights into how therapeutic effects on function and quality of life 
differed in comorbid patients – highlighting the need to optimise comorbidities not just 
axSpA. 
The most clinically significant effect sizes came from time-to-event analyses. Interestingly, 
the association between comorbidity count and TNFi discontinuation was limited to males. 
Male participants with 1 comorbid condition had similar hazard rate of treatment 
discontinuation as those with no comorbidities, which concurs with analyses of binary and 
absolute responses. Male participants with 2 comorbidities had 68% higher hazard rates 
and ≥3 comorbidities over 5-fold higher. The same was not observed among the female 
population. Note that the large effect size showing reduced risk of TNFi discontinuation in 
females with ≥3 comorbidities had a wide confidence interval, arising from just 10 
individuals; therefore, it should not be interpreted as being protective. The reasons for 
these findings are unclear. Data on causes of discontinuation in the BSRBR-AS had 
limitations (see Methods above) that precluded inclusion into primary analyses; causes did 
not differ according to gender or the presence of comorbidities (data not shown).  
Males had higher prevalence of diabetes but lower prevalence of depression. The high 
prevalence of depression among female participants and the lack of association between 
comorbidity count and TNFi discontinuation are not consistent with existing evidence that: 
1) depression was negatively associated with disease severity (as shown in prior chapters) 
and 2) mental health symptoms was a negative predictor of binary treatment response in 
MacFarlane and colleagues’ analysis of the BSRBR-AS [134]. It is also notable that having 
only one comorbidity was not associated with treatment response or discontinuation, when 
the commonest condition among those with one single comorbidity was depression (40%, 
see Figure 6.3). More research is needed to further dissect the role of depression as an 





6.5.1 Strengths and limitations 
The strengths of the BSRBR-AS dataset have been discussed in detail in the previous 
chapter. The systematic approach of the current analysis – using different approaches for 
comorbidity and outcome variables – provided a contextual overview that prior studies 
lacked [114,118,134]. Results were also robust to a battery of sensitivity analyses testing 
several assumptions. There were, however, limitations. Most importantly is the causal 
interpretation of the role of comorbidity: Did the presence of comorbidities cause blunted 
improvement in function and quality of life and increased treatment discontinuation among 
males? It would be inappropriate to confidently attribute a causal relationship with 
treatment response, since many comorbidities are not ‘manipulatable’ (i.e., one cannot 
‘assign’ individuals to having a history of a certain comorbidity in an RCT). Using 
comorbidity history collected at baseline meant that the complex time-varying relationship 
between comorbidities and disease activity, before and after TNFi initiation, could not be 
captured.  
Results from analyses of binary response definitions suggested clinically meaningful effect 
sizes but lacked precision. Results from analysis of change over time should be interpreted 
with one important caveat: participants who did not respond by the first assessment 
(usually after 3 months) or those who lost response would have had their treatment 
stopped under NICE guidance [190]; therefore, record of such high disease activity would 
be censored. However, such informative censoring should not affect data within the first 3 
months [42]. This may help explain the dramatic difference between the relatively 
unimpressive effect sizes of the response analyses compared to treatment discontinuation. 
Lastly, analyses of comorbidity count assume that individual comorbidities affect the 
outcomes equally. This is unlikely to be true and larger studies are required to examine 





Participants with multiple (≥2) comorbidities had reduced absolute improvement in 
function and health-related quality of life compared to those without. Overall, participants 
with comorbidities generally had reduced odds of achieving binary response definitions 
compared to those with none, although most effect estimates were small and with 
uncertainty. They also had significantly higher rate of TNFi discontinuation. Taken together, 
results can be used to better inform clinicians and educate patients about the likelihood of 
response to the first TNFi given baseline comorbidity status. Further research is needed to 
identify potentially modifiable comorbidities that may improve response. This will be the 




Chapter 7: Depression and anxiety and response to TNF 
inhibitors 
 
This chapter uses longitudinal data from the BSRBR-AS to examine the impact of baseline 
depression and anxiety on response to TNF inhibitors. This thesis set out to study 
comorbidities in general, without a priori aims to focus on a single disease group. However, 




Symptoms of axSpA commonly begin in early adulthood, which can be a critical time for 
education, career, and relationships. The consequence of these disruptive symptoms on 
mental health is compounded by the often-significant delays to diagnosis and treatment 
[10]. Depression is well-known to influence the experience and reporting of symptoms 
[231]. This is particularly relevant for assessment of axSpA disease activity, since indices are 
mostly (e.g., ASDAS) or entirely subjective (BASDAI and spinal pain). Though a recent 
systematic review identified numerous studies that consistently showed depression to be 
associated with disease activity [9], none have examined whether they influence 
longitudinal treatment outcomes.  
This chapter includes an in-depth assessment of depression and anxiety and their 
associations with treatment response. These two mental health comorbidities were chosen 
because they are the most prevalent and were available in the BSRBR-AS. Studying 
depression presents unique challenges – namely under-diagnosis and documentation – that 
can be addressed using the BSRBR-AS data. Diagnosis of depression and depressive 
symptoms (according to the Hospital Anxiety and Depression Score, HADS) were both 
recorded to allow comparison. 
Unlike other chronic comorbidities, symptoms of depression and anxiety are potentially 
modifiable, for example, by pharmacological or talking therapies [232]. Estimating the 
impact of potential mental health interventions on TNFi response could help inform future 
clinical trials or guidelines. Finding modifiable factors to improve TNFi response is important 
since up to half do not respond adequately [228] and the number of therapeutic options 




1. To describe correlations between symptoms and diagnosis of depression. 
2. To examine the association between history of depression at baseline and response 
to TNFi. 
3. To examine the association between baseline symptoms of depression or anxiety 
and response to TNFi. 
 
7.3 Methods 
7.3.1 Patient population 
Participants in the BSRBR-AS who started on their first TNFi (including those who switched 
from the non-biologic group) were eligible for inclusion in this analysis. Eligible individuals 
were required to have a clinic visit or questionnaire within 1 year before, or 7 days after, 
the TNFi start date, from which the baseline values of time-varying data (i.e., measures of 
disease activity and severity) were obtained. For aims relating to baseline symptoms of 
depression or anxiety, only those who completed the baseline HADS questionnaire were 
eligible. 
7.3.2 ‘Exposures’ – baseline depression and anxiety 
7.3.2.1 History of depression 
The BSRBR-AS recorded physician-confirmed diagnosis (or ‘past medical history’) of 
depression as a binary variable. In clinical practice, depression typically remains on a 
patient’s list of diagnoses only when it is currently relevant (i.e., ongoing symptoms or 
treatment), whereas a resolved depressive episode from many years ago should not. This 
assumption is difficult to test since the time of diagnosis was not recorded, and reflects the 
challenges of studying a condition with dynamic symptoms over time. Therefore, mental 
health symptoms at TNFi initiation were also examined.  
7.3.2.2 Symptoms of depression and anxiety 
Symptoms of depression and anxiety were measured using the HADS. The original 
description of the HADS use each sub-scale to describe ‘case-ness’ (i.e., presence) of 
depression or anxiety using the following thresholds: 0-7 indicating ‘non-cases’, 8-10 
‘doubtful cases’, 11-21 ‘cases’ [176,177]. These thresholds were not validated for diagnosis 
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or classification purposes. For example, the HADS depression sub-scale (HADS-D) does not 
include all components relevant for diagnostic criteria of depression according to Diagnostic 
and Statistical Manual of Mental Disorders (e.g., appetite, sleep, and self-harm). HADS-D≥8 
was reported to have a sensitivity of 82% and specificity of 74% for major depressive 
disorder; the corresponding performance for ≥11 was 56% and 92%, respectively [233]. For 
HADS-A≥8, sensitivity was reported as 90% and specificity 78% [234].  
Since HADS reflects symptom severity, commonly used thresholds were labelled as the 
following: mild (8-10), moderate (11-14) and severe (≥15). Snaith described the 0-7 
category as ‘being in the normal range’ [176]. For convenience, this category was referred 
to as ‘none’ (though this includes less than ‘mild’ symptoms). For models, the moderate 
and severe groups (i.e., scores ≥11) were combined due to their small numbers.  
7.3.3 Outcomes 
Outcomes included: 1) binary response (BASDAI 50/2, ASDAS-MI, BASDAI<4, ASDAS<2.1) at 
6 months, 2) absolute improvement in disease activity over the first 3 years, and 3) time to 
treatment discontinuation. In this chapter, only absolute improvement in disease activity 
(i.e., BASDAI, ASDAS, spinal pain) were considered. This is because causal pathways 
involving ‘downstream’ outcomes (e.g., sleep or quality of life that may be mediated by 
improvement in both disease activity and mental health symptoms) invoke greater 
complexity and number of assumptions. 
7.3.3 Covariates 
The following covariates were included: age, gender (female as reference), BMI, Index of 
Multiple Deprivation (IMD, as a continuous variable) and educational attainment (as 
dummy variables). Additional covariates included: elevated CRP (defined as per ASAS 
classification criteria; low as reference), comorbidity count (continuous variable), and 
baseline values of each outcome measure. Inflammation, measured here using CRP, is a 
potential confounder since 1) it is suggested to have a causal role in depression [235], 2) 
‘high CRP’ has been shown to be associated with response [236], and 3) depression is less 
likely to cause elevated CRP, unlike many other comorbidities. The dichotomous variable 
‘elevated CRP’ (recorded for eligibility purposes) was used instead of CRP levels because the 
latter had higher proportion of missing values at baseline. The presence of other 
comorbidities may also be a confounder since they will influence mental health and 
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response. Baseline disease activity was additionally included as a covariate in the marginal 
models (see below).  
Sensitivity analyses additionally included baseline smoking/alcohol status and HLA-B27 
status as covariates. Prevalence of HLA-B27 positivity differed between those with and 
without depression, and has been shown to predict response [236].  
7.3.4 Statistics 
7.3.4.1 History of depression (Aim 2) 
For analyses using history of depression as the independent variable, logistic regression was 
used for binary response definitions, mixed effects model for change in continuous 
outcome indices over time (using interaction terms between depression diagnosis and 
time), and Cox models for time to treatment discontinuation; that is, the same conditional 
approaches as used in the previous chapter, replacing comorbidity with depression 
diagnosis. All analyses were adjusted for the above covariates. 
These approaches describe association between history of depression and diagnosis, which 
is inherent in conditional models and when using an exposure that cannot be modified (it is 
not possible to modify a past medical history of depression) [237]. By contrast, symptoms 
of depression can be modified, thus a marginal approach was used to estimate the 
potential impact of mental health interventions on TNFi response. Further discussion on 
conditional vs. marginal approaches are given in Appendix 10.6. 
7.3.4.2 Symptoms of depression or anxiety (Aim 3) 
For symptoms of depression and anxiety, marginal approaches were used: inverse-
probability (IP) weighted logistic regression for binary outcomes, IP weighted GEE for 
absolute response, and marginal structural Cox models (i.e., IP weighted pooled logistic 
regression) for time to treatment discontinuation. IP weights aim to balance all covariates 
in the weighted model, thus the outcome models were not additionally adjusted for 
(‘conditioned on’) any additional variables.  
Marginal approaches estimate the potential change in TNFi response at the group level 
(akin to randomised controlled trials) if mental health symptoms were modified. Studying 
the causal effect of baseline mental health status has some conceptual challenges. For 
example, a hypothetical intervention would need to successfully improve baseline mental 
health symptoms and also their prior history (of unknown duration); this is not equivalent 
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to a mental health intervention administered at TNFi initiation, but can be considered as 
one delivered (at an unknown time) before. Nevertheless, IPTW methods are still useful for 
‘unconfounded descriptive comparisons’ [238]. 
7.3.4.3 Inverse-probability weights 
IPTWs were originally devised to compare treatments (hence ‘treatment’ weights). 
Although the exposure here is prevalent mental health symptoms, the term ‘IPTW’ is 
retained to distinguish it from inverse probability of censoring weights (IPCW, discussed 
later). IPTWs, in effect, create a hypothetical (‘pseudo’-)population where some individuals 
are upweighted (represented more than once) and others are down-weighted, such that 
the weighted populations have comparable values of all covariates.  
Detailed descriptions of IPTW are given in Appendix 10.6.1. In brief, the numerator was the 
predicted probability from multinomial logistic model with three-level HADS-categories as 
the only variable, and the denominator was the same model conditioned on all covariates. 
This approach to confounding has an important advantage over inclusion of the baseline 
covariates in the outcome model. IPTW accounts for baseline disease activity without 
adjusting for it [42]. Baseline covariate balance was checked in the weighted population; 
one example (balancing between HADS-D groups) is provided in the Results for 
demonstration. 
The marginal risk of treatment discontinuation can be estimated using a marginal approach 
to Cox models (e.g., standardisation or IPTW). However, an important assumption is that 
censoring is random; that is, censoring should not differ between exposure groups 
conditioning on covariates. This can be remediated using IPCWs. Its numerator is the 
probability of being uncensored at month t, given the individual was uncensored at month 
t-1, the exposure history (unchanged baseline mental health symptoms) and baseline 
covariates. The denominator is the same but additionally adjusting for the history of time-
varying disease activity. 
The product of two weights – baseline time-invariant IPTW and time-varying IPCW – was 
used in a pooled logistic regression model. Pooled logistic regression is equivalent to a Cox 
model since the event hazard is small at each time point [239]. (For demonstration, the 
equivalence of Kaplan-Meier and Cox proportional hazard models using this data is shown 
in the Appendix 10.6.3). All weights were examined for means close to 1 and extreme 
values (summary statistics on weights provided in Appendix 10.6: Table S7.3).  
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To generate the above weights, multinomial logistic models required complete data for all 
covariates. Multiple imputation was therefore performed (see Chapter 3, Section 3.5.8). 
7.3.4.4 Gender interaction 
Since treatment discontinuation differed by gender in the previous chapter, and that 
depression and anxiety are more prevalent among females [240], all analyses took gender 
into consideration. For descriptive statistics (Aim 1), results were stratified by gender where 
relevant. For models (Aims 2 and 3), interaction terms were used (e.g., gender-by-
depression interaction in the logistic and survival analyses, or gender-by-depression-by-
time interaction in the repeated measure analyses). Adding interaction terms into marginal 
structural models does not require their inclusion into the weights [237]. 
7.3.4.5 Power considerations 
Power considerations were analogous to the previous chapter for analyses using history of 
depression. Conducting a priori power calculations for analyses using IPTW is difficult since 
such a calculation is dependent on the weights, which are only known after the analysis has 
been conducted. In general, IPTW reduces the statistical power [241] through the need for 
robust standard errors. 
7.3.5.6 Sensitivity analyses 
First, all analyses were repeated with IP weights including baseline smoking, HLA-B27, and 
alcohol status. Since HADS sub-scales are correlated with disease activity, HADS categories 
may have poor overlap in distribution of disease activity (and other covariates). Models that 
extrapolate to non-overlap areas have limited causal interpretation. In the second 
sensitivity analysis, overlap was ensured using matching weights, which replaced the 
numerator with the smallest value weight of the other comparator groups and in doing so 
emulates a (multi-group propensity score) matched population [242]. Lastly, missing binary 
outcomes were imputed as response if patients remained on drug for longer than one year 





Participants with a history of depression at baseline were more often female than those 
without history of depression at baseline; they were also more frequently current smokers 
and resided in more deprived areas (Table 7.1). Participants with comorbid depression also 
had higher disease activity across all three indices. The mean age and proportion of those 
meeting the modified New York criteria for AS were similar between those with and 
without a history of depression, but HLA-B27 positivity was significantly more common 
among those without depression. Those with depression more frequently had other 





Table 7. 1: Baseline characteristics of 994 participants compared according to history of 
depression diagnosis. 









Age, years 43.7 (12.0) 44.9 (13.7) 0.35 
Males 84 (58%) 595 (70%) 0.005 
Meeting modified New York criteria 85 (59%) 512 (60%) 0.71 
Age at symptom onset, years 27.0 (10.5) 28.9 (11.4) 0.056 
Symptom duration, years 16.7 (11.7) 15.9 (12.8) 0.47 
HLA-B27 positive* 67 (64%) 473 (76%) 0.015 
BMI, kg/m2 28.4 (6.5) 28.0 (5.7) 0.45 
Smoking 
status 
Never smoked 31 (24%) 320 (43%) <0.001 
Ex-smoker 43 (33%) 248 (33%) 
Current smoker 57 (44%) 184 (24%) 
Education Secondary school 43 (33%) 246 (33%) 0.42 
Apprenticeship 9 (7%) 73 (10%) 
Further education 
college 
52 (40%) 224 (30%) 
University degree 19 (15%) 159 (21%) 
Further degree 8 (6%) 45 (6%) 
Deprivation index 3.0 (1.4) 3.4 (1.5) 0.002 
NSAID use in past 6 months 107 (74%) 627 (75%) 0.76 
DMARD use in past 6 months 19 (13%) 127 (15%) 0.61 
BASDAI, median (IQR) 7.4 (6.2, 8.5) 6.6 (5.2, 7.7) <0.001 
Spinal pain, median (IQR) 7.0 (7.0, 8.0) 7.0 (5.0, 8.0) <0.001 
ASDAS 3.1 (0.8) 2.8 (0.8) <0.001 
Hypertension 24 (16.6%) 82 (9.7%) 0.019 
Asthma 24 (16.6%) 62 (7.3%) <0.001 
Peptic ulcer disease 10 (6.9%) 18 (2.1%) 0.004 
Diabetes mellitus 9 (6.2%) 16 (1.9%) 0.006 
Cancer 3 (2.1%) 13 (1.5%) 0.72 
Ischaemic heart disease 7 (4.8%) 8 (0.9%) 0.003 
Tuberculosis 1 (0.7%) 14 (1.6%) 0.71 
Renal disease 5 (3.4%) 6 (0.7%) 0.014 
COPD 6 (4.1%) 4 (0.5%) 0.001 
Stroke 1 (0.7%) 6 (0.7%) 1.00 
Liver disease 2 (1.4%) 5 (0.6%) 0.27 
Heart failure 1 (0.7%) 5 (0.6%) 1.00 
Demyelinating disease 0 2 (0.2%) 1.00 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
ASDAS, AS disease activity score; ASQoL, AS quality of life questionnaire; BASDAI, 
Bath AS disease activity index; BMI, body mass index; COPD, chronic obstructive 
pulmonary disease; DMARD, disease modifying antirheumatic drug. 
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7.4.1 Comparison of depression diagnosis and symptoms  
HADS was completed by 742 (75%) participants at baseline. Those who did not complete 
the HADS at baseline were younger (43 vs. 45 years, p=0.005) but otherwise had similar 
characteristics to participants included in the analysis (Appendix 10.6: Table S7.1). The 
mean values for the depression and anxiety sub-scale scores were 7.6 (SD 4.1) and 9.2 (SD 
4.4), respectively. Average HADS over time showed that symptoms of both depression and 
anxiety improved after commencing TNFi (Figure 7.1). 
 
Figure 7. 1: Change in HADS sub-scale scores after TNFi initiation, shown alongside change 
in disease activity. 
 
HADSD, HADS depression sub-scale; HADSA, HADS anxiety sub-scale; BASDAI, Bath AS 
disease activity index; ASDAS, AS disease activity score 
 
Baseline HADS-depression categories were poorly concordant with history of depression 
diagnosis (Table 7.2). A quarter of those with history of depression reported HADS values 
consistent with no depressive symptoms, while 1 in 5 without a history of depression 




Table 7. 2: Proportion of patients in each HADS depression category according to history 
of depression. 
 axSpA with history of 
depression (n=145) 
axSpA without 
history of depression 
(n=849) 
p-value 
None 31 (27%) 343 (55%) <0.001 
Mild 31 (27%) 161 (26%) 
Moderate 30 (27%) 98 (16%) 
Severe 21 (19%) 27 (4%) 
HADS-D, depression sub-scale. HADS categories: None, ≤7; Mild 8-10; 
Moderate, 11-14; Severe ≥15. 
 
HADS depression and anxiety sub-scale scores were highly collinear; those with each 
category of depression symptoms generally had the similar level of anxiety or none (Table 
7.3).  
 














None n=278 218 (58%) 43 (22%) 16 (13%) 1 (2%) 37% 
Mild n=169 86 (23%) 55 (29%) 25 (20%) 3 (6%) 23% 
Moderate 
n=205 
58 (16%) 72 (38%) 57 (45%) 18 (38%) 28% 
Severe n=90 12 (3%) 22 (11%) 30 (23%) 26 (54%) 12% 
Total n=742 100% 100% 100% 100% 100% 
HADS-D, depression sub-scale; HADS-A, anxiety sub-scale. Each range from 0 to 21. HADS 
categories: None, ≤7; Mild 8-10; Moderate, 11-14; Severe ≥15. 
 
Despite their collinearity, there were subtle differences in baseline characteristics according 
to HADS anxiety (Table 7.4) and depression categories (Table 7.5). Age and gender were 
comparable between the four HADS-depression categories. By contrast, increasing severity 
of anxiety was associated with younger age. Participants reporting mild to severe 
depressive symptoms had higher BMI compared to those reporting no depressive 
symptoms, whereas BMI were comparable between anxiety categories. Increasing levels of 
anxiety and depression were each associated with higher proportions of current and ever 
smoking and residing in areas with greater deprivation. Participants reporting increasing 
levels of anxiety or depression also had significantly higher disease activity. 
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Table 7. 4: Baseline characteristics compared according to baseline HADS depression categories. 
 None (n=374) Mild (n=192) Moderate (n=128) Severe (n=48) P-value 
Age, years 45.3 (14.6) 45.5 (13.6) 46.6 (13.0) 42.7 (12.0) 0.44 
Males 248 (66%) 133 (69%) 83 (65%) 32 (67%) 0.85 
Meeting modified New York criteria 221 (59%) 118 (61%) 69 (54%) 27 (56%) 0.58 
Age at symptom onset, years 28.0 (10.7) 29.5 (12.2) 29.8 (12.9) 28.5 (10.8) 0.32 
Symptom duration, years 17.3 (13.4) 16.0 (12.5) 16.8 (13.6) 14.2 (11.3) 0.39 
HLA-B27 positive 218 (78%) 106 (75%) 70 (74%) 20 (59%) 0.13 
BMI, kg/m2 27.2 (5.2) 29.0 (6.1) 28.9 (6.3) 28.5 (7.1) 0.005 
Smoking 
status 
Never smoked 187 (50%) 64 (33%) 41 (32%) 6 (13%) <0.001 
Ex-smoker 118 (32%) 67 (35%) 42 (33%) 16 (34%) 
Current smoker 69 (18%) 61 (32%) 45 (35%) 25 (53%) 
Education Secondary school 107 (29%) 71 (37%) 51 (40%) 22 (50%) 0.006 
Apprenticeship 36 (10%) 16 (8%) 14 (11%) 4 (9%) 
Further education college 110 (29%) 62 (33%) 40 (31%) 15 (34%) 
University degree 93 (25%) 34 (18%) 20 (16%) 2 (5%) 
Further degree 28 (7%) 7 (4%) 3 (2%) 1 (2%) 
Deprivation index 2.9 (1.4) 3.1 (1.4) 3.1 (1.4) 3.7 (1.3) <0.001 
NSAID use in past 6 months 277 (75%) 138 (74%) 89 (70%) 34 (74%) 0.74 
DMARD use in past 6 months 44 (12%) 25 (14%) 31 (25%) 7 (15%) 0.009 
BASDAI, median (IQR) 6.0 (4.5, 7.2) 7.0 (6.0, 7.8) 7.4 (6.4, 8.6) 8.6 (7.7, 9.6) <0.001 
Spinal pain, median (IQR) 6.0 (4.0, 7.0) 7.0 (6.0, 8.0) 7.5 (6.0, 8.0) 8.0 (7.0, 9.0) <0.001 
ASDAS 2.6 (0.8) 3.1 (0.7) 3.2 (0.7) 3.6 (0.6) <0.001 
History of depression 31 (8%) 31 (16%) 30 (23%) 21 (44%) <0.001 
HADS depression sub-scale 7.0 (3.7) 10.1 (3.5) 11.9 (3.6) 14.8 (3.6) <0.001 
HADS anxiety sub-scale 4.2 (2.0) 8.9 (0.8) 12.1 (1.1) 16.4 (1.1) <0.001 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
IQR, interquartile range; BMI, body mass index; BASDAI, Bath AS disease activity index; ASDAS, AS disease activity score; 





Table 7. 5: Baseline characteristics compared according to HADS anxiety categories. 
 None (n=278) Mild (n=169) Moderate (n=205) Severe (n=90) P-value 
Age, years 47.0 (14.7) 45.5 (13.9) 44.6 (13.0) 42.0 (12.9) 0.021 
Males 188 (68%) 120 (71%) 131 (64%) 57 (63%) 0.44 
Meeting modified New York criteria 165 (59%) 106 (63%) 118 (58%) 46 (51%) 0.33 
Age at symptom onset, years 28.3 (11.6) 29.3 (11.1) 28.8 (11.5) 28.8 (12.4) 0.84 
Symptom duration, years 18.7 (13.4) 16.2 (13.1) 15.8 (12.7) 13.2 (12.1) 0.003 
HLA-B27 positive 174 (81%) 83 (70%) 112 (74%) 45 (70%) 0.092 
BMI, kg/m2 27.8 (5.5) 27.8 (5.1) 28.7 (6.6) 27.8 (6.0) 0.36 
Smoking 
status 
Never smoked 138 (50%) 70 (41%) 69 (34%) 21 (23%) <0.001 
Ex-smoker 90 (32%) 61 (36%) 72 (35%) 20 (22%) 
Current smoker 50 (18%) 38 (22%) 63 (31%) 49 (54%) 
Education Secondary school 89 (32%) 60 (36%) 70 (35%) 32 (36%) 0.20 
Apprenticeship 29 (10%) 14 (8%) 19 (9%) 8 (9%) 
Further education college 81 (29%) 42 (25%) 76 (38%) 28 (32%) 
University degree 62 (22%) 45 (27%) 27 (13%) 15 (17%) 
Further degree 16 (6%) 8 (5%) 10 (5%) 5 (6%) 
Deprivation index 2.8 (1.4) 3.0 (1.3) 3.1 (1.4) 3.3 (1.4) 0.015 
NSAID use in past 6 months 205 (75%) 125 (75%) 146 (73%) 62 (69%) 0.63 
DMARD use in past 6 months 43 (16%) 18 (11%) 35 (18%) 11 (12%) 0.31 
BASDAI, median (IQR) 5.9 (4.4, 7.2) 6.6 (5.5, 7.4) 7.3 (6.1, 8.3) 7.7 (6.7, 8.9) <0.001 
Spinal pain, median (IQR) 6.0 (4.0, 8.0) 7.0 (5.0, 8.0) 7.0 (6.0, 8.0) 8.0 (7.0, 9.0) <0.001 
ASDAS 2.6 (0.9) 2.9 (0.7) 3.0 (0.7) 3.2 (0.9) <0.001 
HADS depression sub-scale 4.7 (1.9) 9.0 (0.8) 12.1 (1.0) 16.7 (1.6) <0.001 
HADS anxiety sub-scale 5.0 (3.2) 7.4 (3.2) 9.4 (3.5) 11.9 (3.9) <0.001 
Data shown as mean (SD) and n (%) unless otherwise indicated. IQR, interquartile range; BMI, body mass index; BASDAI, Bath AS 
disease activity index; ASDAS, AS disease activity score; BASFI, Bath AS functional index; ASQoL, AS quality of life questionnaire. 
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7.4.2 History of depression vs. treatment outcomes (conditional models) 
7.4.2.1 History of depression vs. binary response 
The proportion of participants achieving binary response according to each definition is 
(Table 7.6). As observed in the previous chapter, models for low disease activity (BASDAI<4 
and ASDAS<2.1) showed reduced effect sizes after adjusting for baseline values, while 
effect sizes increased after such adjustment for models of BASDAI 50/2 and ASDAS-MI. 
Using conservative effect sizes (i.e., baseline adjustment for low disease activity thresholds, 
but not for BASDAI 50/2 and ASDAS-MI), odds of response was 25 to 47% lower in those 
with a history of depression than those without. 
 




Odds ratio without 
adjusting for baseline 
disease activity* 
Odds ratio additionally 
adjusting for baseline 
disease activity* 
BASDAI 50/2 307 (56%) 0.69 (0.40, 1.19) 0.54 (0.31, 0.96) 
ASDAS-MI 130 (26%) 0.75 (0.36, 1.56) 0.52 (0.23, 1.16) 
BASDAI<4 311 (57%) 0.56 (0.32, 0.99) 0.73 (0.41, 1.32) 
ASDAS<2.1 168 (34%) 0.50 (0.25, 0.99) 0.53 (0.26, 1.07) 
*Logistic models adjusted for age, gender, BMI, Index of Multiple Deprivation, 
education, elevated CRP, comorbidity count; full model coefficients shown in 
Appendix 10.6: Table S7.2. 
Bold text highlights statistically significant results. 
BASDAI 50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, major 
improvement i.e. ≥2-unit reduction. 
 
 
7.4.2.2 History of depression vs. continuous response (absolute improvement) 
Improvements in BASDAI and ASDAS were numerically greater in those without history of 
depression at baseline, although interaction terms were only statistically different for 
BASDAI and ASDAS at month 3 (Figure 7.2). For example, BASDAI improvement at month 3 
was 0.6 units (95% CI 0.05 to 1.13) greater for those without history of depression (Table 
7.7). Interaction terms overall were not statistically significant in any models; differences 
between groups were also smaller than the clinically important effect size (i.e., smaller than 




Figure 7. 2: Change in disease activity in response to TNF inhibitors according to history of 
depression at baseline.  
 
 
Table 7. 7: Coefficients from mixed effects models of history of depression vs. disease 
activity over time. 
 
BASDAI ASDAS Spinal pain 
N 1998 1872 2009 
Constant 5.77 (4.88 to 6.66) 2.15 (1.78 to 2.53) 6.22 (5.20 to 7.25) 
3.FU -2.16 (-2.36 to -1.96) -1.05 (-1.14 to -0.96) -2.49 (-2.74 to -2.24) 
6.FU -2.7 (-2.90 to -2.50) -1.27 (-1.37 to -1.18) -3.07 (-3.33 to -2.82) 
12.FU -2.67 (-2.89 to -2.46) -1.3 (-1.40 to -1.19) -3.07 (-3.34 to -2.79) 
24.FU -2.84 (-3.12 to -2.57) -1.32 (-1.46 to -1.19) -3.39 (-3.73 to -3.05) 
36.FU -2.96 (-3.33 to -2.59) -1.34 (-1.54 to -1.15) -3.35 (-3.79 to -2.90) 
Depression* 0.71 (0.28 to 1.14) 0.16 (-0.02 to 0.35) 0.74 (0.23 to 1.25) 
3.FU#Depression 0.59 (0.05 to 1.13) 0.34 (0.09 to 0.59) 0.34 (-0.34 to 1.02) 
6.FU#Depression 0.50 (-0.06 to 1.06) 0.26 (-0.001 to 0.52) 0.31 (-0.40 to 1.02) 
12.FU#Depression 0.29 (-0.33 to 0.92) 0.18 (-0.11 to 0.48) -0.31 (-1.10 to 0.49) 
24.FU#Depression -0.01 (-0.79 to 0.77) 0.09 (-0.30 to 0.48) 0.07 (-0.92 to 1.05) 
36.FU#Depression 1.03 (-0.07 to 2.14) 0.36 (-0.20 to 0.91) 0.52 (-0.83 to 1.87) 
*Depression vs. none. FU, follow-up at numbered month. #, interaction term. 
Bold text highlights statistically significant results. 
Mixed models adjusted for age, gender, BMI, Index of Multiple Deprivation, education, 
elevated CRP, comorbidity count; covariate coefficients omitted. 
Asterisks indicate statistically significant 
differences. ASDAS, AS disease activity score; 
BASDAI, Bath AS disease activity index. 
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7.4.2.3 History of depression vs. time to treatment discontinuation 
Of the 994 participants that started TNFi, 18 (1.8%) did not have any post-baseline data and 
were each assigned one minute of follow-up time. The remaining 976 subjects had 1441 
person-years of follow-up, with a mean of 17 (SD 15) months and median of 12 (IQR 6 to 
27) months. Patients with history of depression at baseline had a significantly higher risk of 
drug discontinuation (Figure 7.3).  
 
Figure 7. 3: Kaplan-Meier curves comparing drug survival between participant with and 
without a history of depression. 
 
 
In multivariable (conditional) Cox models, the variable high-CRP violated the proportional 
hazards assumption and was stratified in the models. The hazard rate of TNFi 
discontinuation in the group with a history of depression was higher (HR1.17; 95%CI 0.81 to 
1.68) than those without a history of depression, but the estimate lacked precision.  
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7.4.3 Baseline symptoms of depression/anxiety vs. treatment outcomes (marginal 
models) 
 
This section compares each response definition according to baseline HADS categories. The 
group categorised as ‘none’ (i.e., sub-scale <8) was used as the referent. Covariates were 
balanced using IPTWs (Figure 7.4). All models in this section are marginal (i.e., without 
covariates). The only exception is for testing gender interactions (Section 7.4.4), where two 
additional variables – gender and comorbidity-by-gender interaction – were added. All 
IPTWs had a mean of 1 (see Appendix 10.6: Table S7.3). 
 
Figure 7. 4: Standardised mean differences in each variable before and after inverse 
probability weighting. 
IPTW for analysis of HADS depression categories is shown. SMD <0.1 indicates negligible 
difference. BASDAI, Bath AS disease activity index; IMD, index of multiple deprivation; SMD, 




7.4.3.1 Baseline symptoms vs. binary response 
The number of individuals included for analysis was 542 for BASDAI-based and 492 for 
ASDAS-based outcomes. BASDAI50/2 was achieved by 304 (56%), BASDAI<4 by 308 (57%), 
ASDAS-MI by 129 (26%) and ASDAS<2.1 by 167 (34%). Odds of achieving binary response 
reduced with increasing severity of baseline depression symptoms (Figure 7.5). In the 
weighted logistic models, groups with moderate-severe HADS-depression had around half 
the odds of achieving BASDAI 50/2, BASDAI<4 and ASDAS-MI, and 62% lower odds of 
ASDAS<2.1 compared to the ‘none’ group, after accounting for all covariates including 
differences in baseline BASDAS or ASDAS. Groups with mild depression had 39 to 48% lower 
odds of achieving these binary responses. 
 
Figure 7. 5: Associations between HADS depression sub-scale categories and binary 
responses at 6 months. 
 
Model coefficients shown in Appendix 10.6: Table S7.4. HADS-D categories: None, 
HADSD≤7; Mild, 8-10; Moderate-severe, ≥11. BASDAI 50/2, 50% or 2-unit reduction in 




Compared to the ‘none’ group for HADS-anxiety, those with mild or moderate-severe 
anxiety had around half the odds of achieving BASDAI-based responses (Figure 7.6). Using 
the same referent, the effect sizes were smaller for ASDAS-based definitions. The sole 
statistically significant comparison was 42% lower odds of achieving ASDAS<2.1 in 
moderate-severe anxiety vs ‘none’. 
 
Figure 7. 6: Associations between HADS anxiety sub-scale categories and binary responses 
at 6 months. 
 
Model coefficients shown in Appendix 10.6: Table S7.4. HADS-A categories: None, 
HADSA≤7; Mild, 8-10; Moderate-severe, ≥11. BASDAI 50/2, 50% or 2-unit reduction in 





7.4.3.2 Baseline symptoms vs. continuous response (absolute improvement) 
Groups reporting mild or moderate-severe baseline depressive symptoms had smaller 
improvement in all three disease activity indices (Figure 7.7). All data points were 
statistically significantly different between none vs. moderate-severe depressive symptom 
groups. For example, the group with no depression at 3-months had approximately 2.1 
units greater response in BASDAI, 0.9 units greater response in ASDAS and 2.3 units greater 
response in spinal pain than the group with moderate-severe depression (Table 7.8). This 
blunted response persisted throughout the first three years of follow-up. Effect sizes 
comparing mild vs. ‘none’ groups were smaller but nevertheless statistically and clinically 
significant at approximately 1.1- to 1.6-unit greater response in BASDAI, 0.4 to 0.7 units in 




Figure 7. 7: Change in disease activity in response to TNF inhibitors according baseline 
HADS depression symptom categories. 
 
  
ASDAS, AS disease activity score; 
BASDAI, Bath AS disease activity index. 
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BASDAI ASDAS Spinal pain 
N, participants 
(follow-ups) 
738 (2050) 673 (1840) 740 (2065) 
Constant 6.45 (6.23 to 6.68) 2.90 (2.78 to 3.01) 6.29 (6.04 to 6.54) 
3.FU -2.94 (-3.28 to -2.60) -1.37 (-1.52 to -1.22) -3.23 (-3.58 to -2.88) 
6.FU -3.06 (-3.38 to -2.75) -1.46 (-1.60 to -1.31) -3.46 (-3.81 to -3.12) 
12.FU -3.13 (-3.45 to -2.81) -1.57 (-1.72 to -1.41) -3.61 (-3.96 to -3.26) 
24.FU -3.26 (-3.77 to -2.75) -1.63 (-1.84 to -1.42) -3.63 (-4.27 to -2.99) 
36.FU -3.37 (-3.79 to -2.95) -1.61 (-1.83 to -1.39) -3.87 (-4.33 to -3.41) 
Mild* 0.08 (-0.32 to 0.48) 0.001 (-0.19 to 0.18) 0.11 (-0.45 to 0.66) 
Mod-severe** 0.03 (-0.62 to 0.68) 0.05 (-0.13 to 0.24) 0.17 (-0.34 to 0.69) 
3.FU#Mild 1.53 (0.91 to 2.14) 0.73 (0.46 to 0.99) 1.83 (1.00 to 2.67) 
6.FU#Mild 1.14 (0.54 to 1.73) 0.69 (0.41 to 0.96) 1.44 (0.64 to 2.24) 
12.FU#Mild 1.23 (0.54 to 1.93) 0.64 (0.33 to 0.95) 1.34 (0.36 to 2.31) 
24.FU#Mild 1.07 (0.30 to 1.84) 0.43 (0.08 to 0.78) 0.61 (-0.16 to 1.37) 
36.FU#Mild 1.59 (0.60 to 2.57) 0.64 (0.27 to 1.01) 2.50 (0.92 to 4.08) 
3.FU#Mod-sev 2.14 (1.33 to 2.95) 0.86 (0.60 to 1.12) 2.29 (1.54 to 3.05) 
6.FU#Mod-sev 1.88 (1.18 to 2.58) 0.65 (0.36 to 0.93) 2.06 (1.12 to 2.99) 
12.FU#Mod-sev 2.03 (1.19 to 2.87) 0.92 (0.56 to 1.28) 1.53 (0.42 to 2.63) 
24.FU#Mod-sev 1.62 (0.93 to 2.30) 0.88 (0.47 to 1.28) 1.52 (0.45 to 2.60) 
36.FU#Mod-sev 1.90 (1.03 to 2.78) 0.83 (0.51 to 1.15) 2.44 (0.94 to 3.94) 
*Mild (8-10) vs. None (<8). **Moderate-severe (≥11) vs. None. 
Bold text highlights statistically significant results. 




Results were similar for anxiety categories (Figure 7.8). At month 3, the group with no 
anxiety symptoms had approximately 1.6 units greater response in BASDAI, 0.6 units in 
ASDAS and 1.8 units in spinal pain than the group with moderate-severe depression (Table 
7.9). Effect sizes comparing mild vs. ‘none’ were also clinically important, by approximately 
0.7 to 1.2 units in BASDAI, 0.2 to 0.5 units in ASDAS, and 0.5 to 0.8 units in spinal pain over 
3 years. 
Figure 7. 8: Change in disease activity in response to TNF inhibitors according baseline 
HADS anxiety symptom categories. 
 
ASDAS, AS disease activity score; 
BASDAI, Bath AS disease activity index. 
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BASDAI ASDAS Spinal pain 
N, participants 
(follow-ups) 
738 (2050) 673 (1840) 740 (2065) 
Constant 6.52 (6.28 to 6.76) 2.89 (2.78 to 3.00) 6.30 (6.04 to 6.57) 
3.FU -2.84 (-3.20 to -2.49) -1.29 (-1.45 to -1.13) -3.24 (-3.64 to -2.85) 
6.FU -3.3 (-3.64 to -2.96) -1.47 (-1.62 to -1.32) -3.5 (-3.90 to -3.10) 
12.FU -3.32 (-3.71 to -2.93) -1.58 (-1.74 to -1.42) -3.68 (-4.09 to -3.27) 
24.FU -3.53 (-3.92 to -3.15) -1.66 (-1.83 to -1.48) -3.88 (-4.30 to -3.47) 
36.FU -3.52 (-3.98 to -3.06) -1.59 (-1.81 to -1.37) -3.83 (-4.33 to -3.33) 
Mild* -0.22 (-0.61 to 0.18) -0.03 (-0.23 to 0.16) -0.02 (-0.45 to 0.41) 
Mod-severe** 0.05 (-0.33 to 0.43) 0.02 (-0.14 to 0.18) 0.13 (-0.32 to 0.58) 
3.FU#Mild 0.66 (0.09 to 1.23) 0.18 (-0.11 to 0.46) 0.63 (-0.06 to 1.31) 
6.FU#Mild 1.05 (0.50 to 1.61) 0.31 (0.05 to 0.57) 0.47 (-0.18 to 1.12) 
12.FU#Mild 1.16 (0.57 to 1.75) 0.48 (0.22 to 0.73) 0.81 (0.12 to 1.51) 
24.FU#Mild 1.17 (0.53 to 1.80) 0.36 (0.03 to 0.68) 0.72 (0.04 to 1.40) 
36.FU#Mild 0.76 (-0.01 to 1.52) 0.49 (0.11 to 0.88) 0.41 (-0.74 to 1.56) 
3.FU#Mod-sev 1.58 (1.05 to 2.12) 0.59 (0.35 to 0.82) 1.75 (1.12 to 2.38) 
6.FU#Mod-sev 1.71 (1.12 to 2.31) 0.7 (0.45 to 0.96) 1.78 (1.07 to 2.48) 
12.FU#Mod-sev 1.35 (0.79 to 1.90) 0.49 (0.23 to 0.76) 0.70 (0.07 to 1.33) 
24.FU#Mod-sev 1.44 (0.74 to 2.14) 0.82 (0.46 to 1.18) 0.84 (0.02 to 1.66) 
36.FU#Mod-sev 2.00 (1.19 to 2.82) 0.62 (0.27 to 0.98) 1.68 (0.39 to 2.97) 
*Mild (8-10) vs. None (<8). **Moderate-severe (≥11) vs. None (<8). 
Bold text highlights statistically significant results. 
Covariate coefficients omitted. FU, follow-up at numbered month. #, interaction term. 
 
 
7.4.3.3 Baseline symptoms vs. time to treatment discontinuation 
Analyses included 1036 person-years of follow-up, with mean of 17 (SD 15) months and 
median 12 (IQR 5 to 25) months. Very few individuals had follow-up beyond 4 years. 
31% of the cohort stopped treatment over the study. 38% of participants with moderate-
severe depression discontinued, 35% with mild, 26% with none. 37% of those with 
moderate-severe anxiety discontinued, 31% with mild, 25% with none. Drug survival 




Figure 7. 9: Kaplan-Meier curves comparing drug survival between participant-groups 





Symptoms of depression or anxiety were associated with greater hazard rate of treatment 
discontinuation (i.e., greater number of individuals discontinued at any one time, assuming 
rates are proportional). Compared to the ‘none’ category for depression, the mild 
depression group had 32% higher (95% CI 0.93 to 1.87), and moderate-severe group 45% 
higher (95% CI 0.99 to 2.12), hazard rate of treatment discontinuation (Figure 7.10). 
Compared to the ‘none’ category for anxiety, the group with mild anxiety at baseline had 
36% higher (95% CI 0.91 to 2.05), and moderate-severe group 59% higher (95% CI 1.12 to 
2.26), hazard of TNFi discontinuation. 
 








Kaplan-Meier estimators in Figure 7.9 suggest potential violation of the proportional 
hazards assumption. Comparison between none and moderate-severe groups was 
approximately proportional, as shown by marginal structural Cox models using flexible 
baseline hazards (Figure 7.11). 
 
Figure 7. 11: TNFi discontinuation modelled using proportional and non-proportional 
hazards. 
 
HADSA, hospital anxiety and depression scale – anxiety sub-scale; HADSD, hospital anxiety 





7.4.4 Gender interactions between baseline depression or anxiety symptoms and 
each outcome. 
 
All analyses were repeated with consideration of the effect modification by gender (by 
stratification or interaction). In summary, there were no statistically or clinically significant 
effect modification in the three aims (data not shown) except one. Marginal longitudinal 
models of BASDAI according to baseline HADS-depression categories showed significant 
effect modification by gender. The Wald test p-value for all interaction terms was <0.001. 
Marginal estimates are plotted in Figure 7.12. Female groups with mild and mod-severe 
depression had markedly poorer response compared to their male counterparts. 
 
Figure 7. 12: Significant effect modification by gender in the longitudinal analysis of 





7.4.5 Sensitivity analysis 
Models using weights that additionally included baseline smoking status, HLA-B27, and 
alcohol status did not produce significantly different results (data not shown). Analyses 
repeated using matching weights also did not produce meaningfully different results (data 
not shown).  
 
7.5 Discussion 
In this longitudinal analysis of the BSRBR-AS, history of depression was poorly concordant 
with depressive symptoms; 1 in 5 of those with no documented depression reported at 
least moderate symptoms. AxSpA patients with mild to severe symptoms of depression or 
anxiety had markedly poorer response to their first TNFi compared to those with less than 
mild symptoms. Interventions to optimise mental health at or before TNFi initiation may 
dramatically improve treatment response. 
In a recent meta-analysis, numerous cross-sectional studies have shown higher disease 
activity in axSpA patients with depression [9]. Only one prior study – that used an early 
version of the same BSRBR-AS dataset – examined mental health in the context of 
treatment response in axSpA [6]. Macfarlane et al used stepwise selection of predictors to 
show that, for each unit increase in the mental component summary of the SF12 (higher 
score indicating higher level of health), odds of ASDAS clinically important response 
(reduction by ≥1.1) and ASDAS low disease activity (<2.1) were significantly increased by 
5%. Similarly, ASAS20 response was reduced by 6% for each unit increase in the HADS 
anxiety subscore. However, predictors do not necessarily have a causal interpretation [20]; 
for example, stepwise variable selection provides final models that may omit important 
confounders [21,22]. The current analysis was designed to best approximate a causal 
interpretation, and extended outcome measures beyond binary response definitions. Such 
definitions have inherent limitations when using observational data [23]; for example, high 
baseline DAS28 is a predictor that simultaneously increases odds of ACR70 response and 
decreases odds of DAS remission in RA [24]. 
Results of the current analysis are consistent with studies in rheumatoid arthritis using the 
BSRBR-RA, where history of depression and symptoms of depression were associated with 
reduced response [243]. The authors used mixed models to examined linear improvement 
through months 6 and 12, showing an adjusted difference in DAS28 of 0.01 units between 
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those with and without depression symptoms. This and other effect sizes were an order of 
magnitude smaller than that deemed clinically meaningful. Contrast this to a difference of 
proximately 2 BASDAI units and 0.9 ASDAS units between axSpA patients in the moderate-
severe and ‘none’ group for depression, where clinically meaningful differences are around 
1 unit for BASDAI and ASDAS [180]. This may be explained by forcing linearity onto a clearly 
non-linear response trajectory, or the use of the Short-Form 36-item questionnaire which 
was designed to measure quality of life not to assess depression. The main reason is likely 
the unique way in which axSpA disease activity is assessed: BASDAI and spinal pain are 
completely patient-reported. Depression is known to influence the experience and 
reporting of symptoms [199,231], which is supported by larger effect sizes for BASDAI than 
(the more objective) ASDAS. Optimising mental health may offer substantial improvements 
in axSpA treatment response. Conversely, neglecting mental health may lead those with 
severe mental health symptoms to ‘double jeopardy’, where apparent inadequate response 
in disease indices means their TNFi are withdrawn in healthcare systems like the UK. 
This study is the first to assess the impact of anxiety on treatment outcomes. Anxiety is 
often assumed to exist in parallel with depression and thus overlooked in clinical practice 
and research. Symptoms of both depression and anxiety were associated with treatment 
discontinuation, but the effect sizes were larger for anxiety: moderate-severe depression 
(vs. ‘none’) was associated with 45% higher hazard rate compared to 59% for anxiety. 
Although correlated, the depression and anxiety are not equivalent. Of those without 
depressive symptoms, nearly half had at least mild symptoms of anxiety and 1 in 5 had at 
least moderate. Conversely, 22% of those without anxiety had at least mild symptoms of 
depression.  
Mental health disorders are under-recognised and -diagnosed in axSpA, despite their high 
prevalence [9] and association with many other important health factors such as 
alcohol/drug abuse and suicide [143]. Under-diagnosis of depression was clearly 
demonstrated by the data: 20% of those without a recorded diagnosis of depression 
reported HADS-D≥11, which has 92% specificity for major depressive disorder [233]. 
Conversely, diagnosed depression may be treated with variable success; 27% of those with 
a history of depression reported HADS-D<8. Mental health symptoms are dynamic and 
should be assessed as such. This likely explains why differences in absolute disease activity 
improvement were more prominent when using symptoms than history of depression. 
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These results suggest that symptoms of both depression and anxiety should be 
systematically screened in routine practice. This allows clinicians to better predict 
treatment response, but more importantly to highlight individuals who may benefit from 
interventions to reduce depression and anxiety (medication and/or psychological therapy). 
Up to half of axSpA patients do not respond to their first TNFi. This study suggests potential 
for substantial improvements in treatment response (e.g., approximately 2 units in BASDAI) 
and treatment persistence if severe depression symptoms can be successfully treated. The 
number of pharmacological options is increasing but as yet not reliably effective in routine 
practice, while talking therapies can be difficult to access. Improving access to the latter, for 
example using internet or telephone delivered cognitive behavioural therapy for those with 
mild to moderate symptoms, may be one solution. Individuals with more severe symptoms 
will still require one-to-one therapy. RCTs of non-pharmacological mental health 
interventions in chronic rheumatic disease are needed to find optimal approaches for these 
prevalent and impactful comorbidities. 
7.5.1 Strengths and limitations 
Strengths of the data were discussed in previous chapters; for example, the large sample 
size recruited from a broad range of rheumatology centres, and use of three response 
definitions that each lends strength to the overall conclusion. Diagnoses correlate poorly 
with dynamic and often under-recognised symptoms. Therefore, symptoms of 
depression/anxiety, rather than documented diagnosis, provide effect estimates that have 
greater relevance to clinical practice and potential interventions. Results were robust 
against several sensitivity analyses.  
There were also important limitations. Studying the causal effect of baseline mental health 
symptoms (a ‘prevalent exposure’) has conceptual difficulty; the implied hypothetical 
intervention would need to successfully improve baseline symptoms, but also symptoms 
pre-baseline of unknown duration. This might be considered as an intervention 
administered before (rather than at) TNFi initiation, but true causal effect sizes are likely to 
be smaller. Even if more realistic effect estimates were half the size, they still remain larger 
and more amenable to intervention that other ‘modifiable risk factors’: Smoking cessation 
did not convincingly impact treatment outcomes and is difficult to achieve [42,189]; BMI is 
associated with treatment outcomes [244] but causal effects are conceptually problematic 
to estimate and interventions practically difficult to implement [245].  
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Categorising HADS sub-scales will have reduced statistical power and effect sizes. Using IP 
weights for continuous HADS requires strong assumptions of its distribution; it would also 
assume a linear relationship between HADS and treatment outcomes, which the above 
results showed not to hold. Results from weighted GEE models should be interpreted with 
the limitation that participants who did not respond by the first assessment (usually after 3 
months) or those who lost response would have had their treatment stopped under NICE 
guidance; therefore, record of such high disease activity would be censored. This 
informative censoring should not affect data within the first 3 months [42]. IP weighting 
methods are known to inflate variance (reduce precision), for example, through use of 
robust standard error. A key limitation is that mental health symptoms improve after TNFi 
initiation; the time-varying interplay between them and axSpA disease activity may be of 
interest for future analyses. This requires consideration of both time-varying ‘exposure’ and 
covariates (Figure 7.13), and is beyond the scope of this thesis [246]. 
The singular significant result for effect modification by gender should not be over-
interpreted. First, binary BASDAI responses were not significantly different according to 
gender. Second, significant effect modification by gender was not observed for any other 
indices or treatment discontinuation. Third, the number of females were small leading to 
uncertainty in the point estimate. Nevertheless, it may be of interest for future studies to 




Figure 7. 13: Causal associations between time-varying mental health symptoms and 
axSpA disease activity, and implications for analytical approaches. 
 
       axSpA onset                   TNFi initiation 
 
Arbitrary units of time    0         1           2                    3                    4                    5                 6 
axSpA disease activity, L(t)                   L(2)                L(3)                L(4)               L(5)            L(6) 
 
Mental health symptoms, A(t)            A(2)               A(3)               A(4)                A(5)            A(6) 
 
At ‘time 2’, axSpA symptoms, L(2), influence mental health, A(2), which in turn affects how 
axSpA symptoms L(3) are experienced and reported. Mental health symptoms at ‘time 3’, 
A(3), are simultaneously affected by axSpA symptoms, L(3), and the history of axSpA L(2) 
and mental health symptoms A(2) before this time point. This complex feedback between 
exposure and outcome continues to TNFi initiation. When treatment improves L(4), A(4) 
also improves. Post-treatment axSpA disease activity L(5) is simultaneously affected by 
treatment (through L(4)) and improvements in mental health A(4).  
This complex causal web has important implications for the analysis. Traditional outcome 
regression ‘adjustment’ to account for different baseline disease activity between mental 
health symptom categories is problematic: L(4) is a confounder for A(4), but also a time-
varying mediator with respect to ?̅?(3) (i.e., history of pre-treatment mental health 
symptoms), and a time-varying confounder that is affected by ?̅?(3). Conditioning on 
(‘adjusting’ for) a time-dependent confounder that is affected by past exposure introduces 
profound bias, whether in repeated measure [247] or time-to-event analyses [248]. 
Conditioning on a mediator (post-treatment mental health symptoms) removes the indirect 
part of the total causal effect of the exposure (total effect = direct effect + indirect effects).   
These observations highlight two issues for the current analysis. First, inverse-probability 
weighting accounts for L(4) without conditioning on it, such that A(4) is not confounded. 
Second, time-varying post-treatment mental health symptoms cannot simply be ‘adjusted 
for’ in GEE or Cox models. To untangle the effect of post-treatment mental health response 
on post-treatment disease activity, complex causal methods are required (e.g., the 






Baseline history of depression is poorly representative of mental health symptom burden. 
Symptoms of depression and anxiety at TNFi initiation were each associated with adverse 
treatment outcomes. Assuming these marginal models provide an adequate approximation 
of real causal effects, reducing depression symptoms (from moderate-severe to less than 
mild) at TNFi initiation may improve binary response at 6 months by up to 2-fold, absolute 
response by as much as 2 BASDAI and 0.9 ASDAS units. Similarly improving anxiety 
symptoms may reduce treatment discontinuation by up to a third. Taken together, these 
findings highlight the importance of routinely screening and optimising depression and 
anxiety. Randomised controlled trials are needed to identify efficacious mental health 








Chapter 8: Discussion and conclusions 
 
This chapter summarises the major research findings across the thesis and discusses their 
significance for future research, clinical practice, and wider health policy. Strengths and 
limitations are outlined, and gaps are identified for further research. 
 
8.1 Summary of findings 
The thesis began with a review of the comorbidity literature, which showed axSpA patients 
to have higher comorbidity burden than control populations [84]. These descriptive studies 
predominantly approached comorbidities as the outcome (e.g., incidence of cardiovascular 
disease or cancer), with few examining its impact on and relevance to axSpA management. 
Of the latter, the majority were studies of individual or related conditions, which lacked 
context for the relative significance of individual conditions [84]. This context is essential to 
help identify areas most in need of future research or intervention. Several research needs 
were identified; for example, the need for a comprehensive description of comorbidity 
burden and differences between axSpA subgroups, how comorbidities co-occur, their 
impact on various aspects of axSpA management, and improved study methods. This 
section summarises findings from this thesis and how they addressed unmet research 
needs. 
8.1.1 Comorbidities in radiographic vs non-radiographic axSpA 
Comorbidity burden was measured in two axSpA populations from academic centres in the 
UK and USA using an adapted version of the multimorbidity index (MMI) [198], which was 
validated in rheumatic diseases and includes 39 chronic conditions deemed important by 
multimorbidity researchers and the UK’s National Health Service [140]. Comorbidity was 
common in both study populations; over half of all axSpA patients had at least one 
additional condition, most frequently belonging to the mental health or cardiometabolic 
groups [127,128,143]. Mean comorbidity count was higher in the older Boston than Aintree 
population, in part due to its older age. 
The novel contribution to the literature was that comorbidity burden was remarkably 
similar between AS and non-radiographic axSpA in both Boston and Aintree populations, in 
terms of individual conditions and the total number of comorbidities. These results were 
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unexpected given these subgroups differed in age, gender, and inflammatory burden; they 
support the need for a unified clinical approach to management of the whole axSpA 
spectrum. 
8.1.2 Clustering of comorbidities 
Several comorbidity clusters were identified in the Aintree axSpA data. Due to the relatively 
low comorbidity burden (most patients in this study had only one or two comorbid 
conditions), clusters were dominated by relatively few diseases. The largest clusters were 
respectively dominated by mental health and cardiovascular diseases. For external 
validation, clustering was reproduced in the older Boston axSpA population with higher 
comorbidity burden. These disease clusters largely confirmed clinical experience: anxiety 
co-occurs with depression and hypertension with coronary heart disease [249]. Chapter 7 
later showed the importance of screening for anxiety when depression is present. An 
equally important finding was the consistently higher disease severity in groups with 
anxiety/depression and fibromyalgia/IBS. These patient groups are clearly in need of 
prioritisation in clinical practice – a conclusion shared by subsequent chapters (namely 
anxiety/depression; see limitations section for fibromyalgia). 
In the validation analysis using the Boston study, substance misuse was clustered with 
mental health disorders. Substance misuse disorders also showed consistent associations 
with disease severity, with potentially important but underpowered effect sizes. 
Subsequent publications using the Boston data confirmed the close relationship between 
depression and this comorbidity group in greater detail [143]. 
Describing comorbidity clusters bridges existing study designs that either focus on total 
counts or individual conditions. This approach could inform screening of other diseases 
within a cluster when one is present, or identification of patient groups in need of greater 
prioritisation for research or clinical care.  
8.1.3 Comorbidities and disease assessment 
Since axSpA symptoms are more severe with increasing comorbidity burden, how should 
clinicians assess axSpA disease activity in the presence of comorbidities? Chapter 5 
addressed this question by comparing whether disease activity measures were differentially 
influenced by comorbidities in the baseline BSRBR-AS data. Results showed that patient-
reported disease activity indices – BASDAI and spinal pain – increased with the number of 
comorbidities. By contrast, ASDAS was not associated with comorbidity count or individual 
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comorbidities by a clinically meaningful effect size. The patient global score, although 
influenced by comorbidities, did not inflate ASDAS independently of other ASDAS 
components. These results are clinically relevant since many treatment decisions are based 
on assessments using these indices. Healthcare providers should be mindful of the potential 
impact of comorbidities on patient reported measures, and consider additionally collecting 
ASDAS to assess disease activity in patients with multiple comorbidities. 
Although the BSRBR-AS comorbidity data differed from the preceding chapters (14 
conditions compared to 39 in Boston and Aintree data), depression was again highlighted as 
highly prevalent (23%) and associated with greater disease severity. When each of the 14 
comorbidities were modelled against a range of indices (disease activity plus fatigue, 
health-related quality of life, and function), depression was consistently and significantly 
associated with them all. 
8.1.4 Comorbidities and response to TNF inhibitors 
Patients with comorbidities were significantly more likely to discontinue their treatment. 
These individuals generally had reduced odds of achieving binary response definitions but 
had comparable absolute improvement in disease activity, demonstrating that greater 
absolute improvement is needed to achieve a binary response in those starting with higher 
disease activity. These subtly different but complementary results highlight the importance 
of analysing a range of response definitions. 
Many comorbid patients would have been ineligible for randomised controlled trials; these 
results provide unique insights into how therapeutic effects on function and quality of life 
differed in comorbid patients – highlighting the need to optimise comorbidities as part of 
axSpA management. Interpreting results of each outcome type in the context of others is 
important. For example, patients with comorbidities may have comparable absolute 
improvement yet lower odds of achieving ‘low disease activity’ states than those with no 
comorbidities. Communication to patients should be more nuanced. Existing definitions of 
response as used for prescribing guidelines, for example in the UK, may need to be 
reconsidered: a patient starting treatment with high BASDAI will have higher odds of 
achieving BASDAI 50/2, while simultaneously having lower odds of BASDAI<4, than an 
identical individual with lower starting BASDAI. Which definition of response is more 
relevant for health-economics remains to be determined.  
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This chapter’s longitudinal design shed further light on causal directions. But is the 
association between comorbidity and treatment outcome causal? Since comorbidity count 
cannot be ‘modified’, it remains difficult to claim causality under this robust definition. 
Causal interpretation of results should therefore be limited. Comorbidities such as 
depression can, however, be modified. 
8.1.5 Depression and anxiety and response to TNF inhibitors 
Baseline history of depression was poorly representative of depressive symptom burden in 
the BSRBR-AS. Symptoms of depression and anxiety at TNFi initiation were each associated 
with adverse treatment outcomes. Assuming these marginal models provide an adequate 
approximation of causal effects, reducing depression symptoms (from moderate-severe to 
less than mild) at TNFi initiation may improve binary response at 6 months by up to 2-fold, 
and absolute response by as much as 2 BASDAI and 0.9 ASDAS units. Similarly improving 
anxiety symptoms may reduce treatment discontinuation by up to a third. These are novel 
findings in the axSpA literature. By contrast, effect sizes from analyses of other ‘modifiable 
risk factors’ such as smoking [41,42] and BMI [250] have been much more modest (or null). 
These results suggest that symptoms of both depression and anxiety should be 
systematically screened in routine practice. This allows clinicians to better predict 
treatment response, but more importantly to highlight individuals who may benefit from 
interventions to reduce depression and anxiety (e.g., medication and/or psychological 
therapy). 
 
8.2 Strengths and limitations 
8.2.1 Strengths 
There are several strengths of this thesis regarding the data, design, analysis, and 
generalisability. Data for comorbidities and outcomes were robust with little missing data. 
For example, comorbidity data in the Aintree study were complete for almost all (>99%) 
patients and validated by multiple researchers and data sources. Comorbidity 
ascertainment in the BSRBR-AS, though different, was again robustly defined using 
physician confirmed diagnoses. This is a key advantage over many existing studies that use 
patient reported diagnoses [93]. Inherent weaknesses of one study was supported by 
strengths in the other. For example, the potentially limited accuracy of comorbidity ICD 
codes in the Boston study were supported by more robust Aintree data; limited number of 
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comorbidities in the BSRBR-AS were supported by comprehensive and standardised 
comorbidity collection in the Aintree and Boston data. 
The design of the two cross-sectional studies were specific to the aims of the thesis, 
allowing clear axSpA definitions, relevant covariates, and disease indices to be captured 
where possible. Notably, this allowed a comprehensive list of comorbidities to be 
standardised across two study populations. The multimorbidity index is also unique in that 
it is not weighted for a specific outcome and has been validated in rheumatic diseases, 
which is an advantage over many other commonly used indices. The BSRBR-AS, although 
not designed to study comorbidities, nevertheless captured most important conditions. Its 
main strength lies in the large and nationally representative secondary care axSpA 
population, for whom a wide range of disease measures were collected at regular time 
points. All three datasets are broadly representative of axSpA populations in 
secondary/tertiary care. However, they do not represent all axSpA patients in the general 
population since many are managed in primary care only [157]. 
Another key strength of this thesis is its methodology. For example, confounder selection 
has historically relied on suboptimal practices such as stepwise, univariate or other 
statistical selection [251]. In this thesis, covariate selection was carefully considered with 
transparent justification (supported by causal graphs) and numerous sensitivity analyses 
examining additional potential confounders. This more robust approach to confounding is 
essential for reducing bias and increasing the validity of results. Another weakness of 
previous research is the heterogenous definition of comorbidity and outcome. Chapter 6 
(summarised in Section 8.1.4 above), demonstrated the potential for very different 
conclusions to be drawn using different outcome definitions (supported by methodology 
work that was performed in parallel but not included in the thesis [41,42]). Thus, analysis 
approaches in this thesis included a diverse set of definitions, for example, using a range of 
approaches for comorbidity (binary, count, individual) and longitudinal outcomes (binary, 
continuous, time-to-event). Different results highlight the underlying assumptions and 
limitations of each approach.  
In the final results chapter, marginal approaches were chosen to provide results that have a 
clearer causal interpretation and would be more clinically informative (i.e., emulating 
output from RCTs), whereas popular conditional approaches may theoretically be less likely 




There were three main limitations in this thesis. First, several (mostly sub-)analyses lacked 
statistical power; for example, regression models of rarer comorbidities (such as peripheral 
vascular disease) or severe mental health symptom categories. However, most primary 
analyses were adequately powered. Increasing the sample size of the cohorts employed 
was not possible: the Aintree and Boston studies sampled from all patients at these 
centres, while the BSRBR-AS had a predetermined sample size and had completed 
recruiting. Some statistical methods (weighted GEE) further inflated variance.  
Second, the main dataset used in this thesis – the BSRBR-AS – collected a list of conditions 
tailored for pharmacovigilance rather than comprehensive study of comorbidity. This is an 
inherent limitation of using pre-collected data. For example, some important conditions 
were not included (e.g., anxiety or other neuropsychiatric conditions) while conditions 
seldom included in comorbidity studies were, for example demyelinating diseases and TB. 
Fibromyalgia was identified as an important comorbidity (Chapter 4) but could not be 
examined in the BSRBR-AS since it was ascertained differently. However, included 
comorbidities were broadly representative of important diseases when compared to prior 
axSpA research [84]. None of the comorbidity data included severity; for example, end-
stage renal/liver/heart disease will have very different impact on patients and treatment 
choices than milder forms. Loss of granularity is somewhat inherent when studying 
comorbidity burden rather than individual conditions. Chapters 6 and 7 showed that 
summarising comorbidities into a count may provide limited information for treatment 
outcomes and may hide the effect of certain comorbidities. Another limitation common to 
almost all published research is the lack of data on the chronology of comorbidities pre-
baseline, which has implications for causal interpretation of some results. 
Third, association is not necessarily causation. This is an intrinsic limitation for the cross-
sectional designs, which cannot distinguish whether high disease severity (directly or 
indirectly through its treatment) cause comorbidities or vice versa. For the longitudinal 
designs, claims of causality depend on the extent of unmeasured confounding (and other 
modelling assumptions) and the ability to modify the ‘exposure’, i.e., comorbidities. The 
latter remains debated [252]. Some relevant confounders such as physical activity and 
time-varying use of co-medication (e.g., NSAIDs) were not available. Sensitivity analysis 
methods such as the E-value are available (i.e., size of potential confounder required to 
explain away the observed results [253]) but not universally accepted [254]. For illustration, 
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the odds ratio of 0.51 (95%CI 0.29 to 0.90) observed when comparing low disease activity 
(BASDAI 50/2) at 6 months between moderate-severe vs less than mild depression (Chapter 
7) could be explained away by an unmeasured confounder that was associated with both 
the exposure and outcome by odds ratio of 2.2-fold each, above and beyond measured 
confounders; weaker confounding could not do so. A single unmeasured confounder of this 
effect size is highly unlikely. 
Additional limitations include the fact that adaptations to the multimorbidity index have 
not been validated in axSpA. The main adaptation – excluding extra-articular manifestations 
– has been shown to make no meaningful difference to performance of another 
comorbidity index [152]. This validation is ongoing as part of research arising from this 
thesis. Comorbidities were considered as a fixed baseline ‘exposure’, whereas additional 
comorbidities are likely to accumulate with time and increasing age in practice. The mean 
follow-up duration was relatively short for the treatment response analyses, during which 
accumulation of comorbidities should have been negligible. Accounting for the time-varying 
nature of comorbidity burden is important for longer-term studies; for example, 
accumulation of comorbidities substantially accounted for excess mortality among women 
with RA [255]. 
 
8.3 Recommendations for clinical practice 
8.3.1 Recording and screening for comorbidities 
Comorbidities are more prevalent in axSpA than control populations and are present in the 
majority of axSpA patients [84]. They influence treatment decisions (e.g., for NSAIDs and 
bDMARDs [85]), while treatments can cause or contribute to many comorbidities (e.g., 
cardiovascular and peptic ulcer diseases). Comorbidities are associated with poorer 
outcomes including disease severity, work productivity and mortality [84]. Rheumatologists, 
who often follow patients over many years through which comorbidities may accrue, are 
uniquely positioned to facilitate the optimisation of these co-existing diseases.  
Systematic and repeated assessments should be integrated into routine clinical practice to 
ensure holistic patient-centred management. The 2016 EULAR ‘points to consider for 
comorbidities’ recommended rheumatology teams to detect and collect information on 
comorbidities, liaise with appropriate healthcare providers to treat comorbidities, and 
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repeat comorbidity reviews [135]. They focused on six conditions: CVD, malignancies, 
infections, peptic ulcer, osteoporosis, and depression. Others have suggested including 
additional comorbidities [136], but this may be limited by feasibility in daily practice – the 
six conditions alone require a 93-item reporting form. 
Recording comorbidities may not be enough. This thesis has shown that depression is the 
most prevalent comorbidity, yet the real burden of mental health in axSpA patients is likely 
much higher [9] given under-diagnosis is common. Data herein confirmed that diagnosis 
and symptoms correlate poorly. Mental health has direct relevance to rheumatologists 
because it significantly impacts treatment response [9,213,243], which may in turn affect 
long-term outcomes such as disability and quality of life. Suboptimal response to the first 
TNFi is common in axSpA and may be improved by optimising mental health symptoms. 
Additional assessment or screening should become part of routine clinical practice. One 
potential barrier to implementation is not knowing the optimal care pathway when mental 
health disorders (or indeed other comorbidities) are found. 
8.3.2 Optimising and treating comorbidities 
Despite the prevalence and impact of comorbidities, their management among patients 
with chronic inflammatory rheumatic diseases are often suboptimal [135]. The ASAS-
COMOSPA study reviewed nearly 4000 SpA patients, and found suboptimal monitoring of 
comorbidities, particularly relating to vaccinations and some cancers (Figure 8.1) [89]. This 







Figure 8. 1: Proportion of patients optimally monitored for comorbidities as reported by 
the ASAS-COMOSPA study. 
 
Figure adapted from Molto et al [89]. Ca, cancer; CV, cardiovascular; DTP, 
diphtheria/tetanus/polio. HBV, hepatitis B virus. 
 
As set out by the EULAR recommendation [135], the first step is to identify and record 
comorbidities, followed by timely referral to appropriate healthcare services. 
Rheumatologists, who are accustomed to managing chronic multisystem diseases, are 
already experienced in facilitating/coordinating such holistic care. For example, axSpA 
patients often require joint management by ophthalmologists or gastroenterologists. 
Screening for comorbidities is also not new to rheumatology teams, who already 
systematically screen for latent or chronic infections and actively take part in their 
treatment prior to bDMARDs. 
Some comorbidities are more challenging to manage. While there are many management 
options for depression and anxiety, they are often limited by accessibility, effectiveness, or 
tolerability [256]. Anti-depressants have limited efficacy and acceptability for severe 
depression and may have little role for milder symptoms. Evidence for talking therapies 
such as cognitive behavioural therapy (CBT) suggest remarkable effectiveness (e.g., number 
needed to treat as low as 3) but may not be suitable for more severe symptoms [257]; more 
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importantly, access to these therapies are often limited and/or accompanied by 
unacceptably prolonged delays [258].  
Unlike many comorbidities, there is often no dedicated healthcare ‘department’ that takes 
ownership of mental health management in people with chronic physical conditions. 
Depression remains underdiagnosed and under-treated in patients with rheumatic 
conditions [259]. There has been growing integration of psychology into multidisciplinary 
rheumatology services in recognition of this [260], but currently only 39% of rheumatology 
departments have access to clinical psychology according to the recent British Society for 
Rheumatology national audit [261]. Management of rheumatic diseases has evolved 
significantly with development of protocolised, target-driven management pathways. As a 
result, patient-encounters have become more pressured with less time to take an 
exhaustive history or perform a holistic assessment. Assessment aids designed to promptly 
highlight psychological aspects of rheumatic illness in a busy clinical environment should be 
considered; for example, the HADS or the 4-question version of the Patient Health 
Questionnaire (PHQ-4). 
8.3.3 Adapting practice in the presence of comorbidities 
Chapter 5 showed that ASDAS was less associated with individual comorbidities and 
comorbidity burden than other indices. For example, individuals with and without 
comorbidity may have similar ASDAS but markedly different BASDAI. This suggests that 
routine assessment and monitoring of axSpA patients with multiple comorbidities should 
additionally include ASDAS. ASDAS is associated with radiographic progression (the axSpA 
disease process) whereas BASDAI is not [219]. This could mean that escalating to bDMARD 
based on BASDAI alone may not treat axSpA-specific pathology. However, until prescribing 
guidelines include ASDAS in healthcare systems such as in the UK, treatment decisions 
based on this index will be difficult to implement. 
Chapter 6 showed that patients with or without comorbidity were able to achieve similar 
degrees of absolute disease activity reduction irrespective of the index used. This provides 
reassurance against the potential for ‘double jeopardy’ in comorbid axSpA patients; that is, 
having TNFi withdrawn after demonstrating inadequate response due to impact of 
comorbidities on disease activity assessment, even if axSpA-specific disease activity was 
improved. Both ASDAS and BASDAI are equally suitable for monitoring treatment response. 
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Patients and clinicians often benefit from being able to anticipate or predict future 
response. Results from this thesis should reassure both patients and clinicians that the 
ability to respond to TNFi, in terms of absolute disease activity reduction, does not appear 
to be significantly predicted by baseline comorbidity burden. Since comorbid patients start 
with higher disease activity, they will need greater absolute improvement and thus have 
lower odds of achieving ‘low disease activity’ states. Education and communication to 
patients should include these subtleties. Binary response definitions are used to determine 
ongoing treatment eligibility in the UK [190] which, along with future research 
methodology, may need to be reviewed in light of these results (see below). Patients with 
comorbidities may also find it helpful to know that, on average, it takes slightly longer to 
experience improvement in disease activity, function, health-related quality of life and 
sleep. Equally, clinicians may make allowances when assessing response; for example, 
delaying review by a few weeks, or allowing further reviews if initial response is not 
demonstrated. It helps both patients and clinicians to know that individuals who have high 
comorbidity burden, particularly males, are much more likely to discontinue their 
treatment. More detailed examination of causes of discontinuation, and why they should 
differ according to gender, are warranted in future studies. 
8.3.4 Taking part in pragmatic trials 
All three datasets used in this thesis have shown that comorbidities are highly prevalent in 
real-world patient populations. Despite this, RCTs – the gold-standard in evidence-based 
medicine – often exclude patients with many of these conditions; Table 8.1 provides some 
examples of exclusion criteria of TNFi trials in axSpA. This has important implications for 
routine practice, where guidelines and protocols are mostly derived from RCTs. Evidence-





Table 8. 1 Examples of randomised controlled trials of TNF inhibitors for axSpA and their 
exclusion criteria. 




AS (mNY) Adalimumab 
(Humira) 
active/untreated TB, recent infections 
requiring antibiotics, hepatitis, HIV, 
demyelinating disease, multiple sclerosis. 
Cardiac, renal, neurologic, psychiatric, 





AS (mNY) Etanercept 
(Enbrel) 
bamboo spine, uncontrolled hypertension, 
unstable angina pectoris, congestive heart 
failure, severe pulmonary disease, cancer, 




AS (mNY) Adalimumab 
(Humira) 
active/untreated TB, bamboo spine, unstable 
EAM (psoriasis, uveitis, IBD), HIV, Hepatitis 
B/C, recent infection (requiring treatment), 
listeriosis, histoplasmosis, 
immunodeficiency, chronic recurring 
infections, moderate/severe heart failure, 












chronic/recurring infection, serious/life 
threatening infection (<6m prior), 
active/high risk TB, Hepatitis B/C, HIV. 
mNY, modified New York criteria for AS; nr-axSpA, non-radiographic axSpA; EAM, extra-
articular manifestations; IBD, inflammatory bowel disease. 
 
The BSRBR-AS chief investigators used an earlier version of the dataset to show that, 
compared to trial participants, TNFi initiators in the registry were older (by 6 years), more 
often female, and had poorer function (BASFI and BASMI) despite having similar BASDAI 
[266]. TNFi initiators in the BSRBR-AS had higher CRP than trial participants, which may be 
explained by BMI and/or comorbidities that were not reported to allow comparison. Only 
41% of those starting TNFi (30% starting adalimumab) in the BSRBR-AS registry would have 
met eligibility criteria for at least one RCT. This highlights the need for real-world data to 
complement RCTs. 
‘Explanatory’ RCTs aim to test efficacy under optimal situations, generally favouring those 
who are better educated, with higher socioeconomic status and better mental/overall 
health (i.e., those who are likely to adhere to treatment without adverse events). ASAS20 
response was achieved by 62% of trial participants which was much higher than in the 
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BSRBR-AS, where 51% achieved ASAS20 (between 10 weeks and 9 months) among the 39% 
with available follow-up data [266]. Since those with unavailable data may have 
discontinued treatment, the true response rate is likely much lower. Differences between 
trial and real-world populations, between efficacy and effectiveness, are evident [266]; the 
same is also likely to apply to safety.  
There is a ‘middle ground’ that bridges real-world observational data and explanatory RCTs: 
pragmatic trials [267]. Pragmatic trials are designed to measure effectiveness under real-
world conditions, and (unlike explanatory RCTs that are often set up with regulatory 
approval in mind) to guide routine clinical practice. Pragmatic trials recruit and randomise 
representative patients, use clinically relevant comparators (i.e., not placebo), and follow 
participants over longer periods of time to study safety and other ‘hard’ (i.e., not surrogate) 
outcomes (e.g., radiographic progression). Clinicians should be aware of pragmatic trials, 
take part in them, and promote/demand their use to inform real-world guidelines. Current 
NICE protocols for guideline development and health technology assessment consider all 
types of randomised trials and observational studies, but they are nevertheless dominated 
by explanatory RCTs [268]. 
 
8.4 Recommendations for health policy 
8.4.1 AxSpA guidelines 
The current UK management guidelines from NICE recommend escalating to bDMARDs 
when high disease activity (typically BASDAI>4) persists despite NSAIDs. Results from this 
thesis suggest that the BASDAI definition of ‘high disease activity’ may need to be 
reconsidered for individuals with high comorbidity burden. ASDAS may be a superior index 
in preventing escalation to these potentially toxic drugs for symptoms that are not specific 
to the axSpA disease process. 
Once started, NICE recommends that response to TNFi should be assessed at 12 weeks (16 
weeks for secukinumab). Treatment should only be continued if there is clear evidence of 
response (i.e., BASDAI 50/2 response and spinal pain reduction of ≥2 units). NICE includes 
the following caveat: ‘healthcare professionals should take into account any physical, 
sensory or learning disabilities, or communication difficulties that could affect the 
responses to the questionnaires, and make any adjustments they consider appropriate. 
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[190]’ Results from this thesis support additional allowances for response to treatment in 
the presence of comorbidities, for example, allowing longer for response assessment. 
The current response definition (based on BASDAI and spinal pain) is a compromise 
between 1) absolute response and 2) a fixed threshold for low disease activity/remission. 
This may be problematic for any patient group with high starting disease activity – for they 
are simultaneously more able to achieve the former and less able to achieve the latter, 
compared to those with lower starting disease activity. There are good arguments for both 
definitions; some patients may only be interested in being ‘in remission’ or having ‘low 
disease activity’, while others would be satisfied with any improvement to their current 
symptoms. One way for policy makers to decide is to look at the personal and societal 
benefits from each; for example, if quality of life or work productivity are only improved 
when remission is achieved, or if they improve proportionately with the degree of absolute 
disease activity change. Until these studies are available, clinicians should be aware that 
binary response definitions are highly dependent on starting disease activity and should be 
interpreted with caution outside of clinical trials. 
8.4.2 Healthcare services 
The main public health message relates to the need to provide holistic care that addresses 
comorbidities, particularly co-existing mental health conditions. In 2012, over half of the UK 
general population over the age of 65 had two or more co-existing chronic conditions [79]; 
this will continue to increase as the population ages. Patients attending rheumatology 
clinics with multiple disorders are increasingly the norm. This demographic shift has 
occurred in parallel with increasingly sub-specialised and protocol-driven disease 
management; therefore, it is essential that specialists remain proactive in treating patients 
holistically. Multidisciplinary services may be part of the answer. Some rare conditions, 
such as Behcet’s disease, already benefit from multidisciplinary clinics involving other 
medical specialties, psychology and social support [260,269]. Similar services have been 
successful and well-received by patients for SpA [270]. 
Musculoskeletal and mental health disorders represent some of the biggest disease 
burdens in the developed world and thus the most likely to co-exist; when they do, there is 
evidence that they are synergistically detrimental on outcomes such as work [271]. 
Screening for depression and anxiety in rheumatology services have been discussed above; 
this should be part of the wider societal effort to improve awareness and provisions for 
mental health disorders. The World Health Organisation set out its comprehensive Mental 
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Health Action Plan in 2013 [272]; this was recently echoed by Public Health England’s ‘Every 
Mind Matters’ campaign [273]. They acknowledge the essential role of mental health in 
achieving overall health for all people – a fact that rheumatology is increasingly recognising 
in both clinical practice and research. 
Finally, lifestyle factors are directly relevant to rheumatic diseases (e.g., smoking in RA) and 
indirectly through comorbidities (e.g., SpA patients have higher risk of cardiovascular 
diseases that can be further increased by poor lifestyle). Education and interventions to 
promote behavioural change toward healthier lifestyles – e.g., relating to diet, smoking, 
weight, alcohol, physical activity – should be emphasised to prevent, or improve 
management of, comorbidities. 
 
8.5 Recommendations for future research 
8.5.1 Clinical research 
8.5.1.1 Evidence for patient-centred care model 
The importance of proactively managing comorbidities in rheumatology was highlighted by 
EULAR and this thesis, but evidence for its benefit on individual or health economic 
outcomes are lacking. Such evidence will be needed to support changes in policy, practice, 
or funding.  
A fully patient-centred approach to care is more compatible within the primary, than 
secondary, care setting. A large pragmatic cluster RCT of 1546 patients in UK primary care 
compared the effectiveness of patient-centred multimorbidity management to usual care 
[274]. The ‘3D intervention’ replaced disease-focused reviews with whole-person reviews 
that included several components thought to be important by this thesis and other 
research, for example, depression screening, social support, and health promotion. The 
intervention significantly improved ‘patient-centred care’ as defined by patient satisfaction, 
physician/nurse empathy, and compatibility with the ‘Chronic Care Model’ (organization of 
health care, clinical information systems, delivery system design, decision support, self-
management support, and community resources). However, the primary outcome – quality 
of life at 15 months – was no different between the intervention and control arms. This 
finding was consistent with meta-analysis of several previous small trials [275]. There were 
also no differences in a series of secondary outcomes including HADS, self-rated health, 
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effect of illness on life, patient-reported treatment burden, medication adherence, or 
hospital admissions. Cost-effectiveness, in terms of cost per quality-adjusted life year 
gained, was also equivocal [276]. 
It is unlikely that similar interventions in secondary care will show superior outcomes given 
the 3D trial findings. But, as the authors pointed out, improving patient experience is one of 
the triple aims of health care, thus providing care that is demonstrably more patient-
centred is arguably sufficient justification for implementation in itself [274]. Future 
research, preferably pragmatic trials, should examine the individual and health economic 
benefits of holistic approaches to comorbidity management in rheumatology services. 
Successful optimisation of comorbidities, particularly depression, may have direct benefits 
on axSpA outcomes such as treatment response and, in turn, quality of life and work 
productivity. 
8.5.1.2 Mental health interventions 
Preliminary observational data show that clinical psychology interventions integrated into 
routine rheumatology services can halve psychological distress and reduced need for 
rheumatology outpatient follow-up by a third [270]. Direct comparison against usual care in 
pragmatic trials are required to support wide adoption of these integrated interventions. 
The following examples can inform the design of such trials. 
Compared to rheumatologist-led care of RA, nurse-led management (that, among other 
things, included a 3.3-fold greater provision of psychosocial support and 1.8-fold more 
education) led to no difference in satisfaction, and no clinically meaningful difference in 
HADS or quality of life improvement. Nurse-led care also resulted in smaller improvements 
in perceived self-efficacy, but superior improvements in pain and physical function. 
Analogous results have been reported for nurse-led (vs GP-led) care of gout that included 1) 
holistic assessment, education, shared decision making and discussion of illness 
perceptions, and 2) treat-to-target urate-lowering therapy. Nurse-led care was superior for 
reducing urate levels and flares; this group also reported superior improvement in the 
physical component of SF-36 (a quality of life instrument) but not mental health [277]. In 
both examples, many other clinical parameters (e.g., treatment changes) differed between 
the trial arms; therefore, it is difficult to attribute results to holistic management.  
Future trials should separate direct axSpA interventions from those for optimising mental 
health. They will also likely need well-defined mental health interventions, rather than non-
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specific psychosocial support. Such interventions could include additional cognitive 
behavioural or related ‘talking’ therapies for individuals with depression/anxiety, 
particularly those who have additional psychosomatic symptom burden. These 
considerations, and the need to expand capacity for mental health research that translates 
to patient benefit, are relevant to chronic disease management beyond rheumatology. 
8.5.1.3 Risk prediction for comorbidities 
Although not directly related to this thesis, targeted and individualised approach to 
comorbidity management should include primary prevention. For example, axSpA patients 
are at higher risk of depression, fractures and cardiovascular disease [9,278,279]. 
Identifying individuals at high risk of developing these comorbidities could inform targeted 
screening or prevention. Such tools for depression or other mental health disorders do not 
exist, while current population-level prediction algorithms for CVD and fractures are 
unlikely to be accurate for axSpA populations [280]. Further research is needed to develop 
and/or optimise risk prediction tools for this patient population. 
8.5.1.4 Pragmatic trials 
Pragmatic trials have been promoted in several sections of this thesis. This section briefly 
describes novel designs that are similar to observational registries and should be 
considered for future research. Challenges in recruiting for a sufficiently large trial on 
psychosocial interventions were recognised by the Scleroderma Patient-centred 
Intervention Network (SPIN). The group are using a cohort multiple RCT (also known as 
‘Trials within Cohorts’ or registry-based RCT [281]) design to regularly collect a set of core 
outcomes from a real-world cohort [282], analogous to the BSRBR-AS. These data are then 
used to identify potential participants to be assigned to an intervention, who are compared 
to non-assigned individuals in the cohort. Multiple interventions can be compared, in this 
case non-pharmacological psychosocial or rehabilitation interventions [282]. One 
advantage of randomisation using an existing cohort is that all eligible individuals will be 
offered the intervention, compared with traditional pragmatic RCT design where, for 
example, 50% of those eligible will be randomised to control. Other differences are shown 




Table 8. 2: Comparison of registries, registry-based RCTs, and RCTs. 




• Ideal for description of 
standards 
• Real-world, generalisable 
cohorts 
• Large numbers allow for the 
study of rare events 
• Relatively inexpensive 
• Data quality is variable 





• Well-designed studies with 
adequate power 
• Removes confounding factors 
• Highly selected populations 
• Recruitment often at specialised 
centres 
• Often uses surrogate end points 
• Expensive 
• Rarely compares interventions 





• Removes confounding 
• Less-selected patient 
populations 
• Large numbers allow for the 
study of rare events 
• Data quality may be variable 
• Dropout will be higher 
• Limited outcomes 
Adapted from James et al [283]. 
 
8.5.2 Research methodology 
This thesis demonstrated the importance of using and reporting a range of different 
methodological approaches. Future research on comorbidities should consider adopting a 
combined approach by examining individual conditions in the context of overall 
comorbidity burden or comorbidity clusters. When using comorbidity count in analyses, 
weighted scores should not be used for outcomes for which it was not validated. 
Comorbidity count should not only be dichotomised (present vs absent), since there may be 
valuable insights offered by continuous or categorical variable types. For example, results 
from this thesis suggested non-linear relationships between comorbidity count and some 
treatment outcomes. 
This thesis also demonstrated markedly different results when using each of the three 
definitions of treatment (binary, absolute change, and time-to-discontinuation). Limitations 
of binary outcome measures on statistical power and causal inference are well-described in 
the literature [284], yet they remain the preferred and often the only outcome used. Their 
limitations should be fully acknowledged in future studies, which should preferably be 
accompanied by analyses using continuous indices. Any patient group with high disease 
activity at baseline will simultaneously be more able to achieve a fixed or proportional 
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reduction (because there is more capacity for improvement) and less able to achieve a 
threshold for low disease activity (because a greater absolute improvement is required). In 
support of results in this thesis, studies in RA showed that high baseline DAS28 
simultaneously increased odds of ACR70 response and decreased odds of DAS remission 
[285]. Using outcomes from RCTs (e.g., ASAS20 or ACR70), where baseline disease activity is 
balanced, is inappropriate for observational comparisons when it is not. Adjusting for 
baseline disease activity may not be a robust solution when using binary outcomes [41].  
Future studies should adopt a more considered approach to confounder selection – one 
that differs according to whether the aim is for prediction or causation [187,251]. For 
causation, confounder selection should be based on existing knowledge and/or literature 
review, preferably supported by transparently declared assumptions in the form of causal 
diagrams. Variable selection methods that are popular for prediction (e.g., univariate 
screening or stepwise variable selection) should not be used for questions of causation. 
Researchers should declare the aim of their analysis and highlight limitations in the ability 
to infer causation. For manipulatable exposures, the gold-standard methodological 
approach is to use observational data to emulate the design of a hypothetical RCT [161]. 
 
8.6 Future research projects related to this thesis 
Results from this thesis (and parallel projects on smoking in the BSRBR-AS [7]) have 
suggested subtle differences between male and female participants, which may be due to 
the different ways in which they respond to questionnaires generally, and in the context of 
some comorbidities, such as depression. The axSpA disease process itself is also well-known 
to differ between sexes, for example, phenotype, prognosis and treatment response [286]. 
Therefore, future research following on from this thesis will include more detailed 
examination of gender differences; for example, why treatment discontinuation differs. 
Having identified depression and anxiety as a major unmet need within rheumatology, 
future research should explore – with input from patients and allied health professionals 
throughout – feasible and acceptable solutions for treatment and strategies for 
implementation. Clinical psychology input would be ideal but is limited, for example, by 
funding. A small pilot study of 35 axSpA patients is underway to assess the feasibility and 
acceptability of internet-delivered CBT for those with depression or anxiety (REC reference 
19/NI/0066). This may be promising given its low cost, availability, and acceptability by the 
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comparatively younger axSpA patients. Lastly, work is ongoing to validate the 
multimorbidity index (MMI [148]) against other comorbidity indices in an axSpA population. 
The MMI is comprehensive but labour-intensive to collect. Other, simpler indices (e.g., the 
self-reported comorbidity index [93]) may be more practical for routine practice. 
 
8.7 Conclusions 
Comorbidities are present in the majority of real-world axSpA populations, regardless of the 
disease stage (i.e., nr-axSpA vs AS). Mental health and cardiovascular comorbidities are by 
far the most prevalent comorbidities, with mental health having the largest and most 
consistent impact on axSpA disease assessment and treatment response. These results 
have important clinical and policy implications for the current approach to disease 
assessment, including eligibility for initiating (using ASDAS rather than BASDAI) and 
continuing bDMARDs (using both binary and continuous response definitions). Evidence-
based practice is underpinned by RCTs that often exclude comorbid patients. Results of this 
thesis also highlighted the potential impact of comorbidities on treatment response (e.g., 
function and health-related quality of life) and discontinuation, that may explain 
differences between real-world effectiveness and RCT efficacy. Future research will benefit 
from a broader and more methodologically robust approach to studying comorbidities and 
treatment outcomes (e.g., comorbidity clusters and outcome-types). Having described the 
problem of poor response rates to bDMARD treatment, the thesis concluded with a search 
for a solution: optimising mental health symptoms before or at treatment initiation may 
provide substantial improvements to treatment response – with effect sizes that are 
magnitudes larger than seen in RA or with other ‘modifiable’ risk factors of poor-response 
(e.g., smoking) in axSpA. Healthcare providers should routinely record and refer 
comorbidities for optimal management. The importance of multimorbidity – particularly 
mental health disorders that are often under-recognised – and methodological approaches 
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10.2 Appendix for Chapter 3 
Table S3. 1: ICD codes used in the Boston axial spondyloarthritis study. 
 ICD 9 ICD 10 
Atrial fibrillation 427.3x I48.x 








571.0, 571.1, 571.2, 571.3 K70.x, K70.xx 
760.71 P04.3, Q86.0 
V11.3 Z65.8 






300.x 301.x 308.x 309.x F40.x F41.x F42.x F43.x F45.x 





Asthma 493.xx J45.x 
Blind/low vision 360.41 360.42 438.7 
 
362.x 366.x 368.x 369.x H35.x H25.x H26.x H27.x H28 
H53.x H54.x 
Bronchiectasis  494.x J47.x 
748.61 Q33.4 

































Chronic liver disease  456.0 456.1 456.2x I85.1x 
571.x K70.x to K77.x 






Chronic sinusitis 473.x J32.x 
Chronic kidney 
disease 
249.4 E08.21 E09.21 




581.x 582.x 583.x N04.x 
585.x 586.x 587.x 588.x N03.x N18.x N19 N25.x N26.x 
753.x Q61.x 
792.5 R88.0 
996.56 996.68 T85.611x T85.621x T85.631x 
T85.691x T85.71x 





COPD 491.x 491.xx J41.x J42 J43.x J44.x 





331.x G30.x G31.x G32.x 
Depression  296.2x 296.3x F32.x F33.x 
296.82 F32.8 
309.0 309.1 F43.21 
311 F32.9 
Diabetes  249.x 250.x E08.x to E13.x 










Diverticulitis 562.x K57.x 





Glaucoma 365.x H40.x H42.x 
377.14 H47.239 
Hearing loss  315.34 F80.4 
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Heart failure  398.91 I09.81 
402.01 402.11 402.11 402.91 I11.0 
404.9x I13.0 I13.2 
428.x I50.x 
Hypertension 401.x to 405.x I10.x to I16.x 
642.x O10.x O11.x O13.x to O16.x 
796.2 R03.0 
997.91 I97.3 
IBD 555.x 556.x 558.x K50.x 51.x K52.x 
IBS 564.x K58.x K59.x 
Learning disability  314.0x 314.1x F90.x 
315.x F80.x to F89.x 
V40.0 F81.9 
Migraine  346.x G43.x 
Multiple sclerosis 340.x 341.x G35.x G37.x 
Obesity 278.0x E66.x 
783.1 R63.5 
V85.3x V85.4x Z68.3x Z68.4 
Osteoporosis 733.0x 733.1x M80.x M81.x 
Other substance 
misuse 
292.x 304.x 305.x F11.x F12.x F13.x F14.x F15.x 




Parkinson’s disease 094.82 A52.19 
332.x G20.x G21.x 
E936.x T42.76x 




600.x 601.x 602.x N40.x N41.x N42.x 
V10.46 Z85.46 
Psoriasis/eczema  696.x L41.x L41.x 







440.2x 440.3x 440.4 I70.2x I70.3x I70.4x I70.5x 
I70.6x I70.7x 
443.x I73.x 
997.2 T81.72XA T81.719A 
Schizophrenia/bipolar 295.x F20.x 
296.x F30.x F31.x 
V11.0 Z65.8 
Stroke/TIA 342.x G81.x 





Thyroid disorders 226 D34 






Constipation 564.0x K59.0x 
Dyspepsia  535.x K29.x K30.x 
787.1 R12 
Viral hepatitis  070.x B15.x to B19.x 
V02.6x 
 
Fibromyalgia 729.1 Z79.7 
Uveitis 364.x H20.x 





10.2.1 Summary of data preparation for the BSRBR-AS 
For the initial analyses of the BSRBR-AS, individual data files were provided by the 
investigators (e.g., 14 visit files, 9 questionnaire files, one file for deprivation indices, etc.). 
The following section describes the process with which they were prepared for analysis. 
Some of the following methods was used by the BSRBR-AS investigators to process final 
versions of the data. The final version of the BSRBR-AS data was used for analyses shown in 
the thesis. This version was provided as only 4 files: recruitment data, visits, questionnaires, 
and TNFi timeline. 
Early downloads of the BSRBR-AS dataset included individuals in the non-biologics arm with 
prior biologic exposure records (could be data entry error or inappropriately recruited). This 
was checked in the latest download. 
Some SpA features (uveitis, IBD, psoriasis) were recorded twice: once as components of 
ASAS criteria, and again in the targeted medical history that 1) specifically enquires about 
the past 6 months and 2) are physician confirmed diagnoses. If patients had physician-
confirmed records of these features, they should also fulfil the corresponding ASAS 
components. Inconsistencies were corrected. For descriptions of participant characteristics, 
physician-confirmed diagnoses were used. A participant with known history of dactylitis, 
arthritis or enthesitis may not report an episode in the past 6 months; therefore, the SpA 
criteria were used instead of the targeted medical history for prevalence description. HLA-
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B27 status was recorded twice: as component of ASAS criteria and again as its own variable. 
Overall, positivity was defined as a positive result from either variable. There were no 
conflicts regarding positive and negative results from the two variables; each helped 
populate unknown variables in the other.  
Classification using the modified New York and ASAS criteria were performed. All patients 
met classification criteria for AS or axSpA: 1757 (65%) met criteria for AS, whilst 2508 (93%) 
met ASAS criteria for axSpA (imaging criteria met by 2395 and clinical by 1406). 
All variables were then renamed and relabelled. The following variables were generated: 
• Age (date of first visit – DOB)/365.25 
• Year of visit 
• Age at symptom onset (year of onset – year of birth) 
o Those with age at symptom onset younger than 5 were replaced as missing 
o Age at symptom onset that were older than age at recruitment were 
replaced with age at recruitment (i.e., they could be diagnosed at 
recruitment, but not after recruitment). 
• Symptom duration (age – age at symptom onset) 
o Due to discrepancies in the accuracy (decimal places) of above variables, 
those with negative symptom duration were set to 0. 
• Number of comorbidities (sum of 13 comorbidities: hypertension, angina, MI, heart 
failure, stroke, diabetes, asthma, ‘bronchitis’, depression, cancer, kidney disease, 
peptic ulcer, and liver disease) 
 
The first visit file was saved as baseline ‘time-independent’ characteristics (File A) (Figure 
S3.1). Visit files (14 in total) were then combined and split into B) biologic information (each 
visit can have up to 3 entries for biologics information; these were converted from wide 




Figure S3. 1: Preparation of the analysis file from data files provided by the BSRBR-AS. 
 
*15 outcome variables including: disease activity (BASDAI, ASDAS, spinal pain, ESR, CRP), 
functional impairment (BASFI, BASMI), quality of life (ASQoL, EQ-VAS, EQ5D-3L), BASG, 
Chalder Fatigue Scale, Jenkins Sleep Evaluation Questionnaire, Hospital Anxiety and 
Depression Scale. 
 
Questionnaire files (9 in total) were then combined and split into: D) all patient reported 
outcome measures (patient global, BASG, ASQoL, EQ5D, EQ-VAS, CFQ, JSEQ, HADS, spVAS, 
BASDAI-Q2/Q3/Q6, BASDAI, BASFI) labelled by questionnaire date, and E) patient 
characteristics variables (education, smoking, alcohol). 
File B) was converted into a treatment timeline: 
1. Only patients with a biologic start-date were kept (this includes those in the non-
biologic group who later start treatment). 
2. Biosimilar names were changed to generic names. For example, switch from Enbrel 
to Benepali was not considered discontinuation of treatment, based on the 
assumption that if a serious adverse event or inefficacy occurred with the bio-
originator, the patient would receive a different TNFi instead of a biosimilar. 
3. For each patient, the earliest start-date for each biologic was selected as the final 
start-date; the latest biologic stop-date or ‘missing’ stop-date (i.e., never stopped) 
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was set as the final stop-date for that biologic. This accounted for those who stop 
and start the same treatment – which can be assumed to be temporary stops, since 
inefficacy or serious AE would necessitate permanent cessation. This process also 
accounted for biosimilar switches.  
4. Pauses in treatment of longer than 3 months was considered discontinuation. 
5. The last visit or questionnaire date to help create a ‘censor’ date (relevant for Cox 
models) for those who do not have a stop-date. (Note many patients do not have 
further visits but still return questionnaires, for these patients their last 
questionnaire date was used as censor date instead.) 
6. All entries were de-duplicated leaving one entry for each biologic for each patient. 
 
Files C) and D) were merged according to ID and categorised time. At this stage, no 
imputation was performed. Note carrying forward/backwards is difficult to justify, 
particularly for baseline values, since treatment is likely to improve all measures. Note also 
that a patient can have ≤1 questionnaire but still have >1 CRP/ESR/BASMI. This file (C+D) 
was then merged with the timeline for first biologic (file B) to establish whether the patient 
was on treatment on that assessment date. 
For file E), missing smoking, education and alcohol data at baseline were carried backwards 
from when they first became available. For example, in the early download of the data, 
smoking data was missing for 85 patients before this process and 24 after; education 43 to 
33; alcohol 98 to 43. File E) was then de-duplicated by patient to give baseline values that 
was then merged with other baseline characteristics derived from baseline visit file (File A). 
For survival analyses, time was defined by duration in days between TNFi start date and: 1) 
TNFi stop date (main even of interest), 2) last visit date or last questionnaire date if no visit 
date (censoring). Individuals with zero follow-up time (i.e., started TNFi but did not have 
further contact with the study) were assigned 0.001 days. 
For longitudinal analyses, date of starting first TNFi was used to define the baseline, that is, 
as the reference point with which the window of acceptable assessments was defined. 
Baseline data from visits or questionnaires had to come from within 1 year before or 7 days 
after the TNFi start date. Only assessments made between TNFi start and stop dates (i.e., 
while on treatment) were included. For any missing disease indices, the last value was 
carried forward provided it was from within 30 days. 
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10.2.2 Covariance/correlation structure for longitudinal analyses 
Measurements take through time on the same individual are correlated. The correlation (or 
covariance) between data points can be assumed, for example, to be equal (exchangeable), 
more closely correlated if closer together in time (auto regressive), different for all pairs of 
observations (unstructured). Specifying the ‘correct’ correlation/covariance structure is 
difficult. For GEE, a temporary assumption can be made before estimating coefficients, with 
subsequent adjustment to the standard errors to give valid inferences (i.e., Huber-White or 
‘robust’ standard errors). Estimates and standard errors tend to be similar regardless of 
correlation structure [191]. 
Covariance structure is analogous for mixed effects models. The random part of the model 
separates within- and between-individual changes (which is further separated into variance 
for intercept and slope and their covariance). This has two implications: 1) effects are 
conditional (i.e., individual, rather than marginal/population-level) and 2) the random 
effects are of direct interest (c.f. GEE where they are not). A detailed discussion of the 
variance-covariance structure is beyond the scope of this section, and derived inference not 
of primary interest in this analysis. In this thesis, the default covariance structure was used 
(‘independent’, i.e., equal variances for random effects, all covariances 0). This may or may 
not be appropriate; therefore, each of the other structures were tested for a single, 




10.3 Appendix for Chapter 4 
Table S4. 1: Characteristics of 646 axSpA Boston patients meeting full classification 









Age, years 52.9 (16.2) 44.4 (14.2) <0.001 
Male 420 (76%) 57 (62%) 0.004 
BMI (kg/m2) 27.8 (6.0) 26.5 (4.3) 0.170 
Smoking 57 (10%) 10 (11%) 0.900 
HLA-B27 tested 334 (60%) 68 (73%) 0.019 
HLA-B27 positive 270 (81%) 54 (79%) 0.790 
Family history* 74 (13%) 19 (21%) 0.054 
Uveitis 148 (27%) 28 (31%) 0.400 
Psoriasis 69 (13%) 6 (7%) 0.110 
IBD 54 (10%) 6 (7%) 0.350 
Peripheral arthritis 101 (18%) 18 (20%) 0.700 
Enthesitis 22 (4%) 5 (6%) 0.490 
Dactylitis 13 (2%) 1 (1%) 0.450 
ESR tested 234 (42%) 39 (42%) 0.950 
ESR result (mm/hr) 
median (IQR) 
13.0 (6.0 to 27.0) 8.0 (4.0 to 17.0) 0.019 
CRP tested 290 (52%) 48 (52%) 0.880 
CRP result (mg/dl), 
median (IQR) 
3.3 (1.2 to 10.6) 2.6 (0.7 to 5.8) 0.034 
Pain VAS available 199 (36%) 38 (41%) 0.370 
Pain VAS 2.3 (3.1) 2.9 (3.2) 0.250 
Comorbidity count**, 
mean (SD) 
1.4 (2.1) 1.1 (1.9) 0.160 
Data shown as mean (SD) and n (%) unless otherwise specified. 
BMI, body mass index; VAS, visual analogue scale; IQR, interquartile range; 
SD, standard deviation; IBD, inflammatory bowel disease. 
*family history of axial spondyloarthritis, psoriasis, uveitis, reactive 
arthritis or IBD. 





Table S4. 2: Medications used among 646 axSpA patients meeting full classification 








bDMARDs 316 (57%) 54 (58%) 0.870 
Adalimumab 187 (34%) 31 (33%) 0.930 
Etanercept 166 (30%) 25 (27%) 0.540 
Infliximab 76 (14%) 13 (14%) 0.950 
Golimumab 25 (5%) 5 (5%) 0.789 
Certolizumab pegol 18 (3%) 2 (2%) 0.754 
Secukinumab 21 (4%) 4 (4%) 0.772 
Ustekinumab 10 (2%) 0 0.372 
csDMARDs 139 (25%) 24 (26%) 0.890 
Sulfasalazine 66 (12%) 12 (13%) 0.790 
Methotrexate 94 (17%) 17 (18%) 0.760 
Leflunomide 3 (1%) 2 (2%) 0.153 
NSAIDs 419 (76%) 78 (84%) 0.086 
Ibuprofen 202 (37%) 46 (49%) 0.018 
Naproxen 181 (33%) 37 (40%) 0.180 
Indomethacin 135 (24%) 22 (24%) 0.870 
Celecoxib 103 (19%) 15 (16%) 0.560 
Diclofenac 79 (14%) 17 (18%) 0.320 
Meloxicam 55 (10%) 16 (17%) 0.038 
Prednisone 194 (35%) 37 (40%) 0.380 
*Each drug category consists of drugs listed in the remainder of the table. 
bDMARD, biologic disease modifying anti-rheumatic drugs; csDMARD, 







Table S4. 3: Characteristics of Aintree axSpA patients according to presence or absence of 
comorbidities, excluding obesity. 






Age, years  40.0 (12.9) 49.0 (14.1) <0.001 
Male  114 (70%) 177 (69%) 0.98 
Modified New York criteria for AS 135 (82%) 210 (82%) 0.99 
HLA-B27 positive* 66 (62%) 92 (56%) 0.34 
Symptom duration, median (IQR) 
years 
10.6 (3.8 to 20.1) 18.9 (8.4 to 30.2) <0.001 
BMI, kg/m2 27.4 (5.2) 28.7 (5.9) 0.045 
Deprivation index**, median (IQR) 2.0 (1.0 to 6.0) 2.0 (1.0 to 5.0) 0.29 
Current smoker 53 (34%) 84 (35%) 0.45 
Ex-smoker 23 (15%) 46 (19%) 
Never smoked 78 (51%) 108 (45%) 
NSAIDs 31 (19%) 40 (16%) 0.392 
Peripheral joint involvement 40 (26%) 73 (30%) 0.48 
Uveitis 39 (25%) 61 (24%) 0.88 
Psoriasis 33 (21%) 40 (16%) 0.18 
IBD 19 (12%) 21 (8%) 0.19 
Disease severity measures: 
EuroQoL, median (IQR) 0.6 (0.1 to 0.8) 0.5 (-0.02 to 0.7) <0.001 
Global health, median (IQR) 4.8 (2.3 to 6.4) 5.2 (3.5 to 7.1) 0.005 
Fatigue, median (IQR) 5.1 (3.0 to 7.1) 6.3 (3.8 to 7.7) 0.021 
BASDAI, median (IQR) 5.6 (3.6 to 7.2) 6.4 (3.9 to 8.1) 0.011 
Spinal pain, median (IQR) 6.0 (3.0 to 8.0) 7.0 (4.0 to 8.0) 0.029 
BASFI, median (IQR) 4.5 (2.2 to 6.7) 6.8 (4.1 to 8.4) <0.001 
ESR (mm/hr), median (IQR) 10.0 (5.0 to 27.0) 13.0 (5.0 to 29.0) 0.067 
CRP (mg/L), median (IQR) 4.0 (1.0 to 17.0) 5.0 (1.0 to 12.0) 0.80 
*HLA-B27 available for 269 patients. 
**Index of multiple deprivation deciles, with 1 representing the top 10% most deprived 
areas and 10 the most affluent. 
***excluding obesity. 
Fatigue and global health were single-question visual analogue scales, ranging from 0 
(worst) to 10 (best). 
EuroQoL, 5-domain quality of life measure; BASDAI, Bath AS disease activity index; BASFI, 





Table S4. 4: Prevalence of 39 comorbidities compared between AS and nr-axSpA patients 










1 Alcohol problems 8 (1%) 2 (2%) 0.64 
2 Anorexia or bulimia 4 (1%) 0 (0%) 1.00 
3 Anxiety and other neuroses 56 (10%) 12 (13%) 0.46 
4 Asthma 23 (4%) 3 (3%) 1.00 
5 Atrial fibrillation 33 (6%) 1 (1%) 0.05 
6 Blind or low vision 16 (3%) 0 (0%) 0.15 
7 Bronchiectasis 3 (1%) 0 (0%) 1.00 
8 Cancer 56 (10%) 8 (9%) 0.85 
9 Chronic kidney disease 17 (3%) 0 (0%) 0.15 
10 Chronic liver disease 23 (4%) 4 (4%) 1.00 
11 Chronic sinusitis 6 (1%) 0 (0%) 0.60 
12 Constipation 22 (4%) 2 (2%) 0.56 
13 COPD 9 (2%) 1 (1%) 1.00 
14 Coronary heart disease 57 (10%) 7 (8%) 0.57 
15 Dementia 4 (1%) 0 (0%) 1.00 
16 Depression 40 (7%) 8 (9%) 0.67 
17 Diabetes mellitus 39 (7%) 5 (5%) 0.66 
18 Diverticular disease 21 (4%) 2 (2%) 0.56 
19 Dyspepsia 16 (3%) 4 (4%) 0.51 
20 Epilepsy 3 (1%) 0 (0%) 1.00 
21 Fibromyalgia 0 (0%) 1 (1%) 0.14 
22 Glaucoma 5 (1%) 1 (1%) 1.00 
23 Hearing loss 17 (3%) 3 (3%) 1.00 
24 Heart failure 18 (3%) 1 (1%) 0.50 
25 Hypertension 51 (9%) 2 (2%) 0.022 
26 Irritable bowel syndrome 28 (5%) 3 (3%) 0.60 
27 Learning disability 6 (1%) 1 (1%) 1.00 
28 Migraine 16 (3%) 5 (5%) 0.21 
29 Multiple sclerosis 1 (<1%) 0 (0%) 1.00 
30 Obesity 28 (5%) 4 (4%) 1.00 
31 Osteoporosis 27 (5%) 3 (3%) 0.60 
32 Parkinson’s disease 0 (0%) 1 (1%) 0.14 
33 Peripheral vascular disease 11 (2%) 1 (1%) 1.00 
34 Prostate disorders 41 (7%) 4 (4%) 0.38 
35 Psychoactive substance misuse 20 (4%) 6 (6%) 0.25 
36 Schizophrenia or bipolar 6 (1%) 1 (1%) 1.00 
37 Stroke or TIA 27 (5%) 3 (3%) 0.60 
38 Thyroid disorders 31 (6%) 4 (4%) 0.81 
39 Viral hepatitis 6 (1%) 0 (0%) 0.60 




Table S4. 5: The pseudo F and T-squared statics to determine the optimal number of 




Pseudo-F* Pseudo T-squared** 
5 7.94 0.8 
6 6.62 1.9 
7 6.07 10.6 
8 7.93 12.42 
9 9.96 6.96 
10 10.52 27.81 
11 15.85 26.63 
12 19.02 4.38 
13 18.32 17.39 
14 19.91 12.29 
15 21.93 13.56 
*The Calinski & Harabasz pseudo-F index; larger values 
indicating more distinct clusters. 
**The Duda-Hart pseudo-T-squared values; smaller values 




Table S4. 6: Sensitivity analysis using 28 morbidities that were prevalent in at least two patients. 
 
Cluster 1 2 3 4 5 6 7 8 9 10 11 
Number of patients 167 40 82 35 5 177 46 12 21 20 21 
Hypertension   1 (2) 3 (17)  72 (88) 4 (25) 1 (11)    
Depression  3 (10) 42 (86) 4 (22)  10 (12) 5 (31)  1 (6)  1 (7) 
Anxiety and other neuroses  2 (6) 7 (14)  4 (100)       
Schizophrenia or bipolar      3 (4)   1 (6)  1 (7) 
Osteoporosis  1 (3) 5 (10)   10 (12) 3 (19)   4 (40) 1 (7) 
Alcohol problems  1 (3) 1 (2) 1 (6)  5 (6) 1 (6)   9 (90)  
Other psychoactive 
substance misuse 
      1 (6)  16 
(100) 
1 (10)  
Chronic liver disease    1 (6)  1 (1)    1 (10)  
Viral hepatitis   1 (2)   1 (1) 1 (6)  1 (6)   
Migraine   6 (12)     1 (11)   1 (7) 
Epilepsy*  1 (3) 3 (6)        1 (7) 
Thyroid disorders   1 (2)   1 (1)  9 (100)    
Diabetes   3 (6)   15 (18) 2 (13)   3 (30)  
Atrial fibrillation      2 (2) 1 (6)     
Coronary heart disease   1 (2)   13 (16) 9 (56)    1 (7) 
Heart failure      3 (4)      
Stroke and TIA   1 (2)   3 (4) 1 (6)   1 (10)  
COPD   3 (6)    12 (75)   1 (10)  
Asthma*      4 (5)     14 (100) 
Chronic sinusitis      1 (1)      
Prostate disorders      5 (6)      
Fibromyalgia   2 (4) 13 (72) 1 (25)  2 (15) 1 (11)    
Irritable bowel syndrome   1 (2) 10 (56)  3 (4)     1 (7) 
Diverticular disease   1 (2)   4 (5)      
Constipation*   1 (2)   2 (2) 1 (6)     
Cancer**   4 (8)         
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Chronic kidney disease  3 (10)    6 (7) 1 (6)     
Dyspepsia*  29 (94) 1 (2) 3 (17)  11 (13) 2 (13)  2 (13)   
*Currently treated. **Cancer diagnoses in the past 5 years. Cells with zero prevalence were left empty for clarity. Bold text highlights 
dominant morbidities in each cluster. Clusters 12 (2 patients with AF) and 13 (1 with sinusitis) were omitted. 
TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary diseases. 
 
Table S4. 7: The pseudo F and T-squared statics to determine the optimal number of clusters in the main analysis using the Boston axSpA study. 
 
Number of clusters Pseudo-F* Pseudo T-squared** 
5 18.42 7.61 
6 18.15 24.58 
7 24.79 8.27 
8 22.32 10.01 
9 22.49 14.88 
10 23.94 6.8 
11 22.95 9.09 
12 23.43 8.79 
13 22.42 19.09 
14 21.8 9.72 
15 22.53 9.86 
*The Calinski & Harabasz pseudo-F index; larger values indicating more 
distinct clusters. 







10.4 Appendix for Chapter 5 







Age, years 49.1 (14.7) 43.9 (13.1) <0.001 
Males 1382 (68%) 446 (69%) 0.47 
Meeting modified New York criteria 1340 (66%) 417 (65%) 0.70 
Age at symptom onset, years 29.1 (13.8) 27.8 (13.1) 0.015 
Symptom duration, years 20.0 (14.6) 16.1 (12.9) <0.001 
HLA-B27 positive* 1193 (79%) 347 (78%) 0.74 
BMI, kg/m2 27.7 (5.5) 27.4 (5.4) 0.33 
Smoking 
status 
Never smoked 900 (44%) 104 (37%) 0.060 
Ex-smoker 743 (36%) 107 (38%) 
Current smoker 394 (19%) 67 (24%) 
Education Secondary school 648 (32%) 93 (33%) 0.78 
Apprenticeship 191 (9%) 16 (6%) 
Further education 
college 
620 (30%) 92 (33%) 
University degree 417 (21%) 52 (19%) 
Further degree 157 (8%) 27 (10%) 
Deprivation index, median (IQR) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 0.21 
NSAID use in past 6 months 1486 (73%) 480 (75%) 0.28 
DMARD use in past 6 months 201 (13%) 71 (14%) 0.50 
CRP (mg/dL), median (IQR)* 0.6 (0.2, 1.9) 0.7 (0.2, 2.0) 0.17 
ESR (mm/hr), median (IQR)* 13.0 (5.0, 23.0) 9.0 (4.0, 21.0) 0.035 
BASMI, median (IQR)* 3.8 (2.2, 5.4) 3.2 (2.0, 5.0) 0.022 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
*Not all variables had complete data; HLA-B27 was available for 74% of participants, 
BASMI 75%, CRP 78%, ESR 39%. 
Deprivation index, 1=most deprived, 5=least deprived; IQR, interquartile range; BMI, body 




Table S5. 2: Full model coefficients for the association between comorbidity count categories and disease activity. 
 
 
BASDAI Spinal pain ASDAS Ln(CRP+1) Ln(ESR) 
N 1803 1808 1450 1438 699 
No comorbidity reference reference reference reference reference 
1 comorbidity 0.54 (0.28, 0.81) 0.64 (0.33, 0.95) 0.06 (-0.06, 0.19) -0.10 (-0.19, -0.01) -0.03 (-0.22, 0.16) 
2 comorbidities 0.76 (0.39, 1.13) 1.05 (0.60, 1.50) 0.15 (-0.04, 0.33) -0.04 (-0.17, 0.10) -0.22 (-0.51, 0.06) 
≥3 comorbidities 1.47 (0.94, 2.00) 1.95 (1.31, 2.59) 0.38 (0.12, 0.63) -0.12 (-0.30, 0.07) 0.04 (-0.33, 0.40) 
Age  -0.03 (-0.03, -0.02) -0.03 (-0.04, -0.02) -0.005 (-0.009, -0.0005) 0.004 (0.001, 0.01) 0.01 (0.004, 0.02) 
Male sex  -0.42 (-0.66, -0.18) -0.25 (-0.54, 0.04) 0.06 (-0.06, 0.18) 0.19 (0.11, 0.28) -0.23 (-0.40, -0.06) 
BMI 0.06 (0.04, 0.08) 0.05 (0.02, 0.07) 0.02 (0.01, 0.03) 0.01 (0.004, 0.02) 0.01 (0.0005, 0.03) 
Ever-smoker 0.53 (0.30, 0.76) 0.59 (0.32, 0.86) 0.20 (0.09, 0.31) 0.01 (-0.07, 0.09) 0.09 (-0.08, 0.26) 
Secondary school reference reference reference reference reference 
Apprenticeship -0.32 (-0.73, 0.10) -0.43 (-0.93, 0.06) -0.14 (-0.34, 0.06) -0.10 (-0.24, 0.05) -0.09 (-0.41, 0.24) 
Further education college -0.46 (-0.74, -0.17) -0.48 (-0.82, -0.14) -0.21 (-0.35, -0.07) -0.04 (-0.14, 0.06) -0.15 (-0.36, 0.05) 
University degree -0.87 (-1.19, -0.55) -0.73 (-1.11, -0.34) -0.38 (-0.53, -0.22) -0.13 (-0.24, -0.01) -0.09 (-0.32, 0.14) 
Further degree -1.53 (-1.97, -1.08) -1.31 (-1.83, -0.78) -0.60 (-0.81, -0.39) -0.08 (-0.23, 0.08) 0.06 (-0.26, 0.37) 
Deprivation  0.18 (0.10, 0.26) 0.23 (0.13, 0.33) 0.09 (0.05, 0.13) 0.02 (-0.01, 0.05) 0.08 (0.02, 0.14) 







Table S5. 3: Full model coefficients for the association between each comorbidity and disease activity. 
 
BASDAI Spinal pain ASDAS Ln(CRP+1) Ln(ESR) 
N 1803 1808 1450 1438 699 
Ischaemic heart disease -0.17 (-0.86, 0.52) 0.22 (-0.61, 1.05) -0.02 (-0.36, 0.31) -0.10 (-0.34, 0.14) -0.14 (-0.64, 0.37) 
Heart failure 1.70 (0.58, 2.81) 1.34 (-0.00, 2.69) 0.59 (0.05, 1.12) 0.22 (-0.18, 0.62) 0.14 (-0.60, 0.88) 
Stroke -0.02 (-0.96, 0.93) 0.55 (-0.59, 1.69) -0.22 (-0.68, 0.25) -0.06 (-0.40, 0.28) 0.07 (-0.69, 0.83) 
Hypertension -0.06 (-0.37, 0.26) -0.02 (-0.40, 0.36) -0.01 (-0.17, 0.14) 0.06 (-0.06, 0.17) 0.12 (-0.13, 0.36) 
Diabetes 0.66 (0.15, 1.17) 0.81 (0.20, 1.43) 0.14 (-0.13, 0.41) -0.13 (-0.34, 0.07) -0.34 (-0.72, 0.03) 
Asthma 0.11 (-0.25, 0.47) 0.37 (-0.07, 0.80) -0.10 (-0.28, 0.07) -0.10 (-0.23, 0.03) -0.36 (-0.62, -0.10) 
COPD 0.07 (-0.79, 0.92) 0.13 (-0.90, 1.16) 0.32 (-0.10, 0.75) 0.38 (0.07, 0.70) 0.03 (-0.53, 0.60) 
Peptic ulcer 1.24 (0.59, 1.88) 1.70 (0.92, 2.47) 0.44 (0.13, 0.75) -0.15 (-0.37, 0.08) 0.29 (-0.17, 0.75) 
Renal  0.91 (0.05, 1.77) 1.13 (0.10, 2.15) 0.25 (-0.15, 0.65) -0.08 (-0.38, 0.22) 0.32 (-0.36, 1.01) 
Liver  -0.31 (-1.52, 0.90) -0.38 (-1.83, 1.07) -0.28 (-0.88, 0.31) -0.07 (-0.50, 0.36) 0.51 (-0.31, 1.33) 
Cancer  -0.01 (-0.60, 0.57) 0.28 (-0.42, 0.98) -0.01 (-0.30, 0.28) 0.04 (-0.17, 0.25) 0.18 (-0.26, 0.62) 
Depression  0.92 (0.61, 1.23) 0.88 (0.51, 1.25) 0.21 (0.06, 0.36) -0.06 (-0.16, 0.05) 0.03 (-0.20, 0.25) 
TB 1.13 (0.21, 2.05) 0.77 (-0.34, 1.87) 0.41 (-0.05, 0.87) -0.08 (-0.42, 0.26) 0.18 (-0.50, 0.85) 
Demyelinating 1.00 (-0.89, 2.90) 1.64 (-0.64, 3.91) -0.16 (-1.07, 0.75) -0.43 (-1.09, 0.23) -0.26 (-1.47, 0.96) 
Age  -0.02 (-0.03, -0.01) -0.03 (-0.04, -0.02) -0.004 (-0.01, 0.0004) 0.003 (-0.0005, 0.01) 0.01 (0.0003, 0.01) 
Gender  -0.39 (-0.63, -0.15) -0.24 (-0.53, 0.05) 0.06 (-0.06, 0.18) 0.19 (0.10, 0.27) -0.25 (-0.43, -0.08) 
BMI 0.06 (0.04, 0.08) 0.05 (0.03, 0.08) 0.02 (0.01, 0.03) 0.01 (0.003, 0.02) 0.02 (0.001, 0.03) 
Ever-smoker 0.49 (0.26, 0.72) 0.55 (0.28, 0.83) 0.18 (0.07, 0.29) 0 (-0.08, 0.08) 0.08 (-0.09, 0.25) 
Secondary school reference reference reference reference reference 
Apprenticeship -0.27 (-0.68, 0.14) -0.40 (-0.89, 0.10) -0.13 (-0.33, 0.07) -0.10 (-0.25, 0.04) -0.13 (-0.45, 0.20) 
Further education college -0.44 (-0.72, -0.16) -0.48 (-0.81, -0.14) -0.20 (-0.33, -0.06) -0.03 (-0.13, 0.07) -0.17 (-0.37, 0.04) 
University degree -0.85 (-1.17, -0.53) -0.72 (-1.10, -0.33) -0.37 (-0.52, -0.21) -0.12 (-0.24, -0.01) -0.13 (-0.36, 0.10) 
Further degree -1.49 (-1.93, -1.05) -1.27 (-1.80, -0.74) -0.58 (-0.79, -0.37) -0.08 (-0.23, 0.07) -0.02 (-0.34, 0.30) 
Deprivation 0.18 (0.10, 0.26) 0.23 (0.13, 0.33) 0.09 (0.05, 0.13) 0.02 (-0.01, 0.05) 0.07 (0.02, 0.13) 




Table S5. 4: Full model coefficients for the association between comorbidity count and other measures of disease severity. 
 
 
Fatigue ASQoL BASFI BASMI Patient global 
N 1818 1802 1814 1404 1741 
No comorbidity reference reference reference reference reference 
1 comorbidity 1.64 (1.06, 2.21) 1.54 (0.97, 2.11) 0.65 (0.36, 0.93) 0.26 (0.05, 0.47) 0.43 (0.12, 0.75) 
2 comorbidities 1.67 (0.85, 2.50) 2.20 (1.39, 3.01) 1.00 (0.59, 1.41) 0.47 (0.18, 0.76) 0.79 (0.34, 1.24) 
≥3 comorbidities 3.84 (2.67, 5.01) 4.12 (2.95, 5.29) 1.96 (1.38, 2.55) 0.79 (0.36, 1.23) 1.38 (0.74, 2.01) 
Age  -0.07 (-0.09, -0.05) -0.07 (-0.09, -0.06) 0.02 (0.01, 0.02) 0.05 (0.04, 0.06) -0.02 (-0.03, -0.01) 
Gender  -0.89 (-1.42, -0.35) -1.55 (-2.08, -1.02) -0.22 (-0.49, 0.04) 0.27 (0.07, 0.47) -0.19 (-0.48, 0.10) 
BMI 0.05 (0.01, 0.10) 0.13 (0.09, 0.18) 0.09 (0.07, 0.11) 0.02 (0.00, 0.04) 0.04 (0.02, 0.07) 
Ever-smoker 0.52 (0.01, 1.02) 1.51 (1.01, 2.01) 0.72 (0.47, 0.97) 0.26 (0.08, 0.45) 0.50 (0.22, 0.77) 
Secondary school reference reference reference reference reference 
Apprenticeship -0.06 (-0.97, 0.85) -0.91 (-1.82, -0.00) -0.24 (-0.69, 0.21) -0.29 (-0.62, 0.03) -0.30 (-0.80, 0.19) 
Further education college -0.11 (-0.73, 0.52) -1.16 (-1.78, -0.54) -0.52 (-0.83, -0.20) -0.38 (-0.61, -0.15) -0.49 (-0.83, -0.15) 
University degree -0.77 (-1.48, -0.07) -2.21 (-2.91, -1.51) -0.94 (-1.29, -0.59) -0.78 (-1.05, -0.52) -0.88 (-1.26, -0.50) 
Further degree -1.86 (-2.83, -0.88) -3.83 (-4.80, -2.87) -1.75 (-2.23, -1.26) -0.85 (-1.23, -0.47) -1.62 (-2.15, -1.09) 
Deprivation  0.28 (0.10, 0.46) 0.49 (0.32, 0.67) 0.26 (0.17, 0.35) 0.14 (0.07, 0.20) 0.15 (0.06, 0.25) 








Table S5. 5: Full model coefficients for the association between each comorbidity and other measures of disease severity. 
 
Fatigue ASQoL BASFI BASMI Patient global 
N 1818 1802 1814 1404 1741 
Ischaemic heart disease 0.43 (-1.07, 1.94) 0.94 (-0.57, 2.44) 0.29 (-0.46, 1.04) 0.32 (-0.23, 0.88) 0.45 (-0.38, 1.29) 
Heart failure 4.06 (1.60, 6.52) 3.84 (1.40, 6.27) 2.12 (0.90, 3.35) -0.23 (-1.15, 0.69) 1.12 (-0.21, 2.44) 
Stroke 2.99 (0.90, 5.08) 1.05 (-1.01, 3.12) 0.52 (-0.52, 1.56) 0.58 (-0.25, 1.40) 0.05 (-1.09, 1.19) 
Hypertension -0.18 (-0.88, 0.51) 0.12 (-0.57, 0.81) 0.25 (-0.10, 0.60) 0.09 (-0.17, 0.35) 0.08 (-0.31, 0.46) 
Diabetes 0.39 (-0.74, 1.51) 1.91 (0.78, 3.04) 1.15 (0.59, 1.71) 0.46 (0.05, 0.86) 0.54 (-0.08, 1.16) 
Asthma 0.21 (-0.59, 1.00) -0.06 (-0.84, 0.73) -0.15 (-0.55, 0.25) -0.20 (-0.50, 0.09) 0.07 (-0.37, 0.50) 
COPD -0.69 (-2.58, 1.20) 0.05 (-1.81, 1.92) 0.49 (-0.45, 1.43) 0.69 (-0.02, 1.40) -0.27 (-1.32, 0.78) 
Peptic ulcer 1.46 (0.04, 2.88) 2.28 (0.87, 3.70) 1.66 (0.95, 2.37) 1.07 (0.52, 1.62) 1.12 (0.33, 1.91) 
Renal  2.67 (0.76, 4.59) 1.64 (-0.28, 3.55) 0.85 (-0.09, 1.79) 0.06 (-0.65, 0.77) 1.26 (0.25, 2.28) 
Liver  -0.54 (-3.20, 2.13) 0.42 (-2.21, 3.05) 0.06 (-1.27, 1.39) -0.05 (-0.98, 0.88) -0.25 (-1.68, 1.18) 
Cancer  0.61 (-0.68, 1.89) 0.03 (-1.25, 1.30) 0.22 (-0.42, 0.86) 0.37 (-0.12, 0.85) -0.19 (-0.89, 0.51) 
Depression  2.93 (2.26, 3.61) 2.97 (2.30, 3.64) 0.92 (0.58, 1.25) 0.34 (0.10, 0.58) 0.79 (0.41, 1.16) 
TB 0.80 (-1.22, 2.82) 1.36 (-0.68, 3.39) 0.84 (-0.17, 1.85) 0.35 (-0.44, 1.13) 0.65 (-0.46, 1.75) 
Demyelinating 4.49 (0.32, 8.65) 2.12 (-2.00, 6.24) 0.05 (-2.03, 2.13) 0.59 (-1.08, 2.25) -0.50 (-2.74, 1.74) 
Age  -0.05 (-0.07, -0.03) -0.06 (-0.08, -0.04) 0.02 (0.01, 0.02) 0.05 (0.04, 0.06) -0.02 (-0.03, -0.01) 
Gender  -0.75 (-1.28, -0.22) -1.48 (-2.01, -0.95) -0.24 (-0.50, 0.03) 0.24 (0.04, 0.44) -0.18 (-0.47, 0.11) 
BMI 0.07 (0.02, 0.11) 0.14 (0.10, 0.19) 0.09 (0.07, 0.12) 0.02 (0.004, 0.04) 0.04 (0.02, 0.07) 
Ever-smoker 0.43 (-0.07, 0.93) 1.39 (0.89, 1.88) 0.67 (0.42, 0.92) 0.23 (0.05, 0.42) 0.44 (0.17, 0.72) 
Secondary school reference reference reference reference reference 
Apprenticeship -0.07 (-0.97, 0.83) -0.81 (-1.71, 0.09) -0.21 (-0.66, 0.24) -0.28 (-0.61, 0.05) -0.28 (-0.77, 0.22) 
Further education college -0.09 (-0.70, 0.53) -1.13 (-1.74, -0.52) -0.51 (-0.82, -0.20) -0.38 (-0.60, -0.15) -0.48 (-0.82, -0.14) 
University degree -0.81 (-1.51, -0.11) -2.23 (-2.92, -1.54) -0.95 (-1.30, -0.60) -0.80 (-1.06, -0.54) -0.88 (-1.26, -0.50) 
Further degree -1.85 (-2.81, -0.88) -3.76 (-4.72, -2.80) -1.72 (-2.21, -1.24) -0.87 (-1.25, -0.49) -1.59 (-2.11, -1.06) 
Deprivation 0.29 (0.11, 0.47) 0.49 (0.31, 0.66) 0.26 (0.17, 0.35) 0.13 (0.06, 0.20) 0.16 (0.06, 0.26) 










Age, years 51.1 (14.6) 44.5 (13.9) <0.001 
Males 963 (68%) 419 (66%) 0.42 
Meeting modified New York 
criteria 
983 (70%) 357 (57%) <0.001 
Age at symptom onset, years 29.1 (13.9) 29.2 (13.6) 0.87 
Symptom duration, years 22.0 (15.0) 15.3 (12.6) <0.001 
HLA-B27 positive* 858 (81%) 335 (74%) 0.002 
BMI, kg/m2 27.5 (5.4) 28.1 (5.7) 0.062 
Smoking 
status 
Never smoked 655 (47%) 245 (39%) <0.001 
 Ex-smoker 540 (38%) 203 (32%) 
Current smoker 213 (15%) 181 (29%) 
Education Secondary school 429 (30%) 219 (35%) 0.12 
Apprenticeship 131 (9%) 60 (10%) 
Further education 
college 
430 (31%) 190 (30%) 
University degree 297 (21%) 120 (19%) 
Further degree 120 (9%) 37 (6%) 
Deprivation index, mean (SD) 2.8 (1.4) 3.1 (1.4) <0.001 
NSAID use in past 6 months 1013 (72%) 473 (75%) 0.20 
DMARD use in past 6 months 137 (13%) 64 (13%) 0.72 
BASDAI, median (IQR) 3.8 (2.0, 5.8) 6.9 (5.6, 7.9) <0.001 
Spinal pain, median (IQR) 3.0 (1.0, 6.0) 7.0 (5.0, 8.0) <0.001 
ASDAS* 1.9 (1.0) 3.0 (0.8) <0.001 
CRP (mg/dL), median (IQR)* 0.5 (0.2, 1.8) 0.7 (0.2, 2.1) 0.030 
ESR (mm/hr), median (IQR)* 9.0 (5.0, 20.0) 14.0 (5.0, 28.0) <0.001 
Fatigue, median (IQR) 13.0 (13.0, 17.0) 18.0 (14.0, 21.0) <0.001 
ASQoL, median (IQR) 6.0 (2.0, 13.0) 13.0 (10.0, 16.0) <0.001 
BASFI, median (IQR) 3.3 (1.4, 5.9) 6.6 (4.8, 8.1) <0.001 
BASMI, median (IQR)* 3.4 (2.0, 5.2) 4.2 (2.8, 5.6) <0.001 
IHD 48 (3%) 15 (2%) 0.27 
Heart failure 16 (1%) 5 (1%) 0.64 
Stroke 25 (2%) 4 (1%) 0.044 
Hypertension 292 (21%) 95 (15%) 0.003 
Diabetes 74 (5%) 27 (4%) 0.38 
Asthma 129 (9%) 74 (12%) 0.078 
COPD 29 (2%) 6 (1%) 0.096 
Peptic ulcer 30 (2%) 28 (4%) 0.006 
Renal  25 (2%) 10 (2%) 0.86 
Liver  9 (1%) 8 (1%) 0.19 
Cancer  67 (5%) 11 (2%) <0.001 
Depression  186 (13%) 130 (21%) <0.001 
TB 17 (1%) 12 (2%) 0.23 
Demyelinating 6 (<1%) 0 (0%) 0.19 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
*Not all variables had complete data; HLA-B27 was available for 74% of participants, 
BASMI 75%, ASDAS 78%, CRP 78%, ESR 39%. 
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**non-parametric test for trend. 
Deprivation index, 1=most deprived, 5=least deprived; IQR, interquartile range; BMI, 
body mass index; BASDAI, Bath AS disease activity index; BASFI, Bath AS functional 
index; BASMI, Metrology Index; ASQoL, AS quality of life questionnaire; ASDAS, AS 





Figure S5. 1: Sensitivity analysis of comorbidity categories restricted to the non-biologic cohort show comparable results for comorbidity count 




Figure S5. 2: Sensitivity analysis of individual comorbidities restricted to the non-biologic cohort show comparable results for comorbidity count 






10.5 Appendix for Chapter 6 
 
Table S6. 1: Baseline characteristics of 994 participants included in the longitudinal 






Age, years 44.7 (13.4) 43.7 (13.7) 0.40 
Males 679 (68%) 84 (60%) 0.044 
Meeting modified New York criteria 597 (60%) 90 (64%) 0.41 
Age at symptom onset, years 28.6 (13.3) 30.2 (12.2) 0.14 
Symptom duration, years 16.0 (12.6) 13.8 (12.1) 0.053 
HLA-B27 positive* 540 (74%) 67 (78%) 0.51 
BMI, kg/m2 28.1 (5.8) 27.4 (5.8) 0.24 
Smoking 
status 
Never smoked 351 (40%) 52 (40%) 0.88 
Ex-smoker 291 (33%) 45 (35%) 
Current smoker 241 (27%) 33 (25%) 
Education Secondary school 289 (33%) 42 (32%) 0.232** 
Apprenticeship 82 (9%) 9 (7%) 
Further education college 276 (31%) 37 (28%) 
University degree 178 (20%) 26 (20%) 
Further degree 53 (6%) 16 (12%) 
Deprivation index, median (IQR) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 0.53 
Depression 145 (15%) 19 (14%) 0.90 
Hypertension 106 (11%) 17 (12%) 0.56 
Asthma 86 (9%) 13 (9%) 0.75 
Peptic ulcer disease 28 (3%) 7 (5%) 0.18 
Diabetes mellitus 25 (3%) 8 (6%) 0.052 
Cancer 15 (2%) 5 (4%) 0.085 
Ischaemic heart disease 16 (2%) 3 (2%) 0.50 
TB 15 (2%) 3 (2%) 0.47 
Renal disease 11 (1%) 1 (1%) 1.00 
COPD 10 (1%) 1 (1%) 1.00 
Stroke 7 (1%) 0 1.00 
Liver disease 7 (1%) 2 (1%) 0.30 
Heart failure 6 (1%) 2 (1%) 0.25 
Demyelinating disease 2 (<1%) 0 1.00 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
**non-parametric test for trend. 
IQR, interquartile range; BMI, body mass index; BASDAI, Bath AS disease activity 
index; ASDAS, AS disease activity score; BASFI, Bath AS functional index; ASQoL, AS 




Table S6. 2: Full model coefficients for associations between binary comorbidity status (present vs. absent) and binary responses at 6 months. 
 Models without adjusting for baseline disease activity Models additionally adjusting for baseline disease activity 
 
BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 
N 534 534 436 436 534 534 436 436 
Comorbidities  
(1 vs. 0) 
0.96 
(0.65 to 1.40) 
0.70 
(0.47 to 1.03) 
0.95 
(0.59 to 1.51) 
0.94 
(0.57 to 1.55) 
0.87 
(0.59 to 1.28) 
0.81 
(0.54 to 1.22) 
0.98 
(0.62 to 1.57) 
0.69 (0.39 to 
1.22) 
Age  1.00 
(0.99 to 1.01) 
1.00 
(0.99 to 1.02) 
0.99 
(0.97 to 1.01) 
1.00 
(0.98 to 1.02) 
1.00 
(0.99 to 1.01) 
1.00 
(0.99 to 1.02) 
0.99 
(0.97 to 1.01) 
1.00 
(0.98 to 1.02) 
Gender  1.67 
(1.14 to 2.47) 
1.71 
(1.15 to 2.54) 
1.44 
(0.90 to 2.30) 
1.38 
(0.84 to 2.29) 
1.81 
(1.22 to 2.68) 
1.56 
(1.03 to 2.36) 
1.47 
(0.92 to 2.36) 
1.23 
(0.71 to 2.12) 
Deprivation  0.83 
(0.73 to 0.95) 
0.79 
(0.69 to 0.90) 
0.83 
(0.71 to 0.97) 
0.95 
(0.81 to 1.13) 
0.81 
(0.71 to 0.92) 
0.81 
(0.71 to 0.93) 
0.84 
(0.72 to 0.98) 
0.92 
(0.76 to 1.10) 
Secondary 
school 
Reference Reference Reference Reference Reference Reference Reference Reference 
Apprenticeship 0.51 
(0.26 to 0.99) 
0.79 
(0.41 to 1.52) 
0.92 
(0.42 to 1.99) 
0.65 
(0.27 to 1.56) 
0.53 
(0.27 to 1.03) 
0.71 
(0.36 to 1.39) 
0.89 
(0.41 to 1.94) 
0.70 





(0.72 to 1.81) 
1.50 
(0.94 to 2.40) 
1.15 
(0.67 to 1.99) 
1.21 
(0.68 to 2.14) 
1.24 
(0.78 to 1.97) 
1.36 
(0.84 to 2.22) 
1.12 
(0.65 to 1.94) 
1.60 




(0.74 to 2.02) 
1.92 
(1.15 to 3.21) 
2.11 
(1.19 to 3.71) 
1.27 
(0.69 to 2.33) 
1.38 
(0.82 to 2.30) 
1.61 
(0.95 to 2.73) 
2.05 
(1.16 to 3.62) 
1.74 
(0.88 to 3.42) 
Further degree 0.82 
(0.36 to 1.85) 
0.99 
(0.43 to 2.26) 
0.85 
(0.32 to 2.29) 
0.40 
(0.11 to 1.44) 
0.98 
(0.42 to 2.26) 
0.68 
(0.29 to 1.61) 
0.78 
(0.29 to 2.12) 
0.69 
(0.17 to 2.82) 
BMI 0.93 
(0.90 to 0.97) 
0.93 
(0.90 to 0.97) 
0.94 
(0.90 to 0.98) 
0.9 
(0.89 to 0.98) 
0.93 
(0.90 to 0.96) 
0.94 
(0.90 to 0.97) 
0.94 
(0.90 to 0.98) 
0.92 
(0.88 to 0.97) 
Baseline 
BASDAI/ASDAS 
    1.18  
(1.07 to 1.31) 
0.71  
(0.64 to 0.80) 
0.84  
(0.65 to 1.09) 
4.23  
(2.92 to 6.12) 
ASDAS, AS disease activity score; BASDAI 50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, major improvement i.e. ≥2-unit reduction; BMI, 






Table S6. 3: Full model coefficients for associations between continuous comorbidity count and binary responses at 6 months. 
 
 Models without adjusting for baseline disease activity Models additionally adjusting for baseline disease activity 
 
BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 




(0.70 to 1.10) 
0.73 
(0.57 to 0.92) 
0.84 
(0.62 to 1.14) 
0.88 
(0.63 to 1.21) 
0.81 
(0.64 to 1.02) 
0.82 
(0.64 to 1.05) 
0.87 
(0.64 to 1.18) 
0.66 
(0.46 to 0.94) 
Age  1.00 
(0.99 to 1.02) 
1.00 
(0.99 to 1.02) 
0.99 
(0.98 to 1.01) 
1.00 
(0.98 to 1.02) 
1.00 
(0.99 to 1.02) 
1.00 
(0.99 to 1.02) 
0.99 
(0.98 to 1.01) 
1.00 
(0.98 to 1.02) 
Gender  1.66 (1.13 to 
2.45) 
1.71 
(1.15 to 2.55) 
1.42 
(0.89 to 2.27) 
1.37 
(0.83 to 2.27) 
1.81 
(1.22 to 2.69) 
1.57 
(1.04 to 2.37) 
1.45 
(0.90 to 2.32) 
1.18 
(0.68 to 2.05) 
Deprivation  0.84 
(0.74 to 0.96) 
0.79 
(0.69 to 0.91) 
0.84 
(0.71 to 0.98) 
0.96 
(0.81 to 1.13) 
0.81 
(0.71 to 0.93) 
0.82 
(0.71 to 0.94) 
0.84 
(0.72 to 0.98) 
0.92 
(0.77 to 1.11) 
Secondary 
school 
Reference Reference Reference Reference Reference Reference Reference Reference 
Apprenticeship 0.52 
(0.27 to 1.01) 
0.82 
(0.42 to 1.58) 
0.94 
(0.43 to 2.05) 
0.66 
(0.27 to 1.59) 
0.54 
(0.28 to 1.06) 
0.72 
(0.37 to 1.43) 
0.91 
(0.42 to 1.99) 
0.78 





(0.74 to 1.85) 
1.56 
(0.98 to 2.50) 
1.18 
(0.68 to 2.04) 
1.22 
(0.69 to 2.17) 
1.28 
(0.80 to 2.05) 
1.4 
(0.86 to 2.28) 
1.14 
(0.66 to 1.99) 
1.69 




(0.74 to 2.01) 
1.93 
(1.15 to 3.22) 
2.09 
(1.19 to 3.69) 
1.26 
(0.69 to 2.32) 
1.38 
(0.83 to 2.31) 
1.61 
(0.95 to 2.74) 
2.04 
(1.16 to 3.60) 
1.75 
(0.89 to 3.45) 
Further degree 0.81 
(0.36 to 1.84) 
0.98 
(0.43 to 2.23) 
0.85 
(0.32 to 2.28) 
0.39 
(0.11 to 1.43) 
0.98 
(0.43 to 2.27) 
0.69 
(0.29 to 1.62) 
0.79 
(0.29 to 2.14) 
0.69 
(0.17 to 2.82) 
BMI 0.93 
(0.90 to 0.97) 
0.93 
(0.90 to 0.97) 
0.94 
(0.90 to 0.98) 
0.93 
(0.89 to 0.98) 
0.93 
(0.90 to 0.96) 
0.94 
(0.90 to 0.97) 
0.94 
(0.90 to 0.98) 
0.93 
(0.88 to 0.97) 
Baseline 
BASDAI/ASDAS 
    1.20 
(1.08 to 1.32) 
0.72 
(0.64 to 0.81) 
0.86 
(0.66 to 1.11) 
4.45 
(3.05 to 6.48) 
ASDAS, AS disease activity score; BASDAI 50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, major improvement i.e. ≥2-unit reduction; BMI, body 





Table S6. 4: Full model coefficients for associations between comorbidity count categories and binary responses at 6 months. 
 
 Models without adjusting for baseline disease activity Models additionally adjusting for baseline disease activity 
 
BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 
N 534 534 436 436 534 534 436 436 
0 comorbidities  Reference Reference Reference Reference Reference Reference Reference Reference 
1 comorbidity 1.03 
(0.67 to 1.60) 
0.76 
 (0.49 to 1.18) 
0.96  
(0.55 to 1.68) 
1.05 
 (0.63 to 1.75) 
0.97  
(0.62 to 1.51) 
0.84 
 (0.53 to 1.33) 
0.81 
 (0.43 to 1.50) 
1.08 
 (0.65 to 1.80) 
≥2 comorbidities 0.81 
(0.45 to 1.45) 
0.57 
 (0.32 to 1.04) 
0.87  
(0.38 to 1.99) 
0.7  
(0.32 to 1.56) 
0.68  
(0.38 to 1.23) 
0.76 
 (0.41 to 1.41) 
0.47 
 (0.18 to 1.19) 
0.75 
 (0.34 to 1.67) 
Age  1.00 
(0.99 to 1.01) 
1.00 
 (0.99 to 1.02) 
1.00 
 (0.98 to 1.02) 
0.99 
 (0.98 to 1.01) 
1.00 
 (0.99 to 1.02) 
1.00 
 (0.99 to 1.02) 
1.00 
 (0.98 to 1.02) 
0.99 
 (0.98 to 1.01) 
Gender  1.68 
(1.14 to 2.47) 
1.71 
 (1.15 to 2.54) 
1.38 
 (0.83 to 2.29) 
1.43 
 (0.90 to 2.28) 
1.81 
 (1.22 to 2.69) 
1.56 
 (1.03 to 2.36) 
1.21 
 (0.70 to 2.09) 
1.46 
 (0.91 to 2.34) 
Deprivation  0.84 
(0.73 to 0.95) 
0.79  
(0.69 to 0.90) 
0.96 
 (0.81 to 1.13) 
0.84 
 (0.71 to 0.98) 
0.81 
 (0.71 to 0.93) 
0.81 
 (0.71 to 0.93) 
0.92 
 (0.77 to 1.10) 
0.84  
(0.72 to 0.98) 
Secondary school Reference Reference Reference Reference Reference Reference Reference Reference 
Apprenticeship 0.52 
(0.27 to 1.00) 
0.8 
 (0.41 to 1.55) 
0.65 
 (0.27 to 1.58) 
0.94 
 (0.43 to 2.05) 
0.54 
 (0.27 to 1.05) 
0.71 
 (0.36 to 1.40) 
0.74 
 (0.26 to 2.13) 
0.91 




(0.73 to 1.83) 
1.52 
 (0.95 to 2.42) 
1.21  
(0.68 to 2.14) 
1.16 
 (0.67 to 2.00) 
1.26 
 (0.79 to 2.00) 
1.37 
 (0.84 to 2.23) 
1.62  
(0.85 to 3.07) 
1.12  
(0.65 to 1.95) 
University degree 1.22 
 (0.74 to 2.02) 
1.92  
(1.15 to 3.21) 
1.27  
(0.69 to 2.33) 
2.1 
 (1.19 to 3.70) 
1.38 
 (0.83 to 2.31) 
1.61 
 (0.95 to 2.73) 
1.74  
(0.88 to 3.43) 
2.04  
(1.16 to 3.61) 
Further degree 0.81  
(0.36 to 1.83) 
0.98 
 (0.43 to 2.24) 
0.39  
(0.11 to 1.43) 
0.83 
 (0.31 to 2.24) 
0.97  
(0.42 to 2.24) 
0.68  
(0.29 to 1.61) 
0.68 
 (0.17 to 2.77) 
0.77  
(0.29 to 2.09) 
BMI 0.93  
(0.90 to 0.97) 
0.93  
(0.90 to 0.97) 
0.93  
(0.89 to 0.98) 
0.94 
 (0.90 to 0.98) 
0.93 (0.90 to 
0.96) 
0.94 (0.90 to 
0.97) 
0.93 (0.88 to 
0.97) 




    1.19 (1.08 to 
1.31) 
0.72 (0.64 to 
0.80) 
4.32 (2.97 to 
6.28) 
0.85 (0.66 to 
1.10) 
ASDAS, AS disease activity score; BASDAI 50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, major improvement i.e. ≥2-unit reduction; BMI, 




Table S6. 5: Cox model coefficients for risk of discontinuing TNF inhibitor according to the 
number of baseline comorbidities 
 
 
All Male Female 
N 767 518 249 
0 comorbidities  Reference Reference Reference 
1 comorbidity 0.91 (0.65 to 1.26) 0.86 (0.56 to 1.33) 0.82 (0.48 to 1.39) 
2 comorbidities 1.32 (0.88 to 2.00) 1.68 (0.99 to 2.83) 0.86 (0.43 to 1.71) 
≥3 comorbidities 2.18 (1.20 to 3.93) 5.04 (2.61 to 9.74) 0.44 (0.10 to 1.96) 
Age 1.00 (0.99 to 1.01) 1.01 (1.00 to 1.02) 0.99 (0.97 to 1.01) 
Gender* 0.77 (0.58 to 1.01) n/a n/a 
Deprivation index 1.19 (1.08 to 1.31) 1.22 (1.08 to 1.37) 1.16 (0.99 to 1.36) 
BMI 1.02 (1.00 to 1.04) 1.02 (0.99 to 1.05) 1.03 (1.00 to 1.06) 
*Female as reference. 
 
 
Table S6. 6: Sensitivity analysis for the association between comorbidity and binary 
response at 6 months, with missing binary outcomes imputed as response if patients 















BASDAI 50/2 445 (60%) Binary* 1.01 (0.71 to 1.44) 0.93 (0.65 to 1.33) 
Continuous count 0.92 (0.75 to 1.13) 0.86 (0.70 to 1.06) 
ASDAS-MI 130 (26%) Binary 1.04 (0.70 to 1.55) 0.88 (0.58 to 1.34) 
Continuous count 1.00 (0.78 to 1.28) 0.88 (0.67 to 1.14) 
BASDAI<4 449 (60%) Binary 0.79 (0.55 to 1.12) 0.89 (0.62 to 1.28) 
Continuous count 0.80 (0.65 to 0.99) 0.88 (0.71 to 1.09) 
ASDAS<2.1 168 (34%) Binary 1.04 (0.71 to 1.54) 1.07 (0.72 to 1.58) 
Continuous count 0.96 (0.75 to 1.23) 0.98 (0.77 to 1.25) 
*as 0 (reference) vs. ≥1 comorbidities. 
BASDAI 50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, major improvement i.e. ≥2-
unit reduction. 




Figure S6. 1: Sensitivity analyses for binary outcomes with missing binary outcomes imputed as response if patients remained on drug for 
longer than one year. 
 
 




a) Without baseline adjustment     b) with baseline adjustment  
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10.6 Appendix for Chapter 7 
10.6.1 Inverse-probability weights 
Inverse-probability of treatment weighting (IPTW) is often conceptualised as one way of 
using propensity scores (PS; others being matching, stratifying, and covariate adjustment). 
Put simply, it is 1 over the probability of being in an exposure group given covariates (i.e., 





where A is the exposure group and L represents all covariates. (The notation is an over-
simplification and not strictly correct in representing counterfactuals, which is beyond the 
scope of this section.) When using IPTW, the overall analysis population size is increased. 
The weights can be ‘stabilised’ by replacing the numerator with the probability of being in 
the exposure group, thus making the mean weight (close to) 1, and the weighted analysis 
population size (almost) unchanged. 




Stabilising weights have the additional advantage of reducing the size of extreme weights, 
which is essential when weights are multiplied, as in marginal structural models discussed 
later. In this thesis, IPTWs were used only to balance baseline covariates. Since none of the 
‘exposures’ were time-varying (e.g., comorbidity status is measured only at baseline), time-
varying IPTWs were not required. 
IPTWs are used in marginal (i.e., population level, c.f. conditional or individual) structural 
(i.e., causal) models. Marginal structural models can be used to analyse repeated measure 
data (weighted GEE), time-to-event data (weighted pooled logistic regression) or other 
purposes (e.g., mediation). The marginal risk of treatment discontinuation can be estimated 
using (a marginal approach to) Cox models (e.g., standardisation or IPTW). However, an 
important assumption is that censoring (loss to follow-up) is random. This assumption is 
often violated but can be remediated using inverse probability of censoring weighs (IPCW). 
To do so, each individual’s follow-up time is discretised into months. This means that 
someone with x months’ follow-up will have x+1 ‘rows’ of data – one for each month. If 
they had BASDAI assessed every month, each row will have a different BASDAI; if not, 
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BASDAI from the previous month will be carried forward until the next BASDAI assessment. 
At each month, IPCWs create weighted populations such that censoring becomes random 
with respect to baseline covariates and time-varying BASDAI. Stabilised IPCW is constructed 
as follows: 





where C(t) is a binary variable taking the value 1 if a subject is censored in month t and 0 
otherwise, ?̅?(t) is the exposure history (in this case unchanged), L(0) are baseline covariates 
including disease activity, and ?̅?(k) is the history of covariates (disease activity at baseline 
and before censoring). In addition, time is included in both numerator and denominator 
models in quadratic (i.e., non-linear) form. In this thesis, all stabilised weights, both IPTW 
and IPCW, were examined for means close to 1 and extreme values. Covariate balance was 
checked in weighted populations. 
10.6.2 Results from marginal and conditional models may not coincide for binary 
and time-to-event outcomes. 
Mixed effects and other conditional models provide conditional estimates, or individual 
effects, that is, ‘if two individuals are randomly selected from a population and both have 
identical covariate values, the person with one comorbidity would have an outcome value 
which is, on average, β units higher’. GEE and IP weighted models assess marginal effects, 
that is, population-level effects or ‘average change in outcome per unit change in 
exposure’. Results from marginal and conditional models coincide for continuous 
outcomes, but not necessarily for binary and time-to-event outcomes (Figure S6.1). Thus, 
marginal estimates should not be used to make inferences about individuals under these 




Figure S7. 1: Dotted lines show individual/conditional estimates, which do not coincide 




10.6.3 Equivalence between Cox and pooled logistic regression models 
This section demonstrates the equivalence between pooled logistic regression and Cox 
models when the event hazard is small at each time point. The unadjusted HR from the Cox 
model for time to treatment discontinuation according to history of depression at baseline 
was HR 1.43 (95% CI 1.04 to 1.97). The same comparison using pooled logistic regression 
with cubic spline for time (months) with clustered sandwich estimator (for individual 
participants) gave HR 1.42 (95% CI 1.02 to 1.98). The minor discrepancy explainable by 
rounding. Figure S7.2 shows Kaplan-Meier estimates using both methods. 
  
Arbitrary units of depressive symptoms 
Probability of (binary) treatment response 
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Figure S7. 2: Equivalence of Kaplan-Meier estimates derived using continuous (top) and 





Table S7. 1: Baseline characteristics of BSRBR-AS participants included and excluded from 












Males 496 (67%) 183 (73%) 0.100 
Meeting modified New York 
criteria 
435 (59%) 162 (64%) 0.12 










HLA-B27 positive* 414 (75%) 126 (72%) 0.43 







Never smoked 298 (40%) 53 (37%) 0.80 
Ex-smoker 243 (33%) 48 (34%) 
 
Current smoker 200 (27%) 41 (29%) 
 
Education Secondary school 251 (34%) 38 (27%) 0.15 




227 (31%) 49 (35%) 
 
University degree 149 (20%) 29 (20%) 
 




1 - most affluent 134 (18%) 49 (20%) 0.75 
2 161 (22%) 45 (18%) 
 
3 145 (20%) 48 (19%) 
 
4 148 (20%) 55 (22%) 
 
5 - most deprived 153 (21%) 54 (22%) 
 
NSAID use in past 6 months 538 (74%) 196 (78%) 0.24 
DMARD use in past 6 months 107 (15%) 39 (16%) 0.76 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
*Not all variables had complete data; HLA-B27 was available for 74% of 
participants 






Table S7. 2: Full model coefficients for associations between depression diagnosis and binary responses at 6 months. 
 
 Models without adjusting for baseline disease activity Models additionally adjusting for baseline disease activity 
 
BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 
N 475 475 436 436 475 475 436 436 
Depression 
diagnosis  
0.69 (0.40, 1.19) 0.56 (0.32, 0.99) 0.75 (0.36, 1.56) 0.5 (0.25, 1.00) 0.54 (0.31, 0.96) 0.73 (0.41, 1.32) 0.52 (0.23, 1.16) 0.53 (0.26, 1.07) 
Age  1.00 (0.98, 1.01) 1.00 (0.99, 1.02) 1.00 (0.98, 1.02) 0.99 (0.97, 1.01) 1.00 (0.98, 1.02) 1.00 (0.98, 1.02) 1.00 (0.98, 1.02) 0.99 (0.97, 1.01) 
Gender  1.51 (0.98, 2.31) 1.48 (0.95, 2.30) 1.10 (0.65, 1.86) 1.19 (0.73, 1.93) 1.69 (1.09, 2.62) 1.31 (0.82, 2.08) 1.00 (0.57, 1.78) 1.21 (0.74, 1.97) 
Deprivation  0.88 (0.77, 1.02) 0.82 (0.71, 0.95) 1.00 (0.84, 1.19) 0.86 (0.74, 1.01) 0.85 (0.74, 0.99) 0.84 (0.72, 0.98) 0.96 (0.79, 1.16) 0.87 (0.74, 1.02) 
Secondary 
school 
Reference Reference Reference Reference Reference Reference Reference Reference 




1.40 (0.86, 2.30) 2.02 (1.21, 3.36) 1.33 (0.74, 2.41) 1.27 (0.73, 2.22) 1.66 (1.00, 2.77) 1.74 (1.02, 2.96) 1.76 (0.91, 3.41) 1.22 (0.70, 2.15) 
University 
degree 
1.60 (0.93, 2.76) 2.89 (1.63, 5.13) 1.38 (0.74, 2.58) 2.27 (1.27, 4.06) 1.98 (1.12, 3.50) 2.35 (1.30, 4.25) 1.81 (0.91, 3.61) 2.20 (1.23, 3.95) 
Further degree 1.00 (0.41, 2.45) 1.21 (0.49, 3.01) 0.40 (0.11, 1.47) 0.86 (0.32, 2.36) 1.34 (0.53, 3.39) 0.81 (0.32, 2.06) 0.66 (0.16, 2.70) 0.78 (0.28, 2.15) 
BMI 0.92 (0.89, 0.96) 0.92 (0.89, 0.96) 0.93 (0.88, 0.97) 0.94 (0.90, 0.98) 0.92 (0.88, 0.95) 0.92 (0.88, 0.96) 0.92 (0.88, 0.97) 0.93 (0.89, 0.97) 
Elevated CRP 1.38 (0.91, 2.10) 1.81 (1.18, 2.80) 3.22 (1.81, 5.73) 2.11 (1.30, 3.43) 1.49 (0.97, 2.29) 1.76 (1.12, 2.77) 2.32 (1.26, 4.30) 2.28 (1.39, 3.75) 
Comorbidity 
count 
1.05 (0.78, 1.40) 0.84 (0.62, 1.14) 0.99 (0.67, 1.46) 1.05 (0.74, 1.48) 0.95 (0.70, 1.28) 0.96 (0.70, 1.32) 0.75 (0.48, 1.16) 1.09 (0.76, 1.55) 
Baseline 
BASDAI/ASDAS 
    1.29 (1.15, 1.44) 0.69 (0.61, 0.79) 4.13 (2.82, 6.05) 0.80 (0.61, 1.04) 
ASDAS, AS disease activity score; BASDAI 50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, major improvement i.e. ≥2-unit reduction; BMI, body mass 








n Mean SD Min Max 
IPTW Depression BASDAI 738 0.99 0.64 0.30 8.78 
ASDAS 673 0.99 0.61 0.38 8.72 
Spinal pain 740 0.99 0.54 0.39 6.40 
Anxiety BASDAI 738 1.00 0.47 0.41 3.94 
ASDAS 673 1.00 0.39 0.40 3.52 
Spinal pain 740 1.00 0.39 0.47 5.13 
IPCW Depression 12949 1.00 0.01 0.95 1.07 
Anxiety 12949 1.00 0.01 0.92 1.10 
Matching 
weight 
Depression BASDAI 738 0.08 0.07 0.03 1.00 
ASDAS 673 0.08 0.06 0.03 1.00 
Spinal pain 740 0.12 0.08 0.04 1.00 
Anxiety BASDAI 738 0.27 0.14 0.10 1.00 
ASDAS 673 0.23 0.11 0.08 1.00 
Spinal pain 740 0.23 0.10 0.10 1.00 
ASDAS, AS disease activity score; BASDAI, Bath AS disease activity index; IPTW, inverse 




Table S7. 4: Model coefficients for associations between HADS sub-scale categories and binary responses at 6 months. 
 BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 
N 542 542 492 492 
HADS-D None reference reference reference reference 
Mild 0.56 (0.36, 0.89) 0.61 (0.38, 0.97) 0.56 (0.34, 0.94) 0.52 (0.31, 0.88) 
Mod-severe 0.51 (0.29, 0.90) 0.49 (0.27, 0.88) 0.49 (0.26, 0.90) 0.38 (0.19, 0.76) 
HADS-A Mod-severe reference reference reference reference 
Mild 0.54 (0.34, 0.86) 0.54 (0.33, 0.88) 0.88 (0.51, 1.51) 0.71 (0.43, 1.18) 
None 0.65 (0.42, 1.01) 0.51 (0.33, 0.80) 0.77 (0.46, 1.27) 0.58 (0.36, 0.95) 
BASDAI 50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, major improvement i.e. ≥2-unit 
reduction; HADS-D, depression; HADS-A; anxiety sub-scale. 
 
Table S7. 5: Model coefficients for associations between HADS sub-scale categories and binary responses at 6 months, with missing binary outcomes 
imputed as response if patients remained on drug for longer than one year. 
 BASDAI 50/2 BASDAI<4 ASDAS-MI ASDAS<2.1 
N 665 665 606 606 
HADS-D None reference reference reference reference 
Mild 0.55 (0.36, 0.85) 0.59 (0.38, 0.92) 0.62 (0.41, 0.95) 0.57 (0.37, 0.89) 
Mod-severe 0.51 (0.31, 0.85) 0.5 (0.30, 0.83) 0.61 (0.37, 1.01) 0.5 (0.30, 0.85) 
HADS-A Mod-severe reference reference reference reference 
Mild 0.55 (0.36, 0.86) 0.56 (0.35, 0.89) 0.9 (0.57, 1.41) 0.76 (0.49, 1.18) 
None 0.71 (0.48, 1.07) 0.58 (0.38, 0.87) 0.92 (0.62, 1.38) 0.74 (0.49, 1.09) 
BASDAI 50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, major improvement i.e. ≥2-unit 
reduction; HADS-D, depression; HADS-A; anxiety sub-scale. 
 
